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About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. 
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
About this series
EMCDDA Insights are topic-based reports that bring 
together current research and study findings on a 
particular issue in the drugs field. This report provides 
a comprehensive European picture on illicit drugs and 
medicines in connection with driving.
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5I Foreword
The mobility provided by road transport, particularly the car, allows many Europeans to 
enjoy a lifestyle characterised by flexibility and independence. However, if we count the 
lives lost and injuries inflicted as a result of road traffic accidents, it is clear that these 
benefits come at a price: the most recent statistics reveal that more than 28 000 people 
die on European roads each year, while a further 1.34 million are injured.
In 2003, the European Union’s third Road Safety Action Programme set the ambitious target 
of halving the number of road deaths in the European Union in 2010. For the now 28 Member 
States of the Union, this would amount to approximately 27 500 lives lost on the roads. 
Many of the accidents and deaths that occur on European roads are caused by drivers 
whose performance is impaired by a psychoactive substance (alcohol, illicit drugs, 
psychoactive medicines or a combination of these substances). In order to meet the 2003 
Action Programme’s target of a significant reduction in fatalities in road traffic, it was 
necessary to address risks associated with all components of the road transport system, 
including driver performance. While public concerns with regard to illicit drugs and 
medicines in traffic were growing, knowledge at that point was insufficient to address 
these concerns.
When the 2003 Action Programme was introduced, it was estimated that about 25 % of 
fatalities on European roads were the result of the influence of alcohol, but a lack of 
comparable studies meant that the proportion due to the effects of illicit drugs or 
psychoactive medicines was unknown. For this reason, the DRUID (Driving Under the 
Influence of Drugs, Alcohol and Medicines) project was established, with the aim of 
estimating the size of the problem and examining the range of countermeasures. The 
DRUID project — part of the 6th Framework Programme — was established in October 
2006, ran for 5 years and involved 38 consortium partners from 17 EU Member States and 
Norway. The overall objective of the DRUID project was to provide scientific support to EU 
road safety policymakers by making science-based recommendations concerning 
responding to driving under the influence of psychoactive substances. It reported its 
research results at the end of 2011.
The prevention of driving under the influence of drugs is included as one of the key actions 
in the recent EU drugs action plan 2013–2016. As part of its aim to provide factual, 
objective, reliable and comparable information on the drug situation and responses to drug 
use in Europe, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is 
updating its 2008 Insights publication on drug use, impaired driving and traffic accidents 
with the findings from the DRUID project and published literature from 2007 to early 2013. 
Together with the EMCDDA’s 2012 thematic paper Driving under the influence of drugs, 
alcohol and medicines — findings from the DRUID project, the present report provides a 
comprehensive European picture on illicit drugs and medicines in connection with driving. 
Both the policymaker and the general reader will find here a commentary on the large 
number of studies that have been published on the topic in recent years, allowing an 
objective appraisal of the known effects of psychoactive substances on the ability to drive 
and an assessment of the extent to which drivers impaired by such drugs are present on 
the roads.
Although this edition of the EMCDDA Insights series does not intend to be definitive, I am 
pleased to present what I hope will be seen as an important signpost towards more 
effective solutions to the problem of driving under the influence of drugs.
Wolfgang Götz 
Director, EMCDDA

7I Executive summary
This literature review provides a comprehensive report on the relationship between drug 
use, impaired driving and traffic accidents. It describes methodological issues (Chapter 1), 
presents the results of prevalence surveys among drivers and provides an overview of 
findings from major international epidemiological surveys published since 2007 
(Chapter 2) and gathers evidence from experimental and field studies of the relationship 
between drug use, driving impairment and traffic accidents (Chapter 3).
The research methods can be broadly separated into experimental and epidemiological 
studies. Every approach has its inherent advantages and disadvantages. Experimental 
studies, in which the drug is administered in measured doses to volunteers, may be 
conducted in a laboratory or a driving simulator or on the public road. They allow the 
effects of a single factor to be measured, but can identify only potential risks, and in some 
cases the results can be of limited value because of the use of non-realistic doses for 
safety reasons or because of the drug use history of the volunteers or inter-individual 
differences. Epidemiological studies examine the prevalence of drug use in various 
populations. They include roadside surveys, studies assessing the prevalence of drugs in a 
subset of drivers, accident risk studies, responsibility analyses, surveys among the general 
population and pharmacoepidemiological studies. However, the study design means that it 
is not possible to completely eliminate all risk factors other than that under examination 
and which may be highly correlated with the risk factor of interest. The results of different 
studies may not be comparable if, for example, different populations or different kinds of 
samples are tested.
The results of experimental studies have indicated that several illicit drugs could have an 
influence on driving performance; the effects of some, but not all, drugs are dose 
dependent. Cannabis can impair some cognitive and psychomotor skills that are 
necessary to drive. 3,4-Methylenedioxymethylamphetamine (MDMA) exerts both negative 
and positive effects on performance, and studies investigating the effects of a 
combination of alcohol and illicit drugs have found that some illicit drugs (e.g. cannabis) 
can act additively with alcohol to increase impairment, while others (e.g. cocaine) can 
partially reverse alcohol-induced impairment. MDMA can diminish some, but not all, 
deleterious effects of alcohol, while other negative effects of alcohol can be reinforced. The 
chronic use of all illicit drugs is associated with some cognitive and/or psychomotor 
impairment, and can lead to a decrease in driving performance even when the subject is 
no longer intoxicated. The results of experimental studies also show that some therapeutic 
drugs can cause obvious impairment. Benzodiazepines, for example, generally have 
impairing effects, but some types (whether long-, medium- or short-acting) cause severe 
impairment, whereas others are unlikely to have residual effects in the morning. First-
generation antihistamines are generally more sedating than second-generation ones, 
though there are exceptions in both groups. Tricyclic antidepressants cause more 
impairment than the newer types, though the results of experimental tests after 
consumption of selective serotonin reuptake inhibitors are not always consistent. In every 
therapeutic class, however, some substances are associated with little or no impairment. 
These therapeutic drugs should preferably be prescribed to those wishing to drive.
Epidemiological studies have confirmed many of the findings from experimental studies. 
The Driving under the Influence of Drugs, Alcohol and Medicines (DRUID) project has 
calculated that, on average, 3.48 % of drivers in the European Union drive with alcohol 
(> 0.1 g/l) in their blood, 1.9 % with illicit drugs, 1.4 % with (a limited list) of medicinal 
drugs, 0.37 % with a combination of alcohol and drugs and 0.39 % with different drug 
classes. Studies assessing the prevalence of drugs, medicines and/or alcohol in drivers 
who were involved in a traffic accident (fatal or otherwise) have found that alcohol is more 
prevalent than any other psychoactive substance, but drugs are also frequently found, and 
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in a higher proportion of drivers than in the general driving population. Of the drugs 
analysed, cannabis is the most prevalent after alcohol, although benzodiazepines, when 
samples have been analysed for these, are sometimes even more prevalent than cannabis. 
Statistically, the use of amphetamines, cannabis, benzodiazepines, heroin and cocaine is 
associated with an increased risk of being involved in and/or responsibility for an accident, 
and in many cases this risk increases when the drug is combined with another 
psychoactive substance, such as alcohol.
From the perspective of traffic safety — especially looking at prevalence rates and risks 
— the following conclusions can be made. Alcohol, especially in high concentrations, must 
remain the principal focus of prevention measures. The combination of alcohol and drugs 
or medicines seems to be a topic that should be addressed more intensively because it is 
associated with a very high risk of a traffic accident. The problems resulting from medicine 
use among drivers should be addressed by providing doctors and patients with 
appropriate information, not by defining thresholds. Based on experimental studies, 
D9-tetrahydrocannabinol and amphetamines would appear to represent a minor risk, but in 
case–control studies amphetamines use is associated with a much increased risk of 
accident. More research is needed to investigate the probable risks of amphetamines in 
real traffic and the mediating factors. From the perspective of risk, sleep deprivation 
should also be addressed as it is associated with a high risk of accidents.
9I Introduction
In many EU Member States, the role of drugs in driver impairment and traffic accidents has 
been a cause for concern and an object of research for several decades. The Driving under 
the Influence of Drugs, Alcohol and Medicines (DRUID) project calculated that, on average, 
3.48 % of drivers in the European Union drive with alcohol in their blood, 1.9 % with illicit 
drugs, 1.4 % with (a limited list) of medicinal drugs, 0.37 % with a combination of alcohol 
and drugs and 0.39 % with a combination of different drug classes (EMCDDA, 2012). Large 
differences were observed among countries, with more alcohol and illicit drugs found in 
southern Europe and more medicinal drugs in northern Europe.
The first report by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA, 1999) on drugs and driving reviewed the available studies evaluating the 
relationship between drug use, impaired driving and traffic accidents for a large range of 
psychoactive substances. It also reviewed Member States’ drug testing procedures and 
associated legislation on drug-impaired driving, as well as the issues raised by such 
testing. Among the report’s conclusions was that more research — both experimental and 
epidemiological — was needed for a better understanding of the effects of drugs on the 
ability to drive. It was also suggested that psychomotor tests and roadside screening 
devices needed to be further developed in order to improve procedures for detecting 
impaired drivers.
The European action plan on drugs 2000–2004 reflected this need, calling for research 
into the effects of driving under the influence of illicit drugs and certain psychoactive 
substances. By 2007, a wealth of European and world research had addressed the issue 
and an update of the EMCDDA (1999) report was published. The main objectives of that 
report were to review the knowledge on driver impairment resulting from drug use from 
experimental and epidemiological studies published between 1999 and 2007, to underline 
the strengths and limitations of the different types of studies and to report on current 
levels of prevalence found in various subsets of drivers on EU roads. This literature review 
was published in 2008 as an EMCDDA Insights, Drug use, impaired driving and traffic 
accidents, (EMCDDA, 2008) and included studies from Europe, Australia, Canada and the 
United States. The report encompassed the main psychoactive substances found in 
Europe: cannabis, opioids, amphetamines, cocaine, benzodiazepines and other medicines 
(antihistamines, antidepressants) and other synthetic drugs.
At the start of the European Union’s third Road Safety Action Programme 2003–2010, it 
was estimated that about 25 % of fatalities on European roads were the result of the 
influence of alcohol, but a lack of comparable studies meant that the proportion caused by 
the effects of illicit drugs or psychoactive medicines was unknown. Non-standardised 
studies of the situation preclude any meaningful evaluation of the effectiveness of the 
various responses and countermeasures. The DRUID project was established for this 
reason, with the aim of estimating the size of the problem using harmonised data 
collection protocols established following an international expert meeting.
The DRUID project reported its results in 2011, necessitating an update of the EMCDDA’s 
2008 Insights, Drug use, impaired driving and traffic accidents. The current report is an 
update of the 2008 Insights, based on the findings of the DRUID project and the published 
literature from 2007 to the end of January 2013. The new results have been integrated 
with those presented in the 2007 report, and this publication focuses more on meta-
analyses and systematic reviews (Asbridge et al., 2012; Dassanayake et al., 2011; Elvik, 
2013; Grotenhermen et al., 2007; Li et al., 2012; Rapoport et al., 2009; Verster et al., 2006, 
2011).
Drug use, impaired driving and traffic accidents
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Chapter 1 addresses methodological issues pertaining to experimental and 
epidemiological studies on drugs and driving. Chapter 2 reviews surveys carried out in 
different parts of the world (since 2007), according to the type of drivers surveyed, and 
provides an overview of the differences found depending on, for example, the studies’ 
sample, screening and design. Chapter 3 discusses the effects and risks in terms of driving 
for each substance considered. When available, results on polydrug use and association 
with alcohol are reported.
Despite the current focus in EU Member States and by researchers on rapid roadside 
testing devices, their efficacy and effectiveness are not addressed here. Several countries 
have passed laws to allow such drug testing; however, the European Union’s roadside 
testing assessment projects (Rosita, Rosita-2 and DRUID) considered no device reliable 
enough for roadside screening, although there has been some progress in recent years 
(Verstraete, 2012).
Although the focus of the present report is drugs and driving, it should be kept in mind that 
the data from European studies clearly demonstrate that the main psychoactive substance 
endangering lives on the roads today is alcohol (EMCDDA, 2007), a fact that has been 
confirmed by the DRUID project.
A search was made in PubMed with the following medical subject heading (MeSH) 
terms or combination of these terms: ‘cannabis’; ‘tetrahydrocannabinol’; 
‘amphetamines’; ‘methamphetamines’; ‘MDMA’; ‘opiate alkaloids’; ‘morphine’; 
‘codeine’; ‘fentanyl’; ‘heroin’; ‘methadone’; ‘benzodiazepines’; ‘zopiclone’; ‘zolpidem’; 
‘zaleplon’; ‘buprenorphine’; ‘cocaine’, ‘antidepressants’; ‘antihistamines’; ‘histamine 
antagonists’; ‘histamine H1 antagonists, non-sedating’; ‘histamine H1 antagonists’; 
‘antidepressive agents’; ‘antidepressive agents, second-generation’; ‘antidepressive 
agents, tricyclic’; ‘antimanic agents’; ‘citalopram’; ‘monoamine oxidase inhibitors’; 
‘serotonin uptake inhibitors’; ‘4-butyrolactone’; ‘4-hydroxybutyric acid’; ‘accident, 
traffic’; ‘adverse effects’; ‘automobile driving’; ‘motor vehicles’.
Examples of searches used:
((((((‘Morphine’[Mesh] OR ‘Buprenorphine’[Mesh]) OR ‘Methadone’[Mesh]) OR 
‘Heroin’[Mesh]) OR ‘Fentanyl’[Mesh]) OR ‘Codeine’[Mesh]) OR ‘Tramadol’[Mesh]) AND 
(‘Automobile Driving’[Mesh] OR ‘Accidents, Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) 
AND (‘2007/01/01’[PDAT]: ‘2013/01/31’[PDAT])
(‘Histamine Antagonists’[Mesh] OR ‘Histamine H1 Antagonists, Non-Sedating’[Mesh] 
OR ‘Histamine H1 Antagonists’[Mesh]) AND (‘Automobile Driving’[Mesh] OR 
‘Accidents, Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) AND (‘2007/01/01’[PDAT]: 
‘2013/01/31’[PDAT])
((‘zolpidem’ [Supplementary Concept] OR (‘Benzodiazepines’[Mesh]) OR ‘zopiclone’ 
[Supplementary Concept]) OR ‘zaleplon’ [Supplementary Concept]) AND 
(‘Automobile Driving’[Mesh] OR ‘Accidents, Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) 
AND (‘2007/01/01’[PDAT]: ‘2013/01/31’[PDAT])
How studies were selected for this report
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((‘Antidepressive Agents’[Mesh] OR ‘Antidepressive Agents, Second-
Generation’[Mesh] OR ‘Antidepressive Agents, Tricyclic’[Mesh] OR ‘Antimanic 
Agents’[Mesh] OR ‘Citalopram’[Mesh] OR ‘Monoamine Oxidase Inhibitors’[Mesh]) OR 
‘Serotonin Uptake Inhibitors’[Mesh]) AND (‘Automobile Driving’[Mesh] OR ‘Accidents, 
Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) AND (‘2007/01/01’[PDAT]: 
‘2013/01/31’[PDAT])
(((‘Methamphetamine’[Mesh]) OR ‘Amphetamine’[Mesh]) OR  
‘N-Methyl-3,4-methylenedioxyamphetamine’[Mesh]) AND (‘Automobile Driving’[Mesh] 
OR ‘Accidents, Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) AND (‘2007/01/01’[PDAT]: 
‘2013/01/31’[PDAT])
(‘Cocaine’[Mesh]) AND (‘Automobile Driving’[Mesh] OR ‘Accidents, Traffic’[Mesh] OR 
‘Motor Vehicles’[Mesh]) AND (‘2007/01/01’[PDAT]: ‘2013/01/31’[PDAT])
(‘4-Butyrolactone’[Mesh] OR ‘4-hydroxybutyric acid’ [Supplementary Concept]) AND 
(‘Automobile Driving’[Mesh] OR ‘Accidents, Traffic’[Mesh] OR ‘Motor Vehicles’[Mesh]) 
AND (‘2007/01/01’[PDAT]: ‘2013/01/31’[PDAT])
Only the references published since the writing of the EMCDDA Insights on Drug use, 
impaired driving and traffic incidents (EMCDDA, 2008) and those relevant for the 
updating of the report were taken into consideration.
1
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Several methods are used to study driving under the 
influence of drugs. These can be largely divided into two 
groups, namely experimental and epidemiological 
studies. The methodology used in the various types of 
experimental and epidemiological studies, possible 
problems associated with these different methodologies 
and recent proposals will be described in this chapter.
I Experimental studies
In experimental studies, the drug under study is 
administered in different doses to volunteers and the 
effects on performance are measured and compared 
with those resulting from administration of a placebo or 
a positive control (e.g. alcohol). The performance of the 
volunteers can be evaluated using tests that assess 
various psychomotor and cognitive functions, tests in a 
driving simulator or ‘real’ driving tests.
Although experimental studies can provide invaluable 
information, the reader should be aware of their 
limitations:
n  Often the potency of the drug administered is lower 
than that of the same drug used on the street. For 
example, in performance studies of cannabis, 
low-potency cannabis with a maximum Δ9-
tetrahydrocannabinol (THC) content of 4 % is 
traditionally used. Ramaekers et al. (2006a) showed 
that high-potency cannabis (13 % THC) diminishes 
additional cognitive functions and has a more 
pronounced effect on performance than the low-
potency cannabis used in previous studies. The 
concentration of THC in cannabis can be higher than 
20 or 30 years ago because of new cultivation 
techniques (EMCDDA, 2004). This underlines the 
importance of using realistic doses to estimate the 
effects of drugs in real life.
n  The route of administration can influence the results. 
For example, Higgins et al. (1990) found that 
intranasally administered cocaine improved 
performance on the digit symbol substitution test 
(DSST), while Rush et al. (1999) found no such 
effects with orally administered cocaine.
n  Results are dependent on the delay between drug 
consumption and performance of the task. 
Dextroamphetamine (1) administered 3–4 hours 
before a movement estimation task has no effect on 
performance of the task (Silber et al., 2006), while 
MDMA administered 4–5 hours before the task 
impairs performance (Lamers et al., 2003). Other 
possible causes of discrepancies in results in these 
studies could include differences in drug type, dose 
and task.
n  The results of experimental studies assessing acute 
effects of drugs among recreational drug users may 
be influenced by the subjects’ drug use history. For 
example, Rush et al. (1999) found that oral cocaine 
had no effect on performance on the DSST, while two 
previous studies found that performance was 
improved. However, the subjects in both previous 
studies reported substantially less cocaine use than 
the subjects used by Rush et al. (1999), who 
suggested that their subjects were perhaps tolerant 
to the performance-improving effects of cocaine.
n  The sensitivity of experimental studies to detect drug 
effects on performance may be reduced by inter-
individual differences in a between-subject paradigm. 
This can be countered by using a within-subject 
design, comparing each subject’s postdrug 
performance with their pre-test baseline 
(1) Dextroamphetamine, also known as dexamphetamine, is the d form of 
amphetamine (the new terminology refers to the S-form). See 
http://www.emcdda.europa.eu/publications/drug-profiles/amphetamine
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two or more simultaneous processes and to respond 
appropriately to specific stimuli.
n  Auditory, time and visual perception: these tests 
assess perception ability. An example of an auditory 
test is the auditory discrimination test: a series of 
pairs of auditory tones is presented to the subject, 
who must indicate whether the second tone is higher 
or lower than the first. Time perception can be 
estimated by asking the volunteers to estimate the 
duration of a certain time interval. An example of a 
visual test is the assessment of visual acuity: the 
subject is shown a series of test patterns of 
increasing complexity or decreasing size and is asked 
to identify or discriminate between the patterns while 
distance, lighting conditions or degree of contrast 
may be varied.
n  Information processing: these tests assess the ability 
of the volunteers to solve problems or to make 
decisions.
n  Logical reasoning: a series of simple sentences, such 
as ‘Birds grow on trees’, is presented and the subject 
must indicate whether each statement is true or 
false.
n  Memory: subjects’ memory functioning (long- or 
short-term), such as delayed recall, episodic memory 
or working memory, is assessed.
n  Vigilance: this task generally uses an electronic 
device that presents a visual stimulus moving in a 
rather monotonous pattern on a screen. The subject 
must observe and report deviations in this pattern 
over a prolonged period of time without feedback 
from the apparatus. An auditory pattern of signals 
may be used instead of a visual stimulus.
Cognitive tests specifically used in assessing the effects 
of a psychoactive substance on the ability to drive 
include:
n  Benton visual retention test (BVRT): this assesses 
visual perception, visual memory and visual 
constructive abilities.
n  Critical flicker fusion (CFF): the subject is asked to 
view one or more lights on a computer screen or 
electronic apparatus and to indicate whether the light 
appears to be flickering or is continuous. The rate of 
flicker is constantly increased or decreased, and the 
frequency of the subject’s discriminative threshold is 
recorded.
performance (Swerdlow et al., 2003). Mattay et al. 
(2000) showed that, in healthy subjects, the 
behavioural and neurophysiological effects of 
dextroamphetamine are not homogeneous because 
of genetic variation and differences in baseline 
cognitive capacity.
n  Experimental studies can identify only potential risks. 
The risk demonstrated in the experiment may not 
necessarily occur in real road traffic. The risk seen in 
a study might be qualitatively so small that it does not 
result in a crash, or it might be so severe that the 
subjects feel so impaired that they do not drive 
(Berghaus et al., 2007).
n  Some limitations are inherent to a specific type of 
experimental study: performance tests, driving 
simulator tests and ‘real’ driving tests. These are 
described below.
The advantage of experimental research is that it offers 
the chance to work on far more differentiated questions 
and less frequently occurring risk factors than 
epidemiological research. Another advantage is that, 
with an adequate design, experiments can focus on a 
single causative factor, which is not the case for 
epidemiological research (Berghaus et al., 2007).
I Performance tests
Subjects’ performance may be evaluated with tests 
performed in a laboratory setting. These laboratory tests 
are intended to measure specific skills and abilities that 
are involved in driving. Several publications have 
reviewed the available tests (Baselt, 2001; Ferrara et al., 
1994; Irving and Jones, 1992). The tests that are most 
often used can be divided into five major groups: 
cognitive, psychomotor, impulsivity, physiological and 
subjective evaluations.
Cognitive tests
Cognition is the conscious process of knowing or being 
aware of thoughts or perceptions, including 
understanding and reasoning. Cognitive tests can 
assess a variety of cognitive functions:
n  Attention: these tests can be subdivided into simple 
and divided attention tasks. In a simple attention 
task, the subject is asked to monitor one process and 
to respond appropriately to specific stimuli. In a 
divided attention task, the subject is asked to monitor 
CHAPTER 1 I Methodological issues in determining the relationship between drug consumption, impaired driving and traffic accidents
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n  Mini-mental state examination (MMSE): this is a tool 
for measuring global cognitive function. It is an 
11-question measure that tests orientation, 
registration, attention, calculation, recall and 
language. The maximum score is 30. A score of 23 or 
lower is indicative of cognitive impairment. The 
MMSE takes only 5–10 minutes to administer and is 
therefore practical to use repeatedly and routinely.
n  Paced auditory serial addition task (PASAT): this 
measures working memory. It requires addition of 
simple digits presented verbally in a series with a 
successively higher pace of presentation. The task 
reflects the capacity for divided attention, is a 
measure of information processing speed and 
appears to be sensitive to minor attention deficits.
n  Rapid visual information processing task (RVIPT): 
this is a test of sustained attention, during which 
single digits are presented in quick succession (100 
or 200 digits per minute) on a computer screen. 
When target sequences of numbers are be identified, 
the subject presses a button.
n  Repeated acquisition task: the subject is given the 
opportunity in a series of trials to learn the 
appropriate responses to a collection of images. 
Following a specific interval, the subject is then 
tested on his or her ability to recall the previously 
acquired responses.
n  Sternberg test: this test explores short-term memory 
and working memory. A series of two to six numbers 
is presented to the subject, followed immediately by a 
target number. The subject indicates as rapidly as 
possible whether the target number was part of the 
list to be memorised.
n  Stroop word/colour test: the subject is asked to 
depress one of four keys labelled with a different 
colour in response to a stimulus. The stimulus is 
the name of one of the four colours or of a non-
represented colour or does not represent a colour 
at all.
n  Time wall test: during this test of time estimation, 
subjects observe a brick descending from the top of 
the computer screen at a constant rate towards a 
target at the bottom of the screen. The target 
disappears behind a brick wall about two-thirds of the 
way down the screen. The subject responds by 
pressing a designated key at the exact time that he or 
she estimates the object contacts the target.
n  Digit symbol substitution test (DSST): the subject is 
shown a code sheet containing a series of numbers 
assigned to a series of symbols. Afterwards, the 
subject is shown the symbols in random order and is 
asked to assign the corresponding number. During 
repetitions of the task, the pattern of the digit–
symbol pairings is usually scrambled.
n  Hopkins verbal learning test: the subject repeats as 
many words as he or she can recall from a list of 
words that was read by the instructor. Afterwards, the 
instructor reads another list of words and the subject 
has to respond with ‘yes’ if the word was on the first 
list and ‘no’ if it was not.
n  Learning memory task (LMT): a list of 21 simple, 
concrete and familiar words must be learned in four 
attempts. The words are presented on a computer 
screen in lower-case letters at a rate of one word 
every 500 milliseconds, without any gaps between 
stimuli. The words are presented in a different order 
at each attempt. At the end of each presentation, the 
subject makes an immediate free recall. The subject 
is asked for a delayed free recall of the words for 1.5 
minutes, about 1 hour after learning.
n  Letter cancellation test: the subject is given a page 
filled with random letters and is asked to strike 
through one or more specific target letters whenever 
they appear (Figure 1).
FIGURE 1
Four examples of a letter cancellation task
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directions over a specified period of time using some 
type of metering device, such as an electronic 
platform.
n  Motor coordination: the finger-tapping test (FTT) 
assesses motor speed and motor control. Other tests 
assess the motor response of volunteers to a certain 
visual or auditory stimulus:
–  The circular lights task (CLT) typically employs an 
electronic device with a series of 10–20 lights 
arranged in a circular pattern. The lights are 
illuminated in random order, and the subject must 
trigger a switch corresponding to that light.
–  The grooved pegboard test is a manual dexterity 
test consisting of a board containing holes with 
randomly positioned slots. Pegs with a key along 
one side must be rotated to match the hole before 
they can be inserted.
–  During the trail-making test (TMT), the subject is 
shown a page containing jumbled numbers or 
letters, and is asked to connect the numbers in 
numerical sequence or the letters in alphabetical 
sequence. Accuracy and time to complete the task 
are assessed.
–  During the simplest form of a tracking task, the 
subject is asked to control the position of a light 
bar on a screen using a hand-operated device. 
More sophisticated versions involve variable speed 
control of the visual stimulus and/or a 
computerised representation of a vehicle moving 
along a road. For example, during the critical 
tracking test (CTT), the subject is asked to control 
the position of a light bar on a display screen using 
a steering wheel or joystick. The instability of the 
bar gradually increases until the subject reaches a 
threshold of ability to control its position. In the 
compensatory tracking test, subjects are also 
required to track a moving arrow on a visual display 
unit, but in addition a peripheral awareness task is 
included in which the subject responds to a 
stimulus presented in the periphery of vision while 
simultaneously attending to the tracking test.
n  Reaction time: Several tests exist to measure 
psychomotor speed:
–  The simple reaction time (SRT) is the interval 
elapsing between the brain receiving a sensory 
impression (visual, auditory or somatosensory) 
and the execution of a movement in response to 
that impression.
n  Tower of London task: this measures planning 
function. The subject is asked to plan mentally a 
sequence of moves to match a start set of discs to a 
goal, and then to execute the moves one by one 
(Figure 2).
n  Wechsler adult intelligence scale (WAIS): this is a 
comprehensive test of cognitive ability for adults — a 
general test of intelligence. It is made up of 14 
subtests, comprising verbal (seven subtests: 
information, comprehension, arithmetic, similarities, 
vocabulary, digit span, letter–number sequencing) 
and performance scales (seven subtests: picture 
completion, digit symbol-coding, block design, matrix 
reasoning, picture arrangement, symbol search, 
object assembly).
n  Wisconsin card sorting test (WCST): this measures 
abstract conceptual skills, cognitive flexibility and 
ability to test hypotheses, and utilises error feedback. 
The subject sorts 128 cards that depict coloured, 
numbered shapes into four categories using accuracy 
feedback given after each trial. The criterion for 
correct categorisation changes whenever 10 
consecutive cards are sorted correctly.
Psychomotor tests
Psychomotor tests assess movements that are 
generated by stimulation of certain parts of the brain.
n  Body sway: measurements of body movement of the 
subject with or without his or her eyes closed are 
usually taken in both the lateral and sagittal 
FIGURE 2
A Tower of London test
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of cards picked from C and D minus the total 
number of cards picked from A and B).
Physiological measurements
The parameters that can be assessed include eye 
movements, pupillary response (miosis, mydriasis), 
pulse, blood pressure and tunnel vision. 
Electroencephalography (EEG) can also be used. The 
Maddox wing device is sometimes used to measure the 
balance of the extraocular muscles; it quantifies 
exophoria as an indicator of extraocular muscle 
relaxation and esophoria as an indicator of extraocular 
muscle tension.
Subjective evaluations
In some experimental studies the subjects report their 
own observations on visual analogue scales. These 
scales measure a characteristic or attitude that is 
believed to range across a continuum of values. Visual 
analogue scales can be indicative of both pleasant (e.g. 
drug liking, increased calmness) and unpleasant (e.g. 
‘feel bad’, ‘nauseous’, sedation, pain) effects of a drug. 
The line analogue rating scale (LARS) consists of 10-cm 
line analogue scales on which the subjects indicate their 
present feeling (concerning sedation) relative to a 
mid-point that represents their normal state of mind 
before treatment was started (Figure 3). Another 
example is the Stanford sleepiness scale, a seven-level 
measurement in which subjects select a specific 
statement best describing their state of sleepiness.
There are limitations inherent to studies that use 
performance tests. First, these tests measure only a part 
of the performance needed to complete a task and do 
not cover driving ability as a whole. Second, the 
selection of specific tests can influence the results of 
the study. For example, when the effect of the 
combination of cannabis and alcohol is studied, some 
studies find an additive or even synergistic effect, while 
other studies find the opposite. Liguori et al. (2002) 
–  In a choice reaction time (CRT) task, a series of 
stimuli, which may be auditory and/or visual, is 
presented to the subject using an electronic 
apparatus or a computer screen. The subject is 
instructed to respond appropriately and rapidly 
through hand or foot movements to preselected 
signals. The test may include disturbance signals 
to distract the subject, and it may involve two or 
more simultaneous tasks. The subject is graded on 
speed and accuracy. Three components of 
reaction time are measured: the motor reaction 
time (MRT) between the start and response 
buttons, the total reaction time (TRT) from 
stimulus onset to completion of response and the 
processing or recognition reaction time (RRT), 
obtained by subtracting the MRT from the TRT.
–  A go/no go task can be used to assess reaction 
time instead of impulsivity (see below).
–  The serial reaction time task produces sequence 
learning through repetition of uncued and 
unannounced serially ordered stimuli. Learning is 
assessed by observing a deterioration in task 
performance when a random sequence replaces a 
regularly repeating sequence.
Impulsivity tests
Some performance tasks are behavioural measures of 
impulsivity:
n  In a go/no go task or a stop signal task, the subject is 
asked to respond to one particular event (e.g. a red 
colour or a horn sound) but ignore other events (e.g. a 
blue colour or a rooster sound).
n  The Iowa gambling task measures decision-making 
and risk sensitivity as defined by the inability to 
anticipate and reflect on the consequences of 
decision-making. The subject sees four decks of 
cards on a computer screen labelled A, B, C and D. 
The gains and losses for each card selection are set 
so that in each block of 10 cards from deck A or B 
over the course of the trials there is a total gain of 
USD 1 000, interspersed with unpredictable losses 
totalling USD 1 250. For decks C and D, the gains 
and losses for each card selection are set so that in 
each block of 10 cards there is a total gain of 
USD 500, interrupted by losses totalling USD 250. 
Thus, decks A and B are ‘disadvantageous’ in the 
long term whereas decks C and D are 
‘advantageous’. One dependent measure is 
collected from this task: net score (the total number 
FIGURE 3
A visual analogue scale for the subjective feeling of 
‘high’
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of ‘high’
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n  Pulling-out events: these are situations where a car 
pulls out in front of the driver’s car. The driver takes 
avoiding action that can be detected and a reaction 
time is estimated.
n  Braking events: these events are controlled in a 
similar way to pulling-out events, except that the 
trigger vehicle brakes at a certain distance from the 
driver’s car.
The test that best assesses the effects of using a 
psychoactive substance on driving performance is a 
‘real’ driving test. The test can be performed in the 
presence or absence of normal traffic, but one 
disadvantage is the necessity of taking traffic safety into 
consideration. A ‘real’ driving test can be more sensitive 
than laboratory tests in assessing impairment of driving 
ability. For example, Veldhuijzen et al. (2006a) evaluated 
the effect of chronic non-malignant pain on driving 
performance. An on-the-road driving test showed 
significant differences in driving performance between 
drivers with chronic pain and drivers with no chronic 
pain, whereas laboratory tests did not.
The outcome measures used to assess performance 
during a driving simulation test or a ‘real’ driving test 
include (de Waard et al., 2000; Ramaekers et al., 2004; 
Sexton et al., 2000; Veldhuijzen et al., 2006a):
n  Standard deviation of the lateral position (SDLP): this 
parameter measures the extent to which the car 
‘weaves’ within a traffic lane. It is reasonable to 
assume that SDLP represents overall highway driving 
ability since it encompasses several levels of 
information processing which are combined in an 
integrated driving model. For example, whereas basic 
vehicle control, such as road tracking, involves 
automatic or effortless performance, negotiation of 
common driving situations, such as curves, 
intersections and gap acceptance, requires 
controlled processing and thus more effort. In 
addition, the test measures motivational aspects, 
such as the risks subjects are willing to take, and 
subjects’ ability to evaluate risk. As SDLP increments 
ultimately result in lane crossing into the adjacent 
traffic lane, it can be regarded as an index of driving 
safety. Sexton et al. (2000) showed that SDLP in the 
road-tracking test was the most sensitive measure of 
the adverse effects of THC on driving ability.
n  Standard deviation of speed.
n  Mean speed.
n  Mean lateral position.
found no significant additive effects of alcohol and 
cannabis on brake latency. According to the authors, this 
might have been because of the use of reaction time as 
the key dependent variable, as several other studies 
found additive or multiplicative cannabis and alcohol 
effects on other aspects of performance, such as visual 
search and road tracking (Lamers and Ramaekers, 2001; 
Sexton et al., 2002). Ramaekers et al. (2006a) found that 
THC use did not affect performance on the Iowa 
gambling task; however, the sensitivity of this task to 
acute drug effects may be low as the task was never 
specifically designed for this purpose.
I Driving simulator and ‘real’ driving tests
Driving performance can be evaluated using tests in a 
driving simulator or ‘real’ driving tests. In a driving 
simulator, subjects perform a computer simulation of a 
driving task. Hoffman and Buld (2006) described and 
evaluated the design of a driving simulator. The main 
advantages of driving simulation are that driving tasks 
can be standardised and data can be obtained safely. 
However, because a real environment can never be fully 
replicated in a simulator, subjects must compensate for 
the incomplete driving environment, delays and 
distortions in the graphics and for having to act in two 
different worlds. Since this often cannot be achieved 
immediately, subjects need a dry run to learn how the 
simulator works. A major problem during dry runs is 
so-called ‘simulator sickness’: nausea that can be mild to 
severe and lasts a few minutes to several hours, possibly 
resulting in inadequate driving behaviour, whether 
consciously or not. As a consequence, both the internal 
and the external validity are limited and the acceptance 
of the method itself is likely to decrease. Experience 
shows that repeated exposure to the simulator situation 
usually reduces physical discomfort; however, empirical 
studies are very rare. Equally detailed information 
concerning dry runs is not consistently given in studies 
using driving simulation, and, if so, the dry runs may vary 
in length from 5 minutes to several hours. Commonly 
used guidelines do not exist. Hoffmann and Buld (2006) 
assessed the effectiveness of a training programme, 
consisting of a familiarisation phase followed by special 
exercises (braking, accelerating, steering, driving on a 
motorway, turning at intersections and a final driving 
test), in reducing dropout rate. They found that without 
the simulator training programme the dropout rate as a 
result of nausea was quite high, whereas no subject who 
received training dropped out. The authors concluded 
that extensive training is necessary to be able to drive 
satisfactorily in a simulator. Several situations can be 
simulated, including (Sexton et al., 2002):
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gender. One study which reported results of drivers 
who were killed in traffic accidents in France included 
only drivers under the age of 30 years and found a 
much higher proportion of cannabis-positive samples 
than other similar studies (Mura et al., 2006).
n  The time at which the studies are performed can 
differ. Not only can the year in which samples are 
collected differ, but so can the day of the week. 
Studies conducted on weekend nights find higher 
percentages of drug-positive drivers than studies 
conducted over the whole week (Mathijssen, 1999).
n  Biological samples are analysed for different types of 
psychoactive substances. For example, for 
benzodiazepines, opioids and amphetamines, 
prevalence results can depend upon the number and 
types of substances that are searched for in the 
samples. In Norway, a study assessing 
benzodiazepines in drivers suspected of driving 
under the influence of drugs reported only the 
percentage of samples that were positive for 
diazepam and flunitrazepam (Christophersen, 2000), 
while in a study in Switzerland the samples were 
analysed for diazepam, desmethyldiazepam, 
midazolam, oxazepam and lorazepam (Augsburger et 
al., 2005). For cannabis detection, some studies test 
only for the presence of THC, while others test for the 
THC metabolites THC-COOH (11-nor-Δ9-
tetrahydrocannabinol-9-carboxylic acid) or 11-OH-
THC (11-hydroxy-Δ9-tetrahydrocannabinol) or for 
several metabolites. As the detection time of these 
metabolites differs, the choice of the substances 
tested for can influence the results of the study 
(Verstraete, 2004).
n  Different types of biological samples are used, with 
varying detection times. The use of urine samples can 
pose some problems. As the metabolites of cannabis 
can be detected in urine for a relatively long period of 
time following consumption, their presence in urine 
does not necessarily mean that the subject was 
under the influence of the drug at the time of 
sampling; this can lead to different results from when 
blood or saliva is sampled (Verstraete, 2004). It is 
important to have ‘equivalent’ cut-offs for different 
types of samples to ensure that measurements of 
drug prevalence based on samples of blood and oral 
fluid taken simultaneously are comparable (Gjerde 
and Verstraete, 2010, 2011).
n  Different analytical techniques are used to analyse 
the samples, with different limits of detection and 
quantification.
n  Car following: in a ‘real’ driving test, the subject may 
be asked to follow a car driven by the investigator.
n  Brake reaction time (BRT).
n  Gap acceptance: this parameter measures whether 
or not judgement is impaired.
n  Accident involvement.
I Epidemiological studies
Epidemiological studies on drugs and driving examine 
the prevalence of drug use in various driving populations. 
Some studies investigate the prevalence of drug use in 
the general driving population, while others focus on 
certain subpopulations, such as persons admitted to a 
hospital emergency department. By comparing the 
prevalence of a certain drug among the general driving 
population with the prevalence among persons admitted 
to an emergency department, an estimation can be 
made of the risk of injury as the result of a traffic 
accident while under the influence of a certain drug: 
these figures indicate whether a person under the 
influence of the drug has a higher risk than a sober 
person of being injured in a traffic accident. 
Responsibility studies calculate the risk of being 
responsible for a traffic accident while driving under the 
influence of a drug.
The prevalence of drugs in various populations can be 
assessed by analysing biological samples of the involved 
subjects, or by conducting surveys or 
pharmacoepidemiological studies.
Epidemiological research is, however, limited because 
there may be risk factors associated with drug use that 
do not emerge from the study findings. This may be 
because the appropriate study design (e.g. a long-term 
study or a multicentre study) is difficult to put into place 
from a methodological point of view (because of a 
change in screening methods, lack of homogeneity of 
data, etc.). Another disadvantage of epidemiological 
research is that it is not able to distinguish between a 
‘real’ risk factor and other factors that may be highly 
correlated with the risk factor (Berghaus et al., 2007).
Epidemiological studies are also difficult to compare 
with each other because of several kinds of differences 
among them, such as the following:
n  The sample populations are different. They can differ 
in several sociodemographic factors, such as age and 
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administration during emergency care or 
resuscitation efforts.
n  Drivers involved in a traffic accident: samples are 
collected from all drivers who were involved in a 
traffic accident. In some studies, only fatal accidents 
are included.
n  Drivers suspected of driving under the influence of 
drugs: the methodology of these studies can vary in 
several ways, as the testing procedure varies by 
country. For example, in some countries a field 
sobriety test is used, while in others it is not. This field 
sobriety test can consist of different tests, and 
various on-site drug screening tests can be used.
n  Drivers suspected of driving under the influence of 
alcohol: in these ‘re-analysis’ studies, samples that 
were initially collected for alcohol detection are later 
tested for the presence of drugs, medicines and 
alcohol.
Thus, studies that try to assess the prevalence of 
psychoactive substances in drivers who were injured or 
killed in a traffic accident must be able to determine 
whether positive test results for medicines are due to 
pre-injury use or administration of medicines after 
admission.
I Surveys
Surveys about driving under the influence of drugs, 
medicines and/or alcohol are conducted over the 
telephone or in face-to-face interviews. Examples of 
questions asked are ‘Have you ever driven a vehicle 
under the influence of alcohol or drugs?’, ‘Have you ever 
driven a vehicle shortly after the use of alcohol or 
drugs?’, ‘Have you ever been involved in an accident 
while under the influence of alcohol or drugs?’, etc. 
Some surveys include the general driving population, 
while others focus on a subpopulation such as young 
drivers or drug users. Information gathered in surveys 
should, however, be interpreted in the light of several 
limitations. Subjects may, for example, be unwilling to 
divulge certain information, misunderstand the 
questions or forget events (McGwin et al., 2000).
I Accident risk analyses
The accident risk associated with the use of drugs, 
medicines and/or alcohol can be assessed by comparing 
their prevalence among the general driving population 
n  Different cut-off levels are used. For alcohol 
detection, for example, the cut-off level used to define 
a positive sample can range from 0.1 g/l (Logan, 
2005; Logan and Schwilke, 2004; Plaut and Staub, 
2000) to 0.8 g/l (Assum et al., 2005; Brault et al., 
2004; del Rio et al., 2002; Longo et al., 2000a).
In what follows, the methodology and limitations of the 
various types of epidemiological studies are described.
I Roadside surveys
Roadside surveys investigate the prevalence of 
psychoactive substances among the general driving 
population. Drivers are randomly stopped and tested for 
the presence of alcohol, drugs and/or certain medicines 
in their body.
The results of these studies become more representative 
for the general driving population as the number of 
included drivers increases. Some studies try to make the 
results more representative by weighting them 
according to traffic flow (Assum et al., 2005). The study 
design can greatly influence the results. In addition, 
roadside surveys are expensive to conduct, as a large 
number of drivers need to be screened. Moreover, this 
type of epidemiological study cannot be conducted in 
every country as there may be legal obstacles to 
screening drivers without suspicion.
I Subsets of drivers
Epidemiological studies may also look at only a subset of 
drivers, rather than the general driving population:
n  Injured drivers: biological samples are collected from 
drivers admitted to hospital over a given period of 
time, and analysed in order to assess the involvement 
of drugs, medicines and/or alcohol in accidents. 
These studies should take into consideration the 
possibility that certain medications, particularly 
benzodiazepines and opioids, may have been 
administered at the crash site or in hospital before 
the samples were taken.
n  Drivers killed in accidents: for these epidemiological 
studies, the involvement of drugs, medicines and/or 
alcohol in fatal accidents is assessed using samples 
from drivers who were killed in a traffic accident. 
Here, too, there is a need to determine whether 
positive test results for medicines were because of 
initial use by the driver or a result of therapeutic 
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Ramaekers (2003a) discusses two possible pitfalls in 
estimating drug-related crash risk. First, a case–control 
analysis does not necessarily take into account the 
effects of dose or treatment duration when estimating 
the crash risk following medicine use. The possibility 
therefore exists that the failure to find a positive 
association between, for example, the use of tricyclic 
antidepressants (TCAs) and accidents may merely 
reflect the occurrence of tolerance in drivers after 
prolonged treatment, while a positive association might 
have been found in drivers who were just starting 
antidepressant treatment. Second, the study’s statistical 
power may be insufficient to detect significant 
proportional differences, as the prevalence rates of 
drugs in the samples under study are mostly low and 
sample sizes are limited.
Lenguerrand et al. (2008) studied the disparities 
between the quasi-induced exposure (QIE) method and 
a standard case–control approach with crash 
responsibility as variable of interest, based on the 
Stupéfiants et Accidents Mortels [Illicit Drugs and Fatal 
Crashes] (SAM) study. The QIE method selects only 
‘clean crashes’, i.e. two-vehicle crashes in which one 
driver is declared entirely responsible and the other 
entirely not responsible. Drivers who are identified as 
‘not responsible’ are assumed to be passively crash 
involved and to have been randomly ‘selected’ by 
‘responsible’ drivers from among the driver population. 
The prevalence of a given risk factor among not-
responsible drivers is assumed to be a good proxy for its 
prevalence among the whole driver population present 
at the times and locations of crashes (2). While both 
approaches found that being under the influence of 
alcohol or cannabis increased the risk of drivers causing 
a fatal crash, the two approaches were not equivalent. 
They differ mainly with regards to the driver sample 
selected. The QIE method results in the overall road 
safety issue being split into two substudies: a matched 
case–control study dealing with two-vehicle crashes 
and a case–control study dealing with single-vehicle 
crashes but with a specific control group. The standard 
case–control approach studies drivers involved in all 
type of crashes whatever the distribution of the 
responsibility in each crash. This method, also known as 
‘responsibility analysis’ (see the following subsection), is 
the most relevant for assessing the overall road safety 
implications of a driver characteristic.
(2) The SAM study is a population-based case–control study that 
analysed more than 17 000 accidents and almost 11 000 drivers involved 
in fatal accidents between September 2001 and September 2003 in 
France. It was based on a quasi-exhaustive sample of road accidents (all 
the instantly fatal accidents that took place during the 2 years studied) 
and included drivers who were killed, injured or unhurt.
(controls) with the prevalence among drivers who were 
injured, killed or involved in a traffic accident (cases).
The accident risk can be expressed in various ways, such 
as an odds ratio (OR) or relative risk (RR). ORs and RRs 
are calculated as follows, assuming that the data are 
available as in Table 1:
 a c + d
RR = ———— x ————
 a + b c
 a d
OR = —— x ——
 c b
Mostly, data for the control group (b + d) are collected 
using roadside surveys. Some studies use a different 
methodology, for example using samples from drivers 
who were hospitalised for reasons other than a traffic 
accident as control samples (Mura et al., 2003). Other 
studies may use questionnaire survey results rather than 
biological sample analysis to calculate accident risks 
(Asbridge et al., 2005; Blows et al., 2005; Fergusson and 
Horwood, 2001; Gerberich et al., 2003; Jones et al., 
2005; Wadsworth et al., 2006).
One limitation of using questionnaire data to calculate 
accident risk is a possible underestimation of the 
prevalence, while with biological sample collection there 
may be a high percentage of refusals. As most of the 
substances under investigation are illicit, potential 
control subjects who are users are more likely than 
non-users to refuse to supply a sample. This would result 
in bias of the results by showing a stronger positive 
association between the drug and crash risk than is 
really the case. As, generally, the proportion of non-crash 
drivers who test positive for drugs is likely to be small, 
even a relatively small proportion of potential control 
subjects who do not supply a sample would throw study 
results into serious doubt (Bates and Blakely, 1999). Van 
der Linden et al. (2012) found that subjects who gave an 
oral fluid sample but refused to give a blood sample 
were three times more likely to test positive for drugs.
TABLE 1
Symbolic presentation of the data used to calculate 
accident risks
Drugs
Accident
Yes No Total
Yes a b a + b
No c d c + d
Total a + c b + d n
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non-fatally injured drivers, the percentage of drug-
free drivers judged responsible for the crash was 
53 % (Longo et al., 2000b) and 48 % (Lowenstein and 
Koziol-McLain, 2001), while it was 71 % in a study of 
fatally injured drivers (Drummer et al., 2004).
I Pharmacoepidemiological studies
Pharmacoepidemiological studies compare the 
involvement in traffic accidents of drivers using a certain 
medication with that of a control group not using the 
medication, in order to assess the driving risks 
associated with medication use. Most of these types of 
studies gather information through databases, such as 
prescription records, police reports, health insurance 
records and databases from hospitals, but some studies 
gather information in another way, by interviewing 
people, for example. McGwin et al. (2000) used the 
following methodology to evaluate the association 
between elderly drivers’ medication use and their risk of 
responsibility for an accident. A total of 901 drivers aged 
65 years and older were selected from the Alabama 
Department of Public Safety driving records, including 
244 at-fault drivers involved in crashes, 182 not-at-fault 
drivers involved in crashes and 475 drivers not involved 
in crashes. Information on demographic factors, chronic 
medical conditions, medications used, driving habits, 
visual function and cognitive status was collected by 
telephone interview. Frequency distributions were 
calculated for subjects involved in and those not 
involved in crashes, and crude ORs and 95 % confidence 
intervals (CIs) were computed for the use of different 
types of medicines. The results showed the various 
accident risks associated with the use of different 
medications.
Several possible limitations are inherent to 
pharmacoepidemiological studies:
n  The use of databases as a source of information can 
be a limitation. For example, not all traffic accidents 
are reported to the police, which can lead to an 
underestimation of accident rates in the studied 
population when using police reports (Barbone et al., 
1998). In addition, databases do not contain all 
possible information on other risk factors, such as 
alcohol use (Neutel, 1998).
n  Bias might result from the subjects’ patterns of 
medication use, such as non-compliance, or irregular 
as opposed to continuous use (Hemmelgarn et al., 
1997).
Houwing et al. (2013) studied the origin of the variation 
between the ORs calculated in the different countries in 
the Driving under the Influence of Drugs, Alcohol and 
Medicine (DRUID) project. Differences between the ORs 
in the DRUID case–control studies were (partially) 
explained by random and systematic errors. Selection 
bias and errors as a result of small sample sizes and 
small numbers in some categories were the most 
frequently observed errors in the six DRUID case–
control studies. Therefore, Houwing et al. recommended 
that epidemiological studies that assess the risk of 
psychoactive substances in traffic pay specific attention 
to avoid these potential sources of random and 
systematic errors.
I Responsibility analyses
Responsibility analyses investigate whether there is an 
association between driving under the influence of 
drugs, medicines and/or alcohol and responsibility for a 
traffic accident. The prevalence of these substances 
among drivers who were responsible for a traffic 
accident (cases) is compared with the prevalence 
among drivers who were involved in, but not responsible 
for, a traffic accident (controls).
There are a number of limitations to responsibility 
analyses:
n  In some cases, the true source of the responsibility 
can be misjudged, and this might cause a 
misclassification bias, which may lead to an 
underestimation of the real relative risk (Dussault et 
al., 2002).
n  The control group consists mostly of crash-involved 
but ‘not responsible’ drivers. Some of the drivers who 
were judged ‘not responsible’ may, in fact, have borne 
some responsibility, as they failed to avoid the crash. 
The ideal control group would consist of drivers who 
were not involved in crashes but who were on the 
road under similar circumstances of time and place 
(Lowenstein and Koziol-McLain, 2001).
n  A major limitation when fatally injured drivers are 
included is the high percentage of responsible drivers 
among the drug-free group. This high baseline figure 
means that it is difficult to find statistically significant 
differences between drug-free and drug-positive 
drivers with respect to their level of responsibility. 
One of the benefits of using non-fatally injured drivers 
is that the percentage of drug-free drivers judged 
responsible for the crash is generally much lower 
(Longo et al., 2000b). For example, in two studies of 
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studies’ squares to represent the uncertainty of the 
estimate of the treatment effect. The aggregate effect 
size, obtained by combining all the studies, is usually 
displayed as a diamond.
Assessments of the quality of systematic reviews and 
meta-analyses often identify limitations in the ways in 
which they were conducted. Flaws in meta-analyses can 
arise through failure to conduct any of the steps in data 
collection, analysis and presentation described above. 
To summarise the qualities of a robust meta-analysis:
n  The search strategy should be comprehensive and 
likely to avoid bias in the studies identified for 
inclusion.
n  The publication should be bias assessed.
n  The quality of the individual studies should be 
assessed against an appropriate checklist of criteria.
n  The combined effect size should be calculated using 
appropriate statistical methods.
n  Heterogeneity should be considered and tested for.
Meta-analyses offer a systematic and quantitative 
approach to synthesising evidence to answer important 
questions. Nonetheless, pitfalls abound in the execution 
of meta-analyses and they are fundamentally limited by 
the quality of the underlying studies (Crombie and 
Davies, 2009).
I Conclusion
There are broadly two different methods to study driving 
under the influence of drugs, namely experimental and 
epidemiological studies.
In experimental studies, subjects’ performance is 
evaluated by laboratory performance tests, tests in a 
driving simulator or ‘real’ driving tests. Although these 
studies allow the assessment of the effects of a drug on 
differentiated functions, they can identify only potential 
risks, but with an appropriate design they can attribute 
the findings to a single cause. The results of these 
studies may be limited by the use of non-realistic drug 
doses or by inter-individual differences.
Performance tests are conducted in a laboratory setting 
and are intended to measure specific skills and abilities 
that are involved in driving, such as attention, vigilance, 
auditory and visual skills, reaction time, cognitive tests 
n  Some studies do not control for unmeasured 
variation within an individual, and thus cannot 
differentiate between the risks associated with use of 
the medication and those associated with the 
underlying disorder being treated by the medication 
(Barbone et al., 1998).
n  Driving patterns might differ between periods of use 
and non-use of a medication, such as choosing not to 
drive while using the medication. This could lead to 
an underestimation of the risks of driving associated 
with use of the medicine (Barbone et al., 1998; 
Hemmelgarn et al., 1997).
n  Gathering information by interview or questionnaire 
is limited by the restrictions that are inherent to such 
surveys (see previous subsection on surveys).
The DRUID project developed a model for integration of 
results of epidemiological and experimental studies 
based on a reference curve for alcohol: alcohol data 
obtained with different study methodologies are used as 
the gold standard (Hargutt et al., 2011).
I Meta-analyses
Meta-analysis is a statistical technique used to combine 
the findings from independent studies. Meta-analyses 
are most often used to assess the clinical effectiveness 
of healthcare interventions by combining data from two 
or more randomised controlled trials. The validity of the 
meta-analysis depends on the quality of the systematic 
review on which it is based. Good meta-analyses aim for 
complete coverage of all relevant studies, look for the 
presence of heterogeneity and explore the robustness of 
the main findings using sensitivity analysis. Systematic 
review methodology is at the heart of meta-analysis. This 
stresses the need to take great care to find all the 
relevant studies (published and unpublished) and to 
assess the methodological quality of the design and 
execution of each study. The objective of systematic 
reviews is to present a balanced and impartial summary 
of the existing research, enabling decisions on 
effectiveness to be based on all relevant studies of 
adequate quality. Data from a meta-analysis are usually 
displayed pictorially, a representation often referred to 
as a forest plot, which displays the findings from each 
individual study as a dot or square, with squares towards 
the left side indicating the new treatment to be better, 
whereas those on the right indicate the new treatment to 
be less effective. The size of the dot or square is 
proportional to the precision of the study (roughly 
speaking, the sample size). A horizontal line (usually the 
95 % confidence interval) is drawn around each of the 
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Epidemiological studies on drugs and driving examine 
the prevalence of drugs in various driving populations. 
These studies include roadside surveys, prevalence 
studies in subsets of drivers, accident risk studies, 
responsibility analyses, surveys by interview and 
pharmacoepidemiological studies. Legislation, data 
protection, data availability and funding may affect the 
choice of type of survey. A roadside survey offers the 
closest representation of the general driving population.
In epidemiological research, the appropriate study 
design may be difficult to put into place because of 
limitations to the methodology, and there may be risk 
factors associated with drug use that do not emerge 
from the study findings. Moreover, epidemiological 
studies are not always easy to compare, if, for example, 
the data are from different populations, investigators use 
different types of samples or detection techniques or 
samples are tested for different psychoactive 
substances.
and visual–motor coordination skills. They measure a 
part of the performance needed to complete a task, but 
do not cover driving ability as a whole. In addition, the 
selection of the test(s) to be performed can influence the 
results of the study, because the measure of the acute 
drug effect is related to the sensitivity of the test chosen.
In a driving simulator, subjects perform a computer 
simulation of a driving task. The main advantages of this 
type of study are that driving tasks can be standardised 
and data can be gained safely. However, because a ‘real’ 
environment can never be fully replicated, subjects must 
deal with certain difficulties in the driving simulation.
‘Real’ driving tests are able to most realistically show the 
effects of psychoactive drugs on driving performance. 
They can be conducted in the presence or absence of 
normal traffic. One main disadvantage of this kind of 
experimental study is the need to take into consideration 
the safety of other road users.
Because of small sample sizes and a multitude of 
variable factors in experimental studies, it is difficult to 
compare or combine the results of different studies.
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In order to estimate the size of the danger that driving 
under the influence of drugs poses to traffic safety, it is 
necessary to assess the prevalence of driving under the 
influence of drugs. The epidemiological studies on drugs 
and driving published since 2007 are discussed in this 
chapter. A more detailed description of the types, 
methodology and limitations of these studies is given in 
Chapter 1.
I Roadside surveys
Roadside surveys investigate the prevalence of 
psychoactive substances among the general driving 
population. Drivers are randomly stopped and tested for 
the presence of alcohol, drugs and/or medicines in their 
body.
The results of recent roadside surveys are given in Tables 
A1 and A2 (Appendix). Table A1 presents the results of 
the roadside survey performed during the DRUID 
project. Table A2 presents the results of other studies, 
most of which were performed outside Europe.
In the DRUID project, a roadside survey was conducted 
in 2009 and 2010 (see also EMCDDA, 2012). Oral fluid 
and blood were taken from nearly 50 000 drivers in 13 
countries. Based on these results, a weighted average of 
the prevalence of alcohol and illicit and some medicinal 
drugs was calculated. The results for the different drug 
classes are summarised in Table 2. Overall, 7.43 % of 
European drivers had alcohol or one of the 23 tested 
drugs in their oral fluid or blood. Alcohol levels above 
0.1 g/l and above 0.5 g/l were found in 3.5 % and 1.5 % 
of drivers, respectively.
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TABLE 2
Weighted European mean of the prevalence of different 
substances in the general driving population
Substance Weighted European mean (%)
Alcohol > 0.1 g/l (1) 3.5
Alcohol > 0.5 g/l 1.5
Illicit drugs 1.9
Amphetamines 0.08
Cannabis 1.32
Cocaine 0.42
Opioids 0.07
Medicinal drugs 1.4
Benzodiazepines 0.90
Zopiclone and zolpidem 0.12
Medicinal opioids 0.35
Alcohol and drugs 0.37
Different drug classes 0.39
(1)  No alcohol results were available for Sweden. Alcohol-positive drivers 
(> 0.2 g/l) were dealt with by the police, so did not take part in the 
survey.
NB: The prevalence values for named drugs refer to the occurrence of 
those drugs alone; combinations of drugs are given separately.
Large differences were observed among the EU 
countries. The prevalence of alcohol was highest in the 
southern European countries and in Belgium. The 
prevalence of illicit drugs was highest in the southern 
European countries. The prevalence of medicinal drugs 
was highest in northern European countries. The 
prevalence of alcohol and drugs in eastern European 
countries was often much lower than in the rest of 
Europe.
In addition to the DRUID roadside survey, nine other 
surveys were identified, some of which originated from 
developing countries including Brazil, China and Thailand 
(Table A2).
In the United States, the 2007 National Roadside Survey 
(Lacey et al., 2011) was a large national field survey of 
alcohol- and drug-involved driving conducted primarily 
among night-time weekend drivers, but also daytime 
Friday drivers. The survey involved randomly stopping 
drivers at 300 locations across the continental United 
States; sites were selected through a stratified random 
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than therapeutic. Cannabis (0.5–7.6 %) and 
amphetamines (0.1–4.2 %) were the most prevalent illicit 
drugs. The prevalence of Z-hypnotics and medicinal 
opioids ranged from 0 % to 3.8 % and from 1.1 % to 
13.0 %, respectively. The prevalence of illicit drugs 
ranged from 2.3 % to 12.6 %. Alcohol was found in 
combination with drugs in 2.3–13.2 % of drivers. Drug 
combinations were found in 0.5–4.3 % of drivers 
(Legrand et al., 2012).
Table A4 (Appendix) compares 12 other (non-DRUID) 
studies on drug prevalence in injured drivers published 
since 2007: two from Australia, Brazil and Italy and one 
each from Greece, Hong Kong, the Netherlands, Norway, 
Spain and Sweden.
Drugs and/or alcohol were frequently detected in injured 
drivers (between 10 % and 44 %), much more frequently 
than in the general driving population. Alcohol was 
detected in 7–31 % of injured drivers, illicit drugs in 
4–12.5 % and medicinal drugs in 13–21 % (not all drug 
classes were measured in all the studies). In 8 of the 12 
studies, cannabis was the most frequently detected 
drug. However, in Norway (Bogstrand et al., 2011) and 
Sweden (Ahlm et al., 2009), benzodiazepines were the 
most frequently detected drugs, while ketamine was the 
most frequently detected drug in Hong Kong (Wong et 
al., 2010) and cocaine was the most frequently detected 
drug in one of the Italian studies (Siliquini et al., 2007).
The combination of alcohol and drugs was also 
frequently encountered, with prevalence ranging from 
2 % to almost 12 %. Combinations of different drug 
classes were observed in 3.0–9.4 % of injured drivers.
There is a large variation in the percentages of drug-
positive samples in the different studies, but this is 
probably because of the differences in methodology and 
study location (see Chapter 1).
I Drivers killed in traffic accidents
The results of recent epidemiological studies that 
investigated the presence of alcohol, drugs and/or 
medicines in drivers who were killed in traffic accidents 
are given in Table A5 (Appendix) for the DRUID studies 
and in Table A6 for the other studies.
The DRUID project investigated the presence of alcohol 
and drugs in killed drivers in four countries: Portugal, 
Finland, Sweden and Norway (Legrand et al., 2014). The 
prevalence of any psychoactive substance ranged 
between 31 % and 48 %. Alcohol (≥ 0.1 g/l) was the 
sampling procedure. This included data that were 
collected during a 2-hour Friday daytime session at 60 
locations and during four 2-hour night-time periods 
(10.00 p.m. to midnight and 1.00 a.m. to 3.00 a.m. on 
both Friday and Saturday) at 240 locations.
It is difficult to compare the results of the different 
studies because of the many differences in methodology 
(see Chapter 1), including sampling during the whole 
week or only at the weekends, type of biological fluid, 
analytical methods and cut-offs, and reporting (global 
data or data broken down by sex, total prevalence of all 
drugs combined or prevalence of individual drugs, etc.). 
There are, however, some similarities. Higher 
percentages of drug- and alcohol-positive drivers are 
observed in studies that were performed only at the 
weekends or at night. In studies that cover the whole 
driving population, between 4 % and 6 % are drug and/or 
alcohol positive. In truck drivers in Brazil one finds mainly 
stimulant drugs (Leyton et al., 2012), while in Norway the 
percentage of drug-positive drivers is much lower 
(Gjerde et al., 2012). In the US and Canadian studies, 
sampling took place mainly at the weekends and at 
night, and the percentage of drug-positive drivers was 
12–15 %, double the percentage in Europe. In the United 
States, cannabis was by far the most prevalent drug. In 
Australia (Davey and Freeman, 2009), 
methamphetamine and MDMA were most prevalent.
The data in Table A2 (Appendix) also show that a 
combination of alcohol and drugs is found in about 
0.4–3.4 % of the general driving population. 
Combinations of different drug classes were observed in 
0.2–2.3 % of drivers.
I Subsets of drivers
I Drivers injured in traffic accidents
Table A3 (Appendix) shows the results of the DRUID 
study in severely injured drivers. The percentage of 
drivers who tested positive for at least one psychoactive 
substance ranged from 28 % (Lithuania) to 53 % 
(Belgium). Alcohol (≥ 0.1 g/l) was the most common 
substance, with the highest percentage in Belgium 
(42.5 %), followed by Finland (32.1 %). Among the 
alcohol-positive drivers, 90.5 % had a blood alcohol 
concentration (BAC) ≥ 0.5 g/l and 65.7 % had a BAC 
≥ 1.3 g/l. Benzodiazepines (0.0–10.2 %) and medicinal 
opioids (0.5–7.8 %) were the most prevalent medicinal 
drugs, but in half of cases the concentrations were lower 
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most common finding; 87 % had a BAC ≥ 0.5 g/l. 
Benzodiazepines (1.8–13.3 %) and amphetamines 
(0–7.4 %) were the most prevalent psychoactive 
medicines and illicit drugs, respectively. Alcohol–drug 
and drug–drug combinations were also common.
Nine other studies have been published since 2007: 
some of them are very large studies, involving more than 
5 000 killed drivers in the United States (Brady and Li, 
2013), France (Biecheler et al., 2008) and Canada 
(Beasley et al., 2011). The other studies were performed 
in the Nordic countries (Morland et al., 2011), Norway 
(Gjerde et al., 2011), Sweden (Ahlm et al., 2009; Jones et 
al., 2009), the United Kingdom (Elliott et al., 2009) and 
Portugal (Costa et al., 2012).
Alcohol was the most frequently detected psychoactive 
substance in drivers killed in accidents (25–40 %). 
However, drugs were also frequently detected, and, just 
as in injured drivers, at a much higher prevalence than 
among the general driving population. The combination 
of alcohol and drugs was also found in a substantial 
proportion of samples, ranging from 3.0 % to 26 %. In 
four studies, cannabis was the most commonly detected 
drug, with the highest prevalence, about 35 %, found in 
the United Kingdom. In the other studies, 
benzodiazepines were the most prevalent drug in 
Canada and Norway, opioids were the most prevalent in 
Portugal and antidepressants were the most prevalent in 
the study in the United Kingdom (Elliott et al., 2009).
I  Drivers suspected of driving under the influence of drugs and alcohol
Table A7 (Appendix) shows seven studies published 
since 2007 of drivers stopped on suspicion of drug use, 
from Australia (Chu et al., 2012), Canada (Palmentier et 
al., 2009), Austria (Keller et al., 2009), Denmark 
(Steentoft et al., 2010), Hungary (Toth et al., 2009), 
Sweden (Holmgren et al., 2007) and Switzerland (Senna 
et al., 2010).
The studies show a large variation in the number of 
drug-positive samples found on suspicion (80–96 %). 
This reflects differences in methodology, but also 
differences in procedures used to detect drivers who 
may be under the influence of drugs (see Chapter 1).
Ojaniemie et al. (2009) examined the main drug findings 
and their trends in suspected cases of driving under the 
influence of drugs in Finland. A register-based study was 
conducted of all suspected cases of driving under the 
influence of drugs during 1977–2007. The data included 
31 963 offenders apprehended by the police with a 
positive finding for illicit/licit drug impairing driving 
performance. Toxicological results were analysed in 
blood and/or urine specimens in one central laboratory. 
The incidence of suspected cases of driving under the 
influence of drugs increased 18-fold during 1977–2007. 
Most of the suspects (89.7 %) were men. However, the 
male–female ratio decreased over the period from 13.9 
to 7.3. The mean age decreased from 36.2 years in 1977 
to 29.9 years in 2001, but then increased again. The 
substances found most often were benzodiazepines 
(75.7 %), amphetamines (46.0 %), cannabinoids (27.7 %) 
and opioids (13.8 %). The most common illicit drugs, 
amphetamines and cannabinoids, started to appear at 
the end of the 1980s. Polydrug findings were common 
(77.1 %). The number of cases suspected of driving 
under the influence of drugs have increased sharply 
since the introduction of a zero tolerance law, especially 
in regard to amphetamines.
Christophersen and Morland (2008) reported that 
drivers in Norway in whom benzodiazepines are 
detected are probably not representative of patients with 
benzodiazepine prescriptions. In the majority of 
benzodiazepine-positive drivers in their study, 
benzodiazepines were detected at supratherapeutic 
blood concentrations, and frequently in combination 
with illegal drugs, other psychoactive medicines or 
alcohol. Benzodiazepines were found to be the only drug 
present at therapeutic blood levels in less than 5 % of 
positive drivers (with the exception of nitrazepam, which 
was the only drug in 7.6 % of the drivers in whom it was 
detected). The majority of the drivers testing positive for 
benzodiazepines were 20–39 years old (median age for 
the different benzodiazepines 29–33 years), while the 
majority of those in whom benzodiazepines had been 
prescribed were over 50 years old.
I  Occurrence of new psychoactive substances in drivers
As many countries that wish to introduce legislation on 
driving under the influence are faced with the question 
of whether or not to include new psychoactive 
substances, we surveyed the literature for studies that 
had included new psychoactive substances. The results 
can be seen in Table 3. All studies were performed in 
drivers who were suspected of driving under the 
influence of drugs.
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In killed drivers, the prevalence of any psychoactive 
substance ranged between 26 % and 57 %. Alcohol 
(≥ 0.1 g/l) was the most common finding; between 19 % 
and 45 % of drivers tested positive. In the DRUID survey, 
87 % had a BAC ≥ 0.5 g/l. In the DRUID survey, 
benzodiazepines (1.8–13.3 %) and amphetamines 
(0–7.4 %) were the most prevalent psychoactive 
medicines and illicit drugs, respectively. In four studies, 
cannabis was the most commonly detected drug, with 
the highest prevalence, about 35 %, being found in the 
United Kingdom. The combination of alcohol and drugs 
was also frequent in a substantial proportion of samples, 
ranging from 3.0 % to 26 %.
In studies carried out in drivers stopped on suspicion of 
driving under the influence of drugs, a psychoactive 
substance other than alcohol is often detected in more 
than 80 % of the samples; in most studies, it is cannabis. 
Drivers suspected of driving under the influence of 
alcohol are frequently also under the influence of drugs. 
In nearly all studies cannabis was the most frequently 
detected drug, except in Sweden (amphetamines) and 
Denmark (benzodiazepines). Some studies also looked 
for new synthetic drugs and found them in up to 6 % of 
drivers suspected of driving under the influence.
The comparability of these prevalence studies is low. For 
future research, comparability may be improved if 
certain minimum common standards are adopted. 
Nevertheless, from the studies that have been published 
since 2007, it can be concluded that driving under the 
influence of drugs is not uncommon and that it can 
cause substantial risk to road users. 
I Conclusion
In Europe, the United States, Australia and Canada, 
about 2–7 % of drivers stopped during roadside surveys 
tested positive for drugs or alcohol in blood or saliva. In 
the DRUID study, 7.43 % of the drivers tested positive for 
alcohol or one of the 23 tested drugs in their oral fluid or 
blood. Alcohol levels above 0.1 g/l and above 0.5 g/l 
were found in 3.5 % and 1.5 % of drivers, respectively. 
Regarding drugs, 1.9 % tested positive for illicit drugs, 
mainly cannabis, 1.4 % for (a limited list) of medicinal 
drugs, 0.37 % for a combination of alcohol and drugs and 
0.39 % for different drug classes. Not unexpectedly, 
higher prevalence rates were found in studies using 
urine samples (9–10 %) and in studies in which samples 
were collected only on weekend nights (10–12 %). 
Studies conducted among drivers stopped on suspicion 
of alcohol or drug use or other subsets of drivers usually 
find a much higher prevalence rate (50–90 %) of drugs 
than roadside surveys of general driving populations, 
because of the selection bias inherent in such subset 
surveys.
In the DRUID project, the percentage of seriously injured 
drivers testing positive for at least one psychoactive 
substance ranged between 28 % and 53 %, with alcohol 
(≥ 0.1 g/l) being the most common substance. Among 
the alcohol-positive drivers, 90.5 % had a BAC ≥ 0.5 g/l 
and 65.7 % had a BAC ≥ 1.3 g/l. The prevalence of illicit 
drugs ranged between 2.3 % and 12.6 %. Alcohol was 
found in combination with drugs in 2.3–13.2 % of the 
drivers. Drug combinations were found in 0.5–4.3 % of 
the drivers in DRUID and in an even higher percentage 
(3.0–9.4 %) in the other studies. In the other studies of 
injured drivers, drugs and/or alcohol were frequently 
detected (between 10 % and 44 %). In 8 of the 12 
studies, cannabis was the most frequently detected 
drug.
TABLE 3
Overview of the prevalence of some new synthetic drugs in drivers suspected of driving under the influence of drugs
Drug Country Year Percentage/number Reference
Desoxypipradol (2-DPMP) Finland 2010–2012 1.7 % Kriikku et al. (2013)
Fluoroamphetamines Denmark 2009–2011 15 cases Johansen and Hansen (2012)
GHB Germany 2.0 % Dresen et al. (2007)
GHB Germany 2.0 % Lott et al. (2012)
GHB Norway 2000–2007 25 cases Al-Samarraie et al. (2010)
GHB Sweden 1998–2007 548 Jones et al. (2008a)
MDPV Finland 2009 5.7 % Kriikku et al. (2011)
Phenazepam Finland 2010–2011 3.5 % Kriikku et al. (2012)
Synthetic cannabinoids Norway 2011 3 %. All samples contained 
other drugs as well
Bachs et al. (2012)
Abbreviations: GHB, gamma-hydroxybutyrate; MDPV, methylenedioxypyrovalerone.
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significant effect of cannabis on body sway, but no effect 
on brake latency. In agreement with these results, 
Sexton et al. (2000) showed that the SDLP in the 
road-tracking test was the most sensitive measure for 
revealing the adverse effects of THC.
For each type of drug considered, the effects on 
performance that have been assessed by experimental 
studies will be described. These effects are mostly 
divided into acute and chronic effects. Acute effects are 
the effects associated with the use of a single dose of a 
drug. Chronic effects are the effects of using a specific 
drug over a long period of time. Where possible, data on 
the risks associated with these drugs in traffic will also 
be described.
I Cannabis
I Acute effects
The effects of cannabis vary with dose, route of 
administration, experience of the user, vulnerability to 
psychoactive effects and setting of use. Cannabis can 
produce euphoria, relief of anxiety, sedation and 
drowsiness. Occasionally, the use of cannabis can cause 
anxiety that may escalate to panic attacks and paranoia. 
A sense of enhanced well-being may alternate with a 
depressive phase (Huestis, 2002). Users are aware of 
the effects of the drug, and this awareness increases 
with higher doses (Lane et al., 2005; Liguori et al., 2002; 
Menetrey et al., 2005; Sexton et al., 2000). Cannabis can 
also cause some physiological effects such as mydriasis 
(Sexton et al., 2000).
Cannabis acutely reduces some cognitive and 
psychomotor skills that are necessary to drive, such as 
motor control, psychomotor speed, executive function, 
motor impulsivity, visual processing, short-term memory, 
working memory (reaction time and accuracy), 
perception and balance, and these effects are mostly 
dose dependent (Hart et al., 2001; Ilan et al., 2004; 
Kurzthaler et al., 1999; Liguori et al., 2002; Menetrey et 
al., 2005; Nicholson et al., 2004; Ramaekers et al., 
2006a; Sexton et al., 2000). Using driving simulator 
tests, Menetrey et al. (2005) found that keeping a vehicle 
on a track is the most difficult task for participants under 
the influence of cannabis. Liguori et al. (2002) found a 
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Cannabis is a natural product, the main 
psychoactive constituent of which is 
tetrahydrocannabinol (THC). The cannabis plant 
(Cannabis sativa L.) is broadly distributed and 
grows in temperate and tropical areas. Cannabis 
resin is a compressed solid made from the 
resinous parts of the plant, and cannabis (hash) oil 
is a solvent extract of cannabis.
The pharmacology of cannabis is complicated by the 
presence of a wide range of cannabinoids. 
Anandamide has been identified as the endogenous 
ligand for the cannabinoid receptor and has 
pharmacological properties similar to those of THC. 
When cannabis is smoked, THC can be detected in 
plasma within seconds of inhalation; it has a half-life 
of 2 hours. Following smoking of the equivalent of 
10–15 mg over a period of 5–7 minutes, peak 
plasma levels of THC are around 100 μg/l. It is highly 
lipophilic and widely distributed in the body. Two 
active metabolites are formed: 11-hydroxy-Δ9-THC 
and 8β-hydroxy-Δ9-THC. The first is further 
metabolised to Δ9-THC-11-oic acid. Two inactive 
substances are also formed (8α-hydroxy-Δ9-THC 
and 8α,11-dihydroxy-Δ9-THC) as are many other 
minor metabolites, most of which appear in the 
urine and faeces as glucuronide conjugates. Some 
metabolites can be detected in the urine for up to 2 
weeks following smoking or ingestion.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
Pharmacology of cannabis
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subjective feeling of confusion rather than with the 
blood concentration of THC.
Bosker et al. (2012a) measured the acute and chronic 
effects of dronabinol (medicinal THC) on actual driving 
performance and the standard field sobriety test (SFST) 
in 12 occasional and 12 heavy cannabis users who 
received single doses of placebo, 10 mg dronabinol or 
20 mg dronabinol. SDLP (p = 0.008) in occasional users 
increased after dronabinol administration. Dronabinol-
induced impairment, reflected in increments in SDLP, 
was greater than impairment associated with a BAC of 
0.5 g/l in occasional and heavy users, although the 
magnitude of driving impairment was generally smaller 
in heavy users. Levels of the subjective ‘high’ feeling 
were comparable in occasional and heavy users. 
Dronabinol impaired driving performance in occasional 
and heavy users in a dose-dependent way, but to a 
lesser degree in heavy users, possibly because of 
tolerance. The SFST was not sensitive to clinically 
relevant driving impairment caused by oral 
tetrahydrocannabinol.
Lenné et al. (2010) compared the effects of three doses 
of cannabis and alcohol (placebo, low and high doses; 0, 
0.4 and 0.6 g/kg), both alone and in combination, on 
driving performance. The driving performance of 25 
experienced and 22 inexperienced drivers was tested in 
a simulator under nine different drug conditions. The 
simulator replicated the driving environment found on a 
main urban road, and during the test workload was 
varied through both the drive characteristics and the 
inclusion of a secondary task. High levels of cannabis 
generally induced greater impairment than lower levels, 
while alcohol at the doses used had few effects and did 
not produce synergistic effects when combined with 
cannabis. Both cannabis and alcohol were associated 
with increases in speed and lateral position variability: 
high-dose cannabis was associated with decreased 
mean speed, increased mean headway and increased 
headway variability, and a longer reaction time, whereas 
alcohol was associated with a slight increase in mean 
speed.
Mann et al. (2007) examined self-reported collision 
involvement in the last 12 months by lifetime use of 
cannabis, past-year use of cannabis and past-year 
driving after using cannabis, while controlling for 
demographic characteristics, and found that the odds of 
reporting collision involvement was significantly higher 
among cannabis users and among those who reported 
driving after cannabis use. Some evidence of a dose–
response relationship was also seen. In a more recent 
study (Mann et al., 2010), several demographic factors 
were found to be significantly associated with self-
Cannabis can also have an effect on behaviour. The 
effect of cannabis on risk taking is, however, unclear. 
Laboratory experiments revealed an increased impulsive 
response in the stop signal task, indicating that the 
subjects were unable to inhibit a response in a rapid 
response model while under the influence of cannabis 
(McDonald et al., 2003; Ramaekers et al., 2006a). Lane 
et al. (2005) found that, when subjects were presented 
with a choice between two response options 
operationally defined as risky and non-risky, cannabis 
increased selection of the risky option. However, 
performance on other behavioural measures of 
impulsivity (go/no go, Iowa gambling task) was not 
affected (McDonald et al., 2003; Ramaekers et al., 
2006a). In some driving studies that used low doses of 
cannabis, it was observed that the subjects were aware 
of the impairment and compensated for their driving 
style by driving more slowly, overtaking less or keeping 
longer distances. However, they were still unable to 
compensate for the loss of capability in some 
psychomotor skills (Sexton et al., 2000, 2002). 
Experimental studies on cannabis have traditionally 
used low-potency cannabis (maximum 4 % THC). Other 
studies that have used high-potency cannabis (13 % 
THC) have found that impairment is more pronounced 
than in the low-potency studies (see Chapter 1).
In an interesting study that gives us some clues about 
the impairing effect of cannabis on brain mechanisms, 
Battistella et al. (2013) evaluated the impact of 
cannabis on the driving ability of occasional smokers by 
investigating changes in the brain network involved in a 
tracking task. Thirty-one male volunteers were enrolled 
in a study that included functional magnetic resonance 
imaging (fMRI) of the brain and measurements of 
psychomotor skills. Cannabis smoking (42 mg of THC), 
even at low THC blood concentrations, decreased 
psychomotor skills and altered the activity of the brain 
networks involved in cognition. After cannabis smoking, 
blood oxygen level-dependent response decreased in 
the anterior insula, dorsomedial thalamus and striatum, 
suggesting an alteration of the network involved in 
saliency detection. In addition, the decrease in blood 
oxygen level-dependent response in the right superior 
parietal cortex and in the dorsolateral prefrontal cortex 
indicated the involvement of the control executive 
network known to operate once the saliencies are 
identified. Furthermore, cannabis increased activity in 
the rostral anterior cingulate cortex and ventromedial 
prefrontal cortices, suggesting an increase in self-
orientated mental activity. Subjects were more 
attracted by intrapersonal stimuli (‘self’) and failed to 
attend to task performance, leading to an insufficient 
allocation of task-orientated resources and suboptimal 
performance. These effects correlated with the 
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In a review in the Lancet (Hall and Degenhardt, 2009), 
focusing on adverse health effects of the greatest 
potential public health interest (those that are most likely 
to occur and to affect a large number of cannabis users), 
the most probable adverse effects included a 
dependence syndrome, increased risk of motor vehicle 
crashes, impaired respiratory function, cardiovascular 
disease and adverse effects of regular use on adolescent 
psychosocial development and mental health. In a 
review of the effects of cannabis on driving, Hartman 
and Huestis (2013) found that, historically, delays in 
sample collection, evaluating the inactive THC 
metabolite 11-nor-9-carboxy-THC and polydrug use have 
complicated epidemiological evaluations of driver 
impairment after cannabis use. Epidemiological data 
show that the risk of involvement in a motor vehicle 
accident (MVA) increases approximately twofold after 
cannabis smoking. The adjusted risk of driver culpability 
also increases substantially, particularly with increased 
blood concentrations of THC. Experimental data show 
that drivers attempt to compensate by driving more 
slowly after smoking cannabis, but control deteriorates 
with increasing task complexity. Cannabis smoking 
increases lane weaving and impaired cognitive function. 
Reaction times, performance on CTTs and divided 
attention tasks and maintenance of lane position are all 
impaired by cannabis. Despite purported tolerance in 
frequent smokers, performance of complex tasks still 
shows impairment.
The dose–effect relationship between the THC dose 
contained in cannabis cigarettes and cognitive and 
psychomotor effects for THC doses up to 69.4 mg (23 %) 
were studied in a double-blind, placebo-controlled, 
randomised, four-way crossover study of 24 male 
non-daily cannabis users. Participants smoked four 
cannabis cigarettes containing 0, 29.3, 49.1 and 69.4 mg 
THC on four exposure days. The THC dose in smoked 
cannabis was linearly associated with a slower response 
time on all tasks (SRT, visuospatial selective attention, 
sustained attention, divided attention and short-term 
memory tasks) and with motor control impairment in the 
motor control task. The number of errors on the short-
term memory and the sustained attention tasks 
increased significantly with increasing doses. Some 
participants showed no impairment of motor control 
even at THC serum concentrations higher than 40 ng/ml. 
The ‘high’ feeling and drowsiness differed significantly 
between treatments (Hunault et al., 2009).
Meta-analysis of experimental studies
Berghaus et al. (2010) performed a meta-analysis of the 
experimental studies. For oral administration of THC, 21 
reported collision involvement. The logistic regression 
model revealed that age, region, income, marital status 
and number of kilometres driven in a typical week were 
all significantly related to collision involvement, after 
adjusting for other factors. Respondents who reported 
having driven after cannabis use within the past 12 
months had an increased risk of collision involvement 
(OR 1.84) than those who never drove after using 
cannabis, and this increase was of a greater magnitude 
than that associated with having reported driving after 
drinking within the past 12 months (OR 1.34).
Weinstein et al. (2008a) investigated the acute effects of 
13 mg and 17 mg THC on skills important for 
coordinated movement and driving and on subjective 
and autonomic measures in 14 regular users of 
marijuana. Regular marijuana users hit the walls on the 
virtual maze task more often after smoking a cigarette 
containing 17 mg THC than after smoking cigarettes 
without THC. This effect was not seen in subjects after 
they smoked cigarettes containing 13 mg THC. 
Performance on the WCST was also affected by 17 mg 
THC and, to a lesser extent, by the use of 13 mg THC. 
Decision-making in the gambling task was affected after 
smoking cigarettes with 17 mg THC, but not 13 mg THC. 
These findings imply that smoking of 17 mg THC results 
in impairment of cognitive–motor skills that could be 
important for coordinated movement and driving, 
whereas the lower dose of 13 mg THC appears to cause 
less impairment of such skills in regular users of 
marijuana. In another study from the same group 
(Weinstein et al., 2008b), 12 regular users of marijuana 
underwent two positron emission tomography (PET) 
scans using [18F]-fluorodeoxyglucose, one while subject 
to the effects of 17 mg THC, the other without THC. In 
both sessions, a virtual reality maze task was performed 
during the fluorodeoxyglucose uptake period. Again, 
regular marijuana smokers more often hit the walls on 
the virtual maze task when subject to the effects of 
17 mg THC than without THC. Compared with results 
without THC, 17 mg THC increased brain metabolism 
during task performance in areas that are associated 
with motor coordination and attention in the middle and 
medial frontal cortices and anterior cingulate, and 
reduced metabolism in areas that are related to visual 
integration of motion in the occipital lobes.
Khiabani et al. (2008) found that a substantial fraction of 
D9-THC-positive drivers were tachycardic, but there was 
no correlation between blood D9-THC concentration and 
pulse rate. Without further diagnostic information on the 
cause of the pulse irregularities, their results indicate 
that occasional users of cannabis tend to have irregular 
heart rates at low THC concentrations and at low pulse 
rates.
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In an analysis of the SAM study of fatal crashes in 
France, Biecheler et al. (2008) found that about 40 % of 
drivers under the influence of cannabis also had an 
illegal alcohol level. The ratio of responsible to not 
responsible drivers was 1.2 in the alcohol- and drug-free 
population, 2.3 in the cannabis-only population 
(THC ≥ 1 ng/ml), 9.4 in the alcohol-only population 
(≥ 0.5 mg/l) and 14.1 in the alcohol–cannabis 
combination population.
Lenné et al. (2010) found that alcohol at the doses used 
(up to 0.6 g/kg) did not produce synergistic effects when 
combined with cannabis.
Ronen et al. (2010) investigated the effect of alcohol 
(BAC = 0.05 %) and THC (13 mg) and their combination 
on driving and non-driving tasks, and willingness to drive 
based on subjective sensations and the perceived 
effects of the drugs, in seven healthy men and five 
healthy women, aged 24–29 years, all of whom were 
recreational users of alcohol and marijuana. Overall, the 
combination of alcohol and THC had the greatest effect 
as determined by impaired performance on the driving 
and non-driving tasks, subjective sensations after intake 
and physiological measures. Despite significant 
differences in the size of the effects after the various 
treatments, there were no differences in the distances 
subjects were willing to drive while under the influence 
of each of the treatments. No residual effects were 
observed after 24 hours.
In another responsibility analysis in France Gadegbeku 
et al. (2011) found no interaction between cannabis and 
alcohol intoxication (p = 0.13), ‘only’ a multiplicative 
effect. The OR of responsibility for a fatal crash when 
under the influence of both alcohol and cannabis 
(compared with drivers not exposed to cannabis or 
alcohol) was estimated at 15.86 (8.39 × 1.89). 
Lenguerrand et al. (2008), based on the same data, 
came to the same conclusions: the risk of causing a 
crash for those under the influence of alcohol and 
cannabis while driving (OR 14.2) was similar to the 
product of the adjusted individual effects. Hartman and 
Huestis (2013) found that combining cannabis with 
alcohol increases impairment, especially lane weaving. 
Downey et al. (2013) assessed performance on a driving 
simulator in 49 men and 31 women, previous 
recreational users of alcohol and marijuana, who were 
abstinent at the time of the experiment. In six 
experimental sessions, participants consumed 
cigarettes containing no THC, 1.8 % THC or 3 % THC 
together with alcohol to achieve a BAC of 0 %, 0.03 % or 
0.05 %. Half of the participants were allocated to the 
cannabis with no and low alcohol (0.03 % BAC) group, 
studies measured 482 effects. The doses used varied 
from 7.5 to 39 mg. For the highest dose range (18–
39 mg), the maximal percentage of significantly impaired 
test results was 55 %. The time to maximal impairment 
varied from 2.25 hours to 1 hour with increasing doses. 
The alcohol equivalence of maximum impairment was 
< 0.3 g/l for a dose lower than 9 mg, over 0.5–0.8 g/l for 
9–18 mg and > 0.8 g/l for a dose > 18 mg. The duration 
of impairment was about 5 hours at the middle dose 
range. The 0.5 g/l BAC equivalent THC concentration 
was 3.7 ng/ml in plasma. For smoking of cannabis, 78 
studies with 888 effects were analysed. The doses used 
varied between 1 and 52 mg. For the highest dose range 
(18–52 mg), the maximal percentage of significantly 
impaired test results was 55 %. The time to maximal 
impairment varied from 0.75 hours to 0.25 hours with 
increasing doses. The alcohol equivalence of maximum 
impairment was 0.8 g/l or higher at all doses. The 
duration of impairment was about 4.75 hours for the 
middle dose range. The 0.5 g/l BAC equivalent 
concentration was 3.8 ng/ml in plasma.
Duration of effects
The desired effect of cannabis, the ‘high’, lasts for up to 2 
hours (Couper and Logan, 2004a). However, most 
studies found significant negative effects of cannabis on 
performance up to 10 hours after use (Hart et al., 2001; 
Kurzthaler et al., 1999; Lane et al., 2005; McDonald et al., 
2003; Menetrey et al., 2005; Ramaekers et al., 2006a). 
Nicholson et al. (2004), for example, found that memory 
was impaired in healthy volunteers 10 hours after 
administration of 15 mg of THC.
Combination with other psychoactive substances
Some deleterious effects of cannabis appear to be 
additive or even synergistic with those of alcohol; the 
combination of both substances results in a prolongation 
as well as enhancement of their effects (Baselt, 2001). 
For example, stronger subjective effects are generated 
after the use of a combination of alcohol and cannabis 
than after the use of either substance alone (Sexton et 
al., 2002). Driving studies show that drivers under the 
influence of both alcohol and cannabis are less attentive 
to traffic approaching from side streets, while the use of 
either cannabis or alcohol has no effect (Lamers and 
Ramaekers, 2001), and that the combination of cannabis 
and alcohol generates an additional decrement in lateral 
control on top of the decrement caused by either 
cannabis or alcohol (Sexton et al., 2002). Liguori et al. 
(2002), however, found no additive effects of alcohol and 
cannabis on brake latency or body sway.
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and the other 40 participants were allocated to the 
cannabis with no and high alcohol (0.05 % BAC) group. 
The level of THC detected in blood was higher when THC 
was consumed with alcohol than when cannabis was 
consumed alone, and regular cannabis users returned 
higher levels of THC in plasma than non-regular users. 
Performance on the simulator was more impaired when 
THC and alcohol were combined. Generally, regular 
cannabis users displayed more driving errors than 
non-regular cannabis users.
Romano and Voas (2011) found a link between drug 
consumption and fatal crashes, but the contribution of 
the different drug classes involved varied depending on 
the cause of the crash (speeding, failure to obey/yield, 
inattention) and use or not of a seatbelt. Of the two drug 
classes most commonly used, stimulants more than 
cannabinoids were found to be associated with all four 
categories of crashes under study. The contribution of 
drugs to fatal crashes is important mainly in the absence 
of an impairing level of alcohol. When drivers are alcohol 
impaired, the influence of other drugs is less significant. 
Counter to the commonly held belief, no synergistic 
drugs–alcohol effect was found. Rather, it appeared that, 
when present, alcohol was the main source of 
impairment. The study raises some interesting questions 
regarding the way drugs contribute, and sometimes in 
unexpected ways, to crashes, as the effects of drug 
consumption were found to vary depending on the type 
of crash considered, the class of drug and the presence 
of alcohol.
Sewell et al. (2009) reviewed the literature on cannabis, 
alcohol and driving and concluded that cannabis and 
alcohol acutely impair several driving-related skills in a 
dose-related fashion, but the effects of cannabis vary 
more between individuals than do the effects of alcohol 
because of tolerance, differences in smoking technique 
and different absorptions of THC. The detrimental effects 
of cannabis use vary in a dose-related fashion, and 
highly automatic driving functions are more severely 
impaired than more complex tasks that require 
conscious control; alcohol, in contrast, causes greater 
impairment of consciously performed tasks than of 
automatic tasks. For this reason, and because they have 
greater awareness of their impairment, marijuana 
smokers tend to compensate effectively while driving by 
utilising a variety of behavioural strategies. However, 
concomitant consumption of alcohol eliminates the 
ability to use such strategies effectively and results in 
impairment even at doses which, were they of either 
drug alone, would be insignificant.
I Chronic effects
Chronic use of cannabis can lead to deficiencies in 
memory, attention, manual dexterity, executive 
functioning and psychomotor speed (Bolla et al., 2002; 
Ehrenreich et al., 1999; Pope et al., 2001; Solowij et al., 
2002). These effects can last longer than the period of 
intoxication and worsen with either increasing number of 
years or frequency of cannabis use. The defects are 
partially reversible with prolonged abstinence, but some 
impairment may be permanent. In particular, Bolla et al. 
(2002) showed that very heavy use of marijuana is 
associated with persistent decrements in neurocognitive 
performance even after 28 days of abstinence. Pillay et 
al. (2008) performed fMRI studies on 11 cannabis users 
and 16 comparison subjects for up to 28 days of 
abstinence from cannabis, and demonstrated that 28 
days may not be a sufficient washout period for chronic 
cannabis users to be ensured optimal motor planning 
and execution, as reflected by diminished 
supplementary motor cortex activation as long as 28 
days after discontinuation. Very recently, Bosker et al. 
(2013) assessed performance on the CTT and divided 
attention task in 19 male chronic, daily cannabis 
smokers at baseline and after 8, 14–16 and 21–23 days 
of continuously monitored abstinence. Psychomotor 
performance was compared with that of a control group 
of non-intoxicated occasional drug users. Sustained 
cannabis abstinence moderately improved cannabis 
smokers’ performance of both CTTs and the divided 
attention task, but even after 3 weeks of abstinence 
performance was impaired compared with that of 
control subjects. Thirty-three per cent of the daily 
cannabis smokers had no THC in their blood 3 weeks 
after stopping, and the mean THC, 11-OH-THC and 
THC-COOH concentrations were 0.4, 0.0 and 2.2 ng/ml, 
respectively. The authors cautioned that between-group 
differences need to be interpreted with caution as 
chronic smokers and control subjects were not matched 
for education, socioeconomic status, lifestyle or race.
I Threshold concentration
Ramaekers et al. (2006b) measured performance 
impairment (in terms of motor control, motor impulsivity 
and executive function) as a function of THC 
concentration in serum and oral fluid and concluded that 
impairment of performance first occurs at a serum THC 
concentration between 2 and 5 ng/ml. Binomial tests 
showed an initial and significant shift towards 
impairment of performance on the CTT at serum THC 
concentrations between 2 and 5 ng/ml. At 
concentrations between 5 and 10 ng/ml, approximately 
75–90 % of the observations were indicative of 
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significant impairment in every performance test. At THC 
concentrations above 30 ng/ml, 100 % of observations 
in every performance test were indicative of significant 
impairment. According to Mura et al. (2005), cannabis 
can be detected in those regions of the brain on which it 
has an influence even after it is no longer detectable in 
blood. In the DRUID meta-analysis, a level of 3.8 (3.3–
4.1) ng/ml of THC in plasma has similar effects to 0.5 g/l 
of alcohol.
According to Grotenhermen et al. (2007), based on a 
small number of epidemiological studies, serum 
concentrations of THC below 10 ng/ml are not 
associated with an elevated accident risk. A comparison 
of meta-analyses of experimental studies on the 
impairment of driving-relevant skills by alcohol or 
cannabis suggests that a serum THC concentration of 
7–10 ng/ml is associated with an impairment 
comparable to that caused by a BAC of 0.5 g/l. Thus, a 
suitable numerical limit for THC in serum may fall in that 
range. Other authors suggest much lower cut-off 
concentrations. Battistella et al.’s (2013) findings that 
the effects correlate with the subjective feeling of 
confusion rather than with the blood level of THC lend 
support for the zero-tolerance policy adopted in several 
countries that prohibits the presence of any amount of 
drugs in blood while driving.
In epidemiological studies, an increased accident risk 
was observed at THC concentrations above 2 ng/ml 
(Kuypers et al., 2012; Laumon et al., 2005) or even 
1 ng/ml (Gadegbeku et al., 2011) in whole blood. 
Hartman and Huestis (2013) found evidence that 
suggested that recent cannabis smoking and/or blood 
THC concentrations of 2–5 ng/ml are associated with 
substantial driving impairment, particularly in occasional 
smokers.
Jones et al. (2008b) studied THC concentrations in 
8 794 cases of suspected DUI in Sweden and concluded 
that the concentration of THC in blood at the time of 
driving is probably a great deal higher than at the time of 
sampling (30–90 minutes later). Imposing limits on the 
concentration of THC in blood based on the results of 
scientific studies (e.g. 3–5 ng/ml), as discussed in some 
quarters, would result in many individuals evading 
prosecution. Zero tolerance or limit of quantitation laws 
are a much more pragmatic way to enforce legislation on 
driving under the influence of drugs.
Karschner et al. (2009a) found substantial whole-blood 
THC concentrations 7 days after drug discontinuation in 
heavy chronic cannabis users. In another study 
(Karschner et al., 2009b), plasma cannabinoid 
concentrations were determined in 18 long-term heavy 
cannabis smokers in an in-patient research unit during a 
7-day period of monitored abstinence. THC 
concentrations were > 1 ng/ml (1.2–5.5 ng/ml) in nine 
(50.0 %) participants on abstinence day 7. Measurable 
THC concentrations after 7 days of abstinence indicate 
a potential mechanism for the residual neurocognitive 
impairment observed in chronic cannabis users. The 
presence of THC in plasma after 7 days of abstinence 
suggests that its detection may not indicate recent use 
in daily cannabis users. These findings may also impact 
on the implementation of per se limits in legislation on 
driving under the influence of drugs.
An expert panel in Norway (Vindenes et al., 2012) 
proposed that, for the purpose of imposing sanctions, 
cut-off values for THC in blood of 1.3, 3.0 and 9.0 ng/ml 
should be considered equivalent to alcohol levels of 0.2, 
0.5 and 1.2 g/l, respectively.
I Risks
When studying the risks associated with cannabis use, 
the results can be misleading if samples are analysed for 
THC-COOH, as this is an inactive metabolite of cannabis 
that can be present in blood or urine even though the 
subject is no longer impaired. Better correlation with 
impairment can be achieved by testing for THC, the 
primary active ingredient of cannabis (Verstraete, 2004).
Accident risk
Four epidemiological studies investigated the risk of 
being involved in a traffic accident while driving under 
the influence of cannabis. A case–control study in 
Québec, Canada, found that driving under the influence 
of cannabis alone was associated with an OR of 2.2 
(95 % CI 1.5–3.4); however, taking account of all 
cannabis cases resulted in an OR of 4.6 (95 % CI 
3.4–6.2) (Dussault et al., 2002). Driving under the 
influence of a combination of alcohol (BAC > 0.8 g/l) and 
cannabis was associated with an increased accident risk 
of 80.5 (OR; 95 % CI 28.2–230.2). In France, the 
prevalence of alcohol, cannabis and other drugs was 
compared in 900 injured drivers and 900 control 
subjects (Mura et al., 2003). Among drivers below the 
age of 27 years, driving under the influence of cannabis 
alone was associated with an increased accident risk of 
2.5 (OR; 95 % CI 1.5–4.2); with alcohol (BAC > 0.5 g/l) 
plus cannabis the increased risk was 4.6 (OR; 95 % CI 
2.0–10.7). The Impaired Motorists, Methods of Roadside 
Testing and Assessment for Licensing (Immortal) study 
in the Netherlands and Norway found an increased 
accident risk (albeit not statistically significant) for 
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driving under the influence of cannabis alone (Assum et 
al., 2005).
The accident risk associated with driving under the 
influence of cannabis has also been studied based on 
the results of surveys instead of detection procedures. 
Fergusson and Horwood (2001) examined associations 
between cannabis use and traffic accident risks in a 
birth cohort of 907 New Zealanders aged 18–21 years. 
They found statistically significant relationships between 
reported annual cannabis use and annual accident rates, 
but only for ‘active’ accidents in which the driver’s 
behaviour contributed to the accident. Those using 
cannabis more than 50 times a year had estimated rates 
of active accidents that were 1.6 (95 % CI 1.2–2.0) times 
higher than for non-users. However, when driver 
behaviours and characteristics related to cannabis use 
were controlled for, no association between cannabis 
use and accident risks was apparent. These data thus 
suggest that cannabis use is associated with an 
increased risk of responsibility for an accident, but that 
this increased risk appears to reflect the characteristics 
of the young people who used cannabis rather than the 
effects of cannabis on driver performance.
Fergusson et al. (2008) examined the associations 
between driving under the influence of (a) cannabis and 
(b) alcohol and motor vehicle collisions in a longitudinal 
study of a New Zealand birth cohort (n = 936). 
Participants reported significantly (p < 0.0001) greater 
rates of driving under the influence of cannabis than 
driving under the influence of alcohol at the ages of 
21–25 years. After adjustment for potentially 
confounding factors, the associations between driving 
under the influence of cannabis and motor vehicle 
collisions remained marginally significant (p = 0.064), 
whereas adjustment for confounding factors reduced 
the association between driving under the influence of 
alcohol and motor vehicle collisions to statistical 
non-significance (p > 0.70).
Gerberich et al. (2003) conducted a retrospective study 
in northern California among members of a large health 
insurance cohort who had completed baseline 
questionnaires about health behaviours, including 
cannabis use, and health status between 1979 and 
1985. In addition, all subjects’ hospitalisations for 
injuries until 31 December 1991 were identified. 
Statistical analysis showed a higher incidence of motor 
vehicle injuries in men who were current users of 
cannabis than in non-users. There were no differences 
among female cannabis users or former users.
In a case–control study, Blows et al. (2005) recorded 
drivers’ self-reported cannabis use in the 3 hours prior to 
the crash (or, in the case of the control subjects, the 3 
hours prior to the survey) and habitual cannabis use in 
the previous 12 months. The cases were drivers involved 
in crashes and the control group consisted of drivers in a 
random sample of cars. Acute cannabis use was 
significantly associated with car crash injury. However, 
after adjusting for confounders (BAC, seatbelt use, 
speed and sleepiness score), this effect was no longer 
significant. There was a strong significant association 
between habitual use and car crash injury, even after 
adjustment for all the above confounders plus acute use 
prior to driving (OR 9.5; 95 % CI 2.8–32.3).
Asbridge et al. (2005) questioned 6 087 senior students 
about driving under the influence of cannabis and 
involvement in motor vehicle collisions. Students who 
had driven under the influence of cannabis in the 
previous year were over four times as likely as cannabis-
free drivers to have been involved in a motor vehicle 
collision, but those who used the drug but did not drive 
while they believed themselves to be under its influence 
did not experience more accidents.
A similar study was conducted among cannabis users in 
Australia (Jones et al., 2005). The likelihood of having 
had an accident in the previous year was 7.4 % for those 
who had not driven within an hour of using a drug in the 
previous 12 months and 10.7 % for those who reported 
driving after using cannabis only. The proportion who 
had had an accident in the previous year was much 
higher among those who reported driving after using 
cannabis with alcohol or other illicit drugs — either 
simultaneously (24 %) or on different occasions (23 %) 
— than it was for the other drivers.
Based on the DRUID results in Belgium (Kuypers et al., 
2012), an OR of 12.10 (95 % CI 3.62–40.43, p < 0.001) 
was calculated. For THC concentrations of 1–1.99 ng/ml 
the OR was 5.84 (95 % CI 0.56–60.48, not statistically 
significant), for THC concentrations of 2–4.99 ng/ml the 
OR was 22.24 (95 % CI 2.38–207.77, p = 0.007) and for 
THC concentrations > 5 ng/ml the OR was 13.16 (95 % 
CI 1.90–91.18, p = 0.009). Evaluation of these results 
has shown that the OR might be spuriously elevated as a 
result of selection bias in the control group (Houwing et 
al., 2013).
Pulido et al. (2011a) calculated a RR of driving-related 
injury in the 60 minutes following cannabis use of 7.0 
(95 % CI 3.1–16). This value increased to 11 (95 % CI 
1.3–88) for concurrent exposure to alcohol and 
decreased to 6 (95 % CI 2.4–14) for non-concurrent 
exposure to any other psychoactive drug. The RRs were 
considerably lower when the hazard period was 
increased to 120 minutes. In another study by the same 
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group (Pulido et al., 2011b), logistic regression was used 
to adjust for distance driven and potential confounders 
among 17 484 car or motorcycle drivers in 2005 in 
Spain. Cannabis use on more than 4 days a week was 
associated with a higher number of traffic injuries.
Richer and Bergeron (2009) found that driving under the 
influence of cannabis is associated with self-reported 
and observed risky driving and negative emotional 
driving. They also found that sensation seeking and 
impulsivity are independent psychological predictors of 
driving under the influence of cannabis. Finally, a trend 
suggested that self-reported driving under the influence 
of cannabis is associated with an increased risk of being 
involved in a car accident, after controlling for dangerous 
driving and demographic variables.
In the United Kingdom, results from a postal 
questionnaire survey found that cannabis use was 
associated with an increased risk of road traffic 
accidents (OR 1.9; 95 % CI 1.0–3.5), and this risk 
increased with higher levels of other associated risk 
factors (Wadsworth et al., 2006).
In the DRUID case–control study (Hels et al., 2011), the 
RR of being seriously injured was estimated to be slightly 
increased (1–3). The adjusted OR, based on data for all 
countries, was 1.38 (95 % CI 0.88–2.17) for being 
seriously injured and 1.33 (95 % CI 0.48–3.67) for death.
Responsibility analyses
A study of 3 398 fatally injured drivers conducted in 
Australia from 1990 to 1999 found an OR of 2.7 (95 % CI 
1.02–7.0) for responsibility for an accident while driving 
under the influence of cannabis alone (Drummer et al., 
2004). For drivers with blood THC concentrations of 
5 ng/ml or higher, the OR was greater and more 
statistically significant (OR 6.6, 95 % CI 1.5–28.0). A 
significantly stronger positive association with accident 
responsibility was seen in drivers who tested positive for 
cannabis and had a BAC of 0.5 g/l or higher compared 
with a BAC of 0.5 g/l or higher and no cannabis use (OR 
2.9; 95 % CI 1.1–7.7). In another study in Australia, 
conducted in 1995–1996 and using blood samples from 
2 500 injured drivers, no significant increase in 
responsibility (OR 0.8; 95 % CI 0.4–1.5) was found when 
cannabis was used alone (Longo et al., 2000b). The 
combination of alcohol and cannabis produced a 
significant increase in responsibility (OR 5.4; 95 % CI 
1.2–24.0), but this increase was not significantly greater 
than that produced by alcohol alone. A responsibility 
analysis performed in Canada with 482 fatally injured 
drivers showed no statistically significant results for 
either cannabis alone (OR 1.2; 95 % CI 0.4–3.9) or the 
combination of alcohol (BAC > 0.8 g/l) and cannabis (OR 
2.5; 95 % CI 0.3–20.2) (Dussault et al., 2002). Among 
10 748 drivers involved in fatal crashes in France from 
October 2001 to September 2003, the presence of 
cannabis was associated with increased risk of 
responsibility (OR 3.3; 95 % CI 2.6–4.2) (Laumon et al., 
2005). Moreover, a significant dose effect was identified, 
with OR increasing from 1.6 (95 % CI 0.8–3.0) for THC 
concentrations in blood of 0–1 ng/ml to 2.1 (95 % CI 
1.3–3.4) for THC concentrations above 5 ng/ml. The 
effects of cannabis were adjusted for different co-
factors, including BAC, age, vehicle type and time of 
crash. For driving under the influence of a combination 
of alcohol and cannabis, an OR of 14 (95 % CI 8.0–24.7) 
was calculated, which is very close to the value obtained 
from the product of the adjusted individual effects of 
alcohol and cannabis. In the United States, two analyses 
of injured drivers did not find an association between 
cannabis use and crash responsibility (Lowenstein and 
Koziol-McLain, 2001; Soderstrom et al., 2005). This may 
be the result of some methodological limitations, as both 
studies used urine for the toxicological analysis. As 
cannabis metabolites can be detected in urine for up to 
several days after chronic use, a sample testing positive 
for cannabis does not necessarily indicate recent use. 
Lowenstein and Koziol-McLain (2001), however, 
performed secondary cannabis testing on the same 
urine samples by using a liquid–liquid extraction 
procedure that tests for the parent drug (THC) to 
differentiate between recent and non-recent use. Drivers 
were categorised as follows: acute cannabis use (THC 
positive), recent cannabis use (11-OH-THC positive) and 
remote cannabis use (THC-COOH positive). The 
researchers found no association between crash 
responsibility and acute cannabis use, nor between 
crash responsibility and recent cannabis use or remote 
cannabis use. However, the samples were frozen for up 
to one year; the freezing and thawing may have led to 
some degradation of the cannabis and possibly to an 
underestimation of the prevalence of acute and recent 
cannabis use.
In the Netherlands, Smink et al. (2005) investigated the 
relationship between cannabis use and the severity of a 
traffic accident in drivers involved in crashes from 
October 1998 to September 1999. Blood samples were 
screened for the presence of alcohol, illicit drugs and 
medicinal drugs. Logistic regression analysis showed no 
association between the use of cannabis and the 
severity of a traffic accident.
Gadegbeku et al. (2011) found that the effect of 
cannabis on fatal crash responsibility was significant 
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leading to insufficient allocation of task-orientated 
resources and suboptimal performance. Cannabis 
acutely reduces cognitive and psychomotor skills that 
are necessary for driving such as motor control, 
psychomotor speed, executive function, motor 
impulsivity, visual processing, short-term memory, 
working memory, perception and balance, and these 
effects are mostly dose dependent. In driving studies 
with low doses of cannabis, subjects were aware of the 
impairment and adjusted their driving style accordingly, 
but control deteriorated with increasing task complexity.
Duration of effects: The desired effect of cannabis, the 
‘high’, lasts for up to 2 hours, but most studies found 
significant negative effects of cannabis on performance 
up to 10 hours after use.
Combinations: The risk of causing a crash by driving 
under the influence of alcohol and cannabis is similar to 
the product of the adjusted individual risks. Marijuana 
smokers tend to compensate effectively while driving by 
utilising a variety of behavioural strategies, but 
combining marijuana with alcohol eliminates the ability 
to use such strategies effectively.
Chronic use: Chronic use of cannabis can lead to 
deficiencies in memory, attention, manual dexterity, 
executive functioning and psychomotor speed. These 
effects can last longer than the period of intoxication 
and worsen with both increasing number of years and 
frequency of cannabis use. The defects are partially 
reversible with prolonged abstinence, but some 
impairment may be permanent. Very heavy use of 
marijuana is associated with persistent decrements in 
neurocognitive performance even after 3 or 4 weeks of 
abstinence.
Threshold concentration: Epidemiological studies 
showed that the risk of being in an accident is increased 
at THC concentrations above 1 or 2 ng/ml. Measurable 
THC concentrations after 7 days of abstinence indicate 
a potential mechanism for the residual neurocognitive 
impairment observed in chronic cannabis users.
Accident risk: Meta-analyses of data from epidemiological 
studies have shown that cannabis use is associated with a 
twofold increased risk of being involved in an accident. The 
risk of being involved in or responsible for a traffic accident 
is higher for the combination of alcohol and cannabis (OR 
approximately 15).
after adjustment for age, sex and alcohol level: the 
adjusted OR was 1.89 (95 % CI 1.43–2.51) and the 
dose–response effect was significant (p = 0.0001).
Meta-analyses
Three meta-analyses have been published recently. 
Asbridge et al. (2012) selected nine studies and 
concluded that driving under the influence of cannabis 
was associated with a significantly increased risk of 
motor vehicle collisions compared with unimpaired 
driving (OR 1.91; 95 % CI 1.35–2.73). They noted 
heterogeneity among the individual study effects, with 
higher collision risk estimates in case–control studies 
(2.79; 95 % CI 1.23–6.33) and studies of fatal collisions 
(2.10; 95 % CI 1.31–3.36) than in culpability studies 
(1.65; 95 % CI 1.11–2.46) and studies of non-fatal 
collisions (1.74; 95 % CI 0.88–3.46).
Li et al. (2012) included nine epidemiological studies in 
their meta-analysis and found an OR of 2.66 (2.07–3.41). 
Analysis of individual studies indicated that the 
heightened risk of crash involvement associated with 
marijuana use persisted after adjustment for 
confounding variables (including alcohol) and that the 
risk of crash involvement increased in a dose–response 
fashion with the concentration of THC-COOH detected 
in urine and the frequency of self-reported marijuana 
use. An analysis according to study design, type of drug 
assessment, study time period, study location and age 
of the subjects showed a more than twofold increased 
crash risk in each of the subsets of studies.
In another meta-analysis, Elvik (2013) found that the 
best estimate of the RR of accident involvement with 
cannabis, adjusted for publication bias, was 1.25 (95 % 
CI 0.87–1.79) for fatal accidents, 1.08 (95 % CI 0.86–
1.36) for injury accidents and 1.14 (95 % CI 1.00–1.30) 
for crashes resulting in property damage.
I Conclusion
The results of experimental studies clearly indicate that 
cannabis use can have a detrimental impact on driving 
ability, as it impairs some cognitive and psychomotor 
skills that are necessary for driving. Most of these effects 
increase in a dose-dependent way. A cannabis user is 
aware of the impairment, but can only partially 
compensate for it.
Acute effects: A study using fMRI found that, after use of 
cannabis, subjects were more attracted by intrapersonal 
stimuli (‘self’) and failed to attend to task performance, 
Drug use, impaired driving and traffic accidents
42
morphine can increase visual analogue scale ratings 
indicative of both pleasant (e.g. drug liking, increased 
calmness) and unpleasant (e.g. ‘feel bad’, ‘nauseous’) 
effects (Hill and Zacny, 2000; O’Neill et al., 2000; Walker 
et al., 2001). Hill and Zacny (2000) found that 
psychomotor impairment was absent after a single 
morphine dose of 5 or 10 mg/70 kg. Walker et al. (2001) 
compared the effects of cumulative morphine doses of 
2.5, 7.5 and 17.5 mg/70 kg with the effects of mixed-
action opioids. They found that morphine decreased 
performance on the DSST — in which speed decreased 
while accuracy was not affected — in a dose-dependent 
manner. Morphine also induced miosis and impaired 
eye–hand coordination in a dose-dependent manner. 
The impairment caused by morphine was of lower 
magnitude than that caused by mixed-action opioids. 
Knaggs et al. (2004) also observed an induction of miosis 
with morphine. Intravenous morphine (0.125 mg/kg) 
resulted in a 26 % decrease in pupil diameter in 10 
healthy volunteers. O’Neill et al. (2000) administered 
repeated doses of morphine to subjects, and found one 
major effect, namely an increase in accuracy on the CRT 
task, but the speed of the response tended to be lower. 
Other effects were improvements in the accuracy of 
delayed recall and a reduction in the frequency at which 
fusion was detected in the CFF task. These effects 
lasted for up to 36 hours after repeated doses. The 
authors concluded that the effects of morphine were not 
substantial compared with those of lorazepam (one of 
the comparator drugs in the study).
In their meta-analysis of the experimental studies 
performed as part of the DRUID project, Strand et al. 
(2011) concluded that administration of a single dose of 
morphine of up to 5 mg appears to cause very few 
effects in traffic-relevant performance tasks. At higher 
doses, performance of various tasks is impaired, but with 
no clear dose–effect relationship except on the DSST. It 
is likely that blood morphine concentrations < 14 μg/l 
are accompanied by few effects in traffic-relevant 
performance tasks. Therefore, this level, 14 μg/l, could 
represent a level with little associated traffic risk.
An expert panel in Norway (Vindenes et al., 2012) 
proposed that, for the purpose of imposing sanctions, 
cut-off values for morphine in blood of 9, 24 and 61 μg/l 
should be considered equivalent to alcohol levels of 0.2, 
0.5 and 1.2 g/l, respectively.
Fentanyl
Schneider et al. (1999) found that fentanyl in 
concentrations commonly used in outpatient surgical 
procedures (0.2 μg/kg) produces pronounced cognitive 
I Opioids
Opioids can be divided into three groups, namely those 
with morphine-like activity (e.g. morphine, heroin, 
fentanyl and methadone), those that block the activity of 
morphine (e.g. naloxone and naltrexone) and those that 
exhibit mixed activity (e.g. codeine, buprenorphine and 
pentazocine) (Drummer, 2001). In this report, the acute 
and chronic effects and risks associated with the 
following opioids will be discussed: morphine, heroin, 
methadone, buprenorphine, fentanyl and codeine.
Fishbain et al. (2003) conducted a structured, evidence-
based review of whether the driving-related skills of 
opioid-dependent or -tolerant patients are impaired. 
They found moderate, generally consistent, evidence of 
no impairment of psychomotor abilities and inconclusive 
evidence of no impairment of cognitive function. In 
addition, the evidence that there is no impairment of 
psychomotor abilities immediately after being given 
doses of opioids was strong and consistent. The 
evidence was also strong and consistent that the 
incidence of traffic violations or MVAs is not higher than 
in comparable control subjects. The analysis also 
revealed consistent evidence of no impairment of 
performance in driving simulators and off- or on-road 
studies. The authors also discuss possible causes for the 
inconsistent evidence in the cognitive impairment 
studies. One is the issue of unrelieved pain, as there is 
strong evidence that unrelieved pain may decrease 
psychomotor and cognitive performance. Another 
confounder could be educational level, as this has been 
shown to better correlate with measures of 
neuropsychological function than current or past levels 
of opioid use. In studies of cancer patients, disease state 
could be a confounder, as recent evidence indicates 
that, in cancer patients using opioids, the disease itself 
has the greatest impact on alertness. Another potential 
confounder in the studies in drug addicts is associated 
non-opioid drug abuse history; drug users with a history 
of alcohol dependence/abuse and/or polysubstance 
dependence/abuse show greater neuropsychological 
impairment than cocaine dependence/abuse addicts, 
who in turn will experience greater impairment than 
control subjects.
I Acute effects
Morphine
Experimental studies have investigated the effects of 
single or repeated doses of morphine on healthy 
subjects in a laboratory setting. The results indicate that 
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impairment (auditory reaction time, signal detection, 
sustained attention, recognition) compared with 
placebo. Lichtor et al. (2002) investigated the effects on 
psychomotor function of ambulatory anaesthesia with 
propofol 2.5 mg/kg, propofol 2.0 mg/kg plus fentanyl 
2 μg/kg, propofol 2.0 mg/kg plus midazolam 2 mg/70 kg 
or midazolam 0.07 mg/kg plus fentanyl 2 μg/kg. 
Psychomotor function was impaired up to 2 hours after 
injection with propofol alone and with each of the drug 
combinations. The multiple sleep latency test 
demonstrated sleepiness up to 8 hours after an injection 
of midazolam plus fentanyl. However, in driving simulator 
tests, Sinclair et al. (2003) found no significant 
impairment at 2, 3 or 4 hours after treatment with 
2.5 mg/kg propofol plus 1 μg/kg fentanyl.
In their meta-analysis of the experimental studies 
performed as part of the DRUID project, Strand et al. 
(2011) concluded that fentanyl can be used acutely in 
procedures requiring pain relief at doses resulting in 
blood fentanyl concentrations up to 10 ng/ml before 
serious respiratory problems occur. Fentanyl has a 
half-life of 1–6 hours, which indicates that patients 
should refrain from driving for at least 12 hours after 
such dosages.
Heroin
No experimental studies on the acute effects of heroin in 
humans have been published since 1999. Therefore, a 
short overview will be given on the results of studies that 
were published before 1999. Several studies confirmed 
the acute effects of heroin on subjective sedation and on 
miosis (Cone et al., 1993; Jasinski and Preston, 1986; 
Jenkins et al., 1994; Martin and Fraser, 1961). One study 
found a trend towards decreased performance on the 
CLT, which is an indicator of psychomotor performance 
(Cone et al., 1993). In another study, the administration 
of heroin impaired performance on a reaction time task 
(Jenkins et al., 1994). However, the doses used in these 
studies ranged from 2 to 20 mg, while average daily 
doses in addicts range from 300 to 500 mg (Couper and 
Logan, 2004a). The effects of heroin on performance can 
last up to 6 hours (Cone et al., 1993; Jasinski and 
Preston, 1986; Jenkins et al., 1994; Martin and Fraser, 
1961). The duration of the effects is dependent upon the 
dose and the route of administration. For example, 
Jenkins et al. (1994) assessed subjective effects of 
sedation, miosis and increased reaction time that lasted 
for 2 hours after smoking and 4 hours after intravenous 
administration.
Methadone
Several studies have investigated the effects on 
performance of substances used for substitution 
treatment. In a study of the acute effects of methadone 
in patients admitted to an opioid detoxification 
programme, patients were tested after 3 and 5 days of 
methadone treatment (Curran et al., 2001). Performance 
on an episodic memory task was significantly impaired 
following the 100 % daily dose of methadone. The effect 
could, however, be avoided by giving methadone in 
Heroin is a crude preparation of diamorphine. It is a 
semisynthetic product obtained by acetylation of 
morphine, which occurs as a natural product in 
opium: the dried latex of certain poppy species (e.g. 
Papaver somniferum L.).
Diamorphine, like morphine and many other 
opioids, produces analgesia. It behaves as an 
agonist at a complex group of receptors (the μ, κ 
and δ subtypes) that are normally acted upon by 
endogenous peptides known as endorphins. Apart 
from analgesia, diamorphine produces drowsiness, 
euphoria and a sense of detachment. Negative 
effects include respiratory depression, nausea and 
vomiting, decreased motility in the gastrointestinal 
tract, suppression of the cough reflex and 
hypothermia. Tolerance and physical dependence 
occur with repeated use. Cessation of use in 
tolerant subjects leads to characteristic withdrawal 
symptoms. Subjective effects following injection 
are known as ‘the rush’ and are associated with 
feelings of warmth and pleasure, followed by a 
longer period of sedation. Diamorphine is two to 
three times more potent than morphine. The 
estimated minimum lethal dose is 200 mg, but 
addicts may be able to tolerate 10 times as much. 
Following injection, diamorphine crosses the 
blood–brain barrier within 20 seconds, with almost 
70 % of the dose reaching the brain. It is difficult to 
detect in blood because of rapid hydrolysis to 
6-monoacetylmorphine and slower conversion to 
morphine, the main active metabolite. The plasma 
half-life of diamorphine is about 3 minutes.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
Pharmacology of heroin
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correct or percentage errors. CLT performance was 
decreased at the highest intramuscular dose (16/4 mg). 
There was also a significant increase in the number of 
trails’ sequence errors for the two highest intramuscular 
doses of buprenorphine/naloxone (Stoller et al., 2001). 
Comer et al. (2002) studied the effects of intravenously 
administered buprenorphine (2 or 8 mg) or placebo on 
the performance of detoxified heroin users on a DSST, a 
divided attention task, a rapid information processing 
task and a repeated acquisition of response sequences 
task. There were few effects of buprenorphine on 
performance, with the exception of impairments in 
performance on the divided attention task. The latency 
to respond to a brief target randomly appearing on the 
computer screen was greater, the number of missed 
targets significantly increased and the number of 
correctly identified targets significantly decreased. 
Dagtekin et al. (2007), in a prospective trial, compared 
30 patients suffering from chronic non-cancer pain who 
had been treated with stable doses of transdermal 
buprenorphine with 90 healthy volunteers (matched 
pairs). Driving ability, defined as a result above the 16th 
percentile for normal subjects (individuals performing 
worse than the 16th percentile of the control group are 
considered to be unable to drive according to German 
law), did not differ significantly between the patients and 
the control group. The authors concluded that long-term 
use of transdermal buprenorphine for chronic non-
cancer pain does not impair driving ability, but, because 
of the individual variability of test results, an individual 
assessment is recommended.
Shmygalev et al. (2011), using a battery of tests, 
performed a prospective comparison of opioid 
substitution patients receiving sublingual buprenorphine 
and a control group of untreated, healthy volunteers. 
Patients receiving a stable dose of sublingual 
buprenorphine showed no significant impairment of 
complex psychomotor or cognitive performance 
compared with healthy control subjects. However, intake 
of illicit drugs as well as the lack of social reliability were 
major problems in this specific patient group. The 
authors concluded that, despite the absence of a 
relevant impact of the drug on driving ability, such 
patients should not be allowed to hold a driving licence.
In their meta-analysis performed as part of the DRUID 
project, Strand et al. (2011) found that single-dose 
buprenorphine (0.075–0.6 mg/kg intravenous, 0.4 mg 
oral, 0.3 mg intramuscular) impaired performance in 18 
out of 20 tests administered to drug-naive healthy 
volunteers. When single doses were administered to 
opioid users, these acute effects were less pronounced. 
In patients maintained on methadone or buprenorphine, 
doses of up to 13.4 mg buprenorphine resulted in 
divided doses. No effects were observed on DSST, FTT 
and digit cancellation records.
In their meta-analysis performed as part of the DRUID 
project, Strand et al. (2011) found that single doses of 
methadone of up to 10 mg impaired performance on 
three out of five tests administered to drug-naive, healthy 
subjects. When single doses of methadone were 
administered to opioid users, these acute effects were 
less pronounced. When single doses of methadone were 
administered to methadone-maintained patients, the 
acute effects of methadone also appeared to be less 
pronounced, as dose-related impairment of performance 
on 10 out of 50 tests was found following administration 
of methadone doses of up to 120 mg. Regarding 
performance of methadone maintenance patients 
compared with control subjects, 110 out of 236 tests 
showed impairment. Four studies have compared the 
performance before and after long-term methadone 
intake; one of the studies found impairment and one 
found improvement from baseline measures.
An expert panel in Norway (Vindenes et al., 2012) 
proposed that, for the purpose of imposing sanctions, a 
cut-off value for methadone in blood of 25 ng/ml should 
be considered equivalent to an alcohol concentration of 
0.2 g/l.
Buprenorphine
As a partial opioid receptor agonist, buprenorphine has a 
ceiling effect on its agonist activity, which greatly 
increases its safety profile relative to full-agonist 
medications such as methadone. Strain et al. (2000) 
administered sublingual buprenorphine (4, 8 or 16 mg) 
or a combination of sublingual buprenorphine and 
naloxone to seven non-dependent opioid users, and 
investigated the effects on psychomotor and cognitive 
performance. Results on the DSST showed no 
significant changes at any of the dose conditions tested, 
and there were no significant differences in the total 
number of sequence errors made on a TMT. However, 
the highest buprenorphine/naloxone dose (16/4 mg) 
produced a significantly higher total line length for the 
trails. The CLT showed significant decreases in 
performance with 16 mg buprenorphine. The same 
researchers investigated the effects of a single 
intramuscular or sublingual administration of combined 
buprenorphine and naloxone at various doses in opioid-
dependent subjects. There was no evidence that 
sublingual buprenorphine and naloxone impairs 
psychomotor performance. There were no significant 
effects of any test condition on the trails’ total length or 
total errors or on the DSST’s number attempted, number 
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in the sense that it could cause impairment in some 
traffic-relevant tasks.
One of the DRUID project’s experimental studies 
(Schulze et al., 2012) concluded that combinations of 
codeine and paracetamol in general did not produce 
driving impairment when administered to healthy 
volunteers even at higher doses. However, driving 
impairment became apparent after the lowest dose 
when paracetamol was administered to elderly subjects. 
Thus, the results indicate that the impairing potential of 
codeine and paracetamol varies with age.
Dose change
Gaertner et al. (2008) conducted a prospective trial in 
patients suffering from chronic non-cancer pain in order 
to examine the effects of the daily dose of opioids on 
psychomotor and cognitive functions. A computerised 
test system was administered to patients before and 
7 days after alteration of their opioid therapy. Seven days 
after an increase in the daily dose of an opioid or after 
the initiation of opioid therapy there was no general 
deterioration in patients’ driving ability at group level.
Gomes et al. (2013) conducted a population-based 
nested case–control study of patients aged 18–64 years 
who received at least one publicly funded prescription 
for an opioid and demonstrated that, compared with very 
low opioid doses, drivers who were prescribed low doses 
had a 21 % increased odds of road trauma (adjusted OR 
1.21; 95 % CI 1.02–1.42); those prescribed moderate 
doses had a 29 % increased odds (adjusted OR 1.29; 
95 % CI 1.06–1.57); those prescribed high doses had a 
42 % increased odds (adjusted OR 1.42; 95 % CI 
1.15–1.76); and those prescribed very high doses had a 
23 % increased odds (adjusted OR 1.23; 95 % CI 
1.02–1.49).
I Chronic effects
Opioid therapy
Larsen et al. (1999) compared attention and reaction 
time in patients on long-term opioid therapy (patients 
with cancer pain or chronic non-malignant pain), patients 
receiving non-opioid analgesic therapy for chronic 
non-malignant pain and a control group of patients 
without pain or analgesic therapy. No significant 
difference in attention/concentration between the three 
groups could be demonstrated. However, attention/
concentration was more impaired in cancer patients 
impairment in only 2 out of 21 tests. Furthermore, in 3 
out of 21 tests carried out in methadone- or 
buprenorphine-maintained patients, performance 
improved after buprenorphine doses of 4 to 13.4 mg. 
Buprenorphine-maintained patients showed impairment, 
relative to control subjects, on 14 out of 44 tests.
An expert panel in Norway (Vindenes et al., 2012) 
proposed that, for the purposes of sanctions, a cut-off 
value for buprenorphine in blood of 0.9 ng/ml should be 
considered equivalent to an alcohol concentration of 
0.2 g/l.
Codeine
Bachs et al. (2009) performed a prospective cohort trial 
using data from national population-based registries — 
the Norwegian Prescription Database and the 
Norwegian Road Accident Registry — and observations 
of over 8 million person-years were used in order to 
examine whether a driver who has filled a prescription 
for codeine or tramadol is at increased risk of being 
involved in a road accident resulting in injury to persons. 
The risk of being involved in an accident was significant 
for drivers using codeine [standardised incidence ratio 
(SIR) for both sexes and all age groups combined: 1.9; 
95 % CI 1.6−2.2]. The SIR for tramadol (1.5; 95 % CI 
0.9–2.3) was not significant but showed an upward 
trend. Nilsen et al. (2011) performed a driving simulator 
study in 20 patients with chronic pain on long-term 
codeine therapy, 20 chronic pain patients not using 
codeine and 20 healthy control subjects. The patients 
using codeine 120–270 mg (mean 180 mg) daily 
showed the same driving skills as patients not using 
codeine, and the codeine level did not affect the results, 
either 1 hour after intake of a single dose of 60 mg 
codeine or ≥ 5 hours after the last codeine intake. 
Reaction times in both rural and urban driving conditions 
were significantly higher in the patients with chronic pain 
than in the healthy control subjects (difference 0.11 
seconds and 0.12 seconds, respectively). The chronic 
pain patients missed almost twice as many reactions to 
traffic signs. There was no difference between the 
groups in steering precision. Codeine did not impair 
driving-related abilities over and above what is 
associated with chronic pain per se.
In the meta-analysis performed as part of the DRUID 
project (Strand et al., 2011), the lowest impairing dose of 
codeine was 25 mg. The half-life of codeine is 2–4 hours. 
Thus, 4 hours after an intake of 50 mg there could still be 
impairing effects comparable to the acute effects after 
an intake of 25 mg codeine. A therapeutic schedule with 
dosing of 50 mg every 6 hours would probably be unsafe 
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reverse driving, turning and parallel parking. No 
significant differences were observed between the 
group of patients and the control group.
Several experimental studies have investigated the 
effects of chronic use of specific opioids. Raja et al. 
(2002) compared the cognitive and psychomotor 
effects of morphine versus a TCA in patients with 
neuropathic pain syndrome. Each subject received 
approximately 8 weeks each of morphine, nortriptyline 
and placebo. Patients who could not tolerate a drug 
were offered an alternative drug of the same class 
within that period; for morphine, the alternative was 
methadone. Performance was measured on the symbol 
substitution task from the WAIS (concentration and 
psychomotor function), the Hopkins verbal learning test 
and the grooved pegboard task (manual dexterity and 
psychomotor speed). Treatment with opioids did not 
influence performance on any measure. Tassain et al. 
(2003) investigated the long-term effects of oral 
sustained-release morphine on neuropsychological 
performance in patients with chronic non-cancer pain. 
Evaluations were performed at baseline in patients free 
from opioids and then after 3, 6 and 12 months. There 
was no impairment of any neuropsychological variable 
over time in the morphine-treated patients compared 
with the control group. Information processing speed 
was improved at 6 and 12 months and there were 
significant correlations with pain relief and improvement 
of mood. Patients, however, often require more pain 
relief than is afforded by sustained-release opioid drugs. 
Kamboj et al. (2005) examined the effects of additional 
immediate-release doses of morphine on cognitive 
functioning in patients receiving chronic opioid therapy 
in palliative care. The results suggested that immediate-
release morphine, when taken on top of a sustained-
release opioid, produces transient anterograde and 
retrograde memory impairments and a decrement in 
two-target tracking.
In pre-marketing clinical trials of transdermal fentanyl, 
somnolence and confusion each occurred in more than 
10 % of the 153 cancer patients, and tremor, abnormal 
coordination, abnormal gait, amnesia and syncope each 
occurred in 1 to 2 % (Kornick et al., 2003). Sabatowski et 
al. (2003) compared the performance of patients with 
continuous non-cancer pain, who had received stable 
doses of transdermal fentanyl for at least 2 weeks, on a 
series of computerised tests to measure attention, 
reaction, visual orientation, motor coordination and 
vigilance with the performance of healthy control 
subjects. None of the performance measures was 
significantly inferior in the group of patients compared 
with the control group. In a study of the psychomotor 
effects of long-term fentanyl use, patients with low back 
than in non-cancer patients taking opioids. Auditory and 
optical reaction times were significantly higher in 
patients on opioids than in the non-opioid analgesic 
group and very significantly higher than in the control 
group. Galski et al. (2000) determined the effects of 
medically prescribed stable opioid use on the driving 
abilities of patients with persistent, non-malignant pain, 
using a pre-driver evaluation, a simulator evaluation and 
behavioural observation during simulator performance. 
The control group consisted of cerebrally compromised 
patients who had undergone the same evaluation. The 
opioid-treated patients generally outperformed the 
control group. However, the opioid-treated patients had 
significant difficulty in following instructions and their 
ratings were more similar to the subjects in the control 
group who had failed than to the ratings of those who 
passed the evaluation. Sjogren et al. (2000a) assessed 
neuropsychological performance in chronic non-
malignant pain patients receiving long-term oral opioid 
therapy and in a control group of healthy volunteers. The 
neuropsychological tests consisted of continuous 
reaction time, FTT and PASAT. The patients performed 
more poorly than the control subjects in all the tests, 
with the differences being statistically significant. 
Significantly positive correlations were found between 
the results on the PASAT and the pain visual analogue 
scales. The authors concluded that pain itself seems to 
have an arousal effect on working memory. The same 
research group evaluated the effects of oral opioids and 
pain on performance of cancer patients on the same 
neuropsychological tests (Sjogren et al., 2000b). The use 
of long-term oral opioid treatment per se did not affect 
neuropsychological performance and, according to the 
authors, pain itself, more than oral opioid treatment, 
worsens performance on PASAT. Strumpf et al. (2005) 
studied the safety-relevant performance of patients 
receiving chronic opioid therapy. The patients’ results 
were worse on a concentration test and better on a 
coordination test than the results of healthy control 
subjects. The patients did not perform worse than 
healthy control subjects on tests of reaction time, 
vigilance and perception. Patients receiving an 
antidepressant in addition to the opioid performed more 
poorly on the test for concentration than patients not on 
antidepressants. Pain intensity did not influence 
patients’ results, nor did opioid dose, state of mind or 
side-effects. Byas-Smith et al. (2005) compared the 
psychomotor performance and driving ability of patients 
with chronic pain managed with stable opioid doses with 
that of healthy control subjects. Patients were evaluated 
for errors while driving their own car along a 
predetermined route in the community, including 
variable residential and highway conditions, and for 
speed and accuracy on repeated trials through a 
five-station obstacle course that evaluated forward and 
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only useful procedure to approach the question of 
fitness for driving.
Meta-analyses
Mailis-Gagnon et al. (2012) included 35 studies (2 044 
patients, 1 994 control subjects) in a systematic review 
of the quality and generalisability of studies on the 
effects of opioids on driving and cognitive/psychomotor 
performance. Of the included studies, 9 %, 54 % and 
37 % were of poor, fair and high quality, respectively; 
three-quarters of the studies used high-sensitivity 
cognitive tests. Dose of opioids varied largely in many 
studies. The mean number of possible but unreported 
confounders was 2.2 (range 0–4), and related mainly to 
the failure of the studies to mention co-prescriptions 
with psychotropic effects, pain severity, sleep disorder or 
daytime somnolence and/or significant depressive or 
anxiety-related problems. The authors concluded that 
the commonly held concept that chronic pain patients 
on stable opioids can safely drive cannot be generalised 
to all such patients in everyday practice, but may be 
applicable to only a subset who meet certain criteria.
Dassanayake et al. (2011) performed a meta-analysis of 
epidemiological and experimental evidence and found 
that limited epidemiological research reported that 
opioids may be associated with increased accident risk 
in the first few weeks of treatment.
Heroin dependence
Chronic heroin use can have long-lasting effects on 
some cognitive and psychomotor skills. Studies have 
found an impairment of planning function (Bryun et al., 
2001), reaction time (Liu et al., 2006), time perception 
(Alexandrov, 2004), spatial working memory (Ornstein et 
al., 2000), pattern recognition memory (Ornstein et al., 
2000), executive functioning (Lyvers and Yakimoff, 2003; 
Ornstein et al., 2000; Verdejo et al., 2004) and right–left 
discrimination (Ning et al., 2005). Chronic heroin users 
also tend to be reckless and ignore the rules and 
regulations of tasks (Pau et al., 2002). For some tasks, 
there is a significant relationship between the severity of 
heroin dependence or duration of use and the level of 
impairment (Bryun et al., 2001; Lyvers and Yakimoff, 
2003; Verdejo et al., 2004). For example, male addicts 
with a duration of use longer than 1.5 years perform 
worse on a Tower of London task than addicts with a 
shorter duration of use (Bryun et al., 2001). Some 
chronic effects can persist for more than a year after the 
last use of the drug (Pau et al., 2002), whereas some 
impairments last only a short period; for example, the 
pain were administered two neuropsychological tests 
(DSST and TMT) before being prescribed opioids for 
pain, and tests were readministered after 90 and 180 
days (Jamison et al., 2003). No impaired cognition or 
psychomotor function was observed, and, in fact, test 
scores were even significantly improved while subjects 
were taking opioids for pain. Menefee et al. (2004) 
compared the baseline performance of patients taking 
oxycodone with their performance after being stabilised 
for 1 month on transdermal fentanyl. The tests included 
driving performance in a driving simulator as well as 
cognitive and balance tests. No differences were found 
in driving simulation measures between the pre- and 
post-treatment periods. No decrements in cognitive 
performance were found, nor were there differences in 
balance or body sway. Improvements in visual motor 
tracking, visual memory and attention were observed 
during treatment with transdermal fentanyl.
The fact that pain plays a role in the cognitive defects 
detected in pain patients was confirmed in a study by 
Veldhuijzen et al. (2006a), who determined the effects of 
chronic non-malignant pain on actual highway driving 
performance during normal traffic. In addition, driving-
related skills (tracking, divided attention and memory) 
were examined in the laboratory. Subjective driving 
quality was rated on visual analogue scales. The results 
showed that a subset of pain patients had SDLP values 
that were higher than those of the matched healthy 
control subjects, which resulted in an overall statistically 
significant difference in SDLP between pain patients 
and healthy controls. Further, chronic non-malignant 
pain patients rated their subjective driving quality to be 
normal, although their ratings were significantly lower 
than those of the healthy control subjects. No significant 
effects were found in the laboratory tests.
In one of the DRUID project’s experimental studies 
(Schulze et al., 2012), the results of the driving tests 
revealed that the driving performance of patients 
suffering from chronic pain and receiving long-term 
treatment with opioid analgesics was similar to that of 
healthy control subjects. Nevertheless, 
neuropsychological tests assessing skills related to 
driving revealed that pain patients performed worse than 
healthy controls on a number of tests.
In their meta-analysis performed as part of the DRUID 
project, Strand et al. (2011) concluded that the literature 
is too limited to draw clear conclusions regarding the 
effects of long-term medical use of morphine and 
driving. It is, however, possible that drug effects of 
relevance to driving are not marked in such patients. 
Therefore, evaluation of individual performance of such 
patients seems, with the present knowledge, to be the 
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could thus be caused partially by the heroin addiction 
rather than the methadone treatment.
Some experimental studies have tried to differentiate 
between impairment caused by heroin addiction and 
impairment caused by methadone treatment. Davis et al. 
(2002) compared neuropsychological performance in 
methadone-maintained patients with that of drug-free 
ex-opioid users and of matched control subjects with no 
history of drug abuse. Methadone-maintained patients 
performed more poorly on a measure of verbal fluency 
than the two control groups. The performance of the 
drug-free ex-opioid users fell between that of the other 
two groups, without significant differences. Verdejo et al. 
(2005) also compared patients on methadone 
maintenance treatment with abstinent heroin users in 
terms of neuropsychological performance. A significantly 
slower performance was seen in methadone patients on 
processing speed, visuospatial attention and cognitive 
flexibility tests, and less accuracy was observed on 
working memory and analogical reasoning tests. Mintzer 
et al. (2005) also observed that the cognitive and 
psychomotor performance of patients on methadone 
maintenance treatment was worse than that of abstinent 
former opioid users, whose performance was in turn 
worse than that of healthy control subjects. These data 
suggest that methadone maintenance may be 
associated with additional impairment over and above 
that associated with long-term heroin abuse. Gruber et 
al. (2006) compared cognitive function in 17 opioid-
dependent subjects at baseline and after 2 months of 
methadone treatment. Significant improvements from 
baseline were seen in measures of verbal learning and 
memory, visuospatial memory and psychomotor speed. 
These improvements remained significant after co-
varying for illicit drug use. The authors suggest that 
impairment caused by methadone maintenance 
treatment may be reversible.
In a randomised controlled trial comparing the effects of 
a 28-day withdrawal treatment with either 
buprenorphine or clonidine on DSST performance in 
opioid-dependent adolescents, no evidence of 
psychomotor impairment was observed (Marsch et al., 
2005). Mintzer et al. (2004) evaluated the dose-related 
effects of buprenorphine/naloxone combination therapy 
in opioid-dependent volunteers following a period of 
7–10 days of administration, in a double-blind, within-
subject, crossover design. The tests included measures 
of psychomotor speed, time perception, conceptual 
flexibility, focused attention, working memory, long-
term/episodic memory and meta-memory. The results 
revealed little impairment in performance as the dose 
was increased fourfold (from 8/2 mg to 32/8 mg). The 
only significant effect of dose was impairment of 
effect on time perception disappears after 15 days of 
abstinence (Alexandrov, 2004).
Substitution treatment (methadone and 
buprenorphine)
The effects of substitution treatment on performance 
have been studied in former heroin addicts. Dittert et al. 
(1999) compared the performance of 28 patients taking 
methadone on reaction, visual perception and 
concentration tests with that of a control group matched 
for age, sex and education level. The methadone-treated 
patients showed significantly reduced performance, but 
six of them passed the tests to a level corresponding to 
sufficient driving skills. Darke et al. (2000) found that 
patients receiving methadone maintenance treatment 
showed cognitive deficits compared with a control group 
not using heroin. The patients’ performance was 
significantly worse than that of controls on all 
neuropsychological domains measured: information 
processing, attention, short-term visual memory, delayed 
visual memory, short-term verbal memory, long-term 
verbal memory and problem-solving. A history of alcohol 
dependence and repeated exposure to overdose 
increased the likelihood of cognitive impairment. The 
authors remarked that it was possible that other factors 
(which they did not specify) that were not measured in 
the study may have contributed to the cognitive 
impairment. In another study of methadone-maintained 
patients, higher speed in decision-making and motor 
reaction, but more decision errors on a simple CRT, were 
observed in patients than in healthy control subjects 
(Specka et al., 2000). The patients also showed poorer 
performance on an attention task and a tachistoscopic 
perception task. Performing a tracking test and a test 
concerning visual structuring, patients showed a higher 
accuracy combined with more time needed. However, 
the effects were moderate and, in most cases, the 
observed variance could be better explained by 
sociodemographic features than by treatment group. The 
authors suggest the need to investigate whether 
impairments in one area of demand are not 
compensated by, for example, reducing speed. Mintzer 
and Stitzer (2002) found that patients on methadone 
maintenance treatment exhibit impairment relative to 
healthy control subjects in psychomotor speed, working 
memory, decision-making and metamemory. The results 
also suggested possible impairment in inhibitory 
mechanisms. There was no impairment observed in time 
estimation, conceptual flexibility or long-term memory. 
The control group used in these three studies (Darke et 
al., 2000; Mintzer and Stitzer, 2002; Specka et al., 2000) 
consisted of subjects who were not addicted to heroin. 
The observed effects in the patients on methadone 
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differences in driving skills across the participant groups. 
Giacomuzzi et al. (2005a) compared the driving capacity 
of drug-dependent patients using buprenorphine or 
slow-release oral morphine. The data indicated better 
psychomotor performance in patients taking 
buprenorphine, especially on the visual pursuit test. The 
same researchers compared the driving capacity of 
patients treated with methadone or slow-release oral 
morphine, and observed better psychomotor 
performance in patients taking methadone (Giacomuzzi 
et al., 2005b).
McNamara (2002) studied cognitive function and 
well-being in patients switching treatment from 
morphine to transdermal fentanyl. Cognitive function 
tests revealed a significant improvement in working 
(short-term) memory and speed of memory although not 
in secondary (long-term) memory. The incidence of 
dizziness was significantly reduced, and sleepiness and 
drowsiness were significantly less of a problem.
Baewert et al. (2007) evaluated driving aptitude (in a 
simulator) and traffic-relevant performance (on relevant 
tests) at peak and trough medication levels in 40 
opioid-dependent patients receiving maintenance 
therapy with either buprenorphine (mean dose 13.4 mg) 
or methadone (mean dose 52.7 mg). Traffic-relevant 
performance was analysed 1.5 hours (peak level) and 20 
hours (trough level) after administration of opioid 
maintenance therapy. The results showed that patients 
had significantly more incorrect reactions (p = 0.03) and 
made significantly more simple errors (p = 0.02 ) when 
the level of medication was lowest than when drug levels 
were at their peak. In addition, the study found that, 
when drug levels were at their peak, methadone-
maintained patients tended to perform less well than 
buprenorphine-maintained patients on some of the test 
items. This investigation indicated that opioid-
maintained patients did not differ significantly at peak 
versus trough level in the majority of the investigated 
items and that neither substance appears to affect 
traffic-relevant performance when given as maintenance 
therapy in a population in whom concomitant 
consumption can be excluded.
In their meta-analysis performed as part of the DRUID 
project, Strand et al. (2011) found that eight studies 
compared the performance of buprenorphine- 
maintained patients with that of methadone- 
maintained patients. Overall, patients receiving 
buprenorphine performed better than those receiving 
methadone in 10 out of 59 tests. The differences 
between buprenorphine-maintained patients and 
matched control subjects seemed less evident than for 
methadone.
episodic/long-term memory at the highest dose, relative 
to the two lower doses.
Rogers et al. (1999) assessed decision-making in 13 
opioid users, three of whom were using heroin and 10 of 
whom were receiving methadone. Compared with 
healthy volunteers, the opioid users were found to 
deliberate for a significantly longer time before making 
their choices. There was, however, no difference in the 
quality of decision-making.
Comparison of chronic effects of the two main 
substitution treatments
Soyka et al. (2001) found an overall better psychomotor 
performance in patients taking buprenorphine than in 
those taking methadone, especially in tests under stress 
conditions and monotony. These findings were 
confirmed by several other studies. Schindler et al. 
(2004) found that opioid-dependent patients receiving 
maintenance treatment with either methadone or 
buprenorphine performed worse than control subjects 
on an attention test under monotonous circumstances 
and on decision and reaction time while driving in a 
dynamic environment. However, when separated into 
treatment groups, the mean decision and reaction times 
of buprenorphine-maintained patients did not differ from 
those in the control group, whereas patients on 
methadone showed significantly prolonged mean 
decision and reaction times. A controlled clinical study 
also showed that buprenorphine produces less 
impairment of cognitive functions on psychomotor 
testing than methadone (Soyka et al., 2005). Pirastu et 
al. (2006) evaluated decision-making in individuals on 
maintenance treatment with methadone or 
buprenorphine and in a control group of subjects who 
were not drug dependent. Subjects on buprenorphine 
performed better on the Iowa gambling task than those 
taking methadone, and about the same as the control 
group. The methadone group made more perseverative 
errors on the WCST than the control group, whereas the 
buprenorphine group had intermediate scores. Scores 
on the WAIS-revised and the BVRT were similar for both 
opioid-dependent groups, whereas the drug-free control 
group had significantly higher scores. The effects of 
methadone and buprenorphine substitution treatment 
on performance in a driving simulator were studied by 
Lenné et al. (2003). All participants attended one 
session without alcohol and one session with alcohol 
(BAC of 0.5 g/l). SDLP, speed and steering wheel angle 
were used to measure simulated driving skills, and 
reaction time to a subsidiary task was also assessed. 
While the combination with alcohol impaired all 
measures of driving performance, there were no 
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In a cohort study performed in Norway, Bramness et al. 
(2012) linked data from three administrative registries 
(Norwegian Prescription Database on any prescriptions 
ever received by the individuals for methadone and 
benzodiazepines, Norwegian Road Accident Registry 
with information about MVAs involving personal injuries 
and Central Population Registry with demographic 
information on all residents in Norway) using unique 
person identifiers. During the 4 626 person-years of 
exposure to methadone, there were 26 MVAs. There 
were very few accidents among females who received 
methadone and women showed no increased risk of 
being involved in MVAs (SIR 1.1; 95 % CI 0.2–3.1). The 
authors observed an increased risk of involvement in 
accidents among males (SIR 2.4; 95 % CI 1.5–3.6).
Meuleners et al. (2011), in a retrospective, population-
based, case-crossover study in Western Australia, 
examined the association between psychoactive 
medications and crash risk in drivers aged 60 and older. 
The risk of a crash necessitating hospitalisation was 
higher in drivers who were taking prescribed opioid 
analgesics (OR 1.5; 95 % CI 1.0–2.3). Women who were 
prescribed opioid analgesics (OR 1.8; 95 % CI 1.1–3.0; 
p = 0.03) had a significantly greater crash risk, but men 
did not.
Based on the DRUID results in Belgium, Kuypers et al. 
(2012) calculated an adjusted OR for a crash resulting in 
injury of 2.91 (95 % CI 0.97–8.68) for medicinal opioids. 
For illicit opioids, only the crude OR could be calculated: 
4.57 (95 % CI 0.47–44.15).
In the DRUID case–control study (Hels et al., 2011), 
based on data for all countries, the relative risk of serious 
injury when driving while under the influence of 
medicinal opioids was estimated to be moderately 
increased (RR 2–10). The adjusted OR was 9.06 (95 % CI 
6.40–12.83) for serious injury and 4.82 (95 % CI 2.60–
8.93) for death. For illicit opioids, the risk was also 
estimated to be moderately increased (95 % CI 2–10). 
The adjusted OR, based on data for all countries, was 
2.47 (95 % CI 0.50–12.10) for serious injury. For the risk 
of death, only a crude OR could be calculated: 10.04 
(95 % CI 2.04–49.32).
Responsibility analyses
Three epidemiological studies have studied the risk of 
being responsible for a traffic accident while driving 
under the influence of opioids. Drummer et al. (2004) 
found that driving under the influence of opioids alone is 
not associated with an increased risk of responsibility for 
an accident (OR 1.4; 95 % CI 0.7–2.9). According to the 
I Risks
Accident risk
In a longitudinal study of 13 548 participants from a 
cohort study of workers in France from 1989 to 2000, 
the risk of a serious accident was compared among 
participants who did and did not report a specific health 
problem during the 12 months before the accident 
(Lagarde et al., 2005). The results indicated that pain 
and treatment for pain could increase the risk of a road 
traffic accident.
Epidemiological studies have investigated the risk of 
being involved in a traffic accident while driving under 
the influence of opioids. A case–control study in Canada 
showed that driving under the influence of opioids is not 
associated with an increased accident risk (RR 2.1; 95 % 
CI 0.8–5.3) (Dussault et al., 2002). In contrast, a case–
control study in France found that morphine use is 
associated with an increased accident risk (OR 8.2; 95 % 
CI 2.5–27.3) (Laumon et al., 2005). In the Netherlands, 
the Immortal study, which performed different case–
control studies between 2002 and 2005, found that use 
of codeine alone is not associated with an increased 
accident risk (RR 3.0; 95 % CI 0.7–14.2), whereas use of 
heroin or morphine alone is associated with an increased 
accident risk of 32.4 (OR; 95 % CI 1.8–592.0) (Assum et 
al., 2005). The results of the Immortal study in Norway 
also showed that driving under the influence of any 
opioid alone (morphine, heroin or codeine) is associated 
with an increased accident risk of 13.8 (OR; 95 % CI 
1.2–154.2) (Assum et al., 2005).
In a registry-based cohort study, Engeland et al. (2007) 
compared the incidence of accidents, as measured by 
the SIR, in the exposed person-time with the incidence 
in the unexposed person-time. The risk was markedly 
increased in users of natural opium alkaloids (SIR 2.0; 
95 % CI 1.7–2.4). Somewhat increased SIRs were found 
for non-steroidal anti-inflammatory drugs (1.5; 95 % CI 
1.3–1.9).
Bernard et al. (2009) studied 635 drivers suspected of 
driving under the influence of drugs in Norway between 
2000 and 2006 in whom methadone was subsequently 
detected in a blood sample. They found that confirmed 
cases of driving impairment involving methadone alone 
were very rare, with combination use more frequent. No 
correlation between blood methadone concentration 
and impairment, as judged by the clinical test for 
impairment, was seen in either clinically impaired drivers 
or for the drivers as a whole. 
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(95 % CI 0.86–2.40), 1.89 (95 % CI 1.47–2.43) and 4.76 
(95 % CI 2.10–10.80), respectively.
I Conclusion
Acute effects: Opioids acutely cause some cognitive and 
psychomotor impairment, but these effects are highly 
dependent on the type of opioid and the dose 
administered. The effects are mostly moderate. Single-
dose administration of morphine in doses up to 5 mg 
appears to cause very few effects in traffic-relevant 
performance tasks. At higher doses impairment is found in 
various tasks, but with no clear dose–effect relationship. 
Fentanyl in doses commonly used in outpatient surgical 
procedures produces pronounced cognitive impairment, 
but no significant impairment remains at 2, 3 or 4 hours 
after treatment. Single doses of methadone appear to be 
followed by impairment in drug-naive subjects, but these 
acute effects are less pronounced in opioid users. Acute 
effects of methadone can be avoided by dividing the daily 
dose. Long-term use of transdermal buprenorphine for the 
treatment of chronic non-cancer pain does not impair 
driving ability, but, because of the individual variability of 
test results, an individual assessment is recommended. 
Drivers using codeine have an increased risk of being 
involved in an accident, but codeine does not impair 
driving-related abilities over and above what is associated 
with chronic pain per se.
Duration of effects: Psychomotor function is impaired up 
to 2 hours after administration of fentanyl. The effects of 
heroin on performance can last up to 6 hours. Codeine 
has impairing effects 4 hours after an intake of 50 mg.
Chronic use: Heroin users show clear impairment of 
psychomotor and cognitive skills, some of which can last 
for more than a year after the last use of the drug. 
Patients on long-term opioid therapy exhibit some 
impairment of psychomotor and cognitive performance. 
However, the effect of the opioid drug itself on 
impairment in patients receiving opioid maintenance 
therapy is unclear. Other factors, such as the disease 
and pain, seem to be of greater importance than the 
effects of the opioids per se. The concept that chronic 
pain patients on stable opioids can drive safely cannot 
be generalised to all such patients in everyday practice, 
but may be applicable to only a subset that meet certain 
criteria. Evaluation of individual performance of such 
patients seems, with the present knowledge, to be the 
only useful procedure to approach the question of 
fitness for driving. There is increased accident risk in the 
first few weeks of treatment. Methadone maintenance 
treatment does cause impairment, including additional 
impairment over and above that associated with heroin 
authors, however, this does not mean that opioid use 
does not increase the risk of a driver being responsible 
for a crash. Because 65 % of the opioid-positive drivers 
in the study who were also using other drugs 
(predominantly benzodiazepines and cannabis) were 
excluded from the analysis, the statistical power of the 
analysis was greatly reduced. In addition, some drivers 
would have been tolerant to the effects of opioids and 
effectively misclassified as opioid-intoxicated, further 
reducing the study’s ability to detect a real association 
between opioids and accident responsibility. Dussault et 
al. (2002) found that driving under the influence of 
opioids is associated with an infinite risk of responsibility 
for an accident. This is probably because all of the small 
number of fatally injured drivers testing positive for 
opioids were judged to have been responsible for the 
accident. In a study by Laumon et al. (2005), a blood 
concentration of opioids above 20 ng/ml was not 
associated with an increased risk of responsibility for a 
fatal accident (OR 0.9; 95 % CI 0.6–1.5); however, the 
OR was not adjusted for confounding factors.
Corsenac et al. (2012) extracted and matched data from 
three French national databases — the national 
healthcare insurance database, police reports and the 
national police database of injurious crashes — and 
performed a case–control analysis comparing 
responsible versus non-responsible drivers. Injured 
drivers exposed to buprenorphine or methadone on the 
day of the crash had an increased risk of responsibility 
for the crash (OR 2.02; 95 % CI 1.40–2.91). The 
increased risk could be explained by the combined effect 
of risky behaviours and treatments. A French registry-
based study on the risk of road traffic crashes in people 
who were prescribed medicines (Orriols et al., 2010) 
found an OR of 1.04 (95 % CI 0.94–1.15) for analgesics 
[class N02 in the Anatomical Therapeutic Chemical 
(ATC) classification; this class includes opioids, other 
analgesics and antipyretics and antimigraine 
preparations].
Meta-analyses
In their meta-analysis of 21 epidemiological studies (13 
case–control and eight cohort studies), Dassanayake et 
al. (2011) found that limited epidemiological research 
reported that opioids may be associated with increased 
accident risk in the first few weeks of treatment.
In his systematic review and meta-analysis, Elvik’s 
(2013) best estimate of the relative risk of opioid users 
being involved in an accident resulting in death, injury or 
property damage, adjusted for publication bias, was 1.44 
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I Acute effects
Amphetamine
Laboratory studies investigating the effects of (dextro)
amphetamine on the neurocognitive performance of 
non-fatigued healthy adults have found varying results. 
McKetin et al. (1999) found that 10 and 20 mg 
dextroamphetamine produced a dose–response 
increase in hit rate and a decrease in reaction time 
dependence, though the latter can in some cases be 
better explained by other associated risk factors. 
Impairment caused by methadone maintenance 
treatment may be reversible. Buprenorphine users have 
not generally shown impairment, except at high doses.
Threshold concentration: An expert panel in Norway 
proposed cut-off blood values of 0.9 ng/ml for 
buprenorphine, 25 ng/ml for methadone and 9 ng/ml for 
morphine, each corresponding to an alcohol 
concentration of 0.2 g/l. For morphine the limit was 
24 ng/ml, equivalent to a BAC of 0.5 g/l.
Accident risk: The limited epidemiological studies 
available provide inconclusive evidence for the accident 
risk associated with opioid use. Some studies found 
significantly elevated accident risks associated with 
driving under the influence of opioids. Three out of five 
responsibility analyses found no increased risk of 
responsibility for an accident while under the influence 
of opioids. A systematic review found that limited 
epidemiological research reported that opioids may be 
associated with increased accident risk in the first few 
weeks of treatment. Injured drivers exposed to 
buprenorphine or methadone on the day of the crash 
had an increased risk of responsibility for the crash (OR 
2.02). In a meta-analysis the relative risk of opioid users 
being involved in an accident involvement resulting in 
death, injury or property damage accidents was 1.44 
(95 % CI 0.86–2.40), 1.89 (95 % CI 1.47–2.43) and 4.76 
(95 % CI 2.10–10.80), respectively.
I Amphetamines
On the illicit drug market, the main representatives of the 
amphetamines group are amphetamine, 
methamphetamine and their salts. MDMA is also a 
derivative of amphetamine and a member of the 
phenethylamine family (as are amphetamine and 
methamphetamine).
It is important to mention that the doses of amphetamine 
and methamphetamine administered in the experimental 
studies described below were very low (10–30 mg), and 
thus not representative of realistic situations (100–
1 000 mg/day) (Couper and Logan, 2004a).
No recent experimental studies were found for the 
designer amphetamines 
3,4-methylenedioxyamphetamine (MDA), 
3,4-methylenedioxyethylamphetamine (MDEA) and 
N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine 
(MBDB).
Amphetamine is a central nervous system (CNS) 
stimulant that causes hypertension and 
tachycardia with feelings of increased confidence, 
sociability and energy. It suppresses appetite and 
fatigue and leads to insomnia. Following oral use, 
the effects usually start within 30 minutes and last 
for many hours. Later, users may feel irritable, 
restless, anxious, depressed and lethargic. 
Amphetamine is less potent than 
methamphetamine, but in uncontrolled situations 
the effects are almost indistinguishable. It is rapidly 
absorbed after oral administration. After a single 
oral dose of 10 mg, maximum plasma levels are 
around 0.02 mg/l. The plasma half-life varies from 4 
to 12 hours and is dependent on the urinary pH: 
alkaline urine decreases the rate of elimination. 
Analysis of amphetamine in urine is confounded 
because it is a metabolite of methamphetamine 
and certain medicinal products. Acute intoxication 
causes serious cardiovascular disturbances as well 
as behavioural problems that include agitation, 
confusion, paranoia, impulsivity and violence. 
Chronic use of amphetamine causes 
neurochemical and neuroanatomical changes. 
Dependence — as shown by increased tolerance 
— results in deficits in memory and in decision-
making and verbal reasoning. Some of the 
symptoms resemble those of paranoid 
schizophrenia. These effects may outlast drug use, 
although often they resolve eventually. Fatalities 
directly attributed to amphetamine are rare. The 
estimated minimum lethal dose in non-addicted 
adults is 200 mg.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
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improved psychomotor vigilance speed relative to 
placebo. The effects of the drug on cognitive function 
during sleep deprivation are unclear. Mills et al. (2001) 
found that 10 mg of dextroamphetamine had no 
performance-enhancing effect, while Wesensten et al. 
(2005) observed improvement on some aspects of 
cognitive function (e.g. learning to learn on WCST) and 
impairment on others (e.g. performance on Stroop test) 
after administration of 20 mg dextroamphetamine. 
Magill et al. (2003) examined the effects of tyrosine 
(150 mg/kg), phentermine (37.5 mg), caffeine 
(300 mg/70 kg), dextroamphetamine (20 mg) or 
placebo on cognitive and motor performance in healthy 
young men during sleep deprivation. The substances 
were administered at 15.30 hours following overnight 
sleep deprivation. Performance decrements with sleep 
deprivation occurred in visual scanning, running 
memory, logical reasoning, mathematical processing, 
the Stroop test, the time wall test, tracking and visual 
vigilance. The statistical comparisons of task 
performances 1.5 and 5.5 hours after drug 
administration and at the 13.00 hours pre-drug baseline 
session showed that dextroamphetamine improved 
performance at both post-drug sessions on all but one 
task in which subjects had shown impairment due to 
sleep deprivation. The exception was in logical reasoning 
1.5 hours post drug administration. However, this aspect 
of performance was significantly improved 5.5 hours 
after dextroamphetamine administration.
Jones and Holmgren (2005) presented a case series of 
individuals apprehended in Sweden for driving under the 
influence of drugs who had abnormally high 
concentrations of amphetamine in their blood 
(> 5.0 mg/l). The commonest signs of drug use reported 
by the arresting officers were bloodshot and glazed eyes, 
restlessness, talkativeness, exaggerated reflexes and 
slurred speech. Unsteady gait and dilated pupils were 
observed in some, but not all, individuals. In contrast, in 
another series of 338 apprehended drivers in whom only 
amphetamine was found (Musshoff and Madea, 2012) 
(median and maximum concentration 0.12 and 
1.05 mg/l, respectively), the psycho-physical condition 
of the drivers in many cases suggested that they were 
under the influence of a centrally sedating substance. A 
relationship between concentration and effect could not 
be established. The apparent sedation is probably the 
consequence of sleep deprivation during an 
amphetamine binge and the after-effects of the drug.
Cox et al. (2008) observed that extended-release mixed 
amphetamine salts (Adderall XR) were associated with 
worsening of driving performance, or a drug rebound 
effect, relative to placebo 16–17 hours post ingestion 
(the drugs were given at 8 a.m.). The performance on a 
without changing false alarm rate during a complex 
auditory selective attention task. Asghar et al. (2003) 
also found that the use of dextroamphetamine (25 mg) 
decreased reaction times. Dextroamphetamine (10 mg) 
enhances performance on single-target and divided-
attention responses in different parts of the visual field 
(Mills et al., 2001). Another study found individual-
specific effects of dextroamphetamine (0.25 mg/kg) on 
working memory, with improved performance in subjects 
who had relatively low working-memory capacity at 
baseline and deteriorated performance in subjects with 
high working-memory capacity at baseline (Mattay et al., 
2000). Barch and Carter (2005) also observed that 
dextroamphetamine (0.25 mg/kg) has positive effects 
on cognitive function, namely improved reaction times 
on the spatial working memory and Stroop tasks, 
improved working-memory accuracy and improved 
language production. Silber et al. (2006) found that 
dextroamphetamine (0.42 mg/kg) improves various 
aspects of attention (reaction time during digit vigilance, 
DSST and movement estimation performance) and 
some aspects of psychomotor functioning (tracking 
ability) and perceptual speed (inspection time). 
Experimental studies on the effect of 
dextroamphetamine (10 and 20 mg) on impulsivity and 
decision-making found a decrease in several forms of 
impulsive behaviour, while alcohol (0.2, 0.4 and 0.8 g/l) 
resulted in the opposite effect (de Wit et al., 2000, 
2002). Some laboratory studies, however, report 
negative acute effects of amphetamine on 
neurocognitive performance. Hutchison and Swift 
(1999) found that 20 mg dextroamphetamine causes 
subtle but significant negative effects on prepulse 
inhibition of the startle reflex, reflecting deficits in the 
ability to filter out irrelevant or intrusive stimuli, which 
subsequently causes an overload of information. This 
finding was confirmed by Swerdlow et al. (2003).
Silber et al. (2005) found, during tests in a driving 
simulator, that the intake of dextroamphetamine 
(0.42 mg/kg) causes a decrease in overall simulated 
driving performance by inducing problems such as 
incorrect signalling, failing to stop at a red traffic light 
and slow reaction times. The decrease in simulated 
driving ability was observed only during the daytime, 
which is consistent with the fact that amphetamine 
consumption results in tunnel vision, an effect that 
would be less apparent at night (Mills et al., 2001; Silber 
et al., 2005).
Other studies have assessed the effects of 
dextroamphetamine during sleep deprivation. 
Wesensten et al. (2005) investigated the effects of 
20 mg dextroamphetamine on simple psychomotor 
tasks during sleep deprivation and found that it 
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condition. Performance of vigilance and divided 
attention tasks was significantly impaired in the alcohol 
condition and, to a lesser degree, in the 
dexamphetamine + alcohol condition. The authors 
concluded that single doses of 0.8 g/kg alcohol 
increased risk-taking behaviours and impaired tracking, 
attention and reaction time during a 3-hour period after 
drinking when BAC declined from 0.9 to 0.2 g/l. The 
stimulatory effects of co-administration of 
dexamphetamine 10 mg were not sufficient to overcome 
the impairing effects of alcohol on skills related to 
driving.
Methamphetamine
In healthy volunteers, Comer et al. (2001) found no effect 
of 5 or 10 mg methamphetamine on the performance on 
a battery of tests consisting of a DSST, a repeated 
acquisition task, a divided attention task, a rapid 
information processing task and an immediate and 
delayed digit-recall task. Laboratory studies using higher 
doses did find acute effects on cognitive and 
psychomotor performance. Johnson et al. (2000) 
investigated the cognitive effects induced by 
d-methamphetamine (4) (0.21 or 0.42 mg/kg) in healthy 
volunteers. They found an increase in mean hits and 
decreases in mean false hits and mean reaction time on 
the RVIPT. On the logical reasoning test, 
d-methamphetamine significantly improved the 
percentage correct to time ratio. There was no effect on 
the FTT, a measure of motor speed. The same research 
group studied the effects of d-methamphetamine (15 
and 30 mg) in methamphetamine-dependent individuals 
and found a dose-dependent increase in attention, 
concentration and psychomotor performance (Johnson 
et al., 2005, 2007). Silber et al. (2006) assessed the 
acute effects of 0.42 mg/kg d-methamphetamine and 
d,l-methamphetamine on driving-related cognitive 
functions in healthy volunteers. Both kinds of 
methamphetamine improved attention (digit vigilance, 
DSST and movement estimation), psychomotor 
performance (tracking ability) and perceptual speed 
(inspection time).
Silber et al. (2012a) administered 0.42 mg/kg 
d-methamphetamine or a matching placebo to 20 
healthy recreational users of illicit stimulants. 
Performance was assessed 2.5 hours post drug 
administration. d-Methamphetamine did not significantly 
(4)  There are three different types of methamphetamine (d, d/l and l), and 
each affects the CNS differently. The most common types are the 
dextro/laevo (d/l) and dextro (d) types. The most powerful is 
d-methamphetamine (3–4 times more powerful than 
l-methamphetamine).
virtual reality driving simulator and an on-road drive of 
19 male adolescent drivers aged 17–19 years with 
attention-deficit hyperactivity disorder (ADHD) was 
compared after taking 30 mg of extended-release mixed 
amphetamine salts or placebo. In group comparisons, 
extended-release mixed amphetamine salts were not 
associated with significant worsening of simulator 
performance relative to placebo 17 hours post ingestion. 
However, inattentive on-road driving errors were 
significantly more common on extended-release mixed 
amphetamine salts relative to placebo at midnight 
(p = 0.04), suggesting a possible rebound effect. 
Hjalmdahl al. (2012) found that administration of 
d-amphetamine does not compensate for impairment of 
driving caused by fatigue. The positive effects of 10 mg 
were not further improved when increasing the dose to 
40 mg.
Kay et al. (2009) performed a randomised, double-blind, 
placebo-controlled, crossover study of simulated driving 
performance following administration of extended-
release mixed amphetamine salts 50 mg/day in young 
adults with ADHD. Extended-release mixed 
amphetamine salts significantly improved overall 
simulated driving performance compared with placebo 
up to 12 hours after dosing.
An expert panel in Norway (Vindenes et al., 2012) 
proposed a cut-off value for amphetamine in blood of 
41 ng/ml, corresponding to an alcohol concentration of 
0.2 g/l.
Combinations of amphetamine with other 
substances
Simons et al. (2012) studied the combination of 
dexamphetamine and alcohol. Eighteen subjects 
participated in a randomised, crossover, placebo-
controlled driving simulator study employing four 
conditions: 10 mg dexamphetamine, 0.8 g/kg alcohol, 
10 mg dexamphetamine + 0.8 g/kg alcohol and placebo. 
Mean BAC levels during simulated driving varied 
between 0.64 g/l and 0.91 g/l depending on time after 
administration. In the subjects who consumed alcohol, 
mean SDLP was significantly higher and accepted gap 
time and distance were significantly lower (3). Use of 
alcohol or dexamphetamine plus alcohol was associated 
with a higher frequency of red light running and 
collisions than the dexamphetamine alone or placebo 
(3)  Gap acceptance measures the driver’s ability to safely traverse a 
crossing. The parameters included to assess risk taking are size of the 
accepted gap in seconds and the distance to the car approaching the 
driver while traversing the crossing.
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Stough et al. (2012) gave 0.42 mg/kg methamphetamine 
or a matching placebo to 61 abstinent recreational users 
of illicit drugs. Driving performance was assessed 3 
hours and 24 hours post drug administration on a 
computerised driving simulator. The methamphetamine 
condition impaired driving performance to a greater 
extent than placebo (p = 0.055). Signalling adherence 
was lower in those who received methamphetamine 
(p = 0.006) than in those receiving placebo in the 
daytime simulations.
Bosanquet et al. (2013) compared driving simulator 
performance in current methamphetamine users and a 
control group of non-users. Methamphetamine users, 
most of whom met the criteria for methamphetamine 
dependence, were significantly more likely to speed and 
to weave from side to side when driving. They also left 
less distance between their vehicle and oncoming 
vehicles when making a right-hand turn. There were 
higher levels of impulsivity and antisocial personality 
disorder in the methamphetamine-using cohort.
An expert panel in Norway (Vindenes et al., 2012) 
proposed a cut-off value for methamphetamine in blood 
of 45 ng/ml, corresponding to an alcohol concentration 
of 0.2 g/l.
MDMA
Laboratory studies have variously shown both negative 
and positive as well as no effects of MDMA on driving-
related abilities. Cami et al. (2000) found that MDMA 
(75 mg or 125 mg) produced a mild decrease in responses 
in the DSST in healthy volunteers. Only the 125-mg dose 
induced esophoria in the Maddox wing device. 
Hernandez-Lopez et al. (2002) investigated the effects 
of MDMA (100 mg) on psychomotor performance in 
healthy volunteers, but they found no effect on 
performance on the DSST, SRT or the Maddox wing 
device. MDMA (100 mg), given in two successive doses 
separated by an interval of 24 hours, was studied by 
Farré et al. (2004). In the DSST task, both doses slightly 
decreased the total number of DSST responses, but 
these changes were not significant. MDMA did not 
produce significant effects on reaction time. Both doses 
produced similar levels of esophoria in the Maddox wing 
device. In a study of recreational MDMA users, a single 
dose of MDMA (75 mg) was administered and cognition, 
psychomotor performance and driving-related task 
performance were assessed (Lamers et al., 2003). 
MDMA improved psychomotor performance, such as 
movement speed and tracking performance, in a single 
task as well as in a divided attention task. The ability to 
impair overall simulated driving performance. Compared 
with placebo, the d-methamphetamine condition led to 
four times more infringements, i.e. failure to stop at red 
traffic lights, but this effect was evident only at a trend 
level (p = 0.11). In another study (Silber et al., 2012b), in 
20 healthy recreational users of illicit stimulants, driving 
performance was assessed in two testing sessions 2.5 
hours following oral administration of 0.42 mg/kg 
d,l-methamphetamine or a matching placebo. Mean 
blood and saliva d,l-methamphetamine concentrations 
of approximately 90 and 400 ng/ml, respectively, at 2 
hours and 95 and 475 ng/ml at 3 hours were observed. 
These levels of d,l-methamphetamine were found not to 
significantly impair, or improve, driving performance.
Methamphetamine is a CNS stimulant that causes 
hypertension and tachycardia with feelings of 
increased confidence, sociability and energy. It 
suppresses appetite and fatigue and leads to 
insomnia. Following oral use, the effects usually 
start within 30 minutes and last for many hours. 
Later, users may feel irritable, restless, anxious, 
depressed and lethargic. Methamphetamine has 
higher potency than amphetamine, but in 
uncontrolled situations the effects are almost 
indistinguishable. It is rapidly absorbed after oral 
administration, and maximum plasma levels are in 
the range 0.001–0.005 mg/l. The plasma half-life is 
about 9 hours. Fatalities directly attributed to 
methamphetamine are rare. In most fatal 
poisonings the blood concentration is above 
0.5 mg/l. Analysis of methamphetamine in urine is 
confounded because it is a metabolite of certain 
medicinal products (e.g. selegiline). Acute 
intoxication causes serious cardiovascular 
disturbances as well as behavioural problems that 
include agitation, confusion, paranoia, impulsivity 
and violence. Chronic use of methamphetamine 
causes neurochemical and neuroanatomical 
changes. Dependence — as shown by increased 
tolerance — results in deficits in memory and in 
decision-making and verbal reasoning. Some of the 
symptoms resemble those of paranoid 
schizophrenia. These effects may outlast drug use, 
although often they resolve eventually.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
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subjects drove faster, but only in built-up areas with a 
speed limit of 50 km/h. Speed variance also increased, 
both in the city and on the motorway. Lateral control and 
gap acceptance behaviour was not affected. There were 
two crashes during 20 control drives, and four crashes 
while under the influence of MDMA, a 100 % increase.
In another study of recreational MDMA users, subjects 
took a real on-the-road driving test 3–5 hours after 
consuming MDMA (75 mg) (Ramaekers et al., 2004). 
MDMA significantly decreased SDLP by 2 cm relative to 
placebo, and decreased performance during the 
car-following test. There were no effects on time to 
speed adaptation and BRT.
The doses given in the experimental studies on MDMA 
(75–125 mg) resemble the doses consumed by 
recreational MDMA users (average 120 mg) (Couper and 
Logan, 2004a).
Kuypers et al. (2007) assessed the effects of nocturnal 
doses of 75 and 50 mg MDMA divided over the evening 
on psychomotor performance and impulsivity during the 
night and after a night of sleep deprivation in 14 healthy 
subjects in a double-blind, placebo-controlled, two-way, 
within-subject study. MDMA impaired tracking 
performance in a simple tracking task. Divided attention 
task performance was also impaired. MDMA did not 
affect impulsivity measures. Vigilance performance 
decreased as a function of time on task, but this 
decrement was less during MDMA treatment than with 
placebo. After the administration of MDMA, the 
sleepiness scale scores were lower during the night, and 
this difference disappeared in the morning.
In a simulated car-following task, Dastrup et al. (2010) 
observed that, although all participants drove at 
approximately 90 km/h, ‘drivers who had recently 
consumed MDMA maintained a shorter distance to the 
lead vehicle (mean 64 m) and responded to changes in 
the velocity of the lead vehicle more quickly (mean 
difference in delay 1.04 seconds) than other driver 
groups. Abstinent MDMA users also drove closer to the 
lead vehicle than control subjects, but reacted quickly to 
the changes in the velocity of the lead vehicle. The 
authors concluded that MDMA users’ driving 
performance is no worse than that of control subjects 
but that they may take more risks. In a simulator study, 
Stough et al. (2012) administered 100 mg MDMA to 61 
abstinent recreational users of illicit drugs. Driving 
performance was assessed 3 hours and 24 hours post 
drug administration. Performance in the MDMA 
condition was worse than in either the 
methamphetamine (p = 0.023) or the placebo 
(p < 0.001) condition, and methamphetamine was also 
predict object movement under divided attention was 
impaired in the subjects. There was no effect of MDMA 
on visual search, planning or retrieval from semantic 
memory. Ramaekers et al. (2004) examined MDMA 
(75 mg) and cognition in recreational MDMA users. A 
single dose impaired performance on spatial and verbal 
working memory tasks 1.5 to 2.5 hours after 
administration. MDMA showed no effect on behavioural 
measures of impulsivity. Smith et al. (2006) conducted 
neuropsychological assessments in 13 MDMA users, 
10–15 hours after last use and in a control group. The 
MDMA users showed impairments on measures of 
executive function and short-delay free recall memory. 
No extrapyramidal motor impairments were detected.
Tests in driving simulators revealed that the consumption 
of MDMA can decrease performance. De Waard et al. 
(2000) conducted driving simulator tests in a group of 
young people who had indicated that they regularly use 
MDMA. They were tested 1 hour after the consumption of 
MDMA, after the party, when the subject would normally 
go home, and then again while sober on a control night at 
a comparable time. Under the influence of MDMA, 
Ingestion of MDMA causes euphoria, increased 
sensory awareness and mild central stimulation. 
The terms ‘empathogenic’ and ‘entactogenic’ have 
been coined to describe the socialising effects of 
MDMA. Following ingestion, most of the dose of 
MDMA is excreted in the urine, unchanged. 
Following a dose of 75 mg, the maximum plasma 
concentration of around 0.13 mg/l is reached 
within 2 hours. The plasma half-life is 6–7 hours. In 
animals, MDMA causes neurotoxicity, as evidenced 
by anatomical changes in axon structure and a 
persisting reduction in brain serotonin levels. The 
significance of these findings to human users is still 
unclear, although cognitive impairment is 
associated with MDMA use. Some of the 
pharmacodynamic and toxic effects of MDMA vary, 
depending on which enantiomer is used. However, 
almost all illicit MDMA exists as a racemic mixture. 
Fatalities following a dose of 300 mg have been 
noted, but toxicity depends on many factors, 
including individual susceptibility and the 
circumstances in which MDMA is used.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
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increased by the combination of MDMA and alcohol, but 
not by alcohol alone or MDMA alone. Brookhuis et al. 
(2004) asked a group of young participants who had 
indicated that they regularly used MDMA to complete 
test rides in a driving simulator shortly after having used 
MDMA, just before going to a party. They were tested 
again after having visited the ‘rave’, while they were 
under the influence of MDMA and a number of other 
drugs, and then again when they were sober, at around 
the same time of night. Separately, a control group of 
participants was included in the experiment. Driving 
performance in terms of lateral and longitudinal vehicle 
control was not greatly affected after MDMA use but 
deteriorated after multiple drug use. The most striking 
result was the apparent decrease in risk awareness, both 
after taking MDMA and after multiple drug use, as was 
shown by the significantly smaller accepted gaps than in 
the non-drug condition. Accident involvement was 
increased by 100 % and 150 % after MDMA use and 
multiple drug use, respectively. However, Ramaekers et 
al. (2004) found that the use of MDMA (75 mg or 
100 mg) can diminish some, but not all, deleterious 
effects of alcohol (0.5–0.6 g/l), while other negative 
effects of alcohol can be reinforced.
Dumont et al. (2008) studied the acute effects of 
individual and co-administration of MDMA and ethanol 
on executive, memory and psychomotor, visuomotor, 
visuospatial and attention function, as well as on 
subjective experience, in 16 healthy volunteers between 
the ages of 18 and 29 years. MDMA was given orally 
(100 mg) and BAC was maintained at 0.6 g/l by an 
ethanol infusion regime. Co-administration of MDMA and 
ethanol was well tolerated and did not result in greater 
impairment of performance than the single-drug 
conditions. Impaired memory function was consistently 
observed after all drug conditions, whereas impairment 
of psychomotor function and attention was less 
consistent across drug conditions. In another study by 
the same group (Dumont et al., 2010), MDMA 
significantly increased psychomotor speed but did not 
affect psychomotor accuracy and induced subjective 
arousal. Ethanol impaired both psychomotor speed and 
accuracy and induced sedation. Co-administration of 
ethanol and MDMA improved psychomotor speed but 
impaired psychomotor accuracy compared with placebo 
and reversed ethanol-induced sedation. Maximal effects 
were seen at 90–150 minutes after MDMA 
administration, after which drug effects declined in spite 
of persisting MDMA plasma concentration, with the 
exception of ethanol-induced sedation, which manifested 
itself fully only after the infusion was stopped.
Dumont et al. (2011) performed a four-way, double-blind, 
randomised, crossover, placebo-controlled study in 16 
observed to result in a deterioration in driving ability 
compared with placebo (p = 0.055). Those administered 
MDMA demonstrated poorer signalling adherence 
(p = 0.017) conditions than those administered placebo 
in the daytime simulations.
Bosker et al. (2012b) assessed the effects of MDMA on 
road-tracking and car-following performance in on-the-
road driving tests in normal traffic in 16 recreational 
MDMA users. Participants received a single dose of 0, 
25, 50 or 100 mg MDMA on separate evenings. The 
driving tests were conducted both in the evening, when 
MDMA serum concentrations were maximal, and in the 
morning, after a night without sleep. SDLP was 
significantly increased during driving tests in the 
morning in all treatment conditions, irrespective of 
MDMA dose administered and serum concentration at 
the time of testing. The increments in SDLP were of high 
clinical relevance and comparable to those observed for 
alcohol at BACs > 0.8 g/l. This impairment was primarily 
caused by sleep loss. MDMA did not affect driving 
performance nor did it change the impairing effects of 
sleep loss. MDMA cannot compensate for the impairing 
effects of sleep loss; drivers who are under the influence 
of MDMA and are sleep deprived are unfit to drive.
In the DRUID meta-analysis of experimental studies 
(Berghaus et al., 2010), 10 studies examining 208 
effects of d-amphetamine were analysed. The doses 
used varied between 1 and 36 mg. At the highest dose 
range (> 7.5 mg), the maximal percentage of significantly 
impaired test results was 0 %. The time of maximal 
impairment and the duration of impairment could not be 
determined as there was no impairment. The alcohol 
equivalence of maximum impairment was < 0.3 g/l. The 
equivalent BAC (0.5 g/l) was not reached.
An expert panel in Norway (Vindenes et al., 2012) 
proposed a cut-off value of 48 ng/ml for MDMA in blood 
of 48 ng/ml, corresponding to an alcohol concentration 
of 0.2 g/l.
Combination of MDMA with other psychoactive 
substances
Hernandez-Lopez et al. (2002) investigated the effects 
of MDMA (100 mg) with or without alcohol (0.8 g/l) on 
psychomotor performance in healthy volunteers. The 
combination of alcohol and MDMA produced a similar 
impairment to that of alcohol alone in scores on the 
DSST, but a significant decrease in the number of total 
and correct responses compared with placebo and 
MDMA. MDMA partially reversed the exophoria induced 
by alcohol in the Maddox wing test. SRT was significantly 
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Ornstein et al., 2000; Rapeli et al., 2005; Rogers et al., 
1999). Some of these deficits are correlated with 
increasing years of use (Rogers et al., 1999) or increasing 
severity of use (McKetin and Solowij, 1999). Rapeli et al. 
(2005), however, found that attention deficits of recently 
detoxified amphetamine users may be reversible, although 
recovery of verbal memory is not complete even after 
long-term abstinence. The chronic effects associated with 
the use of methamphetamine are deficits in memory, 
attention, response inhibition and psychomotor speed and 
an increase in impulsivity (Chang et al., 2002; Chou et al., 
2004; Hoffman et al., 2006; Johanson et al., 2006; 
Monterosso et al., 2005; Newton et al., 2004; Salo et al., 
2002, 2005; Simon et al., 2000; Volkow et al., 2001). Some 
of these deficits might persist even after a long period of 
abstinence (Chang et al., 2002; Hoffman et al., 2006; 
Johanson et al., 2006; Salo et al., 2002, 2005; Volkow et 
al., 2001), while others can be reversed after a short period 
of abstinence (Chou et al., 2004).
MDMA users are aware of the consequences of their 
chronic use and report the development of tolerance and 
impaired ability to concentrate (Verheyden et al., 2003). 
In experimental studies, the consequences of chronic 
amphetamine or MDMA use on cognitive functions 
include a decrease in executive functioning, attention 
and memory and an increased impulsivity. Some of these 
impairments become more prominent with increasing 
severity of use, and might persist for up to 2 years after 
the last use of the drug (Gouzoulis-Mayfrank et al., 2000; 
McCann et al., 1999; Quednow et al., 2007; Rizzo et al., 
2005; Verdejo et al., 2004; Wareing et al., 2004).
I Risks
In Norway, Gustavsen et al. (2006) investigated the 
concentration–effect relationship between blood 
amphetamine concentrations and impairment in a 
population of real-life users. They selected 878 cases 
with amphetamine or methamphetamine as the only 
drug present in blood samples from the impaired driver 
registry of the Norwegian Institute of Public Health. In 
each case, the police physician had determined whether 
or not the driver was impaired; 27 % were judged not 
impaired, while 73 % were judged impaired. A positive 
relationship was found between blood amphetamine 
concentration and impairment, but it reached a ceiling at 
concentrations of 270–530 ng/ml.
Accident involvement
Of the four pre-2007 epidemiological studies 
investigating the accident risk associated with driving 
healthy volunteers between the ages of 18 and 27 years. 
MDMA (100 mg) was given orally and THC (4 and 12 mg, 
given at intervals of 90 minutes) was vaporised and 
inhaled. THC induced more robust cognitive impairment 
than MDMA and co-administration did not exacerbate 
single-drug effects on cognitive function. However, 
co-administration of THC with MDMA increased desired 
subjective drug effects and drug strength compared 
with the MDMA condition, which may explain the 
widespread use of this combination. Veldstra et al. 
(2012) studied driver impairment as a consequence of 
ecstasy or combined ecstasy and alcohol use as 
compared with driving under the influence of 0.3 g/l, 
0.5 g/l and 0.8 g/l alcohol. Alcohol and ecstasy mainly 
influenced automated driving performance such as 
lateral and speed control. However, small to no effects of 
the substances were found on more complex driving 
behaviour. Equivalence testing showed that combined 
use may lead to impaired driving in some, but not all, 
drivers. Participants rated their own performance to be 
only slightly worse than normal in both studies. Since 
driving performance, in fact, deteriorated significantly, 
participants overestimated their own ability.
Duration of effects of amphetamines
The effects on cognitive and psychomotor skills of 
amphetamine (Asghar et al., 2003; Barch and Carter, 
2005; de Wit et al., 2000, 2002; Hutchison and Swift, 
1999) and methamphetamine (Johnson et al., 2000, 
2005, 2007; Silber et al., 2006) have been assessed for 
up to 3–4 hours after administration. With MDMA use, the 
duration of the subjective ‘positive’ effects is less than 24 
hours; thereafter, the ‘crash’ phase starts, with the subject 
feeling very tired, unable to combat sleep and even 
depressed, which can last for several days (Verheyden et 
al., 2003). These negative after-effects increase with 
successive doses, while the positive subjective effects 
diminish (Hegadoren et al., 1999). The effects on 
psychomotor performance can last for more than 5 hours 
(Lamers et al., 2003). The duration of the cognitive effects 
is unclear. Some studies have found that the negative 
effects on cognitive performance, especially verbal 
memory, can last for several days (Smith et al., 2006), 
while others have found that impairment disappears after 
a few hours (Farré et al., 2004) or 24 hours after the last 
use (de Waard et al., 2000).
I Chronic effects
Experimental studies of the chronic effects of 
amphetamine use have shown deficits in decision-making, 
attention and memory (McKetin and Solowij, 1999; 
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the fact that only a limited number of fatally injured 
drivers tested positive for amphetamines and that all 
these drivers were judged responsible for the accident. A 
responsibility analysis in France found amphetamines to 
be associated with an increased risk of responsibility for 
an accident (OR 3.8; 95 % CI 1.5–9.5) (Laumon et al., 
2005). However, after adjustment for confounding 
factors such as age, sex, vehicle type and time of crash, 
the increase in risk was no longer significant (OR 2.0; 
95 % CI 0.7–5.3).
The relationship between amphetamine use and the 
severity of a traffic accident was examined in one 
epidemiological study. In the Netherlands, Smink et al. 
(2005) analysed blood sample data from drivers 
involved in crashes from October 1998 to September 
1999. The blood samples had been screened for the 
presence of alcohol, illicit drugs and medicinal drugs. 
The strength of the association between exposure to the 
different classes of substances and the severity of the 
accident was evaluated using logistic regression 
analysis. The results showed no association between the 
use of amphetamines and amphetamine-like substances 
and the severity of a traffic accident.
Meta-analysis
Elvik (2013) performed a meta-analysis of 66 
publications. The best estimate of the relative risk of 
accident involvement with amphetamine, adjusted for 
publication bias, was 4.46 (95 % CI 2.21–9.00) for fatal 
accidents, 6.19 (95 % CI 3.46–11.06) for injury accidents 
and 8.67 (95 % CI 3.23–23.32) for crashes resulting in 
property damage.
I Conclusion
Acute effects: Experimental studies show that 
methamphetamine and amphetamine can have positive 
stimulating effects on cognitive and psychomotor 
functions, especially in fatigued or sleep-deprived 
persons. Negative effects are also observed, such as an 
overall reduced driving capacity in a simulator during 
daytime. Stimulants have repeatedly been shown to 
improve neuropsychological skills, such as tracking, 
impulse control and reaction time, while impairing 
cognitive functions such as working memory and 
movement perception. However, the doses used in these 
studies are not representative of the doses actually 
consumed by users of these drugs. High-dose effects of 
stimulants on driving performance cannot be readily 
assessed in experimental, placebo-controlled studies 
because of obvious medical and ethical constraints. 
under the influence of amphetamines, three studies — 
one in France (Mura et al., 2003) and the Immortal 
studies in the Netherlands and Norway (Assum et al., 
2005) — could not calculate the risks because the 
number of cases positive for amphetamines was too low. 
The fourth, a study in Canada, found that driving under 
the influence of amphetamines is associated with an 
increased accident risk of 12.8 (OR; 95 % CI 3.0–54.0) 
(Dussault et al., 2002).
Based on the DRUID results from Belgium (Kuypers et 
al., 2012), only a crude OR could be calculated: 54.82 
(95 % CI 6.09–493.12). For the combination of alcohol 
and stimulants, the adjusted OR was 20.34 (95 % CI 
4.93–83.82), and for the combination of stimulants and 
sedatives the adjusted OR was 210.97 (95 % CI 4.90–
9089).
In the DRUID case–control study (Hels et al., 2011), the 
relative risk of serious injury when driving under the 
influence of amphetamines was estimated to be greatly 
increased (5–30). The adjusted OR, based on data for all 
countries, was 8.35 (95 % CI 3.91–17.83) for serious 
injury and 24.09 (95 % CI 9.72–59.71) for death.
All these studies show that driving under the influence of 
amphetamines caries a high accident risk.
Responsibility analyses
Drummer et al. (2004) conducted a responsibility 
analysis among 3 398 fatally injured drivers. They 
calculate the risks associated not with amphetamines 
alone, but with a group of substances acting as 
stimulants, namely amphetamine, methamphetamine, 
MDMA, ephedrine, pseudoephedrine, phentermine and 
cocaine. There was no significant association between 
stimulants use and crash responsibility. However, when 
truckers were considered as a discrete driver type, the 
OR increased to 8.8 and was of borderline statistical 
significance (95 % CI 1.0–77.8). In the other study in 
Australia, Longo et al. (2000b) also calculated the risks 
associated with a group of substances acting as 
stimulants, but these included amphetamine, 
methamphetamine, phentermine, pseudoephedrine, 
ephedrine and MDEA. They found that there was no 
significantly increased responsibility risk associated with 
driving under the influence of stimulants alone.
Two studies looked at the responsibility risk associated 
with amphetamines only. In Canada, Dussault et al. 
(2002) found that driving under the influence of 
amphetamines is associated with an infinite risk of 
responsibility for an accident. This is probably caused by 
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Accident risk: Meta-analyses on the risks associated with 
the use of amphetamines have shown high odds ratios. 
Based on a meta-analysis, the relative risk of accident 
involvement with amphetamine was 4.46 (95 % CI 
2.21–9.00) for fatal accidents, 6.19 (95 % CI 3.46–
11.06) for injury accidents and 8.67 (95 % CI 3.23–
23.32) for crashes resulting in property damage.
I Cocaine
I Acute effects
Only two experimental studies of the acute effects of 
cocaine on performance were found. Rush et al. (1999) 
administered a wide range of doses of oral cocaine (50, 
100, 200 and 300 mg) or placebo to nine volunteers with 
recent histories of cocaine use. Their performance on 
the DSST was assessed before drug administration and 
periodically afterwards for 5 hours. Performance was not 
affected in this study, although previous studies found 
performance-enhancing effects with acute 
administration. Rush et al. (1999) remarked that the 
subjects in the previous studies reported substantially 
less cocaine use than the subjects in their study, who 
MDMA and amphetamine concentrations that are 
observed in actual cases of driving under the influence 
can be 10-fold higher than during controlled 
administration in experimental studies. Individuals who 
take stimulants alone at regular doses (e.g. as in 
medicinal use) are generally fit to drive, but are less safe 
drivers when stimulants are taken in combination with 
sleep loss or alcohol intoxication, as is often the case in 
drug users. Neither MDMA nor dexamphetamine 
produces any dose- or concentration-related effects on 
driving (Ramaekers et al., 2012). Experimental studies of 
MDMA have also found both negative and positive 
effects on performance. Positive effects include a 
decrease in SDLP and an increase in psychomotor 
speed, while negative effects include an increase in 
speed and speed variance and a decrease in the ability 
to follow a car.
Duration of effects: The effects on psychomotor 
performance can last for more than 5 hours, and some 
studies have shown that the negative effects on 
cognitive performance, especially verbal memory, can 
last for several days.
Combinations: Other psychoactive substances such as 
alcohol can reinforce the deleterious effects of MDMA, 
and even have some additional negative effects. The use 
of MDMA or amphetamine can diminish some, but not 
all, deleterious effects of alcohol, while other negative 
effects of alcohol can be reinforced. In addition, neither 
stimulant can compensate for the impairing effects of 
alcohol and sleep deprivation even at high doses or 
concentrations. There was a large variation in subjects’ 
sensitivity to the combination of amphetamine and 
alcohol or MDMA and alcohol; some showed impairment, 
whereas others did not.
Chronic use: The chronic use of amphetamines causes 
negative effects on cognitive and psychomotor skills, and 
these last longer than the period of intoxication and are 
sometimes correlated with the severity or duration of use.
Threshold concentration: An expert panel in Norway 
proposed that, for the purposes of sanctions, 
concentrations in blood of 41 ng/ml amphetamine, 
45 ng/ml methamphetamine and 48 ng/ml MDMA 
should be considered equivalent to an alcohol 
concentration of 0.2 g/l. Limits equivalent to higher 
BACs have not been suggested because the correlation 
between drug concentration and risk of traffic 
accidents/impairment is variable or insufficiently 
documented. Marked impairment can be seen at low 
concentrations of some substances, such as 
amphetamine and methamphetamine, particularly some 
time after substantial drug intake.
Cocaine has a similar psychomotor stimulant effect 
to that of amphetamine and related compounds. 
Like amphetamine, it produces euphoria, 
tachycardia, hypertension and appetite 
suppression. Cocaine has a strong reinforcing 
action, causing a rapid psychological dependence, 
an effect even more pronounced in those who 
smoke cocaine base. Following a 25-mg dose, 
blood levels peak in the range 400–700 μg/l, 
depending on the route of administration. When 
consumed with alcohol, cocaine also produces the 
metabolite cocaethylene. Some unchanged 
cocaine is found in the urine. The plasma half-life of 
cocaine is 0.7–1.5 hours and is dose dependent. 
The estimated minimal lethal dose is 1.2 g, but 
susceptible individuals have died from as little as 
30 mg applied to mucous membranes, whereas 
addicts may tolerate up to 5 g daily.
Source: EMCDDA drug profiles (http://www.
emcdda.europa.eu/publications/drug-profiles).
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I Chronic effects
Chronic use of cocaine can cause deficiencies in users, 
such as difficulties in processing cognitive tasks 
concerning attention, visuospatial perception, memory, 
cognitive flexibility, perceptual–motor speed, problem-
solving, abstraction and executive functioning (Di 
Sclafani et al., 2002; Goldstein et al., 2004; Kelley et al., 
2005; Lawton-Craddock et al., 2003; Rahman and 
Clarke, 2005; Smelson et al., 1999; Toomey et al., 2003). 
One study found no effects on attention or spatial 
memory (Kelley et al., 2005). Chronic cocaine use is also 
associated with an effect on behaviour, namely an 
increase in impulsive behaviour (Moeller et al., 2004).
Chronic use of alcohol or cocaine selectively affects 
performance on different neurobehavioural tests in a 
dose-dependent way (Bolla et al., 2000). However, their 
combined use may not cause additional negative effects 
on the brain, as subjects addicted to only cocaine 
demonstrate similar or greater neurocognitive 
impairments than those who abuse both alcohol and 
cocaine (Di Sclafani et al., 2002; Lawton-Craddock et al., 
2003; Robinson et al., 1999).
I Risks
Accident risk
Four epidemiological studies on the accident risk 
associated with driving under the influence of cocaine 
were found. However, three of these studies — one in 
France (Mura et al., 2003) and the Immortal studies in 
the Netherlands and Norway (Assum et al., 2005) — 
could not calculate the risks because the number of 
cases positive for cocaine was too low. A study in 
Canada (Dussault et al., 2002) found that driving under 
the influence of cocaine is associated with an increased 
accident risk of 12.2 (OR; 95 % CI 7.2–20.6). Driving 
under the influence of cocaine alone, a combination of 
cocaine and cannabis, a combination of cocaine and 
alcohol (BAC > 0.8 g/l) or a combination of cocaine, 
cannabis and alcohol (BAC > 0.8 g/l) was associated 
with an increased accident risk of 4.9 (OR; 95 % CI 
1.4–17.4), 8.0 (OR; 95 % CI 3.1–20.7), 170.5 (OR; 95 % CI 
21.2–1371.2) and 85.3 (OR; 95 % CI 9.5–767.0), 
respectively.
Stoduto et al. (2012) examined the association between 
self-reported past-year cocaine use and past-year 
collision involvement in a large representative sample of 
adult drivers in Ontario, Canada. The prevalence of 
self-reported collision involvement within the past year 
may have developed tolerance to cocaine’s 
performance-enhancing effects. Furthermore, the route 
of administration was oral in their study (producing a 
smaller effect and a slower onset of effects) while in one 
of the previous studies it was intranasal.
A study by Hopper et al. (2004) found no effect of a low 
dose of cocaine (0.2 mg/kg) on measures of attention, 
recall or recognition task performance. As acute cocaine 
administration can induce hypercortisolaemia 
(associated with symptoms such as mania, depression, 
poor concentration and hyperactivity), the researchers 
also investigated the effects of cortisol on performance. 
A low dose of cortisol (0.2 mg/kg) enhanced and a high 
dose (0.5 mg/kg) impaired vigilance attention, and a 
trend was found for the same dose–response profile on 
twice-heard words. An opposite trend was observed for 
recognition: cortisol at a low dose impaired and at a high 
dose enhanced recognition of once-heard words, and a 
very weak trend was found for recognition of new words. 
The authors concluded that these results should be 
interpreted with caution, given several methodological 
limitations (e.g. the low dose of cocaine), but that these 
findings suggest that the effects of cocaine can be 
influenced by the induction of hypercortisolaemia.
An expert panel in Norway (Vindenes et al., 2012) 
proposed that, for the purposes of sanctions, a cut-off 
value for cocaine in blood of 24 ng/ml should be 
considered equivalent to an alcohol concentration of 
0.2 g/l.
Combination with other psychoactive substances
No experimental studies on the effects of the 
combination of cocaine with another psychoactive 
substance were found that were published in 1999 or 
later. Therefore, a short overview will be given of studies 
published before 1999.
These studies show that cocaine can partially diminish 
performance impairments caused by alcohol 
consumption. The use of a combination of alcohol and 
cocaine decreases psychomotor impairment and 
improves performance on cognitive tests when 
compared with the use of alcohol alone (Farré et al., 
1993; Foltin et al., 1993). Cocaine use also reduces the 
subjective feeling of drunkenness caused by alcohol 
(Farré et al., 1993; Foltin et al., 1993). The combined use 
of cocaine (96 mg cocaine hydrochloride) and cannabis 
(2.7 % THC) can cause additional performance 
decrements that are not caused by either drug alone, 
such as impaired performance on a repeated acquisition 
task (Foltin et al., 1993).
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sedatives the adjusted OR was 210.97 (95 % CI 4.90–
9089).
In the DRUID case–control study (Hels et al., 2011), the 
relative risk of incurring serious injury when driving under 
the influence cocaine was estimated to be increased to a 
middling degree (RR 2–10). The adjusted OR, based on 
data for all countries, was 3.30 (95 % CI 1.40–7.79) for 
cocaine and serious injury and 3.70 (95 % CI 1.60–8.57) 
for benzoylecgonine and death.
One epidemiological study investigated the relationship 
between cocaine use and the severity of a traffic 
accident. Smink et al. (2005) examined data from a 
group of drivers who were involved in accidents in the 
Netherlands from October 1998 until September 1999. 
All blood samples had been screened for the presence 
of alcohol, illicit drugs and medicinal drugs. Logistic 
regression analysis showed no association between the 
use of cocaine and the severity of the accident.
Meta-analysis
In the meta-analysis of 66 publications by Elvik (2013), 
the best estimate of the relative risk of accident 
involvement with cocaine, adjusted for publication bias, 
was 2.96 (95 % CI 1.18–7.38) for fatal accidents, 1.66 
(95 % CI 0.91–3.02) for injury accidents and 1.44 (95 % 
CI 0.93–2.23) for crashes resulting in property damage.
I Conclusion
Acute effects: Few recent experimental studies exist on 
the acute effects of cocaine, and these are mostly 
restricted by methodological limitations, such as the 
administration of low doses of cocaine. The results of the 
few studies that were found suggest that the effects of 
cocaine can be influenced by the induction of 
hypercortisolaemia.
Duration of effects: Snorting cocaine produces effects 
almost immediately, and the resulting high may last 
15–30 minutes. General effects will persist for 1–2 
hours depending on the dose, and late-phase effects 
following binge use may last several days.
Combinations: Accident risk is higher when cocaine is 
used in combination with another psychoactive 
substance, such as alcohol and/or cannabis. Cocaine 
can partially reverse some negative effects of alcohol, 
while detrimental effects of other drugs such as 
cannabis can be reinforced. The chronic use of cocaine 
was 18.9 % among those who used cocaine, compared 
with 7.4 % among non-users. Logistic regression 
analysis, controlling for the potential confounding effects 
of age, sex, income, driving exposure and drinking–
driving measures, found that the odds of collision 
involvement in the preceding year among cocaine users 
was over twice that of non-users (OR 2.11; 95 % CI 
1.06–4.18). In another study (Pulido et al., 2011b) of 
17 484 car or motorcycle drivers in 2005 in Spain, 
logistic regression was used to adjust for distance driven 
and potential confounders. Cocaine use on 1 day or 
more a week was associated with more traffic injuries 
(OR 2.8; 95 % CI 1.1–7.1).
Responsibility analyses
Drummer et al. (2004), in their responsibility analysis of 
3 398 fatally injured drivers, calculated the risks 
associated with driving under the influence not of 
cocaine alone, but of a group of substances acting as 
stimulants, namely amphetamine, methamphetamine, 
MDMA, ephedrine, pseudoephedrine, phentermine and 
cocaine. There was no significant association between 
stimulant use and crash responsibility, except for the 
subset of truckers, in which case the OR increased to 8.8 
and was of borderline statistical significance (95 % CI 
1.0–77.8). Dussault et al. (2002) investigated the 
contribution of alcohol and other drugs in fatal crashes 
in Québec, Canada. They found that driving under the 
influence of cocaine alone, or in combination with 
cannabis and/or alcohol, is associated with an infinite 
risk of responsibility for an accident. This is probably 
because only a limited number of fatally injured drivers 
tested positive for cocaine and because all these drivers 
were judged responsible for the accident. A 
responsibility analysis in France found that driving under 
the influence of cocaine is associated with an increased 
risk of responsibility for an accident (OR 4.4; 95 % CI 
1.0–19.0) (Laumon et al., 2005). However, after 
adjustment for confounding factors such as age, sex, 
vehicle type and time of crash, the increase in risk was 
no longer significant (OR 4.2; 95 % CI 0.9–19.6). 
Soderstrom et al. (2005) found that drivers under the 
influence of cocaine are significantly more likely to be 
responsible for a crash than drivers who are not under 
the influence of this drug (OR 2.3; 95 % CI 1.4–4.0).
Based on the DRUID results in Belgium (Kuypers et al., 
2012), only a crude OR could be calculated: 6.85 (95 % 
CI 0.62–75.94) for cases in which only benzoylecgonine 
was found and 2.74 (95 % CI 0.32–23.59) for cases in 
which cocaine was found. For the combination of alcohol 
and stimulants, the adjusted OR was 20.34 (95 % CI 
4.93–83.82), and for the combination of stimulants and 
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The 1,5-benzodiazepine derivatives are thought to be 
somewhat less sedating.
Depending on the metabolic pathway, benzodiazepines 
are divided into three groups:
n  short-acting: triazolam and midazolam;
n  medium-acting: alprazolam, bromazepam, brotizolam, 
clotiazepam, loprazolam, lorazepam, lormetazepam, 
oxazepam and temazepam;
n  long-acting: clobazam, clonazepam, clorazepate, 
cloxazolam, diazepam, ethyl loflazepate, 
flunitrazepam, flurazepam, nitrazepam, nordazepam, 
prazepam and tetrazepam.
The short-acting benzodiazepines generally do not 
produce a ‘hangover’ effect if taken at bedtime. If the 
drug is stopped after a prolonged period of use, 
withdrawal symptoms occur; these can be quite severe, 
especially with the short- and medium-acting 
substances.
The newer benzodiazepine-like drugs (zolpidem, zaleplon 
and zopiclone, collectively called Z-hypnotics) were 
thought less likely to lead to dependence, although 
recent evidence suggests that they are no different from 
the benzodiazepines.
Effects
Table A8 (Appendix) summarises the results of 
experimental studies on benzodiazepines.
Short-acting benzodiazepines and benzodiazepine-
like drugs
Danjou et al. (1999) compared the residual effects of 
administering zaleplon (10 mg), zolpidem (10 mg) or 
placebo 2–5 hours before awakening. A battery of tests 
(including CRT, DSST, CFF and LARS) were conducted 
15 minutes after the subjects’ morning awakening. 
Zaleplon showed no residual effect at any time at any 
point, whereas zolpidem’s effects were still apparent up 
to 5 hours after administration. The effects of zolpidem 
lasted longer with this night-time administration than in 
previous studies using daytime administration, 
according to the authors.
A comparison of zaleplon (10 or 20 mg), zolpidem (10 or 
20 mg), placebo and triazolam (0.25 mg) revealed no 
changes in memory or learning 1.25 hours and 8.25 
can lead to cognitive defects, impaired psychomotor 
performance and impulsive behaviour.
Chronic use: Chronic use of cocaine can cause 
difficulties in processing cognitive tasks requiring 
attention, visuospatial perception, memory, cognitive 
flexibility, perceptual–motor speed, problem-solving, 
abstraction and executive functioning and an increase in 
impulsive behaviour.
Threshold concentration: An expert panel in Norway 
proposed a cut-off value for cocaine in blood of 24 ng/ml 
corresponding to an alcohol concentration of 0.2 g/l. 
Limits equivalent to higher BACs have not been 
suggested because the correlation between drug 
concentration and risk of traffic accidents/impairment is 
variable or insufficiently documented.
Accident risk: Epidemiological studies show that cocaine 
may increase the risk of being involved in or responsible 
for an accident. A meta-analysis showed that the relative 
risk of accident involvement with cocaine is 1.5 to 3.
I Benzodiazepines and other medicines
I Benzodiazepines (anxiolytics and hypnotics)
Benzodiazepines are used primarily for rapid relief of 
anxiety and for muscle relaxation, sedation and 
anticonvulsant effects. Chemically, these substances 
consist of a benzene ring fused with a diazepine ring 
which has a substituted benzene ring on its fifth 
position. Most structures resemble the 
1,4-benzodiazepine skeleton; however, there are also 
1,5-benzodiazepine derivatives (e.g. clobazam). The first 
benzene ring is sometimes substituted by a 
heteroaromatic system (e.g. clotiazepam). 
Benzodiazepines bind to the gamma-aminobutyric acid 
(GABA) receptor GABA
A
, where they exert their 
pharmacological effect. In contrast to the barbiturates, 
they modulate the effects of the neurotransmitter GABA. 
In the absence of GABA, chloride channels do not open 
in the presence of benzodiazepines but they do with 
barbiturates, which may explain the narrow therapeutic 
window of the latter. Benzodiazepines tend to be safe in 
overdose when taken alone. When combined with other 
substances, especially alcohol, lethality is increased. At 
therapeutic doses, benzodiazepines do not suppress 
respiration in healthy individuals. They exert only minor 
effects on the cardiovascular system. Adverse effects 
most frequently encountered are impairment of mental 
and motor functions, drowsiness and light-headedness. 
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memory task and the least reversal for accuracy on the 
Sternberg working memory task.
An overview of the pharmacodynamic profile of zaleplon 
is given by Patat et al. (2001). In young adults, the 
recommended dose of zaleplon, 10 mg, produced 
minimal or no impairment of psychomotor function and 
memory performance even when administered at night 
as little as 1 hour before awakening. No impairment of 
actual driving was observed when zaleplon 10 mg was 
administered either at bedtime or in the middle of the 
night as little as 4 hours before awakening. Zaleplon 
20 mg generally produced significant impairment of 
performance and cognitive functions when these 
functions were measured at the time of peak plasma 
concentration (1 hour after dose administration), and no 
impairment of driving abilities when measured 4 hours 
after a middle-of-the-night administration.
A single oral dose of zolpidem (5, 10 or 20 mg/70 kg) or 
triazolam (0.125, 0.25 or 0.5 mg/70 kg) produced similar 
dose-related effects on memory for target information 
(Mintzer and Griffiths, 1999). The results suggested that 
triazolam, but not zolpidem, impaired memory for the 
screen location of picture stimuli.
Greenblatt et al. (2005) compared the effects of 
triazolam 0.375 mg on EEG and the DSST. The changes 
for the measures are highly correlated.
Vermeeren et al. (2002a) examined the effects of alcohol 
(0.3 g/l), zaleplon (10 mg) or zopiclone (7.5 mg). A 
highway driving test was performed 40 minutes after 
administration of alcohol and 10 hours after 
administration of zaleplon or zopiclone. Zopiclone and 
alcohol each produced marked impairment, with the 
magnitude of impairment with zopiclone being twice 
that with alcohol. Zaleplon produced no impairment.
Bocca et al. (2011) administered zopiclone (7.5 mg), 
zolpidem (10 mg), flunitrazepam (1 mg) as a positive 
control or a placebo at each subject’s home at 11.00 p.m. 
The next morning, at 9.00 a.m., the subjects were asked 
to drive in a simulated monotonous driving environment 
for 1 hour. In comparison with placebo, zopiclone and 
zolpidem equivalently and significantly increased the 
SDLP, the standard deviation of speed and the number 
of road exits.
Gustavsen et al. (2009) found a strong relationship 
between zopiclone concentration and effect on both 
driving ability and control behaviours, and a weaker 
relationship between zopiclone concentration and effect 
on executive planning behaviour. Significant impairment 
(of automotive and control behaviour) was first observed 
hours after administration of zaleplon 10 mg (Troy et al., 
2000). At the 1.25-hour mark, zolpidem 10 mg produced 
greater psychomotor impairment than the other 
substances. At 8.25 hours, cognitive impairment 
persisted in those administered zolpidem 20 mg and 
triazolam 0.25 mg.
Hindmarch et al. (2001a) administered zolpidem (10 mg) 
or zaleplon (10 or 20 mg) at night-time, 5 hours, 3 hours 
and 1 hour before awakening at 8.00 a.m., at which time 
tests were conducted (including CFF, CRT, DSST and 
LARS). Zaleplon 10 mg did not produce any effects, 
except a small effect on the DSST score 1 hour after 
administration. Zaleplon 20 mg led to significant residual 
effects on memory and performance 1 hour after 
administration. Zolpidem had residual effects on DSST 
and Sternberg memory scanning for up to 3 hours 
following administration, and an effect on CRT and 
delayed free recall of words that lasted up to 5 hours 
after administration. Zolpidem 10 mg showed more 
residual effects than zaleplon 20 mg.
In another night-time administration study, Verster et al. 
(2002a) examined the effects of zaleplon (10 or 20 mg) 
and zolpidem (10 or 20 mg) on driving ability, memory 
and psychomotor performance. Driving ability was 
assessed 4–5 hours after drug administration. Zaleplon 
did not affect performance, whereas zolpidem did so in a 
dose-dependent manner.
Although zaleplon generally does not impair driving, a 
case report by Stillwell (2003) shows the contrary. The 
subject, whose blood concentration of zaleplon was 
0.13 μg/ml, showed symptoms of slow movements and 
reactions, and poor coordination and lack of balance. 
The author concluded that higher than therapeutic blood 
concentrations of zaleplon have the potential to cause 
impairment of psychomotor functions. Logan and 
Couper (2001) concluded the same for zolpidem. 
Whether zolpidem was used alone or in combination 
with other drugs, the symptoms generally were the 
same. Zolpidem levels in subjects’ blood ranged from 
0.08 to 1.4 mg/l. Even levels consistent with normal 
therapeutic concentrations have the potential to affect 
driving ability.
Mintzer and Griffiths (2007) studied the effects on 
memory tasks of triazolam (0.25 or 0.5 mg/70 kg) alone, 
d-amphetamine sulphate (20 or 30 mg/70 kg) alone, or 
their combination. Relative to the sedative measures, 
d-amphetamine showed less reversal of triazolam’s 
effects on the memory measures. The memory measures 
ranged in degree of reversal: the most reversal was 
observed for reaction time on the n-back working 
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ramelteon (8 mg), lormetazepam (1 and 2 mg), zaleplon 
(10 and 20 mg) or zopiclone (7.5 mg).
Medium-acting benzodiazepines
Alprazolam
Mills et al. (2001) studied the effects of stimulants and 
sedatives on performance on single-target and divided 
attention tasks in different parts of the visual field in fully 
rested participants: alprazolam (0.5 mg) clearly impaired 
performance whereas stimulants (dextroamphetamine 
10 mg) enhanced performance and induced tunnel 
vision.
Verster et al. (2002b) examined the effects of alprazolam 
(1 mg) on driving ability, memory and psychomotor 
performance. One hour after intake, the volunteers took 
a standardised driving test during which SDLP and 
standard deviation of speed were measured. In addition, 
2.5 hours after administration a laboratory test battery, 
including a memory scanning test, tracking test and 
divided attention test, was carried out. Serious driving 
impairment was encountered, which was also confirmed 
by subjective assessments. Moreover, alprazolam 1 mg 
seriously impaired performance on the laboratory test.
In a review of alprazolam studies, Verster and Volkerts 
(2004a) summarised the effects of the drug on memory 
and driving ability. For memory functioning, a clear 
dose–impairment correlation was seen.
Leufkens et al. (2007) studied the effects of 1 mg 
alprazolam extended release and 1 mg alprazolam 
immediate release. A standardised driving test was 
performed 4 hours after dosing, cognitive and 
psychomotor tests were performed 2.5 and 5.5 hours 
after dosing and memory function was assessed 1 hour 
after administration. Severe impairment of driving 
performance was noted. Impairment with the extended-
release formulation was only half of that observed with 
the immediate-release formulation.
Previously, Bourin et al. (1998) showed that low doses of 
lorazepam or alprazolam produced significant 
improvement in cognitive and psychomotor functions in 
healthy volunteers. A study by Bentué-Ferrer et al. 
(2001) in animals found a behavioural stimulatory effect 
with alprazolam (0.005 mg/kg) but not with lorazepam, 
which the authors supposed was because of the 
extracellular rise of dopamine in the striatum.
Snyder et al. (2005) found that alprazolam 0.5 mg 
reduced the speed of attentional performance. With a 
at zopiclone concentrations above 16 μg/l. Acute 
tolerance was found. 
Leufkens and Vermeeren (2009) evaluated the residual 
effects of evening doses of temazepam 20 mg and 
zopiclone 7.5 mg on driving in healthy elderly drivers. 
Participants performed a standardised highway driving 
test between 10 and 11 hours after drug administration. 
Temazepam 20 mg was unlikely to impair driving 10 
hours or more after bedtime administration in healthy 
elderly persons aged 65–75 years. Zopiclone 7.5 mg 
moderately impaired driving in the elderly for at least 11 
hours after administration. The magnitude of impairment 
in the elderly was similar to that found previously in 
younger volunteers.
Mets et al. (2011) found a significant increase in SDLP 
(+ 2.9 cm) in healthy adult subjects the morning after 
administration of 7.5 mg zopiclone. Zopiclone also 
significantly impaired driving performance, cognitive, 
memory and psychomotor performance the morning 
after bedtime administration.
Ramaekers et al. (2011) measured the residual effects of 
single and repeated doses of esmirtazapine 1.5 and 
4.5 mg on real-life driving performance in 32 healthy 
volunteers in a double-blind, placebo-controlled study. 
Treatment with single doses of zopiclone 7.5 mg was 
included as an active control. Treatments were 
administered in the evening. Driving performance was 
assessed in the morning, 11 hours after drug intake. 
Single-dose zopiclone 7.5 mg increased SDLP.
Verster et al. (2011) reviewed eight studies utilising the 
standardised on-the-road driving test that consistently 
showed that in the morning following bedtime 
administration zopiclone (7.5 mg) significantly impaired 
driving performance. Meta-analyses showed no 
significant differences in driving performance after 
zopiclone (7.5 mg) between adult and elderly healthy 
volunteers. The combined effect size for healthy 
volunteers was 0.782 (95 % CI 0.620–0.944). Relative to 
placebo, an average increment in SDLP of 3.0 cm was 
observed following treatment with zopiclone (7.5 mg). 
This deviation was higher than the increment in SDLP 
reported for drivers with a BAC of 0.5 g/l (+2.4 cm). 
Results from driving simulators and psychometric tests 
are consistent with the on-road driving test results. In a 
literature review (Verster and Roth, 2012), significant sex 
differences (higher SDLP in women) in driving 
performance the morning following bedtime 
administration of flurazepam (30 mg) and after middle-
of-the-night administration of zolpidem (10 mg) were 
observed. No significant sex differences were found for 
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A study by Soo-ampon et al. (2004) found that effects on 
recall memory of lorazepam 2 mg alone, alcohol 0.6 g/l 
alone or the two combined were significantly dependent 
on word frequency. Low-frequency words were more 
sensitive to memory impairment by lorazepam or alcohol 
than high-frequency ones. However, subjects’ more 
accurate recall of the high-frequency words was 
eliminated when both lorazepam and alcohol were 
consumed.
Lormetazepam
Iudice et al. (2002) assessed the effects of 
lormetazepam (1 mg) on daytime vigilance, psychomotor 
performance and simulated driving. For 3 days, subjects 
received lormetazepam or placebo at night, and tests 
were conducted on the morning following the last 
administration. Subjects’ results on neuropsychological 
tests, visual reaction times, sleep latency and driving 
ability showed no deterioration following placebo or 
active medication when compared with baseline 
performance.
Psychomotor performance in young adults given a single 
dose of lormetazepam or placebo was assessed using 
visual SRT and visual CRT, measured before and after 
dosing (Fabbrini et al., 2005). Lormetazepam did not 
affect psychomotor performance compared with 
placebo.
Temazepam
Tiplady et al. (2003) tested the difference between 
alcohol (0.8–1.0 g/l) and temazepam (20–30 mg) on 
generating errors in performance tests. Alcohol 
generated more error-prone behaviour with less effect 
on psychomotor speed. Temazepam had no significant 
effect on accuracy but slowed performance. 
Information-processing capacity and long-term memory 
formation were reduced in a similar way with both 
alcohol and temazepam 30 mg.
Morin et al. (2003) reported few adverse effects of 
temazepam (7.5–30 mg) in older adults. Those that were 
observed were in the areas of affective/behavioural/
cognitive function, neurosensory function and neuro-
automatic function. Tolerance to these effects 
developed over time.
Long-acting benzodiazepines
The behavioural and cognitive effects of flunitrazepam 
and clonazepam were examined by Dowd et al. (2002). 
Flunitrazepam (2 mg) affected memory and attention 
dose of 1 mg, impairments in psychomotor functions 
were observed in addition to impairments in working 
memory and learning.
In one of the DRUID experimental studies (Schulze et al., 
2012), zopiclone (7.5 mg) and alprazolam (0.5 mg) 
produced significant driving impairment in patients as 
well as in healthy control subjects. Zolpidem (10 mg) 
produced significant driving impairment in elderly 
subjects. Chronic users did not experience subjectively 
any sedative effects of zopiclone and alprazolam, 
whereas infrequent users and healthy users reported 
feelings of reduced alertness and sleep. This lack of 
awareness of (residual) sedative effects of zopiclone and 
alprazolam may lead patients who suffer from insomnia 
and anxiety to believe that car driving is safe during 
treatment with these drugs.
Lorazepam
In a study of the subchronic use of lorazepam or 
ritanserin, Van Laar et al. (2001) evaluated subjects’ 
driving performance, slow-wave sleep and daytime 
sleepiness. Lorazepam 1.5 mg, ritanserin 5 mg or 
placebo was given twice daily for 7 days. Tests included 
EEG, sleep latency test, driving test (SDLP) and 
subjective assessments. With lorazepam, marked 
impairment on the driving test and a reduction in 
daytime sleepiness were observed.
Matthews et al. (2002) studied the effects on memory 
and behavioural learning of a single dose of lorazepam 
2.5 mg. Marked deficits in delayed free recall, perceptual 
priming and written word fluency were recorded, with 
preservation of digit span. The results suggest an 
impairment of the ability to learn behavioural strategies.
The effects of lorazepam on total and partial retrieval of 
recently learned material and feeling-of-knowing rating 
were studied by Izaute and Bacon (2006). When 
studying four-letter nonsense letter strings, the subjects 
taking lorazepam (0.038 mg/kg) showed an impairment 
of episodic short-term memory. The drug also had an 
effect on the feeling-of-knowing estimates, but not on 
their predictive accuracy.
Clarkson et al. (2004) reviewed driving ability in 
individuals suspected of driving under the influence of 
drugs and in whom a blood sample subsequently tested 
positive for lorazepam. Among those in whom lorazepam 
alone was detected, significant psychomotor disability 
that was independent of the blood concentration (range 
0.01–0.13 mg/l) of lorazepam was found.
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(20 mg) or placebo on driving ability in women with 
non-organic insomnia. The subjects underwent a driving 
simulator test 5.5 hours after intake. No major 
differences in psychomotor performances were 
observed between those taking either zolpidem or 
temazepam and those given placebo, leading the 
authors to conclude that there was an absence of 
significant residual effects. However, differences in 
susceptibility to the drugs were seen among the 
subjects.
The effects of zolpidem 5 mg, zopiclone 3.75 mg or 
lormetazepam 1 mg in elderly people were investigated 
by Allain et al. (2003) using LMT, CTT, SRT and a 
Sternberg test. SRT and CTT results were unaffected by 
the three drugs, whereas lormetazepam led to an 
impairment of performance on the LMT.
Vermeeren (2004) reviewed the effects of 11 hypnotics. 
Zaleplon 10 or 20 mg, zolpidem 10 mg, temazepam 
20 mg (soft gel capsules), lormetazepam 1 mg capsules 
and triazolam 0.125 mg were unlikely to have any 
residual effects the morning after administration. 
Tolerance to these impairment effects upon continued 
administration seems to occur, but it may be only partial 
and dependent upon dose and duration of 
administration.
The acute pharmacological effects of temazepam (15 or 
30 mg), diphenhydramine (50 or 75 mg) and the herbal 
supplement valerian (400 or 800 mg) were examined by 
Glass et al. (2003). Psychomotor effects were assessed 
with the DSST and manual tracking. Valerian had no 
effect, while temazepam 30 mg produced the most 
psychomotor impairment. Diphenhydramine 75 mg and 
temazepam 15 mg produced similar effects on motor 
performance, and no psychomotor impairment was 
detected with diphenhydramine 50 mg.
Staner et al. (2005) evaluated the effects of zolpidem 
(10 mg), zopiclone (7.5 mg) or lormetazepam (1 mg) on 
EEG and a driving simulation test 9–11 hours after 
administration. Zopiclone increased the number of 
collisions and lormetazepam increased the deviation 
from speed limit and deviation from absolute speed, 
while zolpidem had no effects. EEG recordings showed 
typical benzodiazepine-induced alterations.
The modification of visual information processing was 
studied by Berthelon et al. (2003). A night-time dose of 
zolpidem (10 mg), zopiclone (7.5 mg) or flunitrazepam 
(1 mg) was given and the effects on collision anticipation 
capacities were investigated the next morning. Only 
flunitrazepam caused subjects to incorrectly focus their 
attention during the simulation.
4 hours after intake, while clonazepam (3 mg) affected 
memory and attention for 6 hours and reduced 
psychomotor performance 2 hours after intake.
Bramness et al. (2006) investigated the relationship 
between impairment and flunitrazepam concentrations 
in the blood of drivers suspected of impairment. The 
impaired drivers had higher flunitrazepam 
concentrations than the drivers who were not impaired. 
Paradoxical reactions were observed, but were not 
related to the flunitrazepam level.
A study by Rich et al. (2006) evaluated the effect of 
diazepam 0.19 mg/kg on retrospective and prospective 
memory by testing free recall of unrelated word lists and 
instructing the participants to request the return of a 
belonging that they had given to the experimenter at the 
start of the session. Diazepam impaired performance on 
all measures.
Boucart et al. (2007) investigated attentional 
impairments in the temporal domain in conditions 
simulating driving, in which observers had to read the 
name of a city and then detect a vehicle appearing to the 
left or right of the fixation point at short but variable 
temporal intervals. Diazepam, at therapeutic dosage, 
impaired shifting of attention when participants were 
asked to process two events occurring in rapid 
succession.
Between-group comparisons
Bocca et al. (1999) studied the residual effects of 
zolpidem 10 mg, zopiclone 7.5 mg, flunitrazepam 1 mg or 
placebo on driving performance. Doses were given at 
11.00 p.m. Zopiclone and flunitrazepam had residual 
effects during the first part of the morning, while 
zolpidem was free of any effect. In addition, 
flunitrazepam and zopiclone affected eye movements 
(saccadic latency) adversely.
Vignola et al. (2000) compared people with insomnia not 
using medications, people with insomnia using 
medication (lorazepam, flurazepam, nitrazepam or 
temazepam) and good sleepers on neuropsychological 
tests for memory, attention/concentration and 
psychomotor function. Both groups with insomnia 
performed worse than good sleepers. Subjects with 
insomnia who were not taking medications had lower 
performance expectations and rated their own 
performance more negatively.
Partinen et al. (2003) investigated the effects of an 
after-midnight intake of zolpidem (10 mg), temazepam 
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TABLE 4
Impairment limits and limits for graded sanctions proposed in Norway for different benzodiazepines and Z-hypnotics 
(Vindenes et al., 2012)
Impairment limit (ng/ml)
Limit for graded sanctions 
corresponding to BAC 0.5 g/l (ng/ml)
Limit for graded sanctions 
corresponding to BAC 1.2 g/l (ng/ml)
Alprazolam 3 6 15
Clonazepam 1.3 3 8
Diazepam 57 143 342
Flunitrazepam 1.6 3 8
Nitrazepam 17 42 98
Oxazepam 172 430 860
Phenazepam 1.8 5 10
Zolpidem 37 77 184
Zopiclone 12 23 58
Gaboxadol, a selective extrasynaptic GABA
A
 receptor 
agonist previously in development for the treatment of 
insomnia, has a short half-life (1.5–2 hours) and is 
expected to be free from residual effects the next 
morning. Leufkens et al. (2009) assessed the residual 
effects of evening and middle-of-the-night administration 
of 15 mg of gaboxadol on cognitive, psychomotor and 
driving performance in 25 healthy volunteers. On each 
treatment night, subjects ingested one capsule at 
11.00 p.m. and one at 4.00 a.m. Treatments were placebo 
at both times, 15 mg gaboxadol or 7.5 mg zopiclone 
followed by placebo, and placebo followed by 15 mg 
gaboxadol or 10 mg zolpidem. Effects on cognition and 
psychomotor performance were assessed between 
7.30 a.m. and 8.30 a.m. and on driving (SDLP) between 
9.00 and 10.00 a.m. Driving was almost significantly 
(p < 0.07) impaired after evening administration of 
gaboxadol. The effects of all other active treatments on 
driving were significant. Evening administration of 
gaboxadol had minor effects on divided attention only, 
whereas middle-of-the-night administration impaired 
performance significantly in all tests except memory. 
Zolpidem and zopiclone impaired performance 
significantly in every test except tracking after zopiclone.
Several cases of sleep driving, a variant of sleepwalking, 
after use of zolpidem have been described (Hoque and 
Chesson 2009; Poceta, 2011; Pressman, 2011). All 
subjects reported amnesia for 3–5 hours. In some 
cases, the episodes began during daytime wakefulness 
because of accidental or purposeful ingestion of 
zolpidem and are considered automatisms. Other cases 
began after ingestion of zolpidem at the time of going to 
bed and are considered parasomnias.
An expert panel in Norway (Vindenes et al., 2012) 
proposed cut-off values for different benzodiazepines in 
blood, corresponding to alcohol concentrations of 0.2, 
0.5 and 1.2 g/l (Table 4).
A study by Paul et al. (2003) comparing melatonin 6 mg 
slow release, zaleplon 10 mg, zopiclone 7.5 mg and 
temazepam 15 mg showed that all the substances 
except melatonin caused detrimental effects on 
psychomotor performances tested using the SRT, logical 
reasoning task, serial subtraction task and multitask. The 
time to normal recovery on the SRT following zaleplon, 
zopiclone and temazepam was 3.25 hours, 6.25 hours 
and 5.25 hours, respectively.
Berthelon et al. (2008) compared the residual effects of 
zopiclone (7.5 mg), zolpidem (10 mg) and flunitrazepam 
(1 mg) with those of a placebo on the capacity of 
subjects to estimate their own speed of movement and 
to anticipate a situation of collision with another vehicle 
parked along their trajectory. They found that own speed 
perception and time to collision estimation were not 
affected by the residual effects of the hypnotic drugs 
studied. Thus, the behavioural impairment observed in 
previous studies results from the alteration of other 
functions that are used when driving a vehicle.
Meskali et al. (2009) administered zopiclone (7.5 mg), 
zolpidem (10 mg) and flunitrazepam (1 mg; used as 
positive control) to 16 healthy subjects aged 55–65 
years at each subject’s home at 11.00 p.m. The next 
morning, the subjects had to drive in a simulated urban 
environment in which accident scenarios were 
introduced. Hypnotics did not significantly increase the 
number of collisions. However, those subjects given 
zopiclone and flunitrazepam drove at significantly higher 
speeds; moreover, zolpidem and zopiclone induced 
modifications of the lateral position of the car on the 
road. Verster et al. (2007) stated that zolpidem is a safe 
alternative to benzodiazepine hypnotics and zopiclone, 
both of which cause significant driving impairment the 
morning after bedtime administration if patients take the 
medication just before a full 8 hours of uninterrupted 
sleep.
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TABLE 5
Results of the large meta-analysis of the experimental studies in the DRUID project (part 1)
Oxazepam Lorazepam Bromazepam Alprazolam Diazepam Chlordiazepoxide Clobazam Buspirone
Number of studies/
number of effects
26/377 68/1 244 9/202 21/354 103/2 104 9/101 16/287 16/341
Dose (mg) 30 2.5 12 1 20 60 20 20
Maximum percentage of 
impaired results
52 77 45 74 74 < 30 < 15 <10
Time (h) of maximum 
impairment
2.25 3.25 2 2.0 1.25 – 3 2–4
Duration (h) 9.0 19.75 – 14 6.25 – 0 0
Equivalent BAC (g/l) > 0.8 > 0.8 > 0.8 > 0.8 > 0.8 0.3–0.5 < 0.3 < 0.3
Degree of impairment (1) 170 571 – 369 171 – 0 0
Concentration 
equivalent to BAC 0.5 g/l
330 9 – 9 320 – – –
(1) The time that a subject who has taken the drug is impaired by more than 15 % (equivalent to a BAC of 0.3 g/l) in arbitrary units.
NB: –, too few data to calculate the number. If multiple doses were given, only the highest is given in this table. Abbreviation: BAC, blood alcohol 
concentration.
TABLE 6
Results of the large meta-analysis of the experimental studies in the DRUID project (part 2)
Triazolam Lormetazepam Temazepam Flurazepam Flunitrazepam Zopiclone Zoplidem Zaleplon
Number of studies/
number of effects
46/1 305 13/161 30/695 22/203 29/491 21/331 31/857 12/350
Dose (mg) 0.5 2.0 20 30 2 7.5 20 10
Maximum percentage of 
impaired results
71 27 30 70–75 92 58 64 37
Time (h) of maximum 
impairment
1.75 0.5 2 2–11 2.25 2.25 1.5 0.75
Duration (h) 10 4.25 0 > 24 > 15 11.5 17 3.5
Equivalent BAC (g/l) > 0.8 0.3–0.5 0.5 > 0.8 > 0.8 > 0.8 > 0.8 0.5–0.8
Degree of impairment (1) 247 22 0 – 461 240 214 40
Concentration 
equivalent to BAC 0.5 g/l
1.6 9.2 450 – 5.4 26 71
(1) The time that a subject who has taken the drug is impaired by more than 15 % (equivalent to a BAC of 0.3 g/l) in arbitrary units.
NB: –, too few data to calculate the number. If multiple doses were given, only the highest is given in this table. Abbreviation: BAC, blood alcohol 
concentration.
Meta-analysis of experimental studies
Berghaus et al. (2010) performed a large meta-analysis 
of the experimental studies in the DRUID project. A 
summary of the results is given in Tables 5 and 6.
Chronic effects
Vermeeren and Coenen (2011) concluded that studies of 
the long-term use of benzodiazepine hypnotics suggest 
that effects on daytime performance may diminish over 
time owing to tolerance. However, there are also studies 
showing that performance may improve after 
discontinuation of chronic benzodiazepine use, which 
suggests that tolerance may not be complete.
Combination with other substances
Few studies exist on the combined effects of alcohol and 
benzodiazepines. One study by Simpson and Rush 
(2002) showed that triazolam (0.125 or 0.250 mg) and 
temazepam (15 or 30 mg) each produced some 
impairment, whereas alcohol alone (0.5 g/l) did not. 
Triazolam–alcohol and temazepam–alcohol 
combinations resulted in clear impairment, even with 
low amounts of alcohol.
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Accident risk
A case–control analysis in Canada found that drivers 
testing positive for benzodiazepines had a higher risk of 
being involved in a traffic accident (OR 4.2; 95 % CI 
2.7–6.3) (Dussault et al., 2002). Testing positive for 
benzodiazepines alone, a combination of 
benzodiazepines and cannabis or a combination of 
benzodiazepines, cannabis and alcohol was associated 
with an increased accident risk of 2.5 (OR; 95 % CI 
1.4–4.3), 21.3 (OR; 95 % CI 5.3–86.0) and 63.9 (OR; 
95 % CI 6.6–618.0), respectively. A combination of 
benzodiazepines and alcohol (BAC > 0.8 g/l) was 
associated with an infinitely increased risk of being 
involved in a traffic accident, but this is probably because 
of the small number of drivers testing positive for this 
combination. A comparison of the prevalence of alcohol, 
drugs and medicines among 900 injured drivers and 900 
control subjects in France found that benzodiazepines 
alone are associated with an increased accident risk of 
1.7 (OR; 95 % CI 1.2–2.4) (Mura et al., 2003). The 
Immortal study in the Netherlands and in Norway found 
that benzodiazepines alone generate an increased 
accident risk of 3.0 (RR; 95 % CI 1.3–6.8) and 20.6 (OR; 
95 % CI 2.1–201.8), respectively (Assum et al., 2005).
One pharmacoepidemiological study investigated the 
relationship between responsibility for a traffic accident 
and benzodiazepine use in the elderly (McGwin et al., 
2000). The results showed that use of benzodiazepines 
was not associated with an increased risk of 
responsibility for an accident. However, 
pharmacoepidemiological studies published before 
1999 do report that benzodiazepine use is associated 
with an increased accident risk (Barbone et al., 1998; 
Hemmelgarn et al., 1997) and an increased injury risk 
(Neutel, 1995, 1998).
In a registry-based cohort study, Engeland et al. (2007), 
using the SIR, compared the incidence of accidents as a 
function of exposed person-time with the incidence in 
the unexposed person-time. The risk was markedly 
increased in users of benzodiazepine tranquillisers (2.9; 
95 % CI 2.5–3.5) and benzodiazepine hypnotics (3.3; 
95 % CI 2.1–4.7).
Hébert et al. (2007) compared the results of an 
unmatched case–control study with those of a case-
crossover study using the same prescription claims 
database to determine whether current use of 
benzodiazepines increases the risk of motor vehicle 
crashes. The case–control approach identified 5 579 
cases (drivers involved in crash resulting in injury) and 
12 911 controls (a 6.2 % subsample of all 224 734 
eligible drivers) between the years 1990 and 1993 in the 
Maxwell et al. (2010) used data from the Fatality 
Analysis Reporting System (1993–2006) on drivers aged 
20 or older who were tested for both alcohol and drugs. 
Using a case–control design, they compared drivers who 
had at least one unsafe driver action (e.g. weaving) 
recorded in relation to the crash (cases) with drivers who 
did not (controls). Drivers who tested positive for 
intermediate- and long-acting benzodiazepines in 
combination with alcohol had significantly greater odds 
of an unsafe driver action than those under the influence 
of alcohol alone, up to BACs of 0.8 and 0.5 g/l, 
respectively. The odds of an unsafe driver action with 
short-acting benzodiazepines combined with alcohol 
were no different than for alcohol alone.
Concentration–effect relationship
Smink et al. (2008a) studied the relationship between 
the blood concentration of benzodiazepines and 
performance in field sobriety tests in 171 retrospective 
cases. Observations of behaviour (n = 137; p < 0.01), 
walking (n = 109; p < 0.01), walking after turn (n = 89; 
p = 0.02) and Romberg’s test (n = 88; p < 0.05) were 
significantly related to the benzodiazepine 
concentration. There was no significant relation between 
benzodiazepine concentration and effect on pupil size, 
nystagmus or orientation.
Verster and Roth (2013) identified 11 studies that 
employed the on-the-road driving test to examine driving 
performance after administration of benzodiazepine 
receptor agonists and also measured blood drug 
concentrations after the on-the-road driving test was 
performed. Although group mean average ΔSDLP 
(difference in SDLP) and blood drug concentration are 
sometimes correlated, individual differences in blood 
concentrations of benzodiazepine receptor agonists 
correlate poorly with driving impairment. From the 
currently available data, it must be concluded that there 
are no significant relationships between individual blood 
drug concentration and ΔSDLP.
Risks
Bramness et al. (2002) examined the relationship 
between benzodiazepine concentration and impairment 
in apprehended drivers. Substances tested for were 
diazepam, oxazepam, flunitrazepam, nitrazepam, 
alprazolam, triazolam and clonazepam. A higher blood 
concentration of diazepam, oxazepam and flunitrazepam 
was found in the impaired subjects than in the subjects 
who were not impaired. There was a clear concentration-
related effect of benzodiazepines on performance.
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increased risk of an MVA. Using a case-crossover design, 
they selected the day before an MVA as the case period 
for each subject, and days 91, 182 and 273 before the 
case period as three retrospective control periods. The 
adjusted OR for involvement in an MVA after taking one 
defined daily dose of zolpidem was 1.74 (95 % CI 
1.25–2.43).
Gustavsen et al. (2008) investigated whether filling a 
prescription for zopiclone or zolpidem was associated 
with an increased risk of road traffic accidents at a 
national population level in Norway. Nitrazepam and 
flunitrazepam were used as comparator drugs. The first 
week after the hypnotics had been dispensed was 
considered the exposure period. SIRs were calculated by 
comparing the incidence of accidents in the exposed 
person-time with the incidence of accidents in the 
unexposed person-time. The SIRs for all ages and both 
sexes combined were 2.3 (95 % CI 2.0–2.7), 2.7 (95 % CI 
1.8–3.9) and 4.0 (95 % CI 2.4–6.4) for Z-hypnotics 
(zopiclone + zolpidem), nitrazepam and flunitrazepam, 
respectively. The highest SIRs were found among the 
youngest users for all hypnotics.
In a French registry-based study on the risk of road 
traffic crashes in people who were prescribed medicines, 
Orriols et al. (2010) found an OR of 1.27 (95 % CI 
1.15–1.405) for psycholeptics (N05 in the ATC 
classification; this class includes antipsychotics and 
anxiolytics).
Ravera et al. (2011) examined the association between 
the use of commonly prescribed psychotropic 
medications and road traffic accident risk in the 
Netherlands in 2000 and 2007. A significant association 
was found between traffic accident risk and exposure to 
anxiolytics (OR 1.54; 95 % CI 1.11–2.15). A statistically 
significant increased risk was also seen in chronic 
anxiolytic users, females and young users (18–29 years 
old) and users of hypnotics with an intermediate half-life.
Responsibility analyses
In Australia, a study on alcohol and drug use among 
3 398 fatally injured drivers indicated that drivers testing 
positive for benzodiazepines did not have an increased 
risk of responsibility for the accident (OR 1.3; 95 % CI 
0.5–3.3) (Drummer et al., 2004). Another study in 
Australia assessed the relationship between drug 
prevalence, drug concentration and driver responsibility 
among 2 500 injured drivers (Longo et al., 2000b). This 
study found a significant relationship between use of 
benzodiazepines alone and responsibility (OR 2.0; 95 % 
CI 1.1–3.9) as well as between benzodiazepine 
province of Quebec, Canada. An increased rate of 
injurious motor vehicle crashes was associated with 
current use of long-acting benzodiazepines (OR 1.45; 
95 % CI 1.12–1.88). The case-crossover approach 
applied to all cases did not find any association (OR 
0.99; 95 % CI 0.83–1.19). However, when cases were 
restricted to subjects with four or fewer prescriptions 
filled in the previous year, corresponding more to 
transient exposures, the OR was elevated (OR 1.53; 
95 % CI 1.08–2.16). A case–control study in southern 
Taiwan (Hou et al., 2012) from January 2009 to 
December 2009 and involving 254 injured patients and 
254 control drivers found that the risk of hospitalisations 
as a result of motor vehicle crashes was increased in 
those taking benzodiazepines (OR 3.41; 95 % CI 1.76–
6.70) and those taking alcohol (BAC ≥ 0.8 g/l) (OR 3.50; 
95 % CI 1.81–6.85). Among participants taking 
combinations of benzodiazepines and alcohol, the OR 
increased to 5.12 (95 % CI 1.77–15.91).
Based on the DRUID results in Belgium (Kuypers et al., 
2012), only crude ORs for the risk of crash with injuries 
associated with sedative and hypnotic drugs could be 
calculated: 1.34 (95 % CI 0.53–3.40) for 
benzodiazepines and 6.45 (95 % CI 1.63–25.52) for 
Z-hypnotics. For the combination of alcohol and 
sedatives, the adjusted OR was 67.19 (95 % CI 23.91–
188.84), and for the combination of different sedatives 
the adjusted OR was 13.70 (95 % CI 2.95–63.66).
In the DRUID case–control study (Hels et al., 2011), the 
relative risk of serious injury when driving under the 
influence of benzodiazepines and Z-hypnotics was 
estimated to be increased to a middling extent (2–10). 
The adjusted OR, based on data for all countries, was 
1.99 (95 % CI 1.36–2.91) for serious injury and 5.40 
(95 % CI 3.90–7.46) for death.
Meuleners et al. (2011), in a retrospective, population-
based, case-crossover study in Western Australia 
between 2002 and 2008, determined the association 
between psychoactive medications and crash risk in 616 
drivers aged 60 and older. The risk of being involved in a 
crash resulting in hospitalisation was higher for older 
drivers when they were prescribed benzodiazepines (OR 
5.3; 95 % CI 3.6–7.8). Crash risk was significantly higher 
in both men (OR 6.2; 95 % CI 3.2–12.2) and women 
prescribed benzodiazepines (OR 4.9; 95 % CI 3.1–7.8). 
Subgroup analyses further suggested that drivers who 
were prescribed benzodiazepines were at greater crash 
risk whether they had (OR 4.0; 95 % CI 2.9–8.1) or did 
not have (OR 6.0; 95 % CI 3.8–9.5) a chronic condition.
Yang et al. (2011) determined whether the use of 
zolpidem 1 day previously is associated with an 
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hypnotics (OR 1.39; 95 % CI 1.08–1.79) and particularly 
in the drivers to whom a dosage of more than one tablet 
of 10 mg zolpidem a day had been dispensed during the 
5 months before the crash (OR 2.46; 95 % CI 1.70–3.56). 
No association was found between the use of zopiclone 
and risk of traffic accidents.
Meta-analysis
A meta-analysis was performed on the data from the 
case–control studies in France, the Netherlands and 
Norway (Assum et al., 2005; Mura et al., 2003). The 
results indicate that drivers who test positive for 
benzodiazepines alone are at an increased risk of being 
involved in an accident, as shown by an RR of 2.3 (95 % 
CI 2.0–2.7) and an OR of 3.4 (95 % CI 2.5–4.4). A 
meta-analysis was also performed on the data from the 
two responsibility analyses in Australia (Drummer et al., 
2004; Longo et al., 2000b). The combined data showed 
an increasing but non-significant accident risk (OR 1.5, 
95 % CI 0.9–2.4; RR 1.1, 95 % CI 1.0–1.3).
Dassanayake et al. (2011) performed a systematic review 
and meta-analysis. Twenty-one epidemiological studies 
(13 case–control and eight cohort studies) ascertained 
by blood or urine analysis or prescription records were 
included. Sixty-nine experimental studies fulfilled the 
inclusion criteria by testing actual or simulated driving 
performance after administering a single dose or multiple 
doses. Two meta-analyses showed that benzodiazepines 
are associated with a 60 % (for case–control studies: 
pooled OR 1.59; 95 % CI 1.10–2.31) to 80 % (for cohort 
studies: pooled incidence rate ratio 1.81; 95 % CI 
1.35–2.43) increase in the risk of traffic accidents and a 
40 % (pooled OR 1.41; 95 % CI 1.03–1.94) increase in 
‘accident responsibility’. Co-ingestion of benzodiazepines 
and alcohol was associated with a 7.7-fold increase in the 
accident risk (pooled OR 7.69; 95 % CI 4.33–13.65). 
Subgroup analysis of case–control studies showed a 
lower benzodiazepine-associated accident risk in elderly 
(> 65 years of age) drivers (pooled OR 1.13; 95 % CI 
0.97–1.31) than in drivers under the age of 65 (pooled 
OR 2.21; 95 % CI 1.31–3.73). Anxiolytics, taken in single 
or multiple doses during the daytime, impaired driving 
performance independent of their half-lives. Regarding 
hypnotics, converging evidence from experimental and 
epidemiological studies indicates that diazepam, 
flurazepam, flunitrazepam, nitrazepam and the short 
half-life non-benzodiazepine hypnotic zopiclone 
significantly impair driving, at least during the first 2–4 
weeks of treatment.
In their meta-analysis, Rapoport et al. (2009) included 16 
experimental studies using driving simulators and 
concentration and responsibility. The risk of responsibility 
for an accident was higher for a combination of alcohol 
and benzodiazepines (OR 13.4; 95 % CI 1.8–101.0) than 
for benzodiazepines alone or alcohol alone (OR 8.0; 95 % 
CI 5.3–12.2). There was an infinite risk associated with 
the use of a combination of benzodiazepines and 
cannabis because all drivers testing positive for this 
combination were judged responsible. A responsibility 
analysis in Canada of 482 fatally injured drivers found 
that drivers testing positive for benzodiazepines, or for 
benzodiazepines alone, had no higher risk of 
responsibility for an accident (OR 5.8, 95 % CI 0.7–44.4; 
OR 3.6, 95 % CI 0.5–28.2, respectively) (Dussault et al., 
2002). The combination of benzodiazepines with either 
alcohol (BAC > 0.8 g/l) or cannabis or with both 
substances was associated with an infinite accident risk, 
probably because all drivers testing positive for these 
combinations were judged responsible.
Dubois et al. (2008), in a case–control study of drivers 
aged 20 and over involved in fatal crashes in the United 
States from 1993 to 2006, examined the impact of 
benzodiazepines on crash responsibility according to 
drug half-life and driver age. Drivers (all with BAC = 0) 
were classified as having no benzodiazepines detected 
or testing positive for benzodiazepines with a short, 
intermediate or long half-life. Cases were drivers 
deemed to have performed at least one potentially 
unsafe driving action in relation to the crash (e.g. 
speeding), a proxy measure for crash responsibility; 
controls were drivers who took no unsafe driving actions. 
The ORs of taking any unsafe driving action according to 
exposure to benzodiazepines of varying half-life were 
calculated, with adjustment for age, sex, other 
medication usage and prior driving record. The odds of 
an unsafe driving action were increased by taking 
benzodiazepines with an intermediate or long half-life in 
drivers aged 25 (intermediate half-life: OR 1.59, 95 % CI 
1.08–2.33; long half-life: OR 1.68, 95 % CI 1.34–2.12) to 
55 (intermediate half-life: OR 1.50, 95 % CI 1.09–2.06; 
long half-life: OR 1.33, 95 % CI 1.12–1.57). The odds of 
drivers taking short half-life benzodiazepines performing 
an unsafe driving action were not increased compared 
with drivers not using benzodiazepines.
Orriols et al. (2011) investigated the association 
between the use of benzodiazepine or benzodiazepine-
like hypnotics and the risk of road traffic accidents by 
matching data from three French national databases: the 
healthcare insurance database, police reports and the 
police database of injury-related traffic accidents. A total 
of 72 685 drivers involved in injury-related road traffic 
accidents in France, from 2005 to 2008, were included 
in the study. The risk of responsibility for a traffic 
accident was higher in users of benzodiazepine 
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I Conclusion
Acute effects: Benzodiazepines and Z-hypnotics are a 
group of substances that cause impairment ranging 
from severe effects to almost no effect. Of the short-
acting benzodiazepines and benzodiazepine-like drugs, 
zaleplon showed few impairing effects (though some for 
20 mg doses), whereas zolpidem and zopiclone, and to 
some extent triazolam, did produce impairment. Among 
the intermediate-acting benzodiazepines, alprazolam 
and lorazepam caused marked impairment, and 
lormetazepam and temazepam less so. The limited 
studies using long-acting benzodiazepines showed 
impairment for flunitrazepam, clonazepam and 
diazepam. Significant sex differences (higher SDLP in 
women) in driving performance were observed the 
morning following administration of flurazepam and 
zolpidem, but not for other benzodiazepines. Several 
cases of sleep driving, a variant of sleepwalking, after 
zolpidem use have been described.
Duration of effects: A few benzodiazepines should 
generally be regarded as unlikely to have a residual 
effect the morning after night-time use: zaleplon 10 mg, 
lormetazepam 1 mg and temazepam 20 mg (immediate-
release capsules). Zolpidem 10 mg produced no effect 
8.25 hours after administration, while zaleplon 20 mg 
showed conflicting results. Zolpidem is a safe alternative 
to benzodiazepine hypnotics and zopiclone, both of 
which result in significant driving impairment the 
morning following bedtime administration if patients 
take the medication just prior to a full 8 hours of 
uninterrupted sleep. Temazepam 20 mg was found to be 
unlikely to impair driving 10 hours or more after bedtime 
administration in healthy elderly drivers aged 75 years or 
younger. Zopiclone 7.5 mg moderately impaired driving 
in the elderly at least until 11 hours after administration. 
The time of maximum impairment varies between 1.2 
and 11 hours and the maximum duration of impairment 
can be longer than 24 hours, depending on the 
benzodiazepine.
Combinations: When combined with alcohol, 
consumption of temazepam, lorazepam and triazolam 
caused clear impairment. The risk of being involved in or 
responsible for an accident increases when another 
psychoactive substance (usually alcohol and/or 
cannabis) is taken in combination with a benzodiazepine.
Chronic use: With chronic and subchronic use, tolerance 
might develop, partially or completely, to the impairing 
effects. Studies on long-term use of benzodiazepine 
hypnotics suggest that effects on daytime performance 
may diminish over time as a result of tolerance. However, 
there are also studies showing that performance may 
on-road tests and 11 epidemiological studies of a 
case–control or cohort design. Data were extracted by 
blinded raters and pooled using random-effects models. 
They excluded studies without control groups or without 
measures of driving or collisions. Associations between 
motor vehicle collisions and benzodiazepine use were 
found among six case–control studies (OR 1.61; 95 % CI 
1.21–2.13) and three cohort studies (OR 1.60; 95 % CI 
1.29–1.97). Only 10 of 97 experimental driving variables 
could be pooled for analysis. While no consistent findings 
were observed in studies using driving simulators, 
increased SDLP was found on on-road driving tests 
(standardised mean difference 0.80; 95 % CI 0.35–1.25).
In their systematic review of 66 epidemiological studies 
that investigated the association between 
benzodiazepine use and traffic accidents, including 
related outcomes such as culpability and injury or 
accident severity, Smink et al. (2010) found that the 
greatest accident risk is associated with the use of long 
half-life benzodiazepines, increasing dosage and the first 
few weeks of use of benzodiazepines. Clear evidence of 
increased culpability associated with benzodiazepine 
use is scarce.
In their meta-analysis of 10 experimental studies, Verster 
et al. (2006) found that the recommended dose of 
various benzodiazepine hypnotics resulted in significant 
driving impairment the morning after bedtime 
administration, i.e. 10–11 hours after dosing [effect size 
(ES) 0.42; 95 % CI 0.14–0.71]. Twice the recommended 
dose impaired driving both in the morning (ES 0.68; 95 % 
CI 0.39–0.97) and in the afternoon, i.e. 16–17 hours 
after dosing (ES 0.57; 95 % CI 0.26–0.88). Zopiclone 
7.5 mg also impaired driving in the morning (ES 0.89; 
95 % CI 0.54–1.23). Zaleplon (10 and 20 mg) and 
zolpidem (10 mg) did not affect driving performance the 
morning after dosing. Following middle-of-the-night 
administration, significantly impaired driving 
performance was found for zopiclone 7.5 mg (ES 1.51, 
95 % CI 0.85–2.17), zolpidem 10 mg (ES 0.66; 95 % 
CI 0.13–1.19) and zolpidem 20 mg (ES 1.16; CI 0.60–
1.72). Zaleplon (10 and 20 mg) did not affect driving 
performance.
In the meta-analysis of 66 publications by Elvik (2013), 
the best estimate of the relative risk of accident 
involvement with benzodiazepines, adjusted for 
publication bias, was 2.30 (95 % CI 1.59–3.32) for fatal 
accidents, 1.07 (95 % CI 0.98–1.16) for injury accidents 
and 1.35 (95 % CI 1.04–1.76) for crashes with property 
damage. For zopiclone, the ORs were 2.60 (95 % CI 
0.89–7.56) for fatal accidents, 1.42 (95 % CI 0.87–2.31) 
for injury accidents and 4.00 (95 % CI 1.31–12.21) for 
crashes with property damage.
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show affinity for other histamine receptors (sometimes 
acting as agonists rather than antagonists) or 
muscarinergic, adrenergic or serotoninergic receptors as 
well as for cardiac ion channels (calcium and potassium)  
— hence the broad range of adverse effects. The H
1
 
receptor is found in neurons, smooth muscle cells, 
epithelial and endothelial cells and white blood cells. The 
H
1
-receptor antagonists are divided into six different 
chemical groups (Table 7). The first-generation as well as 
the second-generation antihistamines can be 
categorised into these groups. The second-generation 
drugs are generally non-sedating, although exceptions 
have been shown.
Terfenadine and astemizole were withdrawn worldwide 
because of serious cardiovascular adverse events 
(torsades de pointes) especially when combined with 
cytochrome P450 3A4 inhibitors. With polydrug use, 
pharmacokinetic interactions are more likely and may 
increase the adverse effects (such as sedation) if the 
metabolism of the antihistamine is inhibited.
Effects
It should be noted that allergic rhinitis and allergic 
diseases in general can cause sleep disturbances. 
Baiardini et al. (2006) examined the effects of 
respiratory allergies, allergic skin disorders and anti-
allergy drugs on sleep. A high prevalence of sleep 
disturbance was observed. The cognitive effects of 
allergic rhinitis and its treatment were reviewed by 
Bender (2005), who noted the deleterious effects on 
cognition and performance. The author concluded, 
however, that it was not clear whether the increased 
alertness that results from the drug’s histamine 
receptor-blocking effect offsets the sedative effect of the 
medication, or whether there is a combined sedating 
effect of the antihistamine and the disease. Impairments 
in vigilance and cognitive functioning associated with 
allergic rhinitis were studied by Wilken et al. (2002), who 
also concluded that there is a decrease in speed and 
efficiency across several cognitive domains. The 
experimental studies discussed below are summarised 
in Table A9 (Appendix).
improve after discontinuation of chronic benzodiazepine 
use, which suggests that tolerance may not be complete.
Threshold concentration: From the data collected, there 
is a correlation between plasma levels and degree of 
impairment (less obvious for lorazepam), be it on 
memory or on psychomotor performance. However, 
individual susceptibility and tolerance must still be taken 
into account. An expert panel in Norway proposed 
impairment limits for different benzodiazepines in blood 
ranging from 1.3 ng/ml for clonazepam to 172 ng/ml for 
oxazepam.
Accident risk: Epidemiological studies indicate that 
drivers have an increased risk of being involved in a 
traffic accident after having taken a benzodiazepine, 
although no distinction was made between the different 
kinds of benzodiazepines. The results of responsibility 
analyses are contradictory. Only one study (out of three) 
found that drivers testing positive for benzodiazepines 
are at an increased risk of responsibility for an accident, 
and that the risk rises with increased concentrations of 
benzodiazepines. Meta-analyses show that the relative 
risk of crashes is approximately 1.6–1.8 for 
benzodiazepines. In combination with alcohol, the 
relative risk increases to approximately 8.
I Antihistamines
Antihistamines are drugs used to treat allergic reactions. 
They work by blocking the peripheral and central effects 
of histamines by binding to histamine receptors. The 
known histamine receptors include H
1, 
H
2
, H
3
 and H
4
 
receptors. Histamines are released as the result of an 
allergic response to different types of allergens (e.g. 
certain drugs, venoms, peptides), and can lead to 
vasodilation, increased permeability of blood vessels 
and contraction of smooth muscles (including 
bronchoconstriction). Treatment with H
1
 antihistamines 
can rapidly resolve these symptoms but can also cause 
adverse effects. Depending on the distribution of the 
drug in the body, the adverse effects can include 
sedation, effects on the digestive tract and 
anticholinergic effects. The antihistamines discussed 
here are largely H
1
-receptor antagonists, although some 
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Mequitazine
A literature search by Didier et al. (2000) concluded that 
classification based on the chemical structure alone 
may be misleading, as in the case of mequitazine, which 
shows a low sedation profile even though it is a first-
generation antihistamine. Mequitazine 5 mg twice a day 
versus dexchlorpheniramine 6 mg, chlorpheniramine 
4 mg twice a day, brompheniramine 12 mg twice a day 
and hydroxyzine 25 mg twice a day produced less or no 
greater sedation than placebo. Mequitazine 5 mg did not 
produce more CNS side-effects than the second-
generation antihistamines cetirizine, loratadine 10 mg 
and astemizole 10 mg.
Theunissen et al. (2006a) compared the effects of 
mequitazine 5, 10 or 15 mg , cetirizine 10 mg, 
dexchlorpheniramine 6 mg or placebo on two actual 
driving tests (highway driving and car-following test) and 
cognitive and psychometric tests (tracking, divided 
attention, memory, reasoning and CFF). Cetirizine did 
not affect performance on any task, while mequitazine 
increased SDLP and affected divided attention and 
reaction time in a dose-related manner. 
Dexchlorpheniramine impaired driving performance, as 
indicated by a significant rise in SDLP. It was concluded 
that mequitazine is mildly sedating.
Chlorpheniramine
Mochizuki et al. (2002) used PET to determine how 
chlorpheniramine 6 mg, compared with placebo, affects 
different regions of the brain. The alterations observed in 
cortical and subcortical activity caused impairment in 
spatial cognition.
Chlorpheniramine has major adverse effects on the CNS. 
According to Serra-Grabulosa et al. (2002), the patient 
TABLE 7
Overview of the different types of antihistamines
Chemical class First-generation antihistamines Second-generation antihistamines
Ethanolamines Carbinoxamine, clemastine, diphenhydramine, 
dimenhydrinate, triprolidine
Ethylenediamines Pyrilamine, tripelennamine
Alkylamines Chlorpheniramine, brompheniramine Acrivastine
Piperazines Hydroxyzine, cyclizine, meclozine, buclizine, 
cinnarizine, oxatomide
Cetirizine, levocetirizine
Phenothiazines Promethazine, mequitazine, oxomemazine, 
alimemazine
Piperidines Cyproheptadine, pizotifen, ketotifen, 
phenindamine
Levocabastine, loratadine, desloratadine, 
fexofenadine, ebastine, terfenadine (1), 
astemizole (1), rupatadine
Phthalazinones Azelastine
(1) Withdrawn from the market in 1998 and 1999.
First-generation antihistamines
Diphenhydramine
Tolerance to the sedative effects of antihistamines was 
studied by Richardson et al. (2002). Both objective and 
subjective measures of sleepiness showed significantly 
higher levels on day 1 for diphenhydramine compared 
with placebo. By day 4, however, levels of sleepiness on 
diphenhydramine were indistinguishable from placebo. 
Similarly, diphenhydramine produced significant 
impairment of performance that was completely 
reversed by day 4. 
Turner et al. (2006) compared the sedation and memory 
impairment associated with a single dose of 
diphenhydramine (50, 75 or 100 mg) or lorazepam (0.5 
or 1.5 mg). The tests included memory recall, DSST and 
CRT. All doses of diphenhydramine impaired subjects’ 
results on the DSST and CRT and caused subjective 
sedation. Lorazepam 0.5 mg had no effect on any test, 
while lorazepam 1.5 mg impaired subjects’ results on the 
DSST and CRT and caused subjective sedation. Both 
diphenhydramine 100 mg and lorazepam 1.5 mg 
impaired memory recall. Therefore, sedation is not 
always associated with impaired memory.
Clemastine
A study by Meltzer et al. (2003) on the safety and 
efficacy of combined administration of pseudoephedrine 
plus paracetamol versus the combination of clemastine 
0.68 mg, pseudoephedrine 60 mg and paracetamol 
1 000 mg showed a higher degree of somnolence with 
the latter.
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concluded that desloratadine 5 mg has no effect on 
daytime sleep latencies and subjective sleepiness, and 
no adverse effects on psychomotor performance. The 
study was a crossover design with promethazine as an 
active control. Assessments were made 1 hour before 
and from 0.5 to 8 hours after ingestion. Promethazine 
impaired tracking, CRT and DSST, and increased 
objective and subjective sleepiness. Desloratadine did 
not change any of these parameters.
A safety and efficacy study of desloratadine 5 mg in 
asthma patients by Berger et al. (2002) revealed an 
adverse event rate similar to that associated with 
placebo; Monroe et al. (2003) concluded the same in a 
study of patients with chronic idiopathic urticaria.
In a study that simulated ‘real-world’ performance tasks, 
desloratadine either completely restored performance to 
the level of the asymptomatic placebo-treated control 
group or improved performance where it had been 
diminished in subjects with seasonal allergic rhinitis 
(Satish and Streufert, 2003; Satish et al., 2004).
Valk et al. (2004) tested, in conditions that simulated 
cabin pressure at 8 000 feet (about 2 400 m) altitude, 
desloratadine 5 mg, diphenhydramine 50 mg and 
placebo, all in single doses on different days with 7-day 
washout periods in between. Measurements included 
vigilance and tracking, a multi-attribute task battery, the 
Stanford sleepiness scale and pulse oximetry. The use of 
desloratadine 5 mg led to no detrimental effects on 
performance associated with flying ability, which was 
not the case with diphenhydramine.
In a systematic review, Bousquet et al. (2004) concluded 
that desloratadine met the European Academy of 
Allergology and Clinical Immunology’s criteria for 
efficacy, safety and pharmacology of antihistamines. The 
safety parameters included an evaluation of cognitive 
and psychomotor impairment associated with use of the 
drug.
A review article by Berger (2005) evaluated the CNS 
safety of desloratadine and concluded that it caused no 
significant CNS-related adverse events.
A similar conclusion was reached by Limon and Kockler 
(2003), who reviewed studies published between 1966 
and 2002.
Loratadine
A comparison of the administration of loratadine 10 mg 
or rupatadine 10 or 20 mg by Saint-Martin et al. (2004) 
may not even be aware of this. The authors suggest that, 
because of the nature of the adverse effects, the 
prescribing of chlorpheniramine may need to be 
reviewed. These authors found, for example, that the use 
of dexchlorpheniramine 4 mg can lead to auditory 
attention impairment, but that patients were unaware of 
this side-effect (Serra-Grabulosa et al., 2001).
Tashiro et al. (2008) examined regional cerebral blood 
flow (rCBF) responses during a simulated car-driving 
task following oral administration of d-chlorpheniramine 
using PET, based on a single-blind crossover study-
design. They found that the number of lane deviations 
significantly increased in the d-chlorpheniramine 
condition compared with the placebo condition 
(p < 0.01). Subjective sleepiness was not significantly 
different between the two drug conditions. Diminished 
brain responses following d-chlorpheniramine treatment 
were detected in the parietal, temporal and visual 
cortices and in the cerebellum whereas regional cerebral 
blood flow responses in the orbitofrontal cortex and 
cerebellar vermis were found to be augmented. These 
results suggest that d-chlorpheniramine tends to 
suppress visuospatial cognition and visuomotor 
coordinating functions rather than attention and motor 
functions during car driving.
Cinnarizine
Subjects’ performance after taking cinnarizine 15, 30 or 
45 mg was examined by Nicholson et al. (2002), with 
promethazine 10 mg used as an active control. The 
performance assessment included DSST and vigilance. 
Cinnarizine 15 mg had no effects on performance, while 
cinnarizine 45 mg caused impairment.
A study of antivertiginous medications by Philipova et al. 
(2004) found no evidence of impairment of reaction time 
in participants who took four doses of cinnarizine 20 mg 
or dimenhydrinate 40 mg in a 24-hour period.
Another study of antivertiginous medications, by 
Schneider et al. (2003), also found no performance 
effects. This study compared cinnarizine 20 mg plus 
dimenhydrinate 40 mg with dimenhydrinate 50 mg plus 
betahistine 12 mg.
Second-generation antihistamines
Desloratadine
Desloratadine is the active metabolite of loratadine. 
Several studies have examined its effects on 
performance and vigilance. Nicholson et al. (2003) 
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In another study, subjects taking cetirizine 10 mg 
showed less impairment of performance on a 
standardised driving test than those taking emedastine 
2 or 4 mg twice daily (Vermeeren et al., 2002b). The 
driving impairment on the first, fourth and fifth days was 
significant for both doses of emedastine. On the fifth 
day, alcohol was given before the test in order to achieve 
a BAC of 0.5 g/l. Alcohol combined with cetirizine or 
emedastine increased impairment on every test. Women 
were more impaired than men by both drugs.
Fexofenadine
Fexofenadine 360 mg, promethazine 30 mg and placebo 
were evaluated in a crossover, double-blind study 
(Hindmarch et al., 2002). The test battery consisted of 
CFF, CRT, a compensatory tracking test and a subjective 
assessment of sedation. The effects of fexofenadine 
were not different from those of placebo in any of the 
tests, whereas the use of promethazine significantly 
impaired all measures. Even at the high dose of 360 mg, 
fexofenadine had no disruptive effects on psychomotor 
and cognitive function. In another study, Ridout and 
Hindmarch (2003) examined the effects of fexofenadine 
60 or 120 mg, promethazine 25 mg and placebo. Here, 
too, fexofenadine use did not lead to cognitive or 
psychomotor impairment.
Some studies have shown that fexofenadine has mildly 
stimulating properties. Theunissen et al. (2006b) 
investigated whether this was the result of the inhibition 
of dopamine reuptake. The subjects in their study, who 
received fexofenadine 360 mg or placebo, performed a 
DSST and a stop signal task. The authors concluded that 
fexofenadine use improved performance on the DSST 
but did not potentiate dopamine level in the striatum. 
They suggested that the activating effects of 
fexofenadine may be a result of the involvement of H
3
 
receptors and/or GABA receptors.
In a study by Ridout et al. (2003a), the use of 
fexofenadine 180 mg with or without alcohol (BAC of 
0.3 g/l) had no effect on performance, whereas the use 
of hydroxyzine produced significant impairment on CFF, 
RRT and TRT. The combination of hydroxyzine with 
alcohol also impaired MRT. The test battery included 
CFF, RRT, MRT, TRT and BRT.
According to Mohler et al. (2002), fexofenadine can be 
safely used in individuals such as pilots who are involved 
in skilled activities, without the concern of sedation at or 
above the recommended doses.
showed that more somnolence occurred in the subjects 
who consumed rupatadine.
Ebastine
Herberg (2000) investigated the effects of ebastine on 
safety in everyday life and road traffic. The effects of 
ebastine 10 and 20 mg were evaluated using computer-
aided test procedures on days 1, 2 and 7 following 
administration. Ebastine 10 or 20 mg did not cause more 
adverse events than placebo, nor did it impair 
performance. Ebastine 10, 20 or 30 mg was compared 
with both placebo and triprolidine 10 mg (active control) 
by Hindmarch and Shamsi (2001), who concluded that 
the effects of ebastine at all doses were not different 
from those of placebo on any of the objective tests. The 
tests included CFF, CRT, a simulated car tracking task, 
the Sternberg test, LARS and subjective evaluation of 
sleep.
Levocetirizine
Hair and Scott (2006) reviewed the studies on the 
pharmacodynamics, pharmacokinetics, therapeutic 
efficacy and tolerability of levocetirizine. No significant 
effect on cognition and psychomotor performance was 
found with the 5-mg dose. Tolerability was good, but the 
incidence of somnolence was higher than with placebo 
(5.2 % versus 1.4 %; but no statistical analysis of the 
difference was reported).
Cetirizine
The effects of different doses of cetirizine (2.5, 5 or 
10 mg) on cognitive and psychomotor functions were 
evaluated by Shamsi et al. (2001) and compared with 
the effects of loratadine (10, 20 or 40 mg) and 
promethazine 25 mg. The test battery included CFF, 
CRT, a compensatory tracking task and assessment of 
subjective sedation. Administration of cetirizine 10 mg 
did not lead to disruptive effects on aspects of 
psychomotor and cognitive function.
A comparison of cetirizine 10 mg and rupatadine 10 mg 
found no difference between groups in the rates of 
adverse event rates, including somnolence, the 
prevalence of which was as high as 9.6 % among the 
subjects who received cetirizine (Martínez-Cócera et al., 
2005).
However, a case report by Nordness and Zacharisen 
(2003) revealed no sedation or somnolence in a patient 
taking 50 mg cetirizine a day.
Drug use, impaired driving and traffic accidents
78
A study of cetirizine 10 mg versus loratadine 10 mg 
found less somnolence in patients taking loratadine and 
better motivation during the day (Salmun et al., 2000).
Inter-drug differences in sedation caused by 
antihistamines are discussed by Shamsi and Hindmarch 
(2000). They used proportional impairment ratios for 
objective evidence to rank the antihistamines, 
calculating an impairment index for each antihistamine 
and comparing it with the impairment index obtained for 
all antihistamines. Fexofenadine, ebastine and 
astemizole ranked the highest in terms, i.e. caused no 
impairment, while promethazine ranked the lowest 
(caused most impairment).
A prescription event-monitoring study found that four 
second-generation antihistamines (cetirizine, 
fexofenadine, loratadine and acrivastine) resulted in an 
overall low incidence of sedation (Mann et al., 2000). The 
authors suggest that people working in safety-critical 
jobs who need antihistamines be given fexofenadine or 
loratadine.
A letter by Ramaekers and Vermeeren (2000) states that 
ebastine, fexofenadine, loratadine and terfenadine do 
not have any effects on driving performance when given 
at the recommended doses, but have at least 
measurable effects with doses that are twice as high. 
They also noted that these higher doses are often used 
by patients with seasonal allergic rhinitis and urticaria.
Layton et al. (2006) conducted a prescription event-
monitoring study and concluded that the rates of 
drowsiness and sedation are low for desloratadine and 
levocetirizine. However, patients prescribed 
levocetirizine were more likely to experience drowsiness 
and sedation in the first month of observation.
Between-generation comparisons
In a review designed to help physicians select the 
‘optimal’ oral antihistamine for their patients, Meltzer 
(2005) found no impairment associated with 
fexofenadine even at high doses, impairment only at high 
doses with use of desloratadine or loratadine and 
impairment at every dose with cetirizine use. A strong 
sedating effect was found for clemastine and 
diphenhydramine, while brompheniramine, 
chlorpheniramine and cetirizine (at a high dose) 
produced a moderate effect. Desloratadine and 
loratadine were not associated with sedating effects, 
except at high doses, and effects were small. 
Fexofenadine was free of sedative effects at any dose.
Mizolastine
Bachert et al. (2001) studied treatment with mizolastine 
10 mg, and concluded that the incidence of adverse 
events was low.
Azelastine
The effect of topical azelastine was studied by Golden et 
al. (2000), who did not find that azelastine causes 
daytime somnolence.
Within-group comparisons
A review article on the adverse reaction profiles of 
second-generation antihistamines by Lange and Bachert 
(2004) evaluated sedative potential as well as 
cardiotoxicity, hepatotoxicity and teratogenicity. 
Cetirizine, desloratadine, ebastine, fexofenadine, 
levocetirizine, loratadine and mizolastine were included 
in the review. Cetirizine, levocetirizine and mizolastine 
were associated with the highest incidence of sedative 
adverse reactions, whereas desloratadine, ebastine and 
fexofenadine exhibit few sedative effects.
A placebo-controlled comparison of fexofenadine 
120 mg, cetirizine 10 mg and hydroxyzine 30 mg (as 
positive control) found no significant impairment 
associated with fexofenadine use relative to placebo, 
although there was a tendency for use of cetirizine to 
cause increased sleepiness (Tashiro et al., 2004). 
Fexofenadine was less impairing than cetirizine on some 
tasks. Measurements included the Stanford sleepiness 
scale (subjective sleepiness) and objective psychomotor 
tests (SRT, CRT and visual discrimination tests).
A study by Takahashi et al. (2004) evaluated the effects 
of bepotastine 10 mg twice daily, cetirizine 10 mg, 
fexofenadine 60 mg twice daily and olopatadine 5 mg 
twice daily on wheal and flare response, sedation and 
psychomotor performance. A visual analogue scale was 
used to measure sedation and a word processor test 
was used to assess psychomotor activity. Olopatadine, 
fexofenadine and cetirizine all showed a significant 
sedative effect, increasing in that order, while 
bepotastine had the least effect. Psychomotor 
performance was most markedly affected by 
olopatadine, followed by fexofenadine and cetirizine.
Passalacqua and Canonica (2005) reviewed 
comparative studies of levocetirizine and desloratadine. 
Neither drug was shown to alter memory, divert 
attention, decrease alertness or impair performance.
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impairment than alcohol alone, albeit less than with 
hydroxyzine. Subjects taking hydroxyzine or cetirizine 
were not aware of the increased impairment.
A study of tolerance development after repeated doses 
of mequitazine 10 mg, cetirizine 10 mg or controlled-
release dexchlorpheniramine 6 mg revealed that the 
driving impairment wears off after 8 days (Theunissen et 
al., 2006a). Cetirizine did not cause any effect from the 
start of the study.
Levocetirizine 5 mg, in contrast to diphenhydramine 
50 mg, does not significantly affect driving performance 
(Verster et al., 2003a). Subjects underwent a 
standardised driving test, and SDLP was analysed. In 
another study, the same authors found no influence of 
levocetirizine 5 mg on memory, attention or tracking 
performance after acute or subchronic administration 
(Verster et al., 2003b). Diphenhydramine 50 mg did, 
however, significantly affect divided attention and 
tracking after acute administration.
Vuurman et al. (2004) examined the effects of 
desloratadine 5 mg, diphenhydramine 50 mg and 
placebo on a standard driving test 2 hours post dosing. 
No significant effect of desloratadine on SDLP was 
noted (whereas this was not the case for 
diphenhydramine) and BRT was significantly faster 
following desloratadine administration. Desloratadine 
did not impair driving performance.
A meta-analysis by Bender et al. (2003) of studies of 
diphenhydramine and second-generation antihistamines 
did not find consistent diphenhydramine-induced 
sedation. The authors concluded that a clear and 
consistent distinction between sedating and non-
sedating antihistamines does not exist.
Weiler et al. (2000) compared the effects on driving of 
placebo, fexofenadine 60 mg, diphenhydramine 50 mg 
and alcohol 1 g/l (BAC). Driving performance was 
assessed with a 1-hour driving simulation. Fexofenadine 
had the same effect as placebo, whereas 
diphenhydramine had an even greater impact on driving 
performance than alcohol.
An analysis by Verster and Volkerts (2004b) shows that 
the use of first-generation antihistamines is associated 
with significant impairment, even with repeat 
administration. Second-generation antihistamines may 
also impair driving performance, but the magnitude and 
extent depends on dose, the subject’s sex and the time 
between testing and administration. The second-
generation antihistamines fexofenadine and 
levocetirizine do not cause driving impairment.
Fexofenadine 120 mg, compared with hydroxyzine 
30 mg, had no influence on BRT when driving and using 
a mobile phone, while hydroxyzine did slow BRT (Tashiro 
et al., 2005).
An evaluation of the effects of fexofenadine 180 mg, 
diphenhydramine 50 mg and placebo on the test of 
variables of attention found no significant effect 
associated with fexofenadine, which was in contrast to 
the results for diphenhydramine (Mansfield et al., 2003). 
Bower et al. (2003), who evaluated fexofenadine for safe 
use by aviation personnel, found that the psychomotor 
effects following a single dose of the drug were no 
different from those with placebo administration.
An evaluation of the acute effects of fexofenadine 
120 mg, olopatadine 10 mg and d-chlorpheniramine 
versus placebo on psychomotor function found no 
effects of fexofenadine on any of the parameters, 
whereas d-chlorpheniramine and olopatadine had 
sedating effects on psychomotor performance (Kamei et 
al., 2003).
An analysis of the differential cognitive effects of 
ebastine 10 mg or chlorpheniramine 2 or 6 mg versus 
placebo revealed no cognitive impairment with use of 
ebastine 10 mg (Tagawa et al., 2002). Chlorpheniramine, 
however, even at the lower dose of 2 mg, produced 
cognitive function impairment; there was a clear dose–
response relationship.
In a comparison of diphenhydramine 50 mg, loratadine 
10 mg and placebo, diphenhydramine was found to 
produce substantial adverse effects on divided 
attention, working memory, vigilance and speed (Kay, 
2000; Kay and Quig, 2001). There was no difference 
between loratadine and placebo. Although testing on 
days 3 and 5 showed some equilibration between the 
active treatment groups, diphenhydramine generated 
more errors on the divided attention test. The authors 
concluded that individuals may not be aware of their 
reduced level of functioning. A study of desloratadine 
5 mg versus diphenhydramine 50 mg by Wilken et al. 
(2003) found that desloratadine alleviated the 
symptoms of ragweed-induced allergic rhinitis without 
adversely affecting performance.
Barbanoj et al. (2006) investigated the combined effects 
of antihistamines with alcohol on seven psychomotor 
performance tests (e.g. CFF and reaction time). The 
greatest impairment was seen with the combination of 
hydroxyzine 25 mg and alcohol 0.8 g/l. When rupatadine 
10 mg plus alcohol was administered, the impairment 
was not greater than with alcohol alone. Alcohol plus 
cetirizine 10 mg or rupatadine 20 mg produced more 
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Risks
Accident risk
No recent epidemiological studies specifically 
investigating the accident risk associated with 
antihistamines were found. Some studies, however, have 
assessed the possible association between 
antihistamines and injuries in general. Finkle et al. 
(2002) showed that the percentage of injuries 
attributable to diphenhydramine was 55 % (compared 
with before use and with loratadine use). Hanrahan and 
Paramore (2003) found an elevated acute injury risk 
after exposure to sedating antihistamines (OR 2.93).
Responsibility analyses
One responsibility analysis was found that calculated 
the risk of responsibility for a traffic accident while under 
the influence of psychoactive drugs, including sedating 
antihistamines, but also TCAs, phenothiazine 
antipsychotics, phenytoin and carbamazepine (Drummer 
et al., 2004). The results showed that driving under the 
influence of these psychoactive drugs alone is 
associated with an increased risk of responsibility for a 
traffic accident (OR 3.8; 95 % CI 1.3–11).
In a French registry-based study on the risk of road 
traffic crashes in people who were prescribed medicines, 
Orriols et al. (2010) found an OR of 1.05 (95 % CI 
0.81–1.35) for antihistamines (class R06 in the ATC 
classification).
Hindmarch et al. (2001b) compared the effects of 
levocetirizine 5 mg, cetirizine 10 mg, loratadine 10 mg, 
promethazine 30 mg and placebo on tests that included 
CFF, CRT, a continuous tracking task and subjective 
rating scales for sedation (LARS). Levocetirizine and 
cetirizine were found to have no effect, even after 
repeated doses, on psychomotor and cognitive functions.
A review of the evidence for impairment by Moskowitz 
and Wilkinson (2004) states that first-generation 
antihistamines produce objective performance 
impairment, as well as subjective symptoms of sedation. 
This may also be the case with some of the second-
generation drugs in some individuals. Within each group, 
there are substances that lead to less sedation and 
driving-related performance impairment.
Vuurman et al. (2007) compared the acute effects of 
rupatadine 10 mg, relative to placebo and 50 mg 
hydroxyzine (as an active control), on healthy subjects’ 
driving performance. There was no significant difference 
in SDLP between the rupatadine and placebo groups; 
however, hydroxyzine treatment significantly increased 
SDLP. Subjects reported negative effects after receiving 
hydroxyzine but not after receiving rupatadine.
Conen et al. (2011) demonstrated that 50 mg 
hydroxyzine significantly increased SDLP on days 1 and 
8 of treatment. Bilastine, a new second-generation H
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antagonist (20 and 40 mg), did not affect SDLP. 
Hydroxyzine produces severe driving impairment after 
single doses, and this impairment is only partly mitigated 
over time owing to a lack of complete tolerance.
Meta-analysis of experimental studies
Table 8 summarises the results of the large meta-analysis 
of the experimental studies in the DRUID project.
TABLE 8
Results of the large meta-analysis of the experimental studies in the DRUID project
Diphenhydramine Triprolidine Terfenadine Loratadine Fexofenadine
Number of studies/number of effects 28/481 14/233 16/259 13/213 5/170
Dose (mg) 50 2.5 60 10 120–180
Maximum percentage of impaired results 41 60–70 0.5 1 0
Time (h) of maximum impairment 1.75 1.5–2.5 0 0 0
Duration (h) 7.75 5 0 0 0
Equivalent BAC (g/l) 0.5–0.8 > 0.8 0 0 0
Degree of impairment (1) 92 – 0 0 0
Concentration equivalent to BAC 0.5 g/l 60 5.7 – – –
(1) The time that a subject who has taken the drug is impaired by more than 15 % (equivalent to a BAC of 0.3 g/l) in arbitrary units.
NB: –, too few data to calculate the number. If multiple doses were given, only the highest is given in this table. Abbreviation: BAC, blood alcohol 
concentration.
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Accident risk: In a meta-analysis the relative risk of 
accident involvement with antihistamines was 1.12 for 
injury accidents.
I Antidepressants
Antidepressants are substances commonly prescribed 
for mood disorders, anxiety and sometimes pain. These 
substances commonly inhibit the reuptake of 
norepinephrine and/or serotonin and/or, to a minor 
extent, dopamine. There are first- and second-generation 
antidepressants and an atypical group (Table 9). The 
second-generation drugs are associated with fewer 
adverse effects than the first generation, mainly because 
of greater selectivity. Adverse effects encountered in the 
first generation are anticholinergic effects (dry mouth, 
gastric distress, blurred vision and urinary retention), 
cardiovascular effects (palpitations, hypotension, 
tachycardia and arrhythmia) and sedation (with the 
serotoninergic compounds), while second-generation 
selective serotonin reuptake inhibitors (SSRIs) are more 
prone to causing gastrointestinal disturbances and 
sexual dysfunction.
Acute effects
Table A10 (Appendix) summarises the experimental 
studies discussed below.
First generation
Few studies have been conducted on the use of TCAs 
alone after 1999. However, previous studies show that 
these substances are associated with clear impairment. 
According to the International Council on Alcohol, Drugs 
and Traffic Safety classification (5), TCAs cause minor or 
moderate effects, except for trimipramine, amitriptyline, 
doxepin, dosulepine and amoxapine, which can produce 
severe adverse effects and are potentially dangerous.
A study by Podewils and Lyketsos (2002) revealed that 
TCA use is not related to cognitive deficits, nor does it 
appear to significantly compromise memory (measured 
by MMSE) over a prolonged period.
Veldhuijzen et al. (2006b) studied the effects of a 
nocturnal dose of amitriptyline 25 mg on actual driving. 
At the start of the therapy, a significant increase in SDLP 
was noted, higher than with a BAC of 0.5 g/l. In addition, 
(5)  See http://www.icadts.org/reports/medicinaldrugs1.pdf and http://
www.icadts.nl/reports/medicinaldrugs2.pdf for the list of drugs.
Meta-analysis
In the meta-analysis of 66 publications by Elvik (2013), 
the best estimate of the relative risk of accident 
involvement with antihistamines, adjusted for 
publication bias, was 1.12 (95 % CI 1.02–1.22) for injury 
accidents.
Conclusion
Acute effects: Among the first-generation antihistamines, 
mequitazine seems to be associated with less sedation 
than the other substances in this group. 
Diphenhydramine and chlorpheniramine clearly show 
impairment of psychomotor performance. Clemastine 
has proven sedative effects. Among the drugs of the 
second generation, fexofenadine, even at high doses, is 
not associated with impairment, as is the case with 
ebastine. Desloratadine and loratadine are free of any 
disruptive effects on psychomotor performance and they 
also do not lead to sedation. Cetirizine use can result in a 
certain degree of impairment, although the studies show 
contradictory results. Levocetirizine shows a profile 
similar to that of desloratadine. Drivers should preferably 
be prescribed antihistamines that do not cause 
impairment. Based on the studies discussed above, it 
seems that bilastine, desloratadine, ebastine, 
fexofenadine, levoceterizine and rupatadine are the 
safest options. In addition, topical azelastine does not 
appear to have an effect on vigilance.
Duration of effects: In the case of the antihistamines 
that impair driving, the maximum impairing effect 
occurs 2 hours after intake, and the effect can last up to 
8 hours.
Combinations: Alcohol can have an additive effect on 
antihistamines in terms of sedation and psychomotor 
impairment. Fexofenadine does not potentiate the 
effects of alcohol and vice versa.
Chronic use: Tolerance to diphenhydramine was found to 
be complete by the end of 3 days of administration. In 
the case of mequitazine 10 mg, cetirizine 10 mg or 
controlled-release dexchlorpheniramine 6 mg, driving 
impairment wore off after 8 days. Tolerance is 
incomplete for hydroxyzine.
Threshold concentration: The concentration equivalent to 
a BAC of 0.5 g/l was calculated as 60 ng/ml 
diphenhydramine and 5.7 ng/ml triprolidine.
Drug use, impaired driving and traffic accidents
82
Additional dopamine reuptake inhibition can attenuate 
vigilance impairment (Schmitt et al., 2002). Sertraline 
50–100 mg was compared with paroxetine 40–60 mg 
using a vigilance test and a Stroop test. Paroxetine, but 
not sertraline, impaired vigilance. Neither drug resulted 
in impairment on the other tests. Sertraline is known to 
block dopamine reuptake.
Sertraline 50–75 mg was shown by Constant et al. 
(2005) to have beneficial effects on psychomotor 
slowing and on attentional and executive functions, even 
after 1 week of treatment, whereas a study by Devanand 
et al. (2003) found little improvement in cognitive 
function with sertraline 50–200 mg.
Acute intravenous administration of citalopram 10 mg 
was associated with increased memory consolidation on 
an auditory verbal learning test (Harmer et al., 2002).
A study of fluoxetine 20–60 mg and paroxetine 20–
40 mg showed no deterioration in cognition; in fact, most 
of the tested cognitive functions were improved 
(Cassano et al., 2002).
Abrupt discontinuation of an SSRI can result in a 
syndrome of adverse effects. According to Hindmarch et 
al. (2000a), discontinuation only of paroxetine, and not of 
any other SSRI, leads to a deterioration in various 
aspects of health and functioning.
The effects of depression and antidepressant therapy on 
driving performance were evaluated in the Immortal 
study (Schmitt et al., 2004). The results showed that 
performance on the SDLP test improved during SSRI 
use (6–52 weeks). However, performance was still 
significantly worse than that of the healthy control 
reaction times increased significantly. In contrast, after 
2 weeks of treatment, no differences were found 
compared with placebo, suggesting tolerance.
Iwamoto et al. (2008a) detected a significant positive 
correlation between plasma amitriptyline concentration 
and road-tracking performance (r = 0.543; p < 0.05). 
There was no significant correlation between plasma 
amitriptyline concentration and other driving 
performance, cognitive functions or subjective 
somnolence.
Second generation
SSRIs
A review by Dumont et al. (2005) showed that low doses 
of an SSRI in healthy volunteers stimulate attention and 
memory, while high doses tend to impair visual/auditory 
visuomotor systems and subjective performance, but 
cause acceleration of motor function. The CFF test 
showed the most pronounced effect.
Fluoxetine 20–60 mg has been shown to have no effects 
on cognitive performance on the visual verbal learning 
test, concept shifting task, letter–digit substitution test 
and a Stroop colour–word test after 9 weeks of 
treatment (Strik et al., 2006).
SSRIs do not always result in memory improvement in 
healthy subjects. Rose et al. (2006) studied the effects 
of escitalopram 10 mg and found no effects on cognitive 
or haemodynamic functions. However, Wadsworth et al. 
(2005) found SSRI use to be associated with memory 
impairment.
TABLE 9
Overview of the different kinds of antidepressants
Class Mechanism of action Examples
First generation (tricyclic antidepressants) Noradrenergic Nortriptyline, desipramine, protriptyline, 
maprotiline, amoxapine
Serotoninergic Amitriptyline, clomipramine, doxepin, 
imipramine, trimipramine, dosulepine, 
melitracen
Second generation Selective serotonin reuptake inhibitor Paroxetine, sertraline, citalopram, 
escitalopram, fluvoxamine, fluoxetine
Norepinephrine reuptake inhibitor Reboxetine, atomoxetine
Serotonin/norepinephrine-reuptake inhibitor Venlafaxine, milnacipran, duloxetine
Atypical Trazodone, nefazodone, bupropion, 
mianserin/mirtazapine, tianeptine/
amineptine
Monoamine oxidase inhibitors (MAOIs) Selegiline (MAOI-B), phenelzine (MAOI-A), 
tranylcypromine (MAOI-A), moclobemide 
(RIMA)
Abbreviation: RIMA, reversible inhibitor of MAOI-A.
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impairment (Gallassi et al., 2006). Therapy with either 
substance led to a significant but incomplete 
improvement in memory impairment.
A comparison between SSRIs (sertraline, paroxetine, 
citalopram) and a serotonin–norepinephrine reuptake 
inhibitors (SNRI) (venlafaxine) shows that both classes 
of antidepressants impair driving performance (on SDLP 
and CFF) (Wingen et al., 2006a). However, the authors 
remarked that this impairment is probably due to 
residual depressive symptoms.
Brunnauer et al. (2008) studied the effect of reboxetine 
or mirtazapine on fitness to drive according to the 
German guidelines for road and traffic safety. Before the 
institution of treatment with antidepressants, about 
65 % of patients did not reach the threshold for safe 
driving; after 14 days’ treatment with reboxetine or 
mirtazapine patients’ driving ability improved. 
Performance on tests measuring selective attention and 
reactivity improved significantly in both patient groups 
(all p < 0.01). Furthermore, the frequency of accidents in 
the risk simulations markedly decreased in patients 
receiving mirtazapine and reboxetine (all p < 0.05). No 
statistically significant differences between treatment 
groups were found.
Brunnauer and Laux (2013) performed a systematic 
review of 21 studies (1980–2011) of driving 
performance in subjects administered commonly 
prescribed newer antidepressants. Investigations were 
frequently undertaken in an ambulatory setting in 
healthy subjects, predominantly young males, and 
focused on the acute or subchronic effects. 
Agomelatine, duloxetine, bupropion and viloxazine were 
found to have no effects. There was also evidence that 
the SSRIs (citalopram, escitalopram, fluoxetine, 
fluvoxamine, sertraline, paroxetine) and the SNRI 
venlafaxine have no deleterious effects on driving ability. 
In contrast, acute use of mirtazapine does cause 
impairment, but this is diminished to some degree when 
given at night and is not apparent after repeated dosing 
in healthy control subjects. Patients obviously benefit 
from treatment with newer antidepressants; however, at 
least a subgroup does not reach the performance level 
of healthy subjects.
Comparison between generations
Driving performance
The effects on driving performance of use of TCAs and 
SSRIs are summarised in a review by Ramaekers 
(2003b). SDLP was assessed during a 1-hour on-the-
subjects. As for cognitive function, there was no 
significant difference in performance between healthy 
individuals and those taking antidepressants, except for 
a reduction in the CFF threshold in the subjects taking 
antidepressants.
In a review of the literature on the role of SSRIs in traffic 
safety, Ravera et al. (2012) selected 10 articles as 
background information on driving-related adverse 
effects and 15 articles reporting the results of 
experimental and pharmacoepidemiological studies. The 
most commonly reported undesirable effects relevant to 
driving impairment were anxiety, agitation, sleep 
disturbances, headache, increased risk of suicidal 
behaviour and deliberate self-harm. Inconsistencies 
were found between the outcomes of the selected 
experimental and epidemiological studies and between 
the two existing categorisation systems under 
evaluation.
Serotonin–norepinephrine reuptake inhibitors
Venlafaxine had no significant effect on SDLP and failed 
to impair psychomotor performance in a study by 
O’Hanlon et al. (1998). However, serious withdrawal 
symptoms may occur within hours of cessation or 
reduction of the usual dose and may affect motor and 
coordination skills to such a degree that patients should 
be explicitly urged either to adhere to a strict medication 
routine or not to drive a car (Campagne, 2005).
Milnacipran use was evaluated in young and elderly 
volunteers by Hindmarch et al. (2000b). Milnacipran 25 
or 50 mg had no performance effects in young people, 
but significantly raised CFF scores in the elderly. 
Amitriptyline, in contrast, lowered CFF threshold and 
increased both CRT and errors in compensatory 
tracking. Poirier et al. (2004) tested the effect of 
milnacipran on memory and vigilance (CFF and CRT). 
Milnacipran was shown to be free of any disruptive 
effects on cognitive function in young and elderly 
volunteers. In the latter group it seemed to improve 
performance on the CFF. Repeated administration of 
milnacipran 50 mg twice daily had no effects on 
cognitive function (Richet et al., 2004). The authors 
concluded from the results on laboratory tests and a 
‘real’ on-road driving test that milnacipran 50 mg twice 
daily does not affect the psychomotor functions required 
for driving. The drug did not accentuate the negative 
effects of alcohol.
Within-generation comparisons
A study comparing fluoxetine 10–40 mg with reboxetine 
4–8 mg found no difference in reversal of memory 
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use. Fluvoxamine decreased and dothiepine increased 
total sleep time.
Katona et al. (1999) compared reboxetine 4–6 mg with 
administration of imipramine 50–100 mg and found no 
somnolence in the subjects taking reboxetine.
According to a review by Peretti et al. (2000) of SSRIs 
and TCAs, TCAs with anticholinergic and antihistaminic 
properties have a greater risk of affecting memory and 
psychomotor function. CFF was elevated in subjects 
taking fluoxetine and sertraline, while TCAs decreased 
the CFF threshold. Paroxetine produced no impairment 
of performance compared with placebo, while this was 
not the case with amitriptyline. BRT is not impaired with 
use of SSRIs but it is with use of TCAs.
Cognitive dysfunction commonly occurs in older persons 
and is sometimes caused by major depression. Nebes et 
al. (2003) examined the persistence of cognitive 
dysfunction after treatment with paroxetine or 
nortriptyline (information on the doses was not given). 
Neither antidepressant led to changes in cognitive 
function, although the subjects showed good clinical 
outcomes for their depression. However, Doraiswamy et 
al. (2003) found an improvement in cognitive function 
and an improvement in the symptoms of the depression 
with use of sertraline 50 mg, fluoxetine 20 mg or 
nortriptyline 25 mg. Venlafaxine (37.5 mg twice daily) 
compared with dothiepine (25 mg in the morning plus 
75 mg in the evening) does not lead to disruptive effects 
on cognitive function in elderly patients with depression 
(Trick et al., 2004). The tests included CFF, a short-term 
memory test and a questionnaire assessing cognitive 
failure. Butters et al. (2000) also found an improvement 
in specific cognitive domains following antidepressant 
treatment in elderly subjects, but normal levels of 
performance were not always reached, particularly in 
memory and executive functions. The antidepressants 
used were paroxetine or nortriptyline (dosing information 
was not given).
In a study by Wingen et al. (2006b), use of escitalopram 
10–20 mg did not affect immediate or delayed verbal 
memory score, while treatment with mirtazapine 
30–45 mg led to impairment. The authors suggested 
that the effects seen with mirtazapine might be due to 
the antihistaminic effect of the substance.
Compared with nortriptyline 25–100 mg, sertraline 
50–100 mg had a more positive effect on verbal learning 
and recall as well as on visual tracking, coding and motor 
performance (Coffey et al., 2002). The tests included a 
shopping list task (recall), DSST and MMSE.
road driving test. Sedating antidepressants (TCAs and 
mianserin) led to an increase in SDLP similar to that 
associated with a BAC of 0.8 g/l. Nocturnal doses of 
sedating antidepressants (dothiepin, mianserin and 
mirtazapine) did not produce residual driving impairment 
the next morning. Non-sedating antidepressants 
(moclobemide, fluoxetine, paroxetine, venlafaxine and 
nefazodone) did not affect SDLP; however, when they 
were co-administered with a benzodiazepine (with an 
incompatible pharmacokinetic profile), the SDLP rose to 
unacceptable levels.
Brunnauer et al. (2006) found that, in terms of fitness to 
drive, SSRIs and mirtazapine have an advantage over 
TCAs and the SNRI venlafaxine.
Ridout et al. (2003b) found that paroxetine 20 mg has no 
effect on BRT and improves CFF and the RRT 
component of the CRT, while mirtazapine 15 or 30 mg 
taken at night leads to impaired results on laboratory 
performance tests.
Cognitive performance
Physical and cognitive symptoms are frequently 
reported by patients whose major depressive disorder 
has responded to long-term antidepressant therapy. 
Fava et al. (2006) concluded that these symptoms are 
both side-effects of the antidepressant therapy and the 
residual depressive symptoms. In patients with 
depression, Kalb et al. (2006) found increased reaction 
times and reduced error rates compared with healthy 
control subjects. The antidepressant doses correlated 
negatively with reaction time but positively with the error 
rates.
A continuous performance test (CPT) was used by 
Koetsier et al. (2002) to evaluate the attentional 
performance of in-patients with depression before and 
after 4 weeks of taking imipramine (blood level 200–
300 μg/l) and fluvoxamine (150–200 μg/l). CPT 
performance was improved with both drugs, as was the 
clinical state. However, a clear relationship between the 
altered CPT and the changes on the clinical scales was 
absent. A clear difference was seen between 
desipramine 125–200 mg and fluoxetine 20 mg on 
memory impairment (Levkovitz et al., 2002). Fluoxetine 
led to a greater improvement in memory performance 
than desipramine.
A comparison of the effects of fluvoxamine 100 mg and 
dothiepine 100 mg on sleep and daytime sleepiness 
after a single administration showed an alteration of 
night-time sleep with both drugs (Wilson et al., 2000). 
More daytime sleepiness was observed with dothiepine 
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(The untreated group were studied only at baseline and 
on days 2 and 9, following which they underwent no 
further testing and were placed on an active treatment.) 
There was a significant linear relationship between 
treatment and road position in trials at all testing times 
(p = 0.0018), and at 10.00 a.m. (p < 0.001) and 12.00 
p.m. (p = 0.022) and between the treatment and the 
number of crashes in trials at all times (p = 0.034) and at 
the 4.00 p.m. session (p = 0.050). Compared with the 
values at baseline, road position at 10.00 a.m. 
significantly improved on days 2 (p < 0.05), 9 (p < 0.01), 
16 (p < 0.01) and 30 (p < 0.01) and road position at 
12.00 p.m. significantly improved on days 16 (p < 0.05) 
and 30 (p < 0.05). The number of crashes significantly 
decreased on day 30 (p < 0.05). This study showed that 
mirtazapine can increase driving safety in major 
depressive disorder patients.
Ramaekers et al. (2011) measured the residual effects of 
single and repeated doses of esmirtazapine 1.5 and 
4.5 mg on actual driving in 32 healthy volunteers in a 
double-blind, placebo-controlled study. Treatment with 
single doses of zopiclone 7.5 mg was included as active 
control. Treatments were administered in the evening. 
Driving performance was assessed in the morning, 11 
hours after drug intake. Esmirtazapine 1.5 mg did not 
produce any clinically relevant change in SDLP after 
single and repeated dosing. Driving impairment did 
occur after a single-dose administration of 
esmirtazapine 4.5 mg, but this effect was abolished after 
repeated doses. Acute driving impairment was more 
pronounced after both doses of esmirtazapine in a 
select group of poor metabolisers. Single-dose zopiclone 
7.5 mg also increased SDLP.
Meta-analyses of experimental studies
Table 10 shows the results of the meta-analysis of the 
experimental studies in the DRUID project (Berghaus et 
al., 2010).
In a double-blind, three-way crossover trial, 17 healthy 
males received acute doses of 10 mg paroxetine, 25 mg 
amitriptyline and placebo. At 4 hours post dosing, 
amitriptyline significantly impaired road-tracking and 
car-following performance, reduced driver vigilance and 
caused subjective somnolence. Paroxetine impaired 
neither driving performance nor cognitive function 
(Iwamoto et al., 2008b).
Atypical antidepressants
Ridout and Hindmarch (2001) compared the use of 
tianeptine 12.5 or 37.5 mg (an antidepressant promoting 
the reuptake of serotonin and related to the TCAs) with 
mianserin 30 mg and placebo on subjects’ performance 
on the CRT, CFF, BRT and self-assessed ratings of 
sedation (LARS). Tianeptine proved to be free of any 
effects, while mianserin use was associated with 
changes on all of the parameters.
Two studies on Hypericum perforatum (St. John’s wort) 
found no effects on cognitive or psychomotor function. 
Timoshanko et al. (2001) administered 900–1 800 mg of 
the herb and observed only dose-related impairment on 
the DSST and no effects on CRT and CFF, while the 
positive control, amitriptyline 25 mg, impaired subjects’ 
overall performance. Siepmann et al. (2002) found no 
effect of St. John’s wort extract 255–285 mg on 
cognitive function.
The use of moclobemide 150 mg twice daily does not 
appear to affect cognitive function (Siepmann et al., 
2004). The tests included CFF, CRT and memory.
Shen et al. (2009) investigated the effects of mirtazapine 
on driving safety in a driving simulator and on daytime 
alertness in 28 patients who met the Diagnostic and 
Statistical Manual of Mental Disorders (4th edition) 
criteria for major depressive disorder. Half of these 
patients took mirtazapine 30 mg at bedtime for 30 days. 
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Risks
Accident involvement
The Immortal study in the Netherlands attempted to 
evaluate the accident risk associated with TCA use; 
however, there were too few TCA-positive samples to be 
able to calculate the risk (Assum et al., 2005). A case–
control study in France found that 1.8 % of injured 
drivers tested positive for antidepressants, while only 
1.1 % of control subjects tested positive (Mura et al., 
2003). The authors did not calculate accident risk in their 
study, but our own calculations using their data found 
that the risk was not significantly increased for these 
prevalence rates in cases and control subjects.
Meuleners et al. (2011), in a retrospective, population-
based, case-crossover study determined the association 
between psychoactive medications and crash risk in 
older drivers in Western Australia. A total of 616 
individuals aged 60 and older who were hospitalised as 
the result of a motor vehicle crash between 2002 and 
2008 were included. The risk of a crash resulting in 
hospitalisation was higher among older drivers 
prescribed antidepressants (OR 1.8; 95 % CI 1.0–3.3) 
and was significantly higher in men prescribed an 
antidepressant (OR 2.7; 95 % CI 1.1–6.9). Drivers with a 
chronic condition taking antidepressants (OR 3.4; 95 % 
CI 1.3–8.5) also had a greater crash risk.
Bramness et al. (2008) obtained information on 
prescriptions, road accidents and emigrations/deaths 
from three Norwegian population-based registries. Data 
on 3.1 million people between the ages of 18 and 69 
were linked. Exposure consisted of receiving 
prescriptions for any antidepressants. The traffic 
accident risk increased slightly for drivers who had 
TABLE 10
Results of the large meta-analysis of the experimental studies in the DRUID project
Imipramine Amitriptyline Fluoxetine Paroxetine Mianserin Trazodone
Number of studies/number 
of effects
13/210 32/475 5/150 6/118 8/145 8/146
Dose (mg) 50–150 50 20–60 10–40 10–20 50–100
Maximum percentage of 
impaired results
20 51 0 < 10 42 44
Time (h) of maximum 
impairment
6.25 3.25 0 3–5 0.75 2.75
Duration (h) 13.5 23+ 0 – 16.25 6.5
Equivalent BAC (g/l) 0.3–0.5 > 0.8 0 < 0.3 0.5–0.8 0.5–0.8
Degree of impairment (1) 32 380 0 0 185 87
Concentration equivalent to 
BAC 0.5 g/l
– – – – 8.9 1 240
(1) The time that a subject who has taken the drug is impaired by more than 15 % (equivalent to a BAC of 0.3 g/l) in arbitrary units.
NB: –, too few data to calculate the number. If multiple doses were given, only the highest is given in this table. Abbreviation: BAC, blood alcohol 
concentration.
received prescriptions for sedating antidepressants 
[TCAs, mianserin and mirtazapine; SIR 1.4 (95 % CI 
1.2–1.6)] or non-sedating antidepressants [SSRIs, 
moclobemide, venlafaxine and reboxetine; SIR 1.6 (95 % 
CI 1.5–1.7)]. The SIR estimates were similar for male and 
female drivers and slightly higher for young drivers 
(18–34 years of age) using older sedative 
antidepressants. SIR estimates did not change 
substantially for different time periods after dispensing 
of the prescription, for concomitant use of other 
impairing drugs or for new users. No increase in the 
traffic accident risk after exposure to lithium or valproate 
was observed, except for young female drivers on 
lithium. This may be because these drugs carry no 
increased risk or because patients exposed to these 
drugs refrain from driving (Bramness et al., 2009).
In an active-duty military population between 2002 and 
2006, only antidepressant medications were an 
independent predictor of fatal motor vehicle crashes (OR 
3.19; 95 % CI 1.01–10.07). Male gender, black race, 
enlisted rank, service branch (navy and marine corps) 
and selected co-morbidities were also independent 
predictors. The association between prescribed 
antidepressants and fatal motor vehicle crashes may 
reflect unmeasured co-morbidities, such as combined 
effects of prescribed and over-the-counter medications 
and/or alcohol or other substance abuse (Hooper et al., 
2010).
To estimate the risk of road traffic crashes associated with 
prescription of antidepressants, a case–control analysis 
comparing 34 896 responsible versus 37 789 non-
responsible drivers was conducted in France (Orriols et 
al., 2012). A significant association was found between 
the risk of responsibility for a crash and prescription of 
antidepressants (OR 1.34; 95 % CI 1.22–1.47). The 
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Meta-analyses
In the meta-analysis of 66 publications by Elvik (2013), 
the best estimate of the relative risk of accident 
involvement with antidepressants, adjusted for 
publication bias, was 1.32 (95 % CI 1.08–1.70) for injury 
accidents and 1.28 (95 % CI 0.90–1.80) for crashes 
resulting in property damage.
Dassanayake et al. (2011) found that the accident risk 
was higher in the elderly (> 65 years of age) who use 
TCAs; however, the evidence for an association of 
antidepressants with accident risk in younger drivers 
was equivocal. Sedative, but not non-sedative, 
antidepressants were found to cause short-term 
impairment of several measures of driving performance.
Conclusion
Acute effects: There is evidence that moclobemide, 
tianeptine, the SSRIs (citalopram, escitalopram, 
fluoxetine, fluvoxamine, sertraline, paroxetine) and the 
SNRIs venlafaxine and milnacipran have no deleterious 
effects on driving ability. Withdrawal symptoms with 
venlafaxine or paroxetine can cause serious impairment. 
Acute use of mirtazapine produces impairment that is 
diminished to some degree when given at night and 
cannot be seen after repeated dosing in healthy control 
subjects. TCAs, compared with the more recent 
antidepressants, cause more impairment of cognition 
and psychomotor skills. The results of the SSRI studies 
are not always consistent. Sertraline use was found to 
be associated with improvement in psychomotor 
function but most SSRIs had no effect on, or improved, 
cognitive function. The effects of antidepressants on 
memory and cognition can be difficult to interpret since 
depression itself can have detrimental effects on these 
functions. Resolution of the depression can often also 
result in resolution of depression-related cognitive 
deficits. Patients obviously benefit from treatment with 
newer antidepressants; however, at least a subgroup 
does not reach the performance level of healthy 
subjects.
Duration of effects: The time of maximum impairment 
varies between 1 and 6 hours and impairment can 
persist for up to 24 hours.
Chronic use: Tolerance to the cognitive and psychomotor 
effects of TCAs seems to develop with prolonged use. 
Nevertheless, caution should be advised when 
prescribing these older substances, since previous 
studies have clearly demonstrated an impairing effect.
case-crossover analysis showed no association with 
treatment prescription, but the risk of a road traffic crash 
increased after an initiation of antidepressant treatment 
(OR 1.49; 95 % CI 1.24–1.79) or a change in 
antidepressant treatment (OR 1.32; 95 % CI 1.09–1.60).
A record-linkage database was used to perform a 
case–control study in the Netherlands using pharmacy 
prescription data, police traffic accident data and driving 
licence data from 2000 to 2007. A significant association 
was found between traffic accident risk and exposure to 
SSRIs (OR 2.03; 95 % CI 1.31–3.14). A statistically 
significant increased risk was also seen in chronic SSRI 
users (Ravera et al., 2011).
Responsibility analyses
One responsibility analysis was found that calculated 
the risk of responsibility for a traffic accident while under 
the influence of psychoactive drugs, including TCAs, but 
also sedating antihistamines, phenothiazine 
antipsychotics, phenytoin and carbamazepine (Drummer 
et al., 2004). The results showed that driving under the 
influence of these psychoactive drugs alone is 
associated with an increased risk of responsibility for a 
traffic accident (OR 3.8; 95 % CI 1.3–11).
One pharmacoepidemiological study was found that 
investigated the relationship between responsibility for a 
traffic accident and antidepressant use in the elderly 
(McGwin et al., 2000). The use of antidepressants was 
not associated with an increase in the risk of 
responsibility for an accident. Pharmacoepidemiological 
studies that were published before 1999 came to similar 
conclusions: the use of antidepressants was not 
associated with an increased risk of hospitalisation 
(Neutel, 1995) or being involved in a traffic accident 
(Barbone et al., 1998).
In a case–control study of 733 injured drivers (Hours et 
al., 2008), diseases and medicine consumption were 
analysed using logistic regression models. An 
association between antidepressant consumption and 
responsibility was observed (adjusted OR 3.61; 95 % CI 
1.30–10.03).
In a French registry-based study on the responsibility for 
road traffic crashes in people who were prescribed 
medicines, Orriols et al. (2010) found an OR of 1.31 
(95 % CI 1.19–1.44) for psychoanaleptics (N06 in the 
ATC classification; this class includes antidepressants, 
psychostimulants and antidementia drugs).
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Carter et al. (2006) investigated the psychomotor and 
cognitive effects of supratherapeutic doses of GHB 
(2–18 g/70 kg) and compared them with those of 
triazolam (0.5 and 1 mg/70 kg) and pentobarbital (200 
and 400 mg/70 kg). GHB produced effects similar to 
triazolam and pentobarbital; however, memory 
impairment after GHB use was less than that after use of 
triazolam or pentobarbital. The within-subject dose–
effect function for sedation was steeper for GHB than for 
triazolam or pentobarbital. Furthermore, at higher doses, 
GHB was associated with greater sedation and more 
variability between subjects.
Abanades et al. (2006) administered increasing doses of 
oral sodium GHB (40, 50, 60 and 72 mg/kg) to eight 
volunteers. The mean peak GHB plasma concentration 
following doses of 40, 50, 60 and 72 mg/kg was 79.1, 
83.1, 113.5 and 130.1 mg/l , respectively. GHB showed a 
mixed stimulant–sedative pattern, with initially 
increased scores on measures of subjective feelings of 
euphoria, ‘high’ and liking followed by mild–moderate 
symptoms of sedation with impairment of performance 
and balance. GHB produced a slight deterioration in 
psychomotor performance that was apparently dose 
dependent with a peak effect at 30 minutes after 
administration of lower doses and at 1.5 hours post 
administration of the 72-mg/kg dose. A decrease was 
seen in DSST total responses and DSST correct 
responses, while there was a simultaneous increase in 
DSST errors. Doses of 60 and 72 mg/kg were associated 
with an impairment of the balance task with a peak 
effect at 1 hour post administration. At all administered 
doses, GHB induced exophoria, a typical effect of 
sedatives, as measured by the Maddox wing device.
A few case reports were found on driving under the 
influence of GHB.
Couper and Logan (2001) described 13 subjects 
arrested for impaired driving in the United States whose 
blood samples tested positive for GHB. GHB 
concentrations ranged from 26 to 155 mg/l (mean 
87 mg/l, median 95 mg/l). In eight cases, GHB was the 
only drug detected, and signs of impairment were 
consistent with those of a CNS depressant, including 
erratic driving (weaving, swerving and ignoring road 
signs), confusion, incoherent speech, unresponsiveness, 
lack of balance, unsteady coordination, poor 
performance on field sobriety tests and varying states of 
wakefulness. The authors concluded that, given the 
ability of GHB to induce sleep and unconsciousness, 
these cases show that recreational use of the drug has 
the potential to impair driving ability. The same authors 
later described a case report of a 38-year-old man who 
was arrested seven times over an 8-month period for 
Threshold concentration: The concentration equivalent to 
a BAC of 0.5 g/l was calculated as 8.9 ng/ml mianserin 
and 1 240 ng/ml trazodone.
Accident risk: In a meta-analysis the relative risk of 
accident involvement with antidepressants was 
approximately 1.30.
I  Other synthetic psychoactive substances/medicines
I Gamma-hydroxybutyrate
Gamma-hydroxybutyrate (GHB) is a normal component 
of the mammalian CNS. Synthetic GHB was first used as 
an anaesthetic in the 1960s. In the early 1990s, it was 
sold in health food stores and marketed as a treatment 
for anxiety, insomnia and drug and alcohol abuse and for 
use by athletes and body builders. The United States 
Food and Drug Administration removed GHB from the 
market in 1990 following reports of GHB-related coma 
and seizures (Freese et al., 2002).
Acute effects
Four experimental studies on the acute effects of GHB 
were found.
Ferrara et al. (1999) examined the subjective, cognitive 
and motor effects in humans following administration of 
typical therapeutic doses. Oral doses of 12.5 and 
25 mg/kg had no effect on attention, vigilance, 
alertness, short-term memory or psychomotor skills 
based on the tests used. The only adverse effects noted 
were slight dizziness and dullness, and these effects 
disappeared within 60 minutes.
In a double-blind, placebo-controlled, four-arm, 
crossover study, Haller et al. (2004) administered to 
eight healthy adults 50 mg/kg GHB, 0.6 g/l ethanol in 
two doses, both drugs or placebo. Changes in cognitive 
performance were assessed using a computerised test 
battery. GHB impaired specific cognitive tasks: speed of 
attention, quality of episodic memory and speed of 
memory. Although decrements in speed of response 
were identified, the accuracy of those responses was not 
impaired. Additive, but not synergistic, effects of GHB 
and ethanol on cognitive impairment were identified.
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Duration of effects: The effects of GHB last a few hours.
Combinations: There are additive but not synergistic 
effects of GHB and ethanol on cognitive impairment.
Chronic use: No studies were found.
Threshold concentration: In Norway the impairment limit 
was set at 10.3 mg/l.
Accident risk: No risk studies were found.
I Ketamine
Ketamine is a synthetic sedative compound that acts as 
a CNS depressant and produces a rapid dissociative 
effect.
Acute effects
Several experimental studies that assessed the acute 
effects of ketamine were found. Curran and Morgan 
(2000) investigated the cognitive effects of ketamine in 
recreational users on the night of drug use and 3 days 
later. Twenty volunteers who reported having taken 
ketamine were compared with 19 volunteers who 
reported no consumption of ketamine on the relevant 
night (day 0). All 39 participants took a battery of tests of 
memory functions and attention. Doses taken before 
testing varied from 0.0624 g to 0.5 g, with a mean dose of 
0.14 g (± 0.16 g). The ketamine users were profoundly 
impaired on virtually all objective assessments of 
cognitive function compared with the control subjects on 
the day they took the drug. On most objective measures, 
ketamine users performed at much higher levels on day 3 
than on day 0. However, on certain measures, group 
differences were still highly significant on day 3, namely 
on the tasks that assessed semantic memory.
Hetem et al. (2000) gave 26 healthy volunteers a 
60-minute infusion of ketamine (0.5 mg/kg/h) or 
placebo. Subjects carried out episodic memory tasks 
involving words presented before and during infusion. 
Memory performance was assessed using recognition 
and free recall tasks. Ketamine impaired performance in 
free recall and recognition of words presented during, 
but not before, infusion. Ketamine thus decreased 
episodic memory performance by impairing the 
encoding but not the retrieval processes.
Krystal et al. (2000) reported the results of two studies 
designed to examine the effects of ketamine on WCST 
performance. In the first study, 15 healthy subjects 
driving under the influence of GHB (Couper and Logan, 
2004b). Blood GHB concentrations ranged from 44 to 
184 mg/l (mean 100 mg/l, median 73 mg/l). The overall 
signs of impairment included erratic driving (severe lane 
deviation, collisions and near-collisions), slurred speech, 
disorientation, slowness to react, shaking, agitation, 
inability to focus, poor coordination and balance, poor 
performance in field sobriety tests, somnolence and 
unconsciousness. On only one occasion were other 
drugs (thiopental and diazepam) that may have 
contributed to the observed driving impairment present 
in the subject’s blood.
Bosman and Lusthof (2003) described forensic cases 
involving the use of GHB in the Netherlands, including 13 
cases of driving under its influence. GHB concentrations 
in subjects’ blood ranged from 51 to 195 mg/l and in 
urine from 100 to 2 000 mg/l. High concentrations of 
GHB corresponded with extreme sleepiness or 
temporary loss of consciousness. GHB was considered 
to have caused driving impairment in all cases.
Al-Samarraie et al. (2010) described 25 car drivers who 
had tested positive for GHB only in their blood in Norway. 
The police reported that 78 % showed unsafe driving 
behaviour and seven were involved in car accidents 
without serious injury. A total of 61 % of the drivers were 
found to be sleepy or in an even more reduced state of 
consciousness. The median GHB blood concentration 
was 131 mg/l (range 62–228 mg/l), measured a median 
of 69 minutes after the police had stopped the driver 
from driving. In Sweden, the mean and median GHB 
concentrations were 89 mg/l and 82 mg/l, respectively 
(2.5th and 97.5th percentiles: 12 and 220 mg/l) in 548 
arrested drivers (Jones et al., 2008a).
Vindenes et al. (2012) proposed the following limits for 
graded sanctions: 10 300 μg/l (equivalent to a BAC of 
0.2 g/l), 30 900 μg/l (equivalent to a BAC of 0.5 g/l) and 
123 600 μg/l (equivalent to a BAC of 1.2 g/l).
No studies were found on the chronic effects or risks 
associated with the use of GHB.
Conclusion
Acute effects: The limited data that were found for GHB 
suggest that the range of GHB doses that are typically 
consumed by users (25–75 mg/kg) can cause dose-
dependent cognitive and psychomotor impairment. The 
results from case reports also indicate impairment 
following GHB use by drivers, including extreme 
sleepiness, poor coordination and balance and even 
unconsciousness.
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0.27 mg/kg over 10 minutes and a maintenance dose of 
0.00225 mg/kg/minute for the remainder of the 
experiment) in healthy volunteers. Ketamine impaired 
learning of spatial and verbal information, but retrieval of 
information prior to drug administration was preserved. 
The drug did not significantly impair attention, verbal 
fluency or verbal working memory task performance. 
Spatial working memory was slightly impaired.
Passie et al. (2005) investigated the effects of different 
subanaesthetic doses of S-ketamine (a bolus of 5 mg 
over 5 minutes for the low- and the high-dose conditions, 
followed by infusion with 0.003 mg/kg/minute for the 
low-dose condition and 0.005 mg/kg/minute for the 
high-dose condition) on neuropsychological tests in 
healthy male volunteers. The results indicated that both 
doses produce only non-significant impairment on most 
of the tasks. Tasks involving divided and sustained 
attention showed significant impairment in a dose-
dependent manner.
Lofwall et al. (2006) administered single intramuscular 
injections of ketamine (0.2 mg/kg or 0.4 mg/kg) to 
healthy volunteers. Ketamine selectively impaired free 
recall while sparing recognition memory, source memory 
and metamemory. It also disrupted encoding while 
sparing retrieval processes, impaired working memory 
performance while sparing attention, and slowed DSST 
performance while sparing accuracy. Subjective and 
psychomotor effects were dose dependent and present 
at a dose (0.2 mg/kg) that did not produce significant 
memory impairment. Impairment on most of the 
psychomotor measures dissipated within 2 hours of 
injection, whereas performance on the CLT and 
subjective feelings of alertness, drug liking or disliking 
and drug strength persisted 2.5 hours after injection.
Morgan et al. (2006a) examined whether there were 
gender differences in response to ketamine in humans, 
and found that men showed greater impairment in 
memory after ketamine administration than women. No 
other gender differences in cognitive measures were 
found.
Cheng et al. (2007) successfully identified 15 out of a 
sample of 21 ketamine-only users (71 %) by field 
impairment testing. When salivary ketamine 
concentrations were greater than 300 ng/ml, signs of 
impairment were even more evident, and field 
impairment testing achieved a detection rate of over 
90 %. The typical signs observable in subjects under the 
influence of ketamine included lack of convergence, 
horizontal gaze nystagmus, elevated pulse rate and, in 
general, failing the divided attention tests, especially the 
walk-and-turn and one-leg stand.
completed the WCST on two occasions separated by 
1 week. In the second study, 22 healthy subjects 
completed the WCST and other assessments after 
administration of ketamine (intravenous bolus 0.26 mg/kg 
followed by infusion of 0.65 mg/kg/h) or placebo on two 
test days separated by approximately 1 week. In the first 
study, the number of total and perseverative errors was 
reduced on a single repetition of the WCST. In the second 
study, ketamine significantly increased the number of 
total errors and the number and percentage of 
perseverative errors on the first but not the second test 
day. Similarly, it reduced the number of category criteria 
met on the first, but not the second, test day. Ketamine 
also increased distractibility and impaired recall.
Guillermain et al. (2001) investigated the effects of a 
subanaesthetic dose of ketamine (0.5 mg/kg over 60 
minutes) on information processing using a two-choice 
visual reaction time task. The results showed that 
ketamine increased CRT and that there was an additive 
pattern of effects of signal intensity, stimulus response 
mapping and foreperiod duration on both mean reaction 
time and reaction time variance.
Honey et al. (2003) investigated the effects of ketamine 
on executive processes during a working memory task. 
Eleven healthy volunteers received a different 
intravenous infusion on each of three occasions: 
placebo, a low ketamine dose (target plasma 
concentration of 50 ng/ml) or a high ketamine dose 
(target plasma concentration 100 ng/ml). Impairments 
were seen only at the higher dose of ketamine and were 
restricted to a subgroup of the verbal working memory 
tasks. While visuospatial working memory and simple 
maintenance processes during verbal working memory 
showed no evidence of impairment, the higher dose of 
ketamine produced a significant impairment in the 
manipulation of information within working memory.
Morgan et al. (2004a) found that ketamine (infusions of 
two doses of 0.4 or 0.8 mg/kg) produced a dose-
dependent impairment of episodic and working memory 
and a slowing of semantic processing in healthy 
volunteers. Ketamine also impaired recognition memory 
and procedural learning. Attention, perceptual priming 
and executive functioning were not affected. The same 
researchers report in another study that the infusions at 
0.4 or 0.8 mg/kg acutely impaired response inhibition 
and episodic memory in healthy volunteers, while 
semantic memory was not affected; no residual effects 
were observed 3 days after administration (Morgan et 
al., 2004b).
Rowland et al. (2005) investigated the cognitive effects 
of a subanaesthetic dose of ketamine (a loading dose of 
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found that semantic memory impairments associated 
with recreational ketamine were reversible upon marked 
reduction of use. However, impairments of episodic 
memory and possibly attentional functioning appeared 
to be long-lasting.
No epidemiological studies were found on the risk of 
being involved in or responsible for an accident 
associated with the use of ketamine.
Conclusion
Acute effects: Experimental studies using single 
subanaesthetic intravenous or intramuscular doses of 
ketamine indicate that some cognitive and psychomotor 
functions are affected for up to 2.5 hours, whereas other 
functions, such as semantic memory, are not affected. 
Some of these defects are dose dependent.
Duration of effects: Effects last up to 5 hours. Semantic 
memory was impaired for 3 days.
Combinations: Some of the effects can be attenuated by, 
for example, amphetamine or nicotine.
Chronic use: Recreational use of ketamine can cause 
cognitive defects, of which some are reversible and 
others long-lasting.
Threshold concentration: Dose-dependent impairment was 
observed at a plasma concentration level of 113 ng/ml. 
In Norway the impairment limit was set at 55 ng/ml. 
Signs of impairment became evident when salivary 
ketamine concentrations were greater than 300 ng/ml.
Accident risk: No studies of accident risks associated 
with the use of ketamine were found.
I Phencyclidine
Phencyclidine (PCP) was first developed for use as an 
intravenous anaesthesia agent, but was withdrawn from 
clinical trials because of the occurrence of severe 
emergence delirium. It was subsequently abused as a 
recreational drug.
Acute effects
No experimental studies on the acute effects of PCP in 
humans published in 1999 or later were found. Studies 
that were published before 1999 showed that a single 
subanaesthetic dose of PCP (< 20 mg) can induce 
In their meta-analysis performed as part of the DRUID 
project, Strand et al. (2011) concluded that impairment 
was observed after intravenous doses of ketamine over 
0.1 mg/kg (7 mg), and impairment was apparent at a 
plasma concentration level of 113 ng/ml. Impairing 
effects might still be present two half-lives (5 hours) 
after administration of the lowest therapeutic dose.
Vindenes et al. (2012) proposed the following limits for 
graded sanctions: 55 μg/l (equivalent to a BAC of 
0.2 g/l), 137 μg/l (equivalent to a BAC of 0.5 g/l) and 
329 μg/l (equivalent to a BAC of 1.2 g/l).
Combination with other psychoactive substances
Krystal et al. (2005) investigated the effects of 
administering ketamine (1-minute infusion of 0.23 mg/kg 
followed by a 1-hour infusion of 0.5 mg/kg) combined 
with amphetamine (1-minute infusion of 0.25 mg/kg) in 
healthy volunteers. They found that amphetamine 
attenuated the impairment of working memory produced 
by ketamine and that amphetamine and ketamine had 
additive effects on thought disorder, arousal and 
euphoria.
Nicotine is known to enhance attention and information 
processing. Cho et al. (2005) investigated whether 
nicotine attenuates the deficits in cortical information 
processing and cognitive functions produced by 
ketamine (bolus 0.26 mg/kg followed by infusion of 
0.65 mg/kg/h). The results indicated that nicotine can 
attenuate ketamine-induced deficits in information 
processing and attention.
Chronic effects
Curran and Monaghan (2001) investigated whether the 
persisting memory impairment 3 days after ingestion of 
ketamine in recreational users that was assessed by 
Curran and Morgan (2000) reflects chronic effects. They 
assessed the effects of ketamine in frequent and 
infrequent users on the day of ketamine use and 3 days 
later. On day 3, the frequent users showed significant 
impairments on tasks assessing episodic and semantic 
memory compared with the infrequent users. The 
authors concluded that frequent use of ketamine 
produces long-lasting impairments in episodic memory 
and aspects of retrieval from semantic memory. These 
findings were confirmed in later studies (Morgan et al., 
2004c, 2006b). During a 3-year longitudinal 
investigation of the cognitive and subjective effects of 
ketamine in recreational users who substantially 
reduced their use of the drug, Morgan et al. (2004d) 
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(50 mg) use may partially counteract the adverse effects 
of alcohol (0.8 g/l).
No studies of the chronic effects of ephedrine were 
found.
Risks
No studies were found on the risks associated with the 
use of ephedrine alone. However, two responsibility 
analyses were found for the risks associated with the 
use of stimulants, including ephedrine. Drummer et al. 
(2004) conducted a responsibility analysis in 3 398 
fatally injured drivers. They calculated the risks 
associated with a group of substances acting as 
stimulants, namely amphetamine, methamphetamine, 
MDMA, ephedrine, pseudoephedrine, phentermine and 
cocaine. There was no significant association between 
use of stimulants and crash responsibility. However, 
when truckers were considered as a discrete driver type, 
the OR increased to 8.8 and was of borderline statistical 
significance (95 % CI 1.0–77.8). Longo et al. (2000b) 
also calculated the risks associated with a group of 
substances acting as stimulants, including 
amphetamine, methamphetamine, phentermine, 
pseudoephedrine, ephedrine and MDEA. There was no 
significantly increased responsibility risk associated with 
driving under the influence of stimulants alone.
Conclusion
Experimental studies suggest that a dose of 25 mg of 
ephedrine has no significant influence on performance 
in healthy volunteers. A dose of 50 mg, however, can 
partially reverse the adverse effects of depressants such 
as alcohol. No epidemiological studies were found on 
the accident risk associated with ephedrine alone, but 
studies investigating the risks associated with 
stimulants indicate no increase in risk of responsibility 
for an accident.
I Phentermine
Phentermine, like ephedrine, is a stimulant drug similar 
in structure to amphetamine. Its principal indication is as 
a treatment for obesity, while the primary manifestation 
of drug use is central stimulation (Baselt, 2001).
severe impairment of cognitive and psychomotor 
functions lasting up to 14 hours in healthy volunteers 
(Baselt, 2001).
No studies on the chronic effects or risks associated 
with the use of PCP were found.
Conclusion
Experimental studies show that single subanaesthetic 
doses of PCP can cause severe cognitive and 
psychomotor impairment in healthy volunteers. There is 
a need for more experimental studies on the acute 
effects of PCP alone or in combination with other 
psychoactive substances, and on the chronic effects and 
accident risks associated with the use of PCP.
I Ephedrine
Ephedrine is a naturally occurring stimulant drug similar 
in structure to amphetamine. It is commonly used as a 
stimulant, appetite suppressant and decongestant and 
for treating hypotension associated with regional 
anaesthesia (Baselt, 2001). Ephedrine is a key precursor 
of methamphetamine, and is used as a cutting agent in 
amphetamine powder and in other illicit tablets.
Acute effects
Beversdorf et al. (1999) compared the effects of 40 mg 
of propranolol (a β-adrenergic antagonist), 25 mg of 
ephedrine (a β-adrenergic agonist) or placebo on 
problem-solving in healthy volunteers. On the task that 
appeared to rely most heavily on cognitive flexibility 
(anagrams), subjects who were most able to solve these 
problems demonstrated significantly shorter solution 
times after propranolol use than after ephedrine. There 
was a trend towards shorter solution times for ephedrine 
than for placebo, but this was not statistically significant.
Choi et al. (2006) compared the performance of healthy 
volunteers on tasks assessing cognitive flexibility, 
problem-solving and verbal and spatial memory tasks 
after receiving 0.1 mg of clonidine (an α
2
-agonist), 25 mg 
of ephedrine or placebo. Ephedrine use led to 
impairment of verbal memory and a non-significant 
improvement of spatial memory.
No recent studies were found on the effects of ephedrine 
in combination with another psychoactive substance. 
Previously, Alkana et al. (1977) found that ephedrine 
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I Methylphenidate
Acute effects
Barkley et al. (2005) evaluated the effects of two single, 
acute doses of methylphenidate (10 and 20 mg) or a 
placebo on the driving performance of 53 adults with 
ADHD (mean age 37 years, range 18–65 years) using a 
virtual reality driving simulator, examiner and self-ratings 
of simulator performance, and a CPT to evaluate 
attention and inhibition. A significant beneficial effect of 
the high dose of medication was observed on 
impulsiveness on CPT, variability of steering in the 
standard driving course and driving speed during the 
obstacle course. A beneficial effect of the low dose of 
medication was also evident on turn-signal use during 
the standard driving course.
MDMA and methylphenidate significantly decreased 
SDLP in the road-tracking tests by about 2 cm relative to 
placebo on day 1 (intoxication phase) (Ramaekers et al., 
2006c).
Sobanski et al. (2008) performed a study of driving 
behaviour and history of driving outcomes in 27 clinically 
referred German adults with ADHD and 27 non-ADHD 
control subjects. In 19 of the subjects with ADHD, a test 
battery of driving-related cognitive measures was 
performed with the standardised Act and React Test 
(ART) 2020 system battery and reassessed after at least 
6 weeks of treatment with methylphenidate (n = 9) or 
after a 6-week medication-free period (n = 10). 
Compared with control subjects, subjects with ADHD 
drove significantly more kilometres per year, were more 
often registered by traffic authorities and fined more 
frequently, were involved in more accidents and 
described their driving style as more insecure and 
hectic. Methylphenidate treatment resulted in improved 
information processing, for example better visuomotor 
coordination under high-stress conditions, improved 
visual orientation and sustained visual attention 
compared with baseline and the untreated control group.
Verster and Cox (2008) performed a randomised, 
crossover trial examining the effects of methylphenidate 
versus placebo on highway driving in 18 adults with 
ADHD. After 3 days of no treatment, patients received 
either their usual methylphenidate dose (mean 14.7 mg, 
range 10–30 mg) or placebo and then the opposite 
treatment after a 6- to 7-day washout period. Patients 
performed a 100-km driving test during normal traffic, 
1.5 hours after treatment administration. Driving 
performance was significantly better in the 
methylphenidate than in the placebo condition, as 
Acute effects
Magill et al. (2003) investigated the effects of tyrosine 
(150 mg/kg), phentermine (37.5 mg), caffeine 
(300 mg/70 kg), dextroamphetamine (20 mg) or 
placebo on cognitive and motor performance deficits in 
healthy young men during sleep deprivation. The 
substances were administered at 3.30 p.m. following 
overnight sleep deprivation. Performance decrements as 
a result of sleep deprivation occurred in visual scanning, 
running memory, logical reasoning, mathematical 
processing, the Stroop test, the time wall test, tracking 
and visual vigilance. The statistical comparisons of task 
performances 1.5 and 5.5 hours after drug 
administration with baseline performances at 1.00 p.m. 
showed that phentermine improved performance at both 
time points for all tasks that had been affected by sleep 
deprivation. Results with phentermine and 
dextroamphetamine were similar.
No recent studies were found on the effects of 
phentermine in subjects who are not sleep deprived, but 
studies that were published before 1999 indicated that 
phentermine has the capacity to improve cognitive and 
motor performance in healthy volunteers under 
laboratory conditions (Brauer et al., 1996; Volkerts et al., 
1997).
No studies were found on the chronic effects of 
phentermine.
Risks
No studies were found that examined the accident risks 
associated with phentermine, specifically. However, two 
responsibility analyses were found that investigated the 
risk of responsibility for an accident while driving under 
the influence of a stimulant in general (Drummer et al., 
2004; Longo et al., 2000b). Neither study found a 
significant association between the use of stimulants 
and crash responsibility.
Conclusion
Experimental studies show that a dose of 20–38 mg of 
phentermine can improve cognitive and psychomotor 
performance in volunteers following sleep deprivation. 
No studies were found on the chronic effects or on the 
accident risk associated with the use of phentermine 
alone, but studies investigating the risks associated with 
stimulants indicate no increase in the risk of 
responsibility for an accident.
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epidemiological studies have shown that cannabis use is 
associated with a twofold increased risk of being 
involved in an accident.
Numerous studies on the opioids suggest that heroin 
use might lead to severe impairment, while there is much 
less impairment with use of methadone and little 
impairment with buprenorphine use; however, these 
results were highly dependent on the dose given and 
subjects’ drug use history. The effects of medicinal 
opioids are mostly moderate. Methadone maintenance 
treatment does cause impairment, including additional 
impairment over and above that associated with heroin 
dependence, a finding that in some cases can be better 
explained by other associated risk factors. 
Buprenorphine users have not generally shown 
impairment, except at high doses. A systematic review 
found limited epidemiological research suggesting that 
opioids may be associated with increased accident risk 
in the first few weeks of treatment.
Stimulants have repeatedly been shown to improve 
neuropsychological skills, such as tracking, impulse 
control and reaction time, while impairing cognitive 
functions such as working memory and movement 
perception.
Driving under the influence of stimulants is generally 
safe when the drugs are taken alone and in regular doses 
(e.g. as in medicinal use), but stimulant drugs are less 
safe when taken in combination with sleep loss or 
alcohol intoxication, as is often the case in recreational 
drug users. The use of MDMA can diminish some, but not 
all, deleterious effects of alcohol, while other negative 
effects of alcohol can be reinforced. The stimulatory 
effects of dexamphetamine are not sufficient to 
overcome the impairing effects of alcohol or sleep 
deprivation on skills related to driving. There is large 
variation in subjects’ sensitivity to combinations of 
amphetamine and alcohol or MDMA and alcohol; some 
show impairment, whereas others do not. Meta-analyses 
of the crash risk associated with the use of 
amphetamines have shown high odds ratios.
The few studies that were found on the effects of 
cocaine suggest that low doses appear not to affect 
performance or even to improve it, but chronic use 
causes various deficiencies in performance and an 
increase in compulsive behaviour. A meta-analysis 
showed that the relative risk of accident involvement 
with cocaine is 1.5 to 3.
Synthetic drugs such as GHB, ketamine and PCP (in 
subanaesthetic doses) can reduce cognitive and 
psychomotor performance. Ephedrine and phentermine 
reflected by the difference in SDLP (2.3 cm; 95 % CI 
0.8–3.8). Variation in speed was similar on treatment 
and on placebo (–0.05 km/h, 95 % CI –0.4 to 0.2). 
Among adults with ADHD with a history of a positive 
clinical response to methylphenidate, methylphenidate 
significantly improved driving performance.
Cox et al. (2008) investigated whether OROS (osmotic 
controlled release oral delivery system) methylphenidate 
(Concerta) was associated with worsening of driving 
performance, or drug rebound, relative to placebo, 16–17 
hours post ingestion. Nineteen male adolescent drivers 
aged 17–19 with ADHD were compared. Medication was 
taken at 8.00 a.m. in a randomised, double-blind, 
placebo-controlled, crossover study. OROS 
methylphenidate was not associated with significant 
worsening of simulator performance relative to placebo 
17 hours post ingestion in group comparisons.
Cox et al. (2012) demonstrated that long-acting 
methylphenidate improves activities of daily living 
among young adults with ADHD. Specifically, 
methylphenidate improved safety in routine driving while 
reducing ADHD symptoms with minimal adverse effects.
Conclusion
Among patients with ADHD, with a history of a positive 
clinical response to methylphenidate, methylphenidate 
significantly improves driving performance.
I Conclusion
According to experimental studies, most of the illicit 
drugs discussed in this report can affect driving 
performance.
Cannabis may impair some of the cognitive and 
psychomotor skills required to drive. Most of these 
effects increase in a dose-dependent way. A cannabis 
user is aware of the impairment, but can only partially 
compensate for the decrements. In an experimental 
fMRI study (Battistella et al., 2013), subjects were more 
attracted by intrapersonal stimuli (‘self’) and failed to 
attend to task performance, leading to an insufficient 
allocation of task-orientated resources and to 
suboptimal performance. Use combined with alcohol 
can cause additional impairment. Chronic use of 
cannabis can lead to deficiencies in performance that 
last longer than the period of intoxication and worsen 
with either increasing number of years or frequency of 
cannabis use. Meta-analyses of the data from 
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release capsules). It should also be noted that, with 
chronic and subchronic use, tolerance might develop, 
partially or completely, to the impairing effects that have 
been observed for some benzodiazepines. Based on the 
studies on antihistamines, it seems that bilastine, 
desloratadine, ebastine, fexofenadine, levoceterizine and 
rupatadine (which are second-generation antihistamines) 
are the least impairing options. Fexofenadine in 
particular, in contrast to the other drugs, does not 
potentiate the effects of alcohol or vice versa. In addition, 
the use of topical azelastine (second generation, class 
phthalazinones) does not appear to affect vigilance. In a 
meta-analysis the relative risk of accident involvement 
with antihistamines was 1.12 (95 % CI 1.02–1.22) for 
injury, which illustrates the low risk.
Experimental data on antidepressants show that TCAs 
(first generation), when compared with the more recent 
second-generation antidepressants, lead to greater 
impairment of cognition and psychomotor skills, though 
tolerance does seem to develop. Nevertheless, caution 
is advised when prescribing these older substances to 
drivers, since previous studies clearly demonstrate an 
impairing effect. As for the second generation, the 
results from various studies are not always consistent, 
partly because the drugs’ effects on memory and 
cognition can be difficult to interpret since depression 
often leads to cognitive deficits. Patients obviously 
benefit from treatment with newer antidepressants; 
however, at least a subgroup does not reach the 
performance level of healthy subjects. In a meta-analysis 
the relative risk of accident involvement with 
antidepressants was approximately 1.30.
Combinations of therapeutic drugs also increase risk. As 
an illustration, the recent case–control study by 
Bogstrand et al. (2012) found the greatest increase in 
risk of injury was associated with alcohol combined with 
any other substance (OR 231.9; 95 % CI 33.3–1615.4), 
more than three psychoactive substances (OR 38.9; 
95 % CI 8.2–185.0) and alcohol alone (OR 36.1; 95 % CI 
13.2–98.6). The adjusted ORs were 1.4 (95 % CI 
0.4–4.4) for one non-alcohol psychoactive substance, 
17.1 (95 % CI 4.2–41) for two substances and 38.9 (95 % 
CI 8.2–185.0) for three substances.
were found not to affect performance and sometimes 
they even improved it.
Experimental studies on the effects of consuming both 
alcohol and illicit drugs on performance found that the 
combination of some illicit drugs (e.g. cannabis) with 
alcohol can cause impairment in addition to that caused 
by either substance alone, while other illicit drugs (e.g. 
cocaine) may partially reverse the impairment caused by 
alcohol. MDMA diminishes some, but not all, deleterious 
effects of alcohol, while other negative effects of alcohol 
may be reinforced. Generally, the chronic use of illicit 
drugs such as cannabis, amphetamines, cocaine or 
heroin is associated with cognitive and/or psychomotor 
impairment, and may lead to impaired driving 
performance, even when the subject is no longer 
intoxicated.
One limitation to many of the experimental studies on 
illicit drugs is that the doses administered are not always 
representative of doses that might in reality be 
consumed by drug users. For heroin, no recent 
experimental studies have been conducted using 
realistic doses. This is also the case for studies on 
cocaine. In the few experimental studies that exist on 
the acute effects of cocaine, the study limitations 
include the administration of low doses and oral 
administration (which produces fewer effects at a slower 
onset).
The results of experimental studies on therapeutic drugs 
show obvious impairment for some, such as some of the 
first-generation antihistamines, benzodiazepines and 
TCAs. Nevertheless, in every therapeutic class, some 
substances have been associated with little or no 
impairment, and these should preferably be prescribed 
to drivers. Meta-analyses show that the relative risk of 
crashes is approximately 1.6 to 1.8 for benzodiazepines. 
In combination with alcohol, the relative risk increases to 
approximately 8.
Some benzodiazepines and related drugs should 
generally be regarded as unlikely to have a residual effect 
in the morning. These include zaleplon 10 mg, 
lormetazepam 1 mg and temazepam 20 mg (immediate-
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I Overall conclusion
The use of illicit drugs in the European Union as reported by the EMCDDA has, as a whole, 
increased since the late 1990s, but it is now stabilising. Experimental and epidemiological 
studies show that, while alcohol is still the number one substance endangering lives on 
European roads, drug and medicine use among drivers is a problem that needs to be 
addressed. In Europe, overall, 7.43 % of drivers studied tested positive for alcohol or one of 
the 23 tested drugs in their oral fluid or blood. Alcohol above 0.1 g/l was found in 3.48 % of 
the drivers, and above 0.5 g/l in 1.5 %. Regarding drugs, 1.9 % tested positive for illicit 
drugs, mainly cannabis, 1.4 % for medicinal drugs (a limited list of benzodiazepines, 
Z-hypnotics and opioids), 0.37 % for a combination of alcohol and drugs and 0.39 % for 
different drug classes. The range of psychoactive substances available for illicit use is 
increasing, and recent studies are finding evidence of their use among drivers. Whether 
drivers are tested randomly, upon suspicion, in hospital or after a fatal accident, various 
subsets of motorists are being found with a range of drugs in their system.
Research covered in this report can be broadly split into two types: experimental and 
epidemiological. Each type has its advantages and disadvantages. Experimental research 
consists of performance, driving simulator and/or real on-the-road tests. These studies 
avoid unknown external factors and allow the doses to be controlled, but often cannot 
simulate the doses or environment actually experienced by drug users on the roads. In 
contrast, the types of epidemiological studies are manifold, from daytime random roadside 
surveys, which may show a prevalence of 1 %, through to questionnaire surveys of young 
chronic drug users that may indicate a prevalence of 85 %. These results can be used to 
calculate the statistical risks of involvement in and responsibility for an accident. Sample 
sizes can be quite small for various reasons, and different study samples cannot be added 
for the reasons described above. Nevertheless, given the inherent characteristics of each 
type of study, a good estimate of the impact will be obtained by combining the results of 
both.
Cannabis is the most prevalent illicit drug detected in drivers and benzodiazepines are the 
most prevalent therapeutic drug group. In studies that tested for both among drivers 
involved in accidents (fatal or non-fatal), benzodiazepines were sometimes even more 
prevalent than cannabis. However, when drivers were tested only on suspicion, cannabis 
was the most prevalent drug.
Most illicit drugs can have an effect on varying aspects of driving performance. Some 
dose- or concentration-dependent impairment has been shown, but for only a few 
substances, so increased effects at higher doses, or diminished effects at lower doses, 
should not always be assumed. Cannabis, GHB, ketamine and PCP can reduce cognitive 
and psychomotor performance, while low doses of amphetamine or methamphetamine 
may improve cognitive and psychomotor performance but could also reduce driving 
capacity during the day as a result of tunnel vision. Experimental studies with low or 
medium doses of MDMA showed no impairment of, or even improvement in, psychomotor 
function, but some decrease in memory functions. Similarly, of the few studies on cocaine 
since 1999, low doses appear not to affect performance and may even improve it, but 
chronic use causes various deficiencies in performance and an increase in compulsive 
behaviour. Numerous studies on opioids suggest the possibility of severe impairment with 
heroin use, while those in substitution treatment programmes experience much less 
impairment with methadone and little with buprenorphine use; however, it should be kept 
in mind that these results were highly dependent on the dose given and type of subjects 
tested, as well as their history.
Other therapeutic substances also showed considerable differences in the effects by 
group. Benzodiazepines generally have impairing effects, with some types (whether long-, 
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medium- or short-acting) causing severe impairment and others unlikely to have residual 
effects in the morning. First-generation antihistamines are generally more sedating than 
second-generation ones, though there are exceptions in both groups. TCAs cause more 
impairment than the more recent types, though the results of experimental studies on the 
effects of SSRIs are not always consistent. In every therapeutic class, some substances 
have been associated with little or no impairment, and it should preferably be these that 
are prescribed to patients who wish to drive. With most medicinal drugs, tolerance also 
has a significant effect, as does the indication that is being treated (such as pain or 
depression). However, in some cases, although a drug may cause measurable impairment 
of some functions, it may nevertheless improve the patient’s overall ability to drive.
Based on the results of meta-analyses, it is possible to establish the increased risk of 
several drug classes (Figure 4). The odds ratios for the major drug classes, based on 
different meta-analyses, are given in Table 11.
Figure 4 illustrates the ‘position’ of each substance with respect to prevalence and injury 
risk. The three substance categories that are connected with extreme high risks (OR > 10) 
are the two high alcohol concentrations (0.8–1.2 and > 1.2 g/l) and the combination of 
alcohol and drugs, all of them presenting with moderate prevalence rates of about 0.4 %. 
Associated with a 5- to 10-fold increased risk of injury are the amphetamines, medicinal 
opioids and drug–drug combinations, but prevalence rates are much lower (0.08 % for 
amphetamines), and therefore there is less demand for action. Use of illicit opioids, 
Z-hypnotics and cocaine increases the relative risk of injury by a factor of between 2 and 3 
and prevalence rates are below 0.5 %. Alcohol at concentrations between 0.5 and 0.8 g/l, 
benzodiazepines and THC show all prevalence rates higher than 0.5 %, which would call 
for action from this point of view. However, the epidemiological risks associated with 
benzodiazepines (OR 3) and THC (OR 2) are smaller than the risk associated with alcohol 
concentrations that are comparable to the legal limit in most European countries. 
Additionally, it is important to remember that the benzodiazepines group comprises a huge 
FIGURE 4
Plot of the prevalence of driving under the influence of different drugs and the accident 
risk (after Hargutt, 2011).
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Overall conclusion
number of substances that result in very different impairment levels depending on their 
concentration. Last, but not least, no elevated risk could be proved for low alcohol 
concentrations (0.1–0.5 g/l) and amphetamines, as shown in the experimental studies 
and the meta-analysis.
Some of the conclusions from the DRUID project (Hargutt et al., 2011), from the 
perspective of traffic safety, especially looking at prevalence rates and risks, were as 
follows. Alcohol, especially in high concentrations, must remain focus number one. The 
combination of alcohol and drugs or medicines seems to be a topic that should be 
addressed more intensively because it leads to very high risks in traffic. The problems of 
medicine use among drivers should be addressed by providing doctors and patients with 
relevant information, rather than by defining thresholds. THC and amphetamines are a 
minor risk based on experimental studies, but the OR for amphetamines is high in 
case–control studies. More research is needed to investigate probable risks of 
amphetamines in real traffic and the mediating factors. From the perspective of risk, sleep 
deprivation should also be addressed as a high accident risk factor.
This report aims to add to the knowledge accumulated in the 1999 and 2008 literature 
reviews (EMCDDA, 1999, 2008), but it bears repeating that, while the EMCDDA strives for 
comparable statistics on the drug situation in Europe, there is no indication of the 
comparability of the statistics analysed here. To give a simple example, cases ‘positive’ for 
a drug registered at above 1 ng/ml cannot be equated with ‘positives’ registered at above 
3 ng/ml. To obtain more compatible methodologies, in 2006–07 a committee of 
international experts, including representatives from the EMCDDA and National Institute 
on Drug Abuse, drafted guidelines for future research into drugs and driving (Walsh et al., 
2008). According to these guidelines, comparisons of such cases should take into account 
the different study designs, biological matrices tested, cut-off levels and so on. The DRUID 
project took account of these guidelines but, based on the findings of this project, more 
widespread implementation of the guidelines is required.
Prevention programmes that address drugs and driving are in place in the form of training 
in driving schools as well as various public safety campaigns, though these may not always 
be effectively targeted. In prescribing psychoactive medications, whether for traditional 
pain management, antidepressant use or substitution treatment, the challenge is to 
prescribe a dose that is high enough to have the desired therapeutic effect but not enough 
TABLE 11
Typical odds ratios for injury or death as a result of a car crash while under the influence 
of alcohol, medicinal or recreational drugs, based on meta-analyses and DRUID 
case–control studies
Odds ratio (95 % CI) Reference
Alcohol 0–0.49 g/l 1.18 (0.81–1.73) Hels et al. (2011)
Alcohol 0.5–0.79 g/l 3.64 (2.31–5.72) Hels et al. (2011)
Alcohol 0.8–1.2 g/l 13.35 (8.15–21.88) Hels et al. (2011)
Alcohol ≥ 1.2 g/l 62.79 (44.51–88.58) Hels et al. (2011)
Amphetamines 6.19 (3.46–11.06) Elvik (2013) (1)
Antidepressants 1.32 (1.08–1.70) Elvik (2013) (1)
Antihistamines 1.12 (1.02–1.22) Elvik (2013) (1)
Benzodiazepines 1.59 (1.10–2.31) Dassanayake et al. (2011)
Cannabis 1.92 (1.35–2.73) Asbridge et al. (2012)
Cocaine 1.66 (0.91–3.02) Elvik (2013) (1)
Opioids 1.89 (1.47–2.43) Elvik (2013) (1)
(1) As odds ratios are given for different crashes, we give the odds ratio for injury crashes here.
NB: Significantly increased odds ratios are shown in bold.
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to cause loss of driving skills or ability, something that could seriously affect the patient’s 
quality of life. There remain concerns about the accuracy of roadside detection 
mechanisms, whether traffic police with special training or testing of drivers’ biological 
samples, although considerable progress has been observed very recently.
To deliver a clear public message, both scientists and policymakers must attempt to 
define, for each drug, a cut-off blood concentration above which performance is impaired, 
similar to the commonly understood BAC. This would give a simple legal threshold to 
indicate at what stage impairment becomes dangerous for users or for those around them. 
Yet, although the BAC figure has become generally accepted after decades of research, 
Member States have resisted attempts by the European Union to harmonise it (similarly, 
they are still sharply divided on the issue of testing at random or only on suspicion, even for 
excess alcohol).
In addition, it is difficult to implement a threshold analogous to BAC for other psychoactive 
substances because of the vastly different pharmacological natures of the range of 
substances involved, the limitations of experimental and epidemiological research in trying 
to determine any such cut-off level, the ethical considerations involved in its enforcement 
and the question of combining or separating drug abuse control and road safety measures. 
Specifically, it is unacceptable to some that a driver be punished for driving with an 
amount of drug that has no relevant effect on driving, while it is equally unacceptable to 
others to condone illicit drug use by stating that, up to a certain threshold, it will not be 
punished. This can be seen in the various country legislations, some of which will use a 
positive blood sample to convict only for a driving offence, while others will use that 
sample, taken for proving a driving offence, to prosecute for a drug use offence. On top of 
all this complexity comes the finding that a considerable number of drivers have been 
found to have multiple drugs, including alcohol, in their blood, some combinations of which 
have been proven to have synergistic effects. In Norway, where limits for graded sanctions 
have been implemented, and in the Netherlands, cut-off levels based on equivalence to a 
BAC of 0.5 g/l are under consideration.
Studying the relationships between drug use, impaired driving and traffic accidents is a 
remarkably complex subject, and this simple review does not pretend to give any definitive 
solutions; as with many research projects, sometimes the answers found merely give rise 
to more questions. Nevertheless, the EMCDDA, particularly now that the data from the 
DRUID project are available, aims to give a more accurate delimitation of the problem to 
date in this fast-moving area of research to assist policymakers in choosing more effective 
solutions for their countries. 
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I Abbreviations
11-OH-THC 11-hydroxy-Δ9-tetrahydrocannabinol
ADHD attention-deficit hyperactivity disorder
ATC Anatomical Therapeutic Chemical
BAC blood alcohol concentration
BRT brake reaction time
BVRT Benton visual retention test
CFF critical flicker fusion
CI confidence interval
CLT circular lights task
CNS central nervous system
CPT continuous performance test
CRT choice reaction time
CTT critical tracking test
DRUID Driving under the Influence of Drugs, Alcohol and Medicines
DSST digit symbol substitution test
EEG electroencephalography
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
fMRI functional magnetic resonance imaging
FTT finger-tapping test
GABA gamma-aminobutyric acid
GHB gamma-hydroxybutyrate
Immortal Impaired Motorists, Methods of Roadside Testing and Assessment for Licensing
LARS line analogue rating scale
LMT learning memory task
MBDB N-methyl-1-(3,4-methylenedioxyphenyl)-2-butanamine
MDA 3,4-methylenedioxyamphetamine
MDEA 3,4-methylenedioxyethylamphetamine
MDMA 3,4-methylenedioxymethylamphetamine
MMSE mini-mental state examination
MRT motor reaction time
MVA motor vehicle accident
OR odds ratio
PASAT paced auditory serial addition task
PET positron emission tomography
QIE quasi-induced exposure
RR relative risk
RRT recognition reaction time
RVIPT rapid visual information processing task
SAM Stupéfiants et Accidents Mortels/illicit drugs and fatal crashes
SDLP standard deviation of lateral position
SFST standard field sobriety test
SIR standardised incidence ratio
SNRI serotonin–norepinephrine reuptake inhibitor
SRT simple reaction time
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
THC Δ9-tetrahydrocannabinol
THC-COOH 11-nor-Δ9-THC-9-carboxylic acid
TMT trail-making test
TRT total reaction time
WAIS Wechsler adult intelligence scale
WCST Wisconsin card sorting test
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TABLE A3
Results of the DRUID studies in injured drivers (percentage of the drivers in whom the drugs were detected)
Belgium Denmark Finland Italy Lithuania Netherlands
Positive drivers 52.6 30.3 44.7 32.0 27.8 33.9
Female
Male
37.2
59.1
15.8
38.1
20.0
51.4
23.7
34.4
20.9
32.4
13.5
38.9
Alcohol
≥ 0.1 g/l 42.5 19.7 32.1 23.1 17.7 29.6
0.1 g/l ≤ alcohol ≤ 0.5 g/l 4.3 1.9 1.9 2.5 1.6 1.6
≥ 0.5 g/l 38.2 17.8 30.2 20.6 16.1 28.0
Amphetamines
Alone
2.6
0.9
4.2
1.0
3.7
0.0
0.1
0.0
0.6
0.3
2.2
1.1
Cocaine
Alone
2.3
0.0
0.6
0.0
0.0 2.7
0.6
0.3
0.3
2.1
0.0
Tetrahydrocannabinol
Alone
7.6
1.5
1.3
0.6
5.7
1.9
3.7
1.6
0.5
0.3
0.5
0.5
Illicit opioids
Alone
0.6
0.0
0.5
0.0
0.0 2.1
0.7
0.3
0.0
0.0
Benzodiazepines
Alone
7.3
1.5
6.7
1.2
10.2
0.0
0.7
0.4
3.6
2.3
0.0
Z-hypnotics
Alone
1.8
0.9
1.2
0.5
3.8
1.9
0.0 0.0 0.5
0.5
Medicinal opioids
Alone
3.3
1.8
4.2
2.5
4.0
2.0
3.7
1.8
7.8
5.7
0.5
0.5
Alcohol–drug combination 13.2 5.4 10.6 4.6 2.3 4.3
Drug–drug combination 2.5 3.5 4.3 2.5 0.8 0.5
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TABLE A5
Overview of the results in killed drivers in DRUID (percentage of the drivers in whom the drugs were detected)
Finland Norway Portugal Sweden Total
Total number 483 193 285 157 1 118
Positive for any substance (%) 42.3 40.0 47.7 30.5 41.8
Alcohol (≥ 0.1 g/l) (%) Prevalence
Alone
31.4
24.4
25.4
18.6
44.9
38.9
19.0
15.1
32.1
25.9
Median BAC 1.8 1.1 1.4 1.5 1.6
Amphetamines (%) Prevalence
Alone
2.1
0.6
7.4
1.1
0.0
0.0
6.6
2.7
3.1
0.8
Cocaine (%) Prevalence
Alone
0.0
0.0
0.0
0.0
0.7
0.0
0.7
0.0
0.3
0.3
Tetrahydrocannabinol (%) Prevalence
Alone
1.3
0.0
6.1
1.7
0.0
0.0
1.3
0.7
1.8
0.4
Illicit opioids (%) Prevalence 0.0 0.0 0.0 0.0 0.0
Benzodiazepines (%) Prevalence
Alone
13.3
5.4
9.7
1.7
1.8
0.7
3.9
0.0
8.3
2.8
Z-hypnotics (%) Prevalence
Alone
3.0
1.7
4.4
1.6
0.0
0.0
3.2
2.6
2.5
1.4
Medicinal opioids (%) Prevalence
Alone
2.1
1.5
1.7
0.6
2.1
0.7
4.1
1.4
2.3
1.1
Abbreviation: BAC, blood alcohol concentration.
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TABLE A7
Overview of the studies in drivers suspected of driving under the influence of drugs and alcohol (percentage of 
drivers in whom the substances were detected)
Australia Austria Canada Denmark Hungary Sweden Switzerland
Study
Chu et al. 
(2012)
Keller et al. 
(2009)
Palmentier 
et al. (2009)
Steentoft et 
al. (2010)
Toth et al. 
(2009)
Holmgren et 
al. (2007)
Senna et al. 
(2010)
Year(s) 2009–10 2003–7 2001–5 1997–2006 2000–7 2001–4 2005
Sample size 853 1 167 733 2 340 1 740 22 777 4 794
Sample Oral fluid Blood Blood Blood Urine/blood Blood or 
urine
Blood
Remark Analysed for 
alcohol: 704
Analysed for 
drugs: 42
Positive (%) 96 87 (80–92) 80–85 in 
blood 
samples
89
Alcohol detected (%) 30 35
> 0.1 ‰ (%)
> 0.2 ‰ (%)
> 0.5 ‰ (%) 18 (9–26)
> 0.8 ‰ (%) 90.9
Drugs (illicit and medicinal) (%) 81 In urine: 74.3
In blood: 18.3 
Illicit drugs (%)
Medicinal drugs (%)
Drugs + alcohol detected (%) 23
> 0.2 ‰ (%)
> 0.5 ‰ (%)
Drug + drug (%)
Amphetamine (%) 18 13 (6–20) In urine: 
4–34
In blood: 
16–48
70
Alone: 27
Methamphetamine (%) 77 In urine: 
6–43
In blood: 
4–66
7
MDMA (%) 17 4.8 3 (0–8)
Cocaine (%) 8.0 15 19.0 12 (6–18) In urine: 9–14
In blood: 
1–26
1.2 25
Cannabis (%) 42 50 42.9 27 (17–38) In urine: 
56–69
In blood: 
7–90
10.7
Alone: 4.5
48
Benzodiazepines (%) 8.0 20 28.8  41(29–55) In urine: 
1.5–6
In blood: 2–9
8–10
Alone: 
2.6–3.0
6
Opioids (%) 14
Codeine: 9.1
Morphine 7.7
20 Morphine: 
14.3
Morphine 13 
(7–20)
In urine: 
10–15
In blood: 
3–17
2.3–4.0
Alone: 
1.4–2.1 
Codeine/
morphine
10
Antihistamines (%)
Methadone (%) 3.3 2.4 15 (9–21) In urine: 1–4 5 
Barbiturates (%)
Tricyclic antidepressants  (%) 3–4
Ketamine (%) 1.5
Abbreviation: MDMA, 3,4-methylenedioxymethylamphetamine.
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TABLE A8
Results of experimental studies on benzodiazepines
Substance Study Tests Doses Effect
Zaleplon
Zolpidem
Danjou et al. (1999) CRT, DSST, CFF Zaleplon: 10 mg
Zolpidem: 10 mg
Zolpidem effects visible 
next morning
Zaleplon
Zolpidem
Triazolam
Troy et al. (2000) Memory
Learning
Zaleplon: 10 or 20 mg
Zolpidem: 10 or 20 mg
Triazolam: 0.25 mg
Cognitive impairment 
with zolpidem and 
triazolam 8.25 hours after 
administration
Zolpidem
Zaleplon
Hindmarch et al. (2001a) CFF
CRT
DSST
Zolpidem: 10 mg
Zaleplon: 10 or 20 mg
Zolpidem had more 
residual effects than 
zaleplon 20 mg
Zolpidem
Zaleplon
Verster et al. (2002a) Memory
Psychomotor 
performance
Zolpidem: 10 or 20 mg 
Zaleplon: 10 or 20 mg
Zolpidem affected 
performance in a 
dose-dependent manner
Zaleplon
Zolpidem
Stillwell (2003)
Logan and Couper
(2001)
Driving cases Driving impairment
Triazolam
Amphetamine
Mintzer and Griffiths 
(2007)
Memory tasks Triazolam: 0.25 or 
0.5 mg/70 kg
Amphetamine: 20 or 
30 mg/70 kg
Amphetamine did not 
reverse effects of 
triazolam
Zaleplon review Patat et al. (2001) 10 or 20 mg No effect with zaleplon
10 mg
Triazolam
Zolpidem
Mintzer and Griffiths 
(1999)
Memory Triazolam: 0.125, 0.25 or 
0.5 mg/70 kg
Zolpidem: 5, 10 or 
20 mg/70 kg
Impairment for triazolam
Triazolam Greenblatt et al. (2005) DSST–EEG correlation 0.375 mg High degree of correlation
Zaleplon
Zopiclone 
Alcohol
Vermeeren et al. (2002a) Highway driving test Zaleplon: 10 mg
Zopiclone: 7.5 mg
BAC: 0.3 g/l
No impairment for 
zaleplon
Zopiclone
Zolpidem
Flunitrazepam
Bocca et al. (2011) SDLP Zopiclone: 7.5 mg
Zolpidem: 10 mg
Flunitrazepam: 1 mg
Impaired
Zopiclone Gustavsen et al. (2009) Automotive and control 
behaviour
Impairment started at 
16 μg/l
Temazepam
Zopiclone 
Leufkens and Vermeeren 
(2009)
SDLP
Residual effects
Temazepam: 20 mg
Zopiclone: 7.5 mg
Zopiclone impaired until 
11 hours after 
administration in elderly 
drivers
Zopiclone Mets et al. (2011) SDLP
Residual effects
7.5 mg Performance impaired on 
the morning after 
administration
Zopiclone Ramaekers et al. (2011) SDLP
Residual effects
7.5 mg SDLP increased
Review of eight 
studies
Zopiclone
Verster et al. (2011) SDLP
Residual effects
Zopiclone 7.5 mg SDLP increased
Zolpidem
Flurazepam
Ramelteon
Lormetazepam
Zaleplon
Zopiclone
Verster and Roth (2012) Gender differences in 
residual effects
Zolpidem: 10 mg
Flurazepam: 30 mg
Ramelteon: 8 mg
Lormetazepam: 1 or 2 mg
Zaleplon: 10 or 20 mg
Zopiclone: 7.5 mg
Gender differences for 
flurazepam and zolpidem
Alprazolam
Dextroamphetamine
Mills et al. (2001) Alprazolam: 0.5 mg 
Dextroamphetamine: 
10 mg
Alprazolam impaired 
performance; 
dextroamphetamine 
enhanced performance, 
except with fatigue
Alprazolam Verster et al. (2002b) SDLP 1 mg Serious driving 
impairment
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Substance Study Tests Doses Effect
Alprazolam Verster and Volkerts 
(2004a)
Memory Dose-dependent 
impairment
Alprazolam extended 
release
Leufkens et al. (2007) Standardised driving test
Memory
Psychomotor tests
1 mg Severe driving impairment
Alprazolam Bentué-Ferrer et al. 
(2001)
Behaviour 0.005 mg/kg Stimulatory effect
Alprazolam Snyder et al. (2005) Attention
Psychomotor function
0.5 or 1 mg 0.5 mg reduced attention; 
1 mg reduced 
psychomotor 
performance and 
attention
Alprazolam
Zopiclone
Zolpidem
Schulze and Schumacher 
(2012)
Alprazolam: 0.5 mg
Zopiclone: 7.5 mg
Zolpidem: 10 mg
Significant driving 
impairment in patients 
and controls. Zolpidem 
significantly impaired 
driving among elderly 
subjects
Lorazepam
Ritanserin
Van Laar et al. (2001) SDLP Lorazepam: 1.5 mg twice 
daily
Ritanserin: 5 mg
Lorazepam showed 
marked driving 
impairment
Lorazepam Matthews et al. (2002) Memory 2.5 mg Impairment in learning 
behavioural strategies
Lorazepam Izaute and Bacon (2006) Memory 0.038 mg/kg Impairment
Lorazepam Clarkson et al. (2004) Driving cases Driving impairment
Lorazepam
Alcohol
Soo-ampon et al. (2004) Recall memory Lorazepam: 2 mg
BAC: 0.6 g/l
Impairment for both 
substances
Lormetazepam Iudice et al. (2002) Daytime vigilance
Driving simulation
1 mg No effect the next 
morning
Lormetazepam Fabbrini et al. (2005) SRT
CRT
No effect
Temazepam
Alcohol
Tiplady et al. (2003) Temazepam: 20 or 30 mg 
BAC: 0.8–1.0 g/l
Temazepam slowed 
performance; alcohol 
generated more errors
Temazepam Morin et al. (2003) 7.5 or 30 mg Few effects and tolerance
Flunitrazepam
Clonazepam
Dowd et al. (2002) Behaviour and cognitive Flunitrazepam: 2 mg
Clonazepam: 3 mg
Flunitrazepam had an 
effect up to 4 hours after 
intake; clonazepam for 6 
hours
Flunitrazepam Bramness et al. (2006) Blood level–impairment 
degree correlation
Clear correlation
Diazepam Rich et al. (2006) Memory 0.19 mg/kg Impairment
Zolpidem
Zopiclone
Flunitrazepam
Bocca et al. (1999) Zolpidem: 10 mg
Zopiclone: 7.5 mg
Flunitrazepam: 1 mg
Residual effects in 
morning for zopiclone and 
flunitrazepam
Lorazepam
Flurazepam
Nitrazepam
Temazepam
Vignola et al. (2000) Memory
Attention
Psychomotor function
Unmedicated insomniacs 
performed worse than 
medicated ones
Temazepam
Triazolam
Alcohol
Simpson and Rush (2002) Temazepam: 15 or 30 mg
Triazolam: 0.125 or 
0.25 mg
BAC: 0.5 g/l
Temazepam and 
triazolam alone had some 
impairment, but a worse 
impairment when 
combined with alcohol
Zolpidem
Temazepam
Partinen et al. (2003) Zolpidem: 10 mg
Temazepam: 20 mg
No difference between 
drugs and placebo
TABLE A8 (continued)
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Substance Study Tests Doses Effect
Zolpidem
Zopiclone
Lormetazepam
Allain et al. (2003) LMT
CTT
SRT
Sternberg test
Zolpidem: 5 mg
Zopiclone: 3.75 mg
Lormetazepam: 1 mg
Lormetazepam impaired 
performance on LMT
11 benzodiazepines Vermeeren (2004) Zaleplon: 10 or 20 mg
Temazepam: 20 mg
Lorazepam: 1 mg
Triazolam: 0.125 mg
Etc.
Four benzodiazepines 
(triazolam 0.125 mg, 
midazolam 7.5 mg, 
temazepam 20 mg and 
lormetazepam 1 mg) were 
unlikely to have residual 
effects
Temazepam
Diphenhydramine
Valerian
Glass et al. (2003) DSST
Manual tracking
Temazepam: 15 or 30 mg
Diphenhydramine: 50 or 
75 mg
Valerian: 400 or 800 mg
No impairment with 
valerian and 
diphenhydramine 50 mg
Zolpidem
Zopiclone
Lormetazepam
Staner et al. (2005) Driving simulation
EEG
Zolpidem: 10 mg
Zopiclone: 7.5 mg
Lormetazepam: 1 mg
Zolpidem had no effect
Zopiclone
Zolpidem
Flunitrazepam
Berthelon et al. (2003) Collision anticipation Zopiclone: 7.5 mg
Zolpidem: 10 mg
Flunitrazepam: 1 mg
Flunitrazepam had a 
negative effect
Melatonin
Zaleplon
Zopiclone
Temazepam
Paul et al. (2003) Serial reaction time
Logical reasoning
Melatonin: 6 mg
Zaleplon: 10 mg
Zopiclone: 7.5 mg
Temazepam: 15 mg
Melatonin showed no 
impairment
Zopiclone
Zolpidem
Flunitrazepam 
Meskali et al. (2009) Driving simulator Zopiclone: 7.5 mg
Zolpidem: 10 mg
Flunitrazepam: 1 mg
No increase in the 
number of collisions. 
Higher speed with 
zopiclone and 
flunitrazepam
Zolpidem Verster et al. (2007) Zolpidem was safer than 
zopiclone and 
benzodiazepine hypnotics 
if taken before 8 hours of 
sleep 
Gaboxadol
Zopiclone
Zolpidem
Leufkens et al. (2009) Residual effects
SDLP
Gaboxadol: 15 mg
Zopiclone: 10 mg
Zolpidem: 7.5 mg
Driving was impaired with 
gaboxadol. Significant 
impairment with zolpidem 
and zopiclone
Benzodiazepine 
hypnotics
Vermeeren and Coenen 
(2011)
Review Effects may diminish as a 
result of tolerance, but 
tolerance may not be 
complete
Zopiclone
Zolpidem
Flunitrazepam 
Berthelon et al. (2008) Residual effects Zopiclone: 7.5 mg
Zolpidem: 10 mg
Flunitrazepam: 1 mg
No residual effect on 
speed perception and 
collision estimation
Intermediate- and 
long-acting 
benzodiazepines
Maxwell et al. (2010) Analysis of crash data In combination with 
alcohol: greater odds of 
unsafe driver action
Dose-dependent 
driving impairment 
benzodiazepines
Bramness et al. (2002) Apprehended drivers Clear drug concentration 
effect
Benzodiazepines Smink et al. (2008a) Relation between blood 
concentration and 
sobriety tests
Observations significantly 
related to concentration
Benzodiazepine 
receptor agonists
Verster and Roth (2013) Review
SDLP
Blood concentrations 
correlate poorly with 
impairment
Abbreviations: BAC, blood alcohol concentration; CFF, critical flicker fusion; CRT, choice reaction time; CTT, critical tracking test; DSST, digit symbol 
substitution test; EEG, electroencephalography; LMT, learning memory task; SDLP, standard deviation of lateral position; SRT, simple reaction time.
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TABLE A9
Results of experimental studies on antihistamines
Substance Author Tests Doses Effect
Diphenhydramine Richardson et al. (2002) 50 mg twice daily Impairment
Diphenhydramine Turner et al. (2006) Memory
CRT
DSST
50, 75, 100 mg Impairment
Clemastine Meltzer et al. (2003) 0.68 mg Somnolence
Mequitazine Didier et al. (2000) 5 mg twice daily Less somnolence than first 
generation, not more than 
second generation
Mequitazine Theunissen et al. (2006a) SDLP 5, 10, 15 mg Dose-related increase
Chlorpheniramine Mochizuki et al. (2002) PET
Chlorpheniramine Serra-Grabulosa et al. 
(2001)
Auditory attention 4 mg Impairment
Chlorpheniramine Tashiro et al. (2008) Lane deviations 6 mg repetab Increased lane deviations
Cinnarizine Nicholson et al. (2002) DSST 15, 30, 45 mg No
Cinnarizine Philipova et al. (2004) DSST 20 mg No
Cinnarizine Schneider et al. (2003) DSST 20 mg No
Desloratadine Nicholson et al. (2003) CRT
DSST
5 mg No
Desloratadine Berger et al. (2002) 5 mg No
Desloratadine Monroe et al. (2003) No
Desloratadine Satish and Streufert 
(2003); Satish et al. (2004)
No
Desloratadine Valk et al. (2004) No
Desloratadine Bousquet et al. (2004) No
Desloratadine Berger (2005) 5 mg No
Desloratadine Limon and Kockler (2003) No
Loratadine Saint-Martin et al. (2004) 10 mg Less somnolence
Ebastine Herberg (2000) 10, 20, 30 mg No
Ebastine Hindmarch and Shamsi 
(2001)
CFF
CRT
Simulated car tracking task
No
Levocetirizine Hair and Scott (2006) 5 mg Somnolence
Cetirizine Shamsi et al. (2001) CFF
CRT
Tracking task
2.5, 5, 10 mg No
Cetirizine Martínez-Cócera et al. 
(2005)
10 mg Somnolence
Cetirizine Nordness and
Zacharisen (2003)
50 mg No
Cetirizine Vermeeren et al. (2002b) Standardised driving test 10 mg Less impairment
Fexofenadine Hindmarch et al. (2002) CFF
CRT
Tracking task
360 mg No
Fexofenadine Ridout and
Hindmarch (2003)
60–120 mg No
Fexofenadine Theunissen et al. (2006b) 360 mg No
Fexofenadine Ridout et al. (2003a) 180 mg No
Fexofenadine Mohler et al. (2002) DSST No
Mizolastine Bachert et al. (2001) 10 mg Low
Azelastine Golden et al. (2000) No
Review second 
generation
Lange and Bachert (2004) Desloratadine, ebastine 
and fexofenadine had no 
effect
Fexofenadine versus 
cetirizine
Tashiro et al. (2004) CRT
SRT
Fexofenadine: 120 mg
Cetirizine: 20 mg
Fexofenadine less 
impairing than cetirizine
Bepotastine versus 
cetirizine, 
fexofenadine and 
olopatadine
Takahashi et al. (2004) Sedation
Psychomotor performance
Bepotastine: 10 mg twice 
daily
Cetirizine: 10 mg
Fexofenadine: 60 mg twice 
daily
Olopatadine: 5 mg twice 
daily
Olapatadine most 
impairing and bepotastine 
least impairing
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Substance Author Tests Doses Effect
Levocetirizine versus 
desloratadine
Passalacqua and 
Canonica (2005)
Memory, attention, 
alertness
No
Cetirizine versus 
loratadine
Salmun et al. (2000) Cetirizine: 10 mg
Loratidine: 10 mg
Loratidine resulted in less 
somnolence
Inter-drug 
differences
Shamsi and Hindmarch 
(2000)
Fexofenadine and ebastine 
had the least effect
Prescription-event 
monitoring
Mann et al. (2000) Fexofenadine and 
loratadine had the least 
effect
Letter Ramaekers and Vermeeren 
(2000)
Fexofenadine, ebastine 
and loratadine had no 
effect
Desloratadine and 
levocetirizine
Layton et al. (2006) Less sedation with 
desloratadine
Review Meltzer (2005) Fexofenadine, loratadine 
and desloratadine had no 
effect
Fexofenadine versus 
hydroxyzine
Tashiro et al. (2005) BRT Fexofenadine: 120 mg
Hydroxyzine: 30 mg
Fexofenadine had no 
effect
Fexofenadine Mansfield et al. (2003) 180 mg No
Fexofenadine Bower et al. (2003) No
Fexofenadine versus 
olopatadine and 
chlorpheniramine
Kamei et al. (2003) Sedation Fexofenadine: 120 mg
Olopatadine: 10 mg
Fexofenadine had no 
effect
Ebastine versus 
chlorpheniramine
Tagawa et al. (2002) Cognitive impairment Ebastine: 10 mg Ebastine had no effect
Loratadine versus 
diphenhydramine
Kay (2000)
Kay and Quig (2001)
Divided attention Loratidine: 10 mg
Diphenhydramine: 50 mg
Loratidine had no effect
Desloratadine versus 
diphenhydramine
Wilken et al. (2003) Desloratidine: 5 mg
Diphenhydramine: 50 mg
Desloratidine had no effect
Tolerance to 
cetirizine, 
mequitazine and 
dexchlorpheniramine
Theunissen et al. (2006a) Driving impairment Mequitazine: 10 mg
Cetirizine: 10 mg
Dexchlorpheniramine: 
6 mg
Tolerance after 8 days
Levocetirizine versus 
diphenhydramine
Verster et al. (2003a) Memory, attention, 
tracking, SDLP
Levocetirizine: 5 mg
Diphenhydramine: 50 mg
Levocetirizine had no 
effect
Desloratadine versus 
diphenhydramine
Vuurman et al. (2004) SDLP Desloratidine: 5 mg
Diphenhydramine: 50 mg
Desloratidine had no effect
Diphenhydramine 
versus second-
generation 
antihistamines: a 
review
Bender et al. (2003) No clear effect of 
diphenhydramine
Fexofenadine versus 
diphenhydramine 
and alcohol
Weiler et al. (2000) Fexofenadine: 60 mg
Diphenhydramine: 50 mg
Diphenhydramine had 
greater effect than alcohol
Review Verster and Volkerts 
(2004b)
Fexofenadine and 
levoceterizine had no 
effect
Levocetirizine versus 
cetirizine, loratadine, 
promethazine
Hindmarch et al. (2001b) CFF, CRT, continuous 
tracking task
Levoceterizine: 5 mg
Cetirizine: 10 mg
Loratidine: 10 mg
Promethazine: 30 mg
Levoceterizine had no 
effect
Review Moskowitz and Wilkinson 
(2004)
Effect depends on 
substance, generation and 
individual
Rupatadine
Hydroxyzine
Vuurman et al. (2007) SDLP Rupatadine: 10 mg
Hydroxyzine: 50 mg
No effect from rupatadine
Bilastine
Hydroxyzine
Conen et al. (2011) SDLP Bilastine: 20 and 40 mg
Hydroxyzine: 50 mg
No effect from bilastine
Abbreviations: BRT, brake reaction time; CFF, critical flicker fusion; CRT, choice reaction time; DSST, digit symbol substitution test; PET, positron emission 
tomography; SDLP, standard deviation of lateral position; SRT, simple reaction time.
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TABLE A10
Results of experimental studies on performance effects associated with the use of antidepressants
Substance Study Tests Doses Effect
TCAs (general) Podewils and Lyketsos 
(2002)
MMSE None
Amitriptyline Veldhuizen et al. (2006b) SDLP 25 mg Significant increase
Amitriptyline Iwamoto et al. (2008a) Road tracking 
performance
25 mg Correlation between 
plasma concentration and 
road tracking 
performance
SSRIs (general) Dumont et al. (2005) Different tests
CFF
Low dose
High dose
Stimulation
Impairment 
Fluoxetine Strik et al. (2006) Stroop
Visual verbal test
Letter digit substitution
20–60 mg None
Escitalopram Rose et al. (2006) 10 mg None
SSRI (general) Wadsworth et al. (2005) Impairment
Sertraline
Paroxetine
Schmitt et al. (2002) Vigilance
Stroop
50–100 mg
40–60 mg
None
Sertraline Constant et al. (2005) Psychomotor slowing/
executive function
50–75 mg Positive effect
Sertraline Devanand et al. (2003) Psychomotor slowing and 
executive function
50–200 mg None
Citalopram Harmer et al. (2002) Memory 10 mg i.v. Positive effect
Fluoxetine versus 
paroxetine
Cassano et al. (2002) Cognitive function Fluoxetine: 10–40 mg
Paroxetine: 20–60 mg
None
Paroxetine Hindmarch et al. (2000a) Withdrawal Impairment
SSRIs Ravera et al. (2012) Literature review Inconsistencies between 
studies
Venlafaxine O’Hanlon et al. (1998) CFF, CTT, divided 
attention, Macworth
37.5–75 mg None
Venlafaxine Campagne (2005) Withdrawal Impairment
Milnacipran Hindmarch et al. (2000b) CFF 50 + 25 mg None (young age)
Positive effect (old age)
Milnacipran Poirier et al. (2004) CFF 50 mg twice daily None
Milnacipran Richet et al. (2004) 50 mg twice daily No effect and no 
potentiation
Fluoxetine versus 
reboxetine
Gallassi et al. (2006) Fluoxetine: 10–40 mg
Reboxetine: 4–8 mg
Improvement
SSRI versus SNRI Wingen et al. (2006a) Impairment
Reboxetine
Mirtazapine
Brunnauer et al. (2008) Driving skills
Frequency of accidents
Patients improved in 
driving skills. Frequency of 
accidents decreased
Newer 
antidepressants 
Brunnauer and Laux 
(2013)
Systematic review SSRIs and venlafaxine 
had no deleterious 
effects. Acute use of 
mirtazapine led to 
impairment
All antidepressants Ramaekers (2003b) SDLP Sedating antidepressant 
led to impairment
Non-sedating 
antidepressant had no 
effect
SSRI (mirtazapine) was 
less impairing than TCA 
(SNRI)
All antidepressants Brunnauer et al. (2006) Fitness to drive Less impairment for 
patients treated with 
SSRIs or mirtazapine 
when compared with 
TCAs or venlafaxine
Paroxetine versus 
mirtazapine
Ridout et al. (2003b) BRT, CFF, CRT Paroxetine: 20 mg
Mirtazapine: 15–30 mg
No effect for paroxetine
Fluvoxamine versus 
imipramine
Koetsier et al. (2002) CPT Improvement for both
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Substance Study Tests Doses Effect
Fluoxetine versus 
desipramine
Levkovitz et al. (2002) Memory Fluoxetine: 20 mg
Desipramine: 125–
200 mg
Improvement with 
fluoxetine was greater 
than with desipramine
Fluvoxamine versus 
dothiepine
Wilson et al. (2000) Sleep Fluvoxamine: 100 mg
Dothiepine: 100 mg
Fluvoxamine decreased; 
dothiepine increased
Reboxetine versus 
imipramine
Katona et al. (1999) Somnolence Reboxetine: 4–6 mg
Imipramine: 50–100 mg
Reboxetine had no effect
TCA and SSRI Peretti et al. (2000) CFF threshold BRT TCA decreased CFF; BRT 
impaired
Paroxetine versus 
nortriptyline
Nebes et al. (2003) Cognitive function in 
elderly
No change
Sertraline, fluoxetine 
and nortriptyline
Doraiswamy et al. (2003) Cognitive function Sertraline: 50 mg
Fluoxetine: 20 mg
Nortriptyline: 25 mg
Improvement
Venlafaxine and 
dothiepine
Trick et al. (2004) Cognitive function: CFF Venlafaxine: 37.5 mg 
twice daily
Dothiepine: 25 + 75 mg
No disruptive effect
Paroxetine and 
nortriptyline
Butters et al. (2000) Memory and executive 
function
Improvement
Escitalopram versus 
mirtazapine
Wingen et al. (2006b) Delayed verbal memory 
score
Escitalopram: 10–20 mg
Mirtazapine: 30–45 mg
Escitalopram had no 
influence
Sertraline versus 
nortriptyline
Coffey et al. (2002) Shopping list task, DSST, 
MMSE
Sertraline: 50–100 mg
Nortriptyline: 25–100 mg
Sertraline had a more 
positive effect
Paroxetine, 
amitriptyline
Iwamoto et al. (2008b) Road-tracking and car 
following
Paroxetine: 10 mg
Amitriptyline: 25 mg
Paroxetine caused no 
impairment
Tianeptine versus 
mianserin
Ridout and
Hindmarch
(2001)
CRT, CFF, BRT Tianeptine: 12.5–37.5 mg
Mianserin: 30 mg
Tianeptine had no effect
Hypericum 
perforatum
Timoshanko et al. (2001)
Siepmann et al. (2002)
DSST 900–1800 mg 
Extract: 255–285 mg
Impairment
None
Moclobemide Siepmann et al. (2004) CFF, CRT, memory 150 mg twice daily None
Mirtazapine Shen et al. (2009) 30 mg Increase in driving safety 
among depressed 
patients
Esmirtazapine Ramaekers et al. (2011) SDLP
Residual effects
1.5 and 4.5 mg 1.5 mg: no increase in 
SDLP
4.5 mg: increased SDLP, 
but this resolved after 
repeated doses
Abbreviations: BRT, brake reaction time; CFF, critical flicker fusion; CPT, continuous performance test; CRT, choice reaction time; CTT, critical tracking 
test; DSST, digit symbol substitution test; i.v., intravenous; MMSE, mini-mental state examination; SDLP, standard deviation of lateral position; SNRI, 
serotonin/noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
TABLE A10 (continued)

121
References
I  Abanades, S., Farre, M., Segura, M., et al. (2006), ‘Gamma-hydroxybutyrate (GHB) in humans: 
pharmacodynamics and pharmacokinetics’, Annals of the New York Academy of Sciences 1074, pp. 
559–76.
I  Ahlm, K., Bjornstig, U. and Ostrom, M. (2009), ‘Alcohol and drugs in fatally and non-fatally injured 
motor vehicle drivers in northern Sweden’, Accident Analysis and Prevention 41, pp. 129–36.
I  Al-Samarraie, M. S., Karinen, R., Morland, J. and Stokke Opdal, M. (2010), ‘Blood GHB concentrations 
and results of medical examinations in 25 car drivers in Norway’, European Journal of Clinical 
Pharmacology 66, pp. 987–98.
I  Alexandrov, S. G. (2004), ‘Dynamics of time intervals evaluation in heroin addicts’, Zhurnal 
Nevropatologii I Psikhiatrii Imeni S S Korsakova 104, pp. 21–4.
I  Alkana, R. L., Parker, E. S., Cohen, H. B., Birch, H. and Noble, E. P. (1977), ‘Reversal of ethanol 
intoxication in humans: an assessment of the efficacy of L-dopa, aminophylline, and ephedrine’, 
Psychopharmacology (Berlin) 55, pp. 203–12.
I  Allain, H., Bentué-Ferrer, D., Tarral, A. and Gandon, J. M. (2003), ‘Effects on postural oscillation and 
memory functions of a single dose of zolpidem 5 mg, zopiclone 3.75 mg and lormetazepam 1 mg in 
elderly healthy subjects. A randomized, cross-over, double-blind study versus placebo’, European 
Journal of Clinical Pharmacology 59, pp. 179–88.
I  Asbridge, M., Poulin, C. and Donato, A. (2005), ‘Motor vehicle collision risk and driving under the 
influence of cannabis: evidence from adolescents in Atlantic Canada’, Accident Analysis and 
Prevention 37, pp. 1025–34.
I  Asbridge, M., Hayden, J. A. and Cartwright, J. L. (2012), ‘Acute cannabis consumption and motor 
vehicle collision risk: systematic review of observational studies and meta-analysis’, BMJ 344, 
p. e536.
I  Asghar, S.J., Tanay, V. A. M. I., Baker, G. B., Greenshaw, A. and Silverstone, P. H. (2003), ‘Relationship 
of plasma amphetamine levels to physiological, subjective, cognitive and biochemical measures in 
healthy volunteers’, Human Psychopharmacology — Clinical and Experimental 18, pp. 291–9.
I  Assum, T., Mathijssen, M. P. M., Houwing, S., et al. (2005), ‘The prevalence of drug driving and relative 
risk estimations. A study conducted in the Netherlands, Norway and United Kingdom’, Immortal 
Deliverable D-R4.2, Austrian Road Safety Board, Vienna.
I  Augsburger, M., Donze, N., Menetrey, A., et al. (2005), ‘Concentration of drugs in blood of suspected 
impaired drivers’, Forensic Science International 153, pp. 11–15.
I  Bachert, C., Vovolis, V., Margari, P., Murrieta-Aguttes, M. and Santoni, J. P. (2001), ‘Mizolastine in the 
treatment of seasonal allergic rhinoconjunctivitis: a European clinical experience with 5408 patients 
managed in daily practice (Paneos SAR Study)’, Allergy 56, pp. 653–9.
I  Bachs, L. C., Engeland, A., Morland, J. G. and Skurtveit, S. (2009), ‘The risk of motor vehicle accidents 
involving drivers with prescriptions for codeine or tramadol’, Clinical Pharmacology and Therapeutics 
85, pp. 596–9.
I  Bachs, L., Karinen, R., Vindenes, V., et al. (2012), ‘Prevalence of synthetic cannabinoids in a 
population of suspected drugged drivers in Norway (Abstract)’, 50th TIAFT conference, Hamamatsu, 
Japan.
I  Baewert, A., Gombas, W., Schindler, S. D., et al. (2007), ‘Influence of peak and trough levels of opioid 
maintenance therapy on driving aptitude’, European Addiction Research 13, pp. 127–35.
I  Baiardini, I., Braido, F., Cauglia, S. and Canonica, G. W. (2006), ‘Sleep disturbances in allergic 
diseases’, Allergy 61, pp. 1259–67.
I  Barbanoj, M. J., Garcia-Gea, C., Antonijoan, R., et al. (2006), ‘Evaluation of the cognitive, psychomotor 
and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, 
in healthy volunteers’, Human Psychopharmacology — Clinical and Experimental 21, pp. 13–26.
Drug use, impaired driving and traffic accidents
122
I  Barbone, F., McMahon, A. D., Davey, P. G., et al. (1998), ‘Association of road-traffic accidents with 
benzodiazepine use’, The Lancet 352, pp. 1331–6.
I  Barch, D. M. and Carter, C. S. (2005), ‘Amphetamine improves cognitive function in medicated 
individuals with schizophrenia and in healthy volunteers’, Schizophrenia Research 77, pp. 43–58.
I  Barkley, R. A., Murphy, K. R., O’Connell, T. and Connor, D. F. (2005), ‘Effects of two doses of 
methylphenidate on simulator driving performance in adults with attention deficit hyperactivity 
disorder’, Journal of Safety Research 36, pp. 121–31.
I  Baselt, R. C. (2001), Drug effects on psychomotor performance, Biomedical Publications, Foster City, 
California.
I  Bates, M. N. and Blakely, T. A. (1999), ‘Role of cannabis in motor vehicle crashes’, Epidemiologic 
Reviews 21, pp. 222–32.
I  Battistella, G., Fornari, E., Thomas, A., et al. (2013), ‘Weed or wheel! FMRI, behavioural, and 
toxicological investigations of how cannabis smoking affects skills necessary for driving’, PLoS One 8, 
p. e52545.
I  Beasley, E. E. and Beirness, D. J. (2012), Alcohol and drug use among drivers following the 
introduction of immediate roadside prohibitions in British Columbia: findings from the 2012 roadside 
survey, Beirness & Associates, Inc., Ottawa.
I  Beasley, E. E., Beirness, D. J. and Porath-Waller, A. J. (2011), A comparison of drug-and alcohol-
involved motor vehicle driver fatalities, Canadian Centre on Substance Abuse, Ottawa.
I  Bender, B. G. (2005), ‘Cognitive effects of allergic rhinitis and its treatment’, Immunology and Allergy 
Clinics of North America 25, pp. 301–12.
I  Bender, B. G., Berning, S., Dudden, R., Milgrom, H. and Tran, Z. V. (2003), ‘Sedation and performance 
impairment of diphenhydramine and second-generation antihistamines: a meta-analysis’, Journal of 
Allergy and Clinical Immunology 111, pp. 770–6.
I  Bentué-Ferrer, D., Reymann, J. M., Tribut, O., et al. (2001), ‘Role of dopaminergic and serotonergic 
systems on behavioral stimulatory effects of low-dose alprazolam and lorazepam’, European 
Neuropsychopharmacology 11, pp. 41–50.
I  Berger, W. E. (2005), ‘The safety and efficacy of desloratadine for the management of allergic 
disease’, Drug Safety 28, pp. 1101–18.
I  Berger, W. E., Schenkel, E. J. and Mansfield, L. E. (2002), ‘Safety and efficacy of desloratadine 5 mg in 
asthma patients with seasonal allergic rhinitis and nasal congestion’, Annals of Allergy, Asthma and 
Immunology 89, pp. 485–91.
I  Berghaus, G., Ramaekers, J. G. and Drummer, O. H. (2007), ‘Demands on scientific studies in 
different fields of forensic medicine and forensic sciences. Traffic medicine — Impaired driver: 
Alcohol, drugs, diseases’, Forensic Science International 165, pp. 233–7.
I  Berghaus, G., Sticht, G., Grellner, W., et al. (2010), ‘Meta-analysis of empirical studies concerning the 
effects of medicines and illegal drugs including pharmacokinetics on safe driving’, DRUID Deliverable 
1.1.2b, Bundesanstalt für Strassenwesen, Cologne.
I  Bernard, J. P., Morland, J., Krogh, M. and Khiabani, H. Z. (2009), ‘Methadone and impairment in 
apprehended drivers’, Addiction 104, pp. 457–64.
I  Berthelon, C., Bocca, M. L., Denise, P. and Pottier, A. (2003), ‘Do zopiclone, zolpidem and 
flunitrazepam have residual effects on simulated task of collision anticipation?’, Journal of 
Psychopharmacology 17, pp. 324–31.
I  Berthelon, C., de Longcamp, A., Coquerel, A. and Denise, P. (2008), ‘Residual effects of zolpidem, 
zopiclone and flunitrazepam on the processing of visual information in driving context’, European 
Review of Applied Psychology–Revue Européenne de Psychologie Appliquee 58, pp. 111–16.
I  Beversdorf, D. Q., Hughes, J. D., Steinberg, B. A., Lewis, L. D. and Heilman, K. M. (1999), 
‘Noradrenergic modulation of cognitive flexibility in problem solving’, Neuroreport 10, pp. 2763–7.
I  Biecheler, M. B., Peytavin, J. F., Facy, F. and Martineau, H. (2008), ‘SAM survey on “drugs and fatal 
accidents”: search of substances consumed and comparison between drivers involved under the 
influence of alcohol or cannabis’, Traffic Injury Prevention 9, pp. 11–21.
References
123
I  Blows, S., Ivers, R. Q., Connor, J., et al. (2005), ‘Marijuana use and car crash injury’, Addiction 100, 
pp. 605–11.
I  Bocca, M. L., Le Doze, F., Etard, O., et al. (1999), ‘Residual effects of zolpidem 10 mg and zopiclone 
7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades’, 
Psychopharmacology 143, pp. 373–9.
I  Bocca, M. L., Marie, S., Lelong-Boulouard, V., et al. (2011), ‘Zolpidem and zopiclone impair similarly 
monotonous driving performance after a single nighttime intake in aged subjects’, 
Psychopharmacology (Berlin) 214, pp. 699–706.
I  Bogstrand, S. T., Normann, P. T., Rossow, I., et al. (2011), ‘Prevalence of alcohol and other substances 
of abuse among injured patients in a Norwegian emergency department’, Drug and Alcohol 
Dependence 117, pp. 132–8.
I  Bogstrand, S. T., Gjerde, H., Normann, P. T., Rossow, I. and Ekeberg, O. (2012), ‘Alcohol, psychoactive 
substances and non-fatal road traffic accidents — a case-control study’, BMC Public Health 12, 
pp. 734–43.
I  Bolla, K. I., Funderburk, F. R. and Cadet, J. L. (2000), ‘Differential effects of cocaine and cocaine plus 
alcohol on neurocognitive performance’, Neurology 54, pp. 2285–92.
I  Bolla, K. I., Brown, K., Eldreth, D., Tate, K. and Cadet, J. L. (2002), ‘Dose-related neurocognitive effects 
of marijuana use’, Neurology 59, pp. 1337–43.
I  Bosanquet, D., Macdougall, H. G., Rogers, S. J., et al. (2013), ‘Driving on ice: impaired driving skills in 
current methamphetamine users’, Psychopharmacology (Berlin) 225, pp. 161–72.
I  Bosker, W. M., Kuypers, K. P., Theunissen, E. L., et al. (2012a), ‘Medicinal Delta(9)-tetrahydrocannabinol 
(dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is 
not detected in Standard Field Sobriety Tests’, Addiction 107, pp. 1837–44.
I  Bosker, W. M., Kuypers, K. P., Conen, S., et al. (2012b), ‘MDMA (ecstasy) effects on actual driving 
performance before and after sleep deprivation, as function of dose and concentration in blood and 
oral fluid’, Psychopharmacology (Berlin) 222, pp. 367–76.
I  Bosker, W. M., Karschner, E. L., Lee, D., et al. (2013), ‘Psychomotor function in chronic daily cannabis 
smokers during sustained abstinence’, PLoS One 8, p. e53127.
I  Bosman, I. J. and Lusthof, M. J. (2003), ‘Forensic cases involving the use of GHB in the Netherlands’, 
Forensic Science International 133, pp. 17–21.
I  Boucart, M., Waucquier, N., Michael, G. A. and Libersa, C. (2007), ‘Diazepam impairs temporal 
dynamics of visual attention’, Experimental and Clinical Psychopharmacology 15, pp. 115–22.
I  Bourin, M., Colombel, M. C. and Guitton, B. (1998), ‘Alprazolam 0.125 mg twice a day improves 
aspects of psychometric performance in healthy volunteers’, Journal of Clinical Psychopharmacology 
18, pp. 364–72.
I  Bousquet, J., Bindslev-Jensen, C., Canonica, G. W., et al. (2004), ‘The ARIA/EAACI criteria for 
antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine’, Allergy 59, 
pp. 4–16.
I  Bower, E. A., Moore, J. L., Moss, M., et al. (2003), ‘The effects of single-dose fexofenadine, 
diphenhydramine, and placebo on cognitive performance in flight personnel’, Aviation Space and 
Environmental Medicine 74, pp. 145–52.
I  Brady, J. E. and Li, G. (2013), ‘Prevalence of alcohol and other drugs in fatally injured drivers’, 
Addiction 108, pp. 104–14.
I  Bramness, J. G., Skurtveit, S. and Morland, J. (2002), ‘Clinical impairment of benzodiazepines 
— relation between benzodiazepine concentrations and impairment in apprehended drivers’, Drug 
and Alcohol Dependence 68, pp. 131–41.
I  Bramness, J. G., Skurtveit, S. and Morland, J. (2006), ‘Flunitrazepam: psychomotor impairment, 
agitation and paradoxical reactions’, Forensic Science International 159, pp. 83–91.
I  Bramness, J. G., Skurtveit, S., Neutel, C. I., Morland, J. and Engeland, A. (2008), ‘Minor increase in risk 
of road traffic accidents after prescriptions of antidepressants: a study of population registry data in 
Norway’, Journal of Clinical Psychiatry 69, pp. 1099–103.
Drug use, impaired driving and traffic accidents
124
I  Bramness, J. G., Skurtveit, S., Neutel, C. I., Morland, J. and Engeland, A. (2009), ‘An increased risk of 
road traffic accidents after prescriptions of lithium or valproate?’, Pharmacoepidemiology and Drug 
Safety 18, pp. 492–6.
I  Bramness, J. G., Skurtveit, S., Morland, J. and Engeland, A. (2012), ‘An increased risk of motor vehicle 
accidents after prescription of methadone’, Addiction 107, pp. 967–72.
I  Brauer, L. H., Johanson, C. E., Schuster, C. R., Rothman, R. B. and deWit, H. (1996), ‘Evaluation of 
phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers’, 
Neuropsychopharmacology 14, pp. 233–41.
I  Brault, M., Dussault, C., Bouchard, J. and Lemire, A. M. (2004), ‘The contribution of alcohol and other 
drugs among fatally injured drivers in Québec: final results’, in: Oliver, J., Williams, P. and Clayton, A. 
(eds.), Proceedings of the 17th International Conference on Alcohol, Drugs and Traffic Safety 
(Glasgow), (CD-ROM), International Council on Alcohol, Drugs and Traffic Safety (ICADTS), Oslo.
I  Breitenbach, T. C., Pechansky, F., Benzano, D. and De Boni, R. (2012), ‘High rates of injured 
motorcycle drivers in emergency rooms and the association with substance use in Porto Alegre, 
Brazil’, Emergency Medicine Journal 29, pp. 205–7.
I  Brookhuis, K. A., de Waard, D. and Samyn, N. (2004), ‘Effects of MDMA (ecstasy), and multiple drugs 
use on (simulated) driving performance and traffic safety’, Psychopharmacology 173, pp. 440–5.
I  Brunnauer, A. and Laux, G. (2013), ‘The effects of most commonly prescribed second generation 
antidepressants on driving ability: a systematic review: 70th Birthday Prof. Riederer’, Journal of 
Neural Transmission 120, pp. 225–32.
I  Brunnauer, A., Laux, G., Geiger, E., Soyka, M. and Moller, H. J. (2006), ‘Antidepressants and driving 
ability: results from a clinical study’, Journal of Clinical Psychiatry 67, pp. 1776–81.
I  Brunnauer, A., Laux, G., David, I., et al. (2008), ‘The impact of reboxetine and mirtazapine on driving 
simulator performance and psychomotor function in depressed patients’, Journal of Clinical 
Psychiatry 69, pp. 1880–6.
I  Bryun, E. A., Gekht, A. B., Polunina, A. G., Davydov, D. M. and Gusev, E. I. (2001), ‘Neuropsychologic 
deficit in chronic heroin abusers’, Zhurnal Nevropatologii I Psikhiatrii Imeni S S Korsakova 101, 
pp. 10–19.
I  Butters, M. A., Becker, J. L., Nebes, R. D., et al. (2000), ‘Changes in cognitive functioning following 
treatment of late-life depression’, American Journal of Psychiatry 157, pp. 1949–54.
I  Byas-Smith, M. G., Chapman, S. L., Reed, B. and Cotsonis, G. (2005), ‘The effect of opioids on driving 
and psychomotor performance in patients with chronic pain’, Clinical Journal of Pain 21, pp. 345–52.
I  Cami, J., Farre, M., Mas, M., et al. (2000), ‘Human pharmacology of 
3,4-methylenedioxymethamphetamine (‘ecstasy’): psychomotor performance and subjective 
effects’, Journal of Clinical Psychopharmacology 20, pp. 455–66.
I  Campagne, D. M. (2005), ‘Venlafaxine and serious withdrawal symptoms: warning to drivers’, 
Medscape General Medicine 7, p. 22.
I  Carter, L. P., Richards, B. D., Mintzer, M. Z. and Griffiths, R. R. (2006), ‘Relative abuse liability of GHB 
in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic 
doses of triazolam, pentobarbital, and GHB’, Neuropsychopharmacology 31, pp. 2537–51.
I  Cassano, G. B., Puca, F., Scapicchio, P. L. and Trabucchi, M. (2002), ‘Paroxetine and fluoxetine effects 
on mood and cognitive functions in depressed nondemented elderly patients’, Journal of Clinical 
Psychiatry 63, pp. 396–402.
I  Ch’ng, C. W., Fitzgerald, M., Gerostamoulos, J., et al. (2007), ‘Drug use in motor vehicle drivers 
presenting to an Australian, adult major trauma centre’, Emergency Medicine of Australasia 19, 
pp. 359–65.
I  Chang, L., Ernst, T., Speck, O., et al. (2002), ‘Perfusion MRI and computerized cognitive test 
abnormalities in abstinent methamphetamine users’, Psychiatry Research: Neuroimaging 114, 
pp. 65–79.
References
125
I  Cheng, W. C., Ng, K. M., Chan, K. K., Mok, V. K. and Cheung, B. K. (2007), ‘Roadside detection of 
impairment under the influence of ketamine — evaluation of ketamine impairment symptoms with 
reference to its concentration in oral fluid and urine’, Forensic Science International 170, pp. 51–8.
I  Cho, H., Mathalon, D., Perry, E. B., et al. (2005), ‘Nicotine reduces deficits in cortical information 
processing and cognitive function produced by ketamine in humans’, Schizophrenia Bulletin 31, 
pp. 509–10.
I  Choi, Y., Novak, J. C., Hillier, A., Votolato, N. A. and Beversdorf, D. Q. (2006), ‘The effect of alpha-2 
adrenergic agonists on memory and cognitive flexibility’, Cognitive and Behavioral Neurology 19, 
pp. 204–7.
I  Chou, Y. H., Huang, W. S., Wan, F. J., et al. (2004), ‘Dopamine transporters and cognitive function in 
methamphetamine abuser after a short abstinence: a SPECT study’, Neuroimage 22, p. T143.
I  Christophersen, A. S. (2000), ‘The occurrence of drugged driving in Norway — existing problems and 
solutions’, Blutalkohol 37, Suppl. 1, pp. 20–7.
I  Christophersen, A. S. and Morland, J. (2008), ‘Frequent detection of benzodiazepines in drugged 
drivers in Norway’, Traffic Injury Prevention 9, pp. 98–104.
I  Chu, M., Gerostamoulos, D., Beyer, J., et al. (2012), ‘The incidence of drugs of impairment in oral fluid 
from random roadside testing’, Forensic Science International 215, pp. 28–31.
I  Clarkson, J. E., Gordon, A. M. and Logan, B. K. (2004), ‘Lorazepam and driving impairment’, Journal of 
Analytical Toxicology 28, pp. 475–80.
I  Coffey, D., Oxman, T., Jenkyn, L., et al. (2002), ‘Does antidepressant therapy improve cognitive 
function in elderly depressed patients?’, European Psychiatry 17, p. 120S.
I  Comer, S. D., Hart, C. L., Ward, A. S., et al. (2001), ‘Effects of repeated oral methamphetamine 
administration in humans’, Psychopharmacology 155, pp. 397–404.
I  Comer, S. D., Collins, E. D. and Fischman, M. W. (2002), ‘Intravenous buprenorphine self-
administration by detoxified heroin abusers’, Journal of Pharmacology and Experimental 
Therapeutics 301, pp. 266–76.
I  Cone, E. J., Holicky, B. A., Grant, T. M., Darwin, W. D. and Goldberger, B. A. (1993), ‘Pharmacokinetics 
and pharmacodynamics of intranasal “snorted’ heroin”, Journal of Analytical Toxicology 17,  
pp. 327–37.
I  Conen, S., Theunissen, E. L., Van Oers, A. C., Valiente, R. and Ramaekers, J. G. (2011), ‘Acute and 
subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving 
performance in healthy volunteers’, Journal of Psychopharmacology 25, pp. 1517–23.
I  Constant, E. L., Adam, S., Gillain, B., et al. (2005), ‘Effects of sertraline on depressive symptoms and 
attentional and executive functions in major depression’, Depression and Anxiety 21, pp. 78–89.
I  Corsenac, P., Lagarde, E., Gadegbeku, B., et al. (2012), ‘Road traffic crashes and prescribed 
methadone and buprenorphine: a French registry-based case–control study’, Drug Alcohol 
Dependence 123, pp. 91–7.
I  Costa, N., Silva, R., Mendonca, M. C., et al. (2012), ‘Prevalence of ethanol and illicit drugs in road 
traffic accidents in the centre of Portugal: an eighteen-year update’, Forensic Science International 
216, pp. 37–43.
I  Couper, F. J. and Logan, B. K. (2001), ‘GHB and driving impairment’, Journal of Forensic Sciences 46, 
pp. 919–23.
I  Couper, F. J. and Logan, B. K. (2004a), ‘Drugs and human performance fact sheets’, DOT HS 809 725, 
National Highway Traffic Safety Administration (NHTSA), Washington, DC, pp. 1–100.
I  Couper, F. J. and Logan, B. K. (2004b), ‘Addicted to driving under the influence — a GHB/GBL case 
report’, Journal of Analytical Toxicology 28, pp. 512–15.
I  Cox, D. J., Moore, M., Burket, R., et al. (2008), ‘Rebound effects with long-acting amphetamine or 
methylphenidate stimulant medication preparations among adolescent male drivers with attention-
deficit/hyperactivity disorder’, Journal of Child and Adolescent Psychopharmacology 18, pp. 1–10.
Drug use, impaired driving and traffic accidents
126
I  Cox, D. J., Davis, M., Mikami, A. Y., et al. (2012), ‘Long-acting methylphenidate reduces collision rates 
of young adult drivers with attention-deficit/hyperactivity disorder’, Journal of Clinical 
Psychopharmacology 32, pp. 225–30.
I  Crombie, I. K. and Davies, H. T. O. (2009), ‘What is meta-analysis’, Hayward Medical Communications, 
London (available at: http://www.medicine.ox.ac.uk/bandolier/:/painres/download/whatis/Meta-An.
pdf, accessed 3 February 2013).
I  Curran, H. V. and Morgan, C. (2000), ‘Cognitive, dissociative and psychotogenic effects of ketamine in 
recreational users on the night of drug use and 3 days later’, Addiction 95, pp. 575–90.
I  Curran, H. V. and Monaghan, L. (2001), ‘In and out of the K-hole: a comparison of the acute and 
residual effects of ketamine in frequent and infrequent ketamine users’, Addiction 96, pp. 749–60.
I  Curran, H. V., Kleckham, J., Bearn, J., Strang, J. and Wanigaratne, S. (2001), ‘Effects of methadone on 
cognition, mood and craving in detoxifying opiate addicts: a dose–response study’, 
Psychopharmacology 154, pp. 153–60.
I  Dagtekin, O., Gerbershagen, H. J., Wagner, W., et al. (2007), ‘Assessing cognitive and psychomotor 
performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain 
patients’, Anesthesia Analgesia 105, pp. 1442–8.
I  Danjou, P., Paty, I., Fruncillo, R., et al. (1999), ‘A comparison of the residual effects of zaleplon and 
zolpidem following administration 5 to 2 h before awakening’, British Journal of Clinical 
Pharmacology 48, pp. 367–74.
I  Darke, S., Sims, J., McDonald, S. and Wickes, W. (2000), ‘Cognitive impairment among methadone 
maintenance patients’, Addiction 95, pp. 687–95. 
I  Dassanayake, T., Michie, P., Carter, G. and Jones, A. (2011), ‘Effects of benzodiazepines, 
antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological 
and experimental evidence’, Drug Safety 34, pp. 125–56.
I  Dastrup, E., Lees, M. N., Bechara, A., Dawson, J. D. and Rizzo, M. (2010), ‘Risky car following in 
abstinent users of MDMA’, Accident Analysis and Prevention 42, pp. 867–73.
I  Davey, J. and Freeman, J. (2009), ‘Screening for drugs in oral fluid: drug driving and illicit drug use in a 
sample of Queensland motorists’, Traffic Injury Prevention 10, pp. 231–6.
I  Davis, P. E., Liddiard, H. and McMillan, T. M. (2002), ‘Neuropsychological deficits and opiate abuse’, 
Drug and Alcohol Dependence 67, pp. 105–8.
I  De Boni, R., Bozzetti, M. C., Hilgert, J., et al. (2011), ‘Factors associated with alcohol and drug use 
among traffic crash victims in southern Brazil’, Accident Analysis and Prevention 43, pp. 1408–13.
I  de Waard, D., Brookhuis, K. A. and Pernot, L. M. C. (2000), ‘A driving simulator study on the effects of 
MDMA (ecstasy) on driving performance and traffic safety’, in: Laurell, H. and Schlyter, F. (eds.), 
Proceedings of the 15th International Conference on Alcohol, Drugs and Traffic Safety (Stockholm), 
International Council on Alcohol, Drugs and Traffic Safety, Oslo.
I  de Wit, H., Crean, J. and Richards, J. B. (2000), ‘Effects of d-amphetamine and ethanol on a measure 
of behavioral inhibition in humans’, Behavioral Neuroscience 114, pp. 830–7.
I  de Wit, H., Enggasser, J. L. and Richards, J. B. (2002), ‘Acute administration of d-amphetamine 
decreases impulsivity in healthy volunteers’, Neuropsychopharmacology 27, pp. 813–25.
I  del Rio, M. C., Gomez, J., Sancho, M. and Alvarez, F. J. (2002), ‘Alcohol, illicit drugs and medicinal 
drugs in fatally injured drivers in Spain between 1991 and 2000’, Forensic Science International 127, 
pp. 63–70.
I  Devanand, D. P., Pelton, D. H., Marston, K., et al. (2003), ‘Sertraline treatment of elderly patients with 
depression and cognitive impairment’, International Journal of Geriatric Psychiatry 18, pp. 123–30.
I  Di Sclafani, V., Tolou-Shams, M., Price, L. J. and Fein, G. (2002), ‘Neuropsychological performance of 
individuals dependent on crack-cocaine, or crack-cocaine and alcohol, at 6 weeks and 6 months of 
abstinence’, Drug and Alcohol Dependence 66, pp. 161–71.
I  Didier, A., Doussau-Thuron, S. and Murris-Espin, M. (2000), ‘Comparative analysis of the sedative 
effects of mequitazine and other antihistaminic drugs: review of the literature’, Current Therapeutic 
Research — Clinical and Experimental 61, pp. 770–80.
References
127
I  Dittert, S., Naber, D. and Soyka, M. (1999), ‘Methadone substitution and ability to drive. Results of an 
experimental study’, Nervenarzt 70, pp. 457–62.
I  Doraiswamy, P.M., Krishnan, K. R. R., Oxman, T., et al. (2003), ‘Does antidepressant therapy improve 
cognition in elderly depressed patients?’, Journals of Gerontology Series A — Biological Sciences 
and Medical Sciences 58, pp. 1137–44.
I  Dowd, S. M., Strong, M. J., Janicak, P. G. and Negrusz, A. (2002), ‘The behavioral and cognitive effects 
of two benzodiazepines associated with drug-facilitated sexual assault’, Journal of Forensic Sciences 
47, pp. 1101–7.
I  Downey, L. A., King, R., Papafotiou, K., et al. (2013), ‘The effects of cannabis and alcohol on simulated 
driving: influences of dose and experience’, Accident Analysis and Prevention 50, pp. 879–86.
I  Dresen, S., Kempf, J. and Weinmann, W. (2007), ‘Prevalence of gamma-hydroxybutyrate (GHB) in 
serum samples of amphetamine, metamphetamine and ecstasy impaired drivers’, Forensic Science 
International 173, pp. 112–16.
I  Drummer, O. H. (2001), The forensic pharmacology of drugs of abuse, Hodder Arnold, London.
I  Drummer, O. H., Gerostamoulos, J., Batziris, H., et al. (2004), ‘The involvement of drugs in drivers of 
motor vehicles killed in Australian road traffic crashes’, Accident Analysis and Prevention 36, 
pp. 239–48.
I  Drummer, O. H., Kourtis, I., Beyer, J., et al. (2012), ‘The prevalence of drugs in injured drivers’, Forensic 
Science International 215, pp. 14–17.
I  Dubois, S., Bedard, M. and Weaver, B. (2008), ‘The impact of benzodiazepines on safe driving’, Traffic 
Injury Prevention 9, pp. 404–13.
I  Dumont, G. J. H., de Visser, S. J., Cohen, A. F. and van Gerven, J. M. A. (2005), ‘Biomarkers for the 
effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects’, British Journal of 
Clinical Pharmacology 59, pp. 495–510.
I  Dumont, G. J., Wezenberg, E., Valkenberg, M. M., et al. (2008), ‘Acute neuropsychological effects of 
MDMA and ethanol (co-)administration in healthy volunteers’, Psychopharmacology (Berlin) 197, 
pp. 465–74.
I  Dumont, G. J., Schoemaker, R. C., Touw, D. J., et al. (2010), ‘Acute psychomotor effects of MDMA and 
ethanol (co-)administration over time in healthy volunteers’, Journal of Psychopharmacology 24, 
pp. 155–64.
I  Dumont, G. J., van Hasselt, J. G., de Kam, M., et al. (2011), ‘Acute psychomotor, memory and 
subjective effects of MDMA and THC co-administration over time in healthy volunteers’, Journal of 
Psychopharmacology 25, pp. 478–89.
I  Dussault, C., Brault, M., Bouchard, J. and Lemire, A. M. (2002), ‘The contribution of alcohol and other 
drugs among fatally injured drivers in Québec: some preliminary results’, in: Mayhew, D. and Dussault, C. 
(eds.), Proceedings of the 16th International Conference on Alcohol, Drugs and Traffic Safety 
(Montréal), La Société de l’Assurance Automobile du Québec, Montréal, Canada.
I  Ehrenreich, H., Rinn, T., Kunert, H. J., et al. (1999), ‘Specific attentional dysfunction in adults following 
early start of cannabis use’, Psychopharmacology 142, pp. 295–301.
I  Elliott, S., Woolacott, H. and Braithwaite, R. (2009), ‘The prevalence of drugs and alcohol found in 
road traffic fatalities: a comparative study of victims’, Science and Justice 49, pp. 19–23.
I  Elvik, R. (2013), ‘Risk of road accident associated with the use of drugs: a systematic review and 
meta-analysis of evidence from epidemiological studies’, Accident Analysis and Prevention 60, 
pp. 254–67.
I  EMCDDA (1999), Literature review on the relation between drug use, impaired driving and traffic 
accidents (CT.97.EP.14), European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
I  EMCDDA (2004), An overview of cannabis potency in Europe, EMCDDA Insights No 6, European 
Monitoring Centre for Drugs and Drug Addiction, Lisbon.
I  EMCDDA (2007), Selected issue: drugs and driving, European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon.
Drug use, impaired driving and traffic accidents
128
I  EMCDDA (2008), Drug use, impaired driving and traffic accidents, EMCDDA Insights No 8, European 
Monitoring Centre for Drugs and Drug Addiction,Lisbon.
I  EMCDDA (2012), Driving under the influence of drugs, alcohol and medicines in Europe — findings 
from the DRUID project, European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
I  Engeland, A., Skurtveit, S. and Morland, J. (2007), ‘Risk of road traffic accidents associated with the 
prescription of drugs: a registry-based cohort study’, Annals of Epidemiolology 17, pp. 597–602.
I  Fabbrini, M., Frittelli, C., Bonanni, E., et al. (2005), ‘Psychomotor performance in healthy young adult 
volunteers receiving lormetazepam and placebo: a single-dose, randomized, double-blind, crossover 
trial’, Clinical Therapeutics 27, pp. 78–83.
I  Farré, M., Delatorre, R., Llorente, M., et al. (1993), ‘Alcohol and cocaine interactions in humans’, 
Journal of Pharmacology and Experimental Therapeutics 266, pp. 1364–73.
I  Farré, M., de la Torre, R., Mathuna, B. O., et al. (2004), ‘Repeated doses administration of MDMA in 
humans: pharmacological effects and pharmacokinetics’, Psychopharmacology 173, pp. 364–75.
I  Fava, M., Graves, L. M., Benazzi, F., et al. (2006), ‘A cross-sectional study of the prevalence of 
cognitive and physical symptoms during long-term antidepressant treatment’, Journal of Clinical 
Psychiatry 67, pp. 1754–9.
I  Fergusson, D. M. and Horwood, L. J. (2001), ‘Cannabis use and traffic accidents in a birth cohort of 
young adults’, Accident Analysis and Prevention 33, pp. 703–11.
I  Fergusson, D. M., Horwood, L. J. and Boden, J. M. (2008), ‘Is driving under the influence of cannabis 
becoming a greater risk to driver safety than drink driving? Findings from a longitudinal study’, 
Accident Analysis and Prevention 40, pp. 1345–50.
I  Ferrara, S. D., Giorgetti, R. and Zancaner, S. (1994), ‘Psychoactive substances and driving: state of 
the art and methodology’, Alcohol, Drugs and Driving 10, pp. 1–55.
I  Ferrara, S. D., Giorgetti, R., Zancaner, S., et al. (1999), ‘Effects of single dose of gamma-
hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy 
volunteers’, European Journal of Clinical Pharmacology 54, pp. 821–7.
I  Finkle, W. D., Adams, J. L., Greenland, S. and Melmon, K. L. (2002), ‘Increased risk of serious injury 
following an initial prescription for diphenhydramine’, Annals of Allergy, Asthma and Immunology 89, 
pp. 244–50.
I  Fishbain, D. A., Cutler, R. B., Rosomoff, H. L. and Rosomoff, R. S. (2003), ‘Are opioid-dependent/
tolerant patients impaired in driving-related skills? A structured evidence based review’, Journal of 
Pain and Symptom Management 25, pp. 559–77.
I  Foltin, R. W., Fischman, M. W., Pippen, P. A. and Kelly, T. H. (1993), ‘Behavioral effects of cocaine alone 
and in combination with ethanol or marijuana in humans’, Drug and Alcohol Dependence 32, 
pp. 93–106.
I  Freese, T. E., Miotto, K. and Reback, C. J. (2002), ‘The effects and consequences of selected club 
drugs’, Journal of Substance Abuse Treatment 23, pp. 151–6.
I  Gadegbeku, B., Amoros, E. and Laumon, B. (2011), ‘Responsibility study: main illicit psychoactive 
substances among car drivers involved in fatal road crashes’, Annals of Advances in Automotive 
Medicine 55, pp. 293–300.
I  Gaertner, J., Elsner, F., Radbruch, L., et al. (2008), ‘[Influence of changes to daily dose of opioids on 
aspects of cognitive and psychomotor performance involved in driving]’, Der Schmerz 22,  
pp. 433–41.
I  Gallassi, R., Di Sarro, R., Morreale, A. and Amore, M. (2006), ‘Memory impairment in patients with 
late-onset major depression: the effect of antidepressant therapy’, Journal of Affective Disorders 91, 
pp. 243–50.
I  Galski, T., Williams, J. B. and Ehle, H. T. (2000), ‘Effects of opioids on driving ability’, Journal of Pain 
and Symptom Management 19, pp. 200–8.
I  Gerberich, S. G., Sidney, S., Braun, B. L., et al. (2003), ‘Marijuana use and injury events resulting in 
hospitalization’, Annals of Epidemiology 13, pp. 230–7.
References
129
I  Giacomuzzi, S., Riemer, Y., Haaser, W. and Pilsz, L. (2005a), ‘Driving impairment on buprenorphine 
and slow-release oral morphine in drug-dependent patients’, Forensic Science International 152, 
pp. 323–4.
I  Giacomuzzi, S. M., Ertl, M., Vigl, A., et al. (2005b), ‘Driving capacity of patients treated with 
methadone and slow-release oral morphine’, Addiction 100, p. 1027.
I  Gjerde, H. and Verstraete, A. (2010), ‘Can the prevalence of high blood drug concentrations in a 
population be estimated by analysing oral fluid? A study of tetrahydrocannabinol and amphetamine’, 
Forensic Science International 195, pp. 153–59.
I  Gjerde, H. and Verstraete, A. G. (2011), ‘Estimating equivalent cutoff thresholds for drugs in blood 
and oral fluid using prevalence regression: a study of tetrahydrocannabinol and amphetamine’, 
Forensic Science International 212, pp. E26–E30.
I  Gjerde, H., Normann, P. T., Pettersen, B. S., et al. (2008), ‘Prevalence of alcohol and drugs among 
Norwegian motor vehicle drivers: a roadside survey’, Accident Analysis and Prevention England 40, 
pp. 1765–72.
I  Gjerde, H., Christophersen, A. S., Normann, P. T. and Morland, J. (2011), ‘Toxicological investigations 
of drivers killed in road traffic accidents in Norway during 2006–2008’, Forensic Science International 
212, pp. 102–9.
I  Gjerde, H., Christophersen, A. S., Normann, P. T., et al. (2012), ‘Analysis of alcohol and drugs in oral 
fluid from truck drivers in Norway’, Traffic Injury Prevention 13, pp. 43–8.
I  Glass, J. R., Sproule, B. A., Herrmann, N., Streiner, D. and Busto, U. E. (2003), ‘Acute pharmacological 
effects of temazepam, diphenhydramine, and valerian in healthy elderly subjects’, Journal of Clinical 
Psychopharmacology 23, pp. 260–8.
I  Golden, S., Teets, S. J., Lehman, E. B., et al. (2000), ‘Effect of topical nasal azelastine on the 
symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis’, Annals of Allergy, 
Asthma and Immunology 85, pp. 53–7.
I  Goldstein, R. Z., Leskovjan, A. C., Hoff, A. L., et al. (2004), ‘Severity of neuropsychological impairment 
in cocaine and alcohol addiction: association with metabolism in the prefrontal cortex’, 
Neuropsychologia 42, pp. 1447–58.
I  Gomes, T., Redelmeier, D. A., Juurlink, D. N., et al. (2013), ‘Opioid dose and risk of road trauma in 
Canada: a population-based study’, JAMA Internal Medicine 173, pp. 196–201.
I  Gouzoulis-Mayfrank, E., Daumann, J., Tuchtenhagen, F., et al. (2000), ‘Impaired cognitive 
performance in drug free users of recreational ecstasy (MDMA)’, Journal of Neurology, Neurosurgery 
and Psychiatry 68, pp. 719–25.
I  Greenblatt, D. J., Gan, L., Harmatz, J. S. and Shader, R. I. (2005), ‘Pharmocokinetics and 
pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-
Symbol Substitution Test’, British Journal of Clinical Pharmacology 60, pp. 244–8.
I  Grotenhermen, F., Leson, G., Berghaus, G., et al. (2007), ‘Developing limits for driving under cannabis’, 
Addiction 102, pp. 1910–17.
I  Gruber, S. A., Silveri, M. M., Renshaw, P. F., et al. (2006), ‘Methadone maintenance improves cognitive 
performance after two months of treatment’, Experimental and Clinical Psychopharmacology 14, 
pp. 157–64.
I  Guillermain, Y., Micallef, J., Possamai, C. A., Blin, O. and Hasbroucq, T. (2001), ‘N-methyl-d-aspartate 
receptors and information processing: human choice reaction time under a subanaesthetic dose of 
ketamine’, Neuroscience Letters 303, pp. 29–32.
I  Gustavsen, I., Morland, J. and Bramness, J. G. (2006), ‘Impairment related to blood amphetamine 
and/or methamphetamine concentrations in suspected drugged drivers’, Accident Analysis and 
Prevention 38, pp. 490–5.
I  Gustavsen, I., Bramness, J. G., Skurtveit, S., et al. (2008), ‘Road traffic accident risk related to 
prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam’, Sleep Medicine 9, 
pp. 818–22.
Drug use, impaired driving and traffic accidents
130
I  Gustavsen, I., Al-Sammurraie, M., Morland, J. and Bramness, J. G. (2009), ‘Impairment related to 
blood drug concentrations of zopiclone and zolpidem compared to alcohol in apprehended drivers’, 
Accident Analysis and Prevention 41, pp. 462–6.
I  Hair, P. I. and Scott, L. J. (2006), ‘Levocetirizine: a review of its use in the management of allergic 
rhinitis and skin allergies’, Drugs 66, pp. 973–96.
I  Hall, W. and Degenhardt, L. (2009), ‘Adverse health effects of non-medical cannabis use’, The Lancet 
374, pp. 1383–91.
I  Haller, C., Thai, D., Manktelow, T. C., Wesnes, K., and Benowitz, N. (2004), ‘Cognitive and mood effects 
of GHB and ethanol in humans (abstract)’, Journal of Toxicology: Clinical Toxicology, 42, pp. 762.
I  Hanrahan, L. P. and Paramore, L. C. (2003), ‘Aeroallergens, allergic rhinitis, and sedating 
antihistamines: risk factors for traumatic occupational injury and economic impact’, American 
Journal of Industrial Medicine 44, pp. 438–46.
I  Hargutt, V., Kruger, H. -P. and Knoche, A. (2011), ‘Driving under the influence of alcohol, illicit drugs 
and medicines. Risk estimations from different methodological approaches’, DRUID Deliverable 
1.3.1., Bundesanstalt für Strassenwesen, Bergisch-Gladbach.
I  Harmer, C. J., Bhagwagar, Z., Cowen, P. J. and Goodwin, G. M. (2002), ‘Acute administration of 
citalopram facilitates memory consolidation in healthy volunteers’, Psychopharmacology 163, 
pp. 106–10.
I  Hart, C. L., van Gorp, W., Haney, M., Foltin, R. W. and Fischman, M. W. (2001), ‘Effects of acute smoked 
marijuana on complex cognitive performance’, Neuropsychopharmacology 25, pp. 757–65.
I  Hartman, R. L. and Huestis, M. A. (2013), ‘Cannabis effects on driving skills’, Clinical Chemistry 59, 
pp. 478–492.
I  Hébert, C., Delaney, J. A., Hemmelgarn, B., Levesque, L. E. and Suissa, S. (2007), ‘Benzodiazepines 
and elderly drivers: a comparison of pharmacoepidemiological study designs’, Pharmacoepidemiol 
Drug Safety 16, pp. 845–9.
I  Hegadoren, K. M., Baker, G. B. and Bourin, M. (1999), ‘3,4-Methylenedioxy analogues of 
amphetamine: defining the risks to humans’, Neuroscience and Biobehavioral Reviews 23,  
pp. 539–53.
I  Hels, T., Bernhoft, I. M., Lyckegaard, A., et al. (2011), ‘Risk of injury by driving with alcohol and other 
drugs’, DRUID deliverable 2.3.5, Bundesanstalt für Strassenwesen, Bergisch-Gladbach.
I  Hemmelgarn, B., Suissa, S., Huang, A., Boivin, J. F. and Pinard, G. (1997), ‘Benzodiazepine use and 
the risk of motor vehicle crash in the elderly’, Journal of the American Medical Association 278, 
pp. 27–31.
I  Herberg, K. W. (2000), ‘Investigation of the effects of the antihistamine ebastine on safety in everyday 
life and road traffic’, Allergologie 23, pp. 73–80.
I  Hernandez-Lopez, C., Farre, M., Roset, P. N., et al. (2002), ‘3,4-Methylenedioxymethamphetamine 
(ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and 
pharmacokinetics’, Journal of Pharmacology and Experimental Therapeutics 300, pp. 236–44.
I  Hetem, L. A. B., Danion, J. M., Diemunsch, P. and Brandt, C. (2000), ‘Effect of a subanesthetic dose of 
ketamine on memory and conscious awareness in healthy volunteers’, Psychopharmacology 152, 
pp. 283–8.
I  Higgins, S. T., Bickel, W. K., Hughes, J. R., et al. (1990), ‘Effects of intranasal cocaine on human 
learning, performance and physiology’, Psychopharmacology (Berlin) 102, pp. 451–8.
I  Hill, J. L. and Zacny, J. P. (2000), ‘Comparing the subjective, psychomotor, and physiological effects 
of intravenous hydromorphone and morphine in healthy volunteers’, Psychopharmacology (Berlin) 
152, pp. 31–9.
I  Hindmarch, I. and Shamsi, Z. (2001), ‘The effects of single and repeated administration of ebastine on 
cognition and psychomotor performance in comparison and placebo volunteers’, Current Medical 
Research and Opinion 17, pp. 273–81.
References
131
I  Hindmarch, I., Kimber, S. and Cockle, S. M. (2000a), ‘Abrupt and brief discontinuation of 
antidepressant treatment: effects on cognitive function and psychomotor performance’, International 
Clinical Psychopharmacology 15, pp. 305–18.
I  Hindmarch, I., Rigney, U., Stanley, N. and Briley, M. (2000b), ‘Pharmacodynamics of milnacipran in 
young and elderly volunteers’, British Journal of Clinical Pharmacology 49, pp. 118–25.
I  Hindmarch, I., Patat, A., Stanley, N., Paty, I. and Rigney, U. (2001a), ‘Residual effects of zaleplon and 
zolpidem following middle of the night administration five hours to one hour before awakening’, 
Human Psychopharmacology — Clinical and Experimental 16, pp. 159–67.
I  Hindmarch, I., Johnson, S., Meadows, R., Kirkpatrick, T. and Shamsi, Z. (2001b), ‘The acute and 
sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive 
function, psychomotor performance, and weal and flare’, Current Medical Research and Opinion 17, 
pp. 241–55.
I  Hindmarch, I., Shamsi, Z. and Kimber, S. (2002), ‘An evaluation of the effects of high-dose 
fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy 
volunteers’, Clinical and Experimental Allergy 32, pp. 133–9.
I  Hjalmdahl, M., Vadeby, A., Forsman, A., et al. (2012), ‘Effects of d-amphetamine on simulated driving 
performance before and after sleep deprivation’, Psychopharmacology (Berlin) 222, pp. 401–11.
I  Hoffmann, S. and Buld, S. (2006), ‘Driving in a simulator. Design and evaluation of a training 
programme’, VDI Berichte 1960, pp. 113–32.
I  Hoffman, W. F., Moore, M., Templin, R., et al. (2006), ‘Neuropsychological function and delay 
discounting in methamphetamine-dependent individuals’, Psychopharmacology 188, pp. 162–70.
I  Holmgren, A., Holmgren, P., Kugelberg, F. C., Jones, A. W. and Ahlner, J. (2007), ‘Predominance of 
illicit drugs and poly-drug use among drug-impaired drivers in Sweden’, Traffic Injury Prevention 8, 
pp. 361–7.
I  Honey, R. A. E., Turner, D. C., Honey, G. D., et al. (2003), ‘Subdissociative dose ketamine produces a 
deficit in manipulation but not maintenance of the contents of working memory’, 
Neuropsychopharmacology 28, pp. 2037–44.
I  Hooper, T. I., DeBakey, S. F., Pearse, L., Pratt, S. and Hoffman, K. J. (2010), ‘The use of electronic 
pharmacy data to investigate prescribed medications and fatal motor vehicle crashes in a military 
population, 2002–2006’, Accident Analysis and Prevention 42, pp. 261–8.
I  Hopper, J. W., Karlsgodt, K. H., Adler, C. M., et al. (2004), ‘Effects of acute cortisol and cocaine 
administration on attention, recall and recognition task performance in individuals with cocaine 
dependence’, Human Psychopharmacology — Clinical and Experimental 19, pp. 511–16.
I  Hoque, R. and Chesson, A. L., Jr. (2009), ‘Zolpidem-induced sleepwalking, sleep related eating 
disorder, and sleep-driving: fluorine-18-fluorodeoxyglucose positron emission tomography analysis, 
and a literature review of other unexpected clinical effects of zolpidem’, Journal of Clinical Sleep 
Medicine 5, pp. 471–6.
I  Hou, C. C., Chen, S. C, Tan, L. B., et al. (2012), ‘Psychoactive substance use and the risk of motor 
vehicle crash injuries in southern Taiwan’, Prevention Science 13, pp. 36–42.
I  Hours, M., Fort, E., Charnay, P., et al. (2008), ‘Diseases, consumption of medicines and responsibility 
for a road crash: a case–control study’, Accident Analysis and Prevention 40, pp. 1789–1796.
I  Houwing, S., Hagenzieker, M., Mathijssen, R. P., et al. (2013), ‘Random and systematic errors in 
case–control studies calculating the injury risk of driving under the influence of psychoactive 
substances’, Accident Analysis and Prevention 52, pp. 144–53.
I  Huestis, M. A. (2002), ‘Cannabis (marijuana) — effects on human behavior and performance’, 
Forensic Science Review 14, pp. 15–60.
I  Hunault, C. C., Mensinga, T. T., Bocker, K. B., et al. (2009), ‘Cognitive and psychomotor effects in 
males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-
tetrahydrocannabinol (THC)’, Psychopharmacology (Berlin) 204, pp. 85–94.
I  Hutchison, K. E. and Swift, R. (1999), ‘Effect of d-amphetamine on prepulse inhibition of the startle 
reflex in humans’, Psychopharmacology 143, pp. 394–400.
Drug use, impaired driving and traffic accidents
132
I  Ilan, A. B., Smith, M. E. and Gevins, A. (2004), ‘Effects of marijuana on neurophysiological signals of 
working and episodic memory’, Psychopharmacology 176, pp. 214–22.
I  Ingsathit, A., Woratanarat, P., Anukarahanonta, T., et al. (2009), ‘Prevalence of psychoactive drug use 
among drivers in Thailand: a roadside survey’, Accident Analysis and Prevention 41, pp. 474–8.
I  Irving, A. and Jones, W. (1992), ‘Methods for testing impairment of driving due to drugs’, European 
Journal of Clinical Pharmacology 43, pp. 61–6.
I  Iudice, A., Bonanni, E., Maestri, M., et al. (2002), ‘Lormetazepam effects on daytime vigilance, 
psychomotor performance and simulated driving in young adult healthy volunteers’, International 
Journal of Clinical Pharmacology and Therapeutics 40, pp. 304–9.
I  Iwamoto, K., Kawamura, Y., Takahashi, M., et al. (2008a), ‘Plasma amitriptyline level after acute 
administration, and driving performance in healthy volunteers’, Psychiatry and Clinical Neurosciences 
62, pp. 610–16.
I  Iwamoto, K., Takahashi, M., Nakamura, Y., et al. (2008b), ‘The effects of acute treatment with 
paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy 
Japanese subjects: a double-blind crossover trial’, Human Psychopharmacology 23, pp. 399–407.
I  Izaute, M. and Bacon, E. (2006), ‘Effects of the amnesic drug lorazepam on complete and partial 
information retrieval and monitoring accuracy’, Psychopharmacology 188, pp. 472–81.
I  Jamison, R. N., Schein, J. R., Vallow, S., et al. (2003), ‘Neuropsychological effects of long-term opioid 
use in chronic pain patients’, Journal of Pain and Symptom Management 26, pp. 913–21.
I  Jasinski, D. R. and Preston, K. L. (1986), ‘Comparison of intravenously administered methadone, 
morphine and heroin’, Drug and Alcohol Dependence 17, pp. 301–10.
I  Jenkins, A. J., Keenan, R. M., Henningfield, J. E. and Cone, E. J. (1994), ‘Pharmacokinetics and 
pharmacodynamics of smoked heroin’, Journal of Analytical Toxicology 18, pp. 317–30.
I  Johansen, S. S. and Hansen, T. M. (2012), ‘Isomers of fluoroamphetamines detected in forensic cases 
in Denmark’, International Journal of Legal Medicine 126, pp. 541–7.
I  Johanson, C. E., Frey, K. A., Lundahl, L. H., et al. (2006), ‘Cognitive function and nigrostriatal markers 
in abstinent methamphetamine abusers’, Psychopharmacology 185, pp. 327–38.
I  Johnson, B. A., Ait-Daoud, N. and Wells, L. T. (2000), ‘Effects of isradipine, a dihydropyridine-class 
calcium channel antagonist, on d-methamphetamine-induced cognitive and physiological changes in 
humans’, Neuropsychopharmacology 22, pp. 504–12.
I  Johnson, B. A., Roache, J. D., Ait-Daoud, N., et al. (2005), ‘Effects of isradipine on methamphetamine-
induced changes in attentional and perceptual-motor skills of cognition’, Psychopharmacology 178, 
pp. 296–302.
I  Johnson, B. A., Roache, J. D., Ait-Daoud, N., et al. (2007), ‘Effects of topiramate on 
methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in 
recently abstinent methamphetamine-dependent individuals’, Progress in Neuro-
Psychopharmacology and Biological Psychiatry 31, pp. 123–30.
I  Johnson, M. B., Kelley-Baker, T., Voas, R. B. and Lacey, J. H. (2012), ‘The prevalence of cannabis-
involved driving in California’, Drug and Alcohol Dependence 123, pp. 105–9.
I  Jones, A. W. and Holmgren, A. (2005), ‘Abnormally high concentrations of amphetamine in blood of 
impaired drivers’, Journal of Forensic Sciences 50, pp. 1215–20.
I  Jones, A. W., Holmgren, A. and Kugelberg, F. C. (2008a), ‘Driving under the influence of gamma-
hydroxybutyrate (GHB)’, Forensic Science Medicine and Pathology 4, pp. 205–11.
I  Jones, A. W., Holmgren, A. and Kugelberg, F. C. (2008b), ‘Driving under the influence of cannabis: a 
10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood’, 
Addiction 103, pp. 452–61.
I  Jones, A. W., Kugelberg, F. C., Holmgren, A. and Ahlner, J. (2009), ‘Five-year update on the occurrence 
of alcohol and other drugs in blood samples from drivers killed in road-traffic crashes in Sweden’, 
Forensic Science International 186, pp. 56–62.
References
133
I  Jones, C., Donnelly, N., Swift, W. and Weatherburn, D. (2005), ‘Driving under the influence of 
cannabis: the problem and potential countermeasures’. Crime and Justice Bulletin 2005, p. 87.
I  Kalb, R., Dorner, M. and Kalb, S. (2006), ‘Opposite effects of depression and antidepressants on 
processing speed and error rate’, Progress in Neuro-Psychopharmacology and Biological Psychiatry 
30, pp. 244–50.
I  Kamboj, S. K., Tookman, A., Jones, L. and Curran, H. V. (2005), ‘The effects of immediate-release 
morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care’, Pain 
117, pp. 388–95.
I  Kamei, H., Noda, Y., Ishikawa, K., et al. (2003), ‘Comparative study of acute effects of single doses of 
fexofenadine, olopatadine, d-chlorpheniramine and placebo on psychomotor function in healthy 
volunteers’, Human Psychopharmacology — Clinical and Experimental 18, pp. 611–18.
I  Karschner, E. L., Schwilke, E. W., Lowe, R. H., et al. (2009a), ‘Do Delta9-tetrahydrocannabinol 
concentrations indicate recent use in chronic cannabis users?’, Addiction 104, pp. 2041–8.
I  Karschner, E. L., Schwilke, E. W., Lowe, R. H., et al. (2009b), ‘Implications of plasma Delta9-
tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic 
cannabis smokers’, Journal of Analytical Toxicology 33, pp. 469–77.
I  Katona, C., Bercoff, E., Chiu, E., et al. (1999), ‘Reboxetine versus imipramine in the treatment of elderly 
patients with depressive disorders: a double-blind randomised trial’, Journal of Affective Disorders 
55, pp. 203–13.
I  Kay, G. G. (2000), ‘The effects of antihistamines on cognition and performance’, Journal of Allergy 
and Clinical Immunology 105, pp. S622–S627.
I  Kay, G. G. and Quig, M. E. (2001), ‘Impact of sedating antihistamines on safety and productivity’, 
Allergy and Asthma Proceedings 22, pp. 281–3.
I  Kay, G. G., Michaels, M. A. and Pakull, B. (2009), ‘Simulated driving changes in young adults with 
ADHD receiving mixed amphetamine salts extended release and atomoxetine’, Journal of Attention 
Disorders 12, pp. 316–29.
I  Keller, T., Keller, A., Tutsch-Bauer, E. and Monticelli, F. (2009), ‘Driving under the influence of drugs 
and alcohol in Salzburg and Upper Austria during the years 2003–2007’, Legal Medicine (Tokyo) 
(11 Suppl. 1), pp. S98–S99.
I  Kelley, B. J., Yeager, K. R., Pepper, T. H. and Beversdorf, D. Q. (2005), ‘Cognitive impairment in acute 
cocaine withdrawal’, Cognitive and Behavioral Neurology 18, pp. 108–12.
I  Khiabani, H. Z., Morland, J. and Bramness, J. G. (2008), ‘Frequency and irregularity of heart rate in 
drivers suspected of driving under the influence of cannabis’, European Journal of Internal Medicine 
19, pp. 608–12.
I  Knaggs, R. D., Crighton, I. M., Cobby, T. F., Fletcher, A. J. and Hobbs, G. J. (2004), ‘The pupillary effects 
of intravenous morphine, codeine, and tramadol in volunteers’, Anesthesia and Analgesia 99, 
pp. 108–12.
I  Koetsier, G. C., Volkers, A. C., Tulen, J. H. M., et al. (2002), ‘CPT performance in major depressive 
disorder before and after treatment with imipramine or fluvoxamine’, Journal of Psychiatric Research 
36, pp. 391–7.
I  Kornick, C. A., Santiago-Palma, J., Moryl, N., Payne, R. and Obbens, E. A. M. T. (2003), ‘Benefit–risk 
assessment of transdermal fentanyl for the treatment of chronic pain’, Drug Safety 26, pp. 951–73.
I  Kriikku, P., Wilhelm, L., Schwarz, O. and Rintatalo, J. (2011), ‘New designer drug of abuse: 
3,4-methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland’, Forensic 
Science International 210, pp. 195–200.
I  Kriikku, P., Wilhelm, L., Rintatalo, J., et al. (2012), ‘Phenazepam abuse in Finland: findings from 
apprehended drivers, post-mortem cases and police confiscations’, Forensic Science International 
220, pp. 111–17.
I  Kriikku, P., Wilhelm, L., Rintatalo, J., Hurme, J., Kramer, J. and Ojanperä, I. (2013), ‘Prevalence and 
blood concentrations of desoxypipradrol (2-DPMP) in drivers suspected of driving under the 
influence of drugs and in post-mortem cases’, Forensic Science International 226, pp. 146–51.
Drug use, impaired driving and traffic accidents
134
I  Krystal, J. H., Bennett, A., Abi-Saab, D., et al. (2000), ‘Dissociation of ketamine effects on rule 
acquisition and rule implementation: possible relevance to NMDA receptor contributions to executive 
cognitive functions’, Biological Psychiatry 47, pp. 137–43.
I  Krystal, J. H., Perry, E. B., Gueorguieva, R., et al. (2005), ‘Comparative and interactive human 
psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and 
dopaminergic model psychoses and cognitive function’, Archives of General Psychiatry 62,  
pp. 985–95.
I  Kurzthaler, I., Hummer, M., Miller, C., et al. (1999), ‘Effect of cannabis use on cognitive functions and 
driving ability’, Journal of Clinical Psychiatry 60, pp. 395–9.
I  Kuypers, K. P., Wingen, M., Samyn, N., Limbert, N. and Ramaekers, J. G. (2007), ‘Acute effects of 
nocturnal doses of MDMA on measures of impulsivity and psychomotor performance throughout the 
night’, Psychopharmacology (Berlin) 192, pp. 111–19.
I  Kuypers, K. P. C., Legrand, S. -A., Ramaekers, J. G. and Verstraete, A. G. (2012), ‘A case–control study 
estimating accident risk for alcohol, medicines and illegal drugs’, PLoS One 7, e43496.
I  Lacey, J. H., Kelley-Baker, T., Voas, R. B., et al. (2011), ‘Alcohol- and drug-involved driving in the United 
States: methodology for the 2007 National Roadside Survey’, Office of Behavioral Safety 
Research, National Highway Traffic Safety Administration, Washington, DC. 
I  Lagarde, E., Chastang, J. F., Lafont, S., Coeuret-Pellicer, M. and Chiron, M. (2005), ‘Pain and pain 
treatment were associated with traffic accident involvement in a cohort of middle-aged workers’, 
Journal of Clinical Epidemiology 58, pp. 524–31.
I  Lamers, C. T. and Ramaekers, J. G. (2001), ‘Visual search and urban driving under the influence of 
marijuana and alcohol’, Human Psychopharmacology 16, pp. 393–401.
I  Lamers, C. T. J., Ramaekers, J. G., Muntjewerff, N. D., et al. (2003), ‘Dissociable effects of a single 
dose of ecstasy (MDMA) on psychomotor skills and attentional performance’, Journal of 
Psychopharmacology 17, pp. 379–87.
I  Lane, S. D., Cherek, D. R., Tcheremissine, O. V., Lieving, L. M. and Pietras, C. J. (2005), ‘Acute 
marijuana effects on human risk taking’, Neuropsychopharmacology 30, pp. 800–9.
I  Lange, B. and Bachert, C. (2004), ‘Adverse reaction profiles of antihistamines and their clinical 
relevance’, Allergologie 27, pp. 49–71.
I  Larsen, B., Otto, H., Dorscheid, E. and Larsen, R. (1999), ‘Effects of long-term opioid therapy on 
psychomotor function in patients with cancer pain or non-malignant pain’, Anaesthesist 48,  
pp. 613–24.
I  Laumon, B., Gadegbeku, B., Martin, J. L. and Biecheler, M. B. (2005), ‘Cannabis intoxication and fatal 
road crashes in France: population based case–control study’, BMJ 331, pp. 1371–6.
I  Lawton-Craddock, A., Nixon, S. J. and Tivis, R. (2003), ‘Cognitive efficiency in stimulant abusers with 
and without alcohol dependence’, Alcoholism — Clinical and Experimental Research 27, pp. 457–64.
I  Layton, D., Wilton, L., Boshier, A., et al. (2006), ‘Comparison of the risk of drowsiness and sedation 
between levocetirizine and desloratadine: a prescription-event monitoring study in England’, Drug 
Safety 29, pp. 897–909.
I  Legrand, S. A., Isalberti, C., der Linden, T. V., et al. (2012), ‘Alcohol and drugs in seriously injured 
drivers in six European countries’, Drug Testing and Analysis 5, pp. 156-65.
I  Legrand, S. A., Gjerde, H., Isalberti, C., et al. (2014), ‘Prevalence of alcohol, illicit drugs and 
psychoactive medicines in killed drivers in four European countries’, International Journal of Injury 
Control and Safety Promotion 21(1), pp. 17–28.
I  Lenguerrand, E., Martin, J. L., Moskal, A., Gadegbeku, B. and Laumon, B. (2008), ‘Limits of the 
quasi-induced exposure method when compared with the standard case–control design. Application 
to the estimation of risks associated with driving under the influence of cannabis or alcohol’, Accident 
Analysis and Prevention 40, pp. 861–8.
I  Lenné, M. G., Dietze, P., Rumbold, G. R., Redman, J. R. and Triggs, T. J. (2003), ‘The effects of the 
opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with 
alcohol, on simulated driving’, Drug and Alcohol Dependence 72, pp. 271–8.
References
135
I  Lenné, M. G., Dietze, P. M., Triggs, T. J., et al. (2010), ‘The effects of cannabis and alcohol on simulated 
arterial driving: influences of driving experience and task demand’, Accident Analysis and Prevention 
42, pp. 859–66.
I  Leufkens, T. R. and Vermeeren, A. (2009), ‘Highway driving in the elderly the morning after bedtime 
use of hypnotics: a comparison between temazepam 20 mg, zopiclone 7.5 mg, and placebo’, Journal 
of Clinical Psychopharmacology 29, pp. 432–8.
I  Leufkens, T. R., Vermeeren A., Smink B. E., van Ruitenbeek P. and Ramaekers J. G. (2007), ‘Cognitive, 
psychomotor and actual driving performance in healthy volunteers after immediate and extended 
release formulations of alprazolam 1 mg’, Psychopharmacology (Berlin) 191, pp. 951–9.
I  Leufkens, T. R., Lund, J. S. and Vermeeren, A. (2009), ‘Highway driving performance and cognitive 
functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and 
zolpidem’, Journal of Sleep Research 18, pp. 387–96.
I  Levkovitz, Y., Caftori, R., Avital, A. and Richter-Levin, G. (2002), ‘The SSRIs drug fluoxetine, but not the 
noradrenergic tricyclic drug desipramine, improves memory performance during acute major 
depression’, Brain Research Bulletin 58, pp. 345–50.
I  Leyton, V., Sinagawa, D. M., Oliveira, K. C., et al. (2012), ‘Amphetamine, cocaine and cannabinoids use 
among truck drivers on the roads in the state of Sao Paulo, Brazil’, Forensic Science International 215, 
pp. 25–7.
I  Li, M. C., Brady, J. E., DiMaggio, C. J., et al. (2012), ‘Marijuana use and motor vehicle crashes’, 
Epidemiological Reviews 34, pp. 65–72.
I  Lichtor, J. L., Alessi, R. and Lane, B. S. (2002), ‘Sleep tendency as a measure of recovery after drugs 
used for ambulatory surgery’, Anesthesiology 96, pp. 878–83.
I  Liguori, A., Gatto, C. P. and Jarrett, D. B. (2002), ‘Separate and combined effects of marijuana and 
alcohol on mood, equilibrium and simulated driving’, Psychopharmacology 163, pp. 399–405.
I  Limon, L. and Kockler, D. R. (2003), ‘Desloratadine: a nonsedating antihistamine’, Annals of 
Pharmacotherapy 37, pp. 237–46.
I  Liu, N., Zhou, D. M., Li, B., Ma, Y. Y. and Hu, X. T. (2006), ‘Gender related effects of heroin abuse on the 
simple reaction time task’, Addictive Behaviors 31, pp. 187–90.
I  Lofwall, M. R., Griffiths, R. R. and Mintzer, M. Z. (2006), ‘Cognitive and subjective acute dose effects 
of intramuscular ketamine in healthy adults’, Experimental and Clinical Psychopharmacology 14, 
pp. 439–49.
I  Logan, B. K. (2005), ‘Adverse effects of stimulants and cannabis on driving’, 17th Meeting of the 
International Association of Forensic Sciences, Hong Kong (presentation).
I  Logan, B. K. and Couper, F. J. (2001), ‘Zolpidem and driving impairment’, Journal of Forensic Sciences 
46, pp. 105–10.
I  Logan, B. K. and Schwilke, E. W. (2004), ‘Changing patterns of alcohol and drug use in fatally injured 
drivers in Washington State 1992–2002’, in: Oliver, J., Williams, P. and Clayton, A. (eds.), Proceedings 
of the 17th International Conference on Alcohol, Drugs and Traffic Safety (Glasgow), International 
Council on Alcohol, Drugs and Traffic Safety (ICADTS), Oslo.
I  Longo, M. C., Hunter, C. E., Lokan, R. J., White, J. M. and White, M. A. (2000a), ‘The prevalence of 
alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in 
driver culpability: part I: the prevalence of drug use in drive the drug-positive group’, Accident Analysis 
and Prevention 32, pp. 613–22.
I  Longo, M. C., Hunter, C. E., Lokan, R. J., White, J. M. and White, M. A. (2000b), ‘The prevalence of 
alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in 
driver culpability: part II: the relationship between drug prevalence and drug concentration, and driver 
culpability’, Accident Analysis and Prevention 32, pp. 623–32.
I  Lott, S., Musshoff, F. and Madea, B. (2012), ‘Estimation of gamma-hydroxybutyrate (GHB) co-
consumption in serum samples of drivers positive for amphetamine or ecstasy’, Forensic Science 
International 221, pp. 98–101.
Drug use, impaired driving and traffic accidents
136
I  Lowenstein, S. R. and Koziol-McLain, J. (2001), ‘Drugs and traffic crash responsibility: a study of 
injured motorists in Colorado’, Journal of Trauma 50, pp. 313–20.
I  Lyvers, M. and Yakimoff, M. (2003), ‘Neuropsychological correlates of opioid dependence and 
withdrawal’, Addictive Behaviors 28, pp. 605–11.
I  McCann, U. D., Mertl, M., Eligulashvili, V. and Ricaurte, G. A. (1999), ‘Cognitive performance in (+/-) 
3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study’, 
Psychopharmacology 143, pp. 417–25.
I  McDonald, J., Schleifer, L., Richards, J. B. and de Wit, H. (2003), ‘Effects of THC on behavioral 
measures of impulsivity in humans’, Neuropsychopharmacology 28, pp. 1356–65.
I  McGwin, G., Sims, R. V., Pulley, L. and Roseman, J. M. (2000), ‘Relations among chronic medical 
conditions, medications, and automobile crashes in the elderly: a population-based case–control 
study’, American Journal of Epidemiology 152, pp. 424–31.
I  McKetin, R. and Solowij, N. (1999), ‘Event-related potential indices of auditory selective attention in 
dependent amphetamine users’, Biological Psychiatry 45, pp. 1488–97.
I  McKetin, R., Ward, P. B., Catts, S. V., Mattick, R. P. and Bell, J. R. (1999), ‘Changes in auditory selective 
attention and event-related potentials following oral administration of d-amphetamine in humans’, 
Neuropsychopharmacology 21, pp. 380–90.
I  McNamara, P. (2002), ‘Opioid switching from morphine to transdermal fentanyl for toxicity reduction 
in palliative care (Reprinted from Palliative Medicine, 16, pp. 425–434, 2002)’, Pain Reviews 9, pp. 
119–30.
I  Magill, R. A., Waters, W. F., Bray, G. A., et al. (2003), ‘Effects of tyrosine, phentermine, caffeine 
d-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation’, 
Nutritional Neuroscience 6, pp. 237–46.
I  Mailis-Gagnon, A., Lakha, S. F., Furlan, A., et al. (2012), ‘Systematic review of the quality and 
generalizability of studies on the effects of opioids on driving and cognitive/psychomotor 
performance’, Clinical Journal of Pain 28, pp. 542–55.
I  Mann, R. D., Pearce, G. L., Dunn, N. and Shakir, S. (2000), ‘Sedation with “nonsedating” 
antihistamines: four prescription-event monitoring studies in general practice’, BMJ 320, pp. 1184–6.
I  Mann, R. E., Adlaf, E., Zhao, J., et al. (2007), ‘Cannabis use and self-reported collisions in a 
representative sample of adult drivers’, Journal of Safety Research 38, pp. 669–74.
I  Mann, R. E., Stoduto, G., Ialomiteanu, A., et al. (2010), ‘Self-reported collision risk associated with 
cannabis use and driving after cannabis use among Ontario adults’, Traffic Injury Prevention 11, 
pp. 115–22.
I  Mansfield, L., Mendoza, C., Flores, J. and Meeves, S. G. (2003), ‘Effects of fexofenadine, 
diphenhydramine, and placebo on performance of the Test of Variables of Attention (TOVA)’, Annals 
of Allergy, Asthma and Immunology 90, pp. 554–9.
I  Marsch, L. A., Bickel, W. K., Badger, G. J., et al. (2005), ‘Comparison of pharmacological treatments for 
opioid-dependent adolescents: a randomized controlled trial’, Archives of General Psychiatry 62, 
pp. 1157–64.
I  Martin, W. R. and Fraser, H. F. (1961), ‘A comparative study of physiological and subjective effects of 
heroin and morphine administered intravenously in postaddicts’, Journal of Pharmacology and 
Experimental Therapeutics 133, pp. 388–99.
I  Martínez-Cócera, C., De Molina, M., Marti-Guadano, E., et al. (2005), ‘Rupatadine 10 mg and cetirizine 
10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study’, Journal of 
Investigational Allergology and Clinical Immunology 15, pp. 22–9.
I  Mathijssen, M. P. M. (1999), Drug-, medicijn- en alcoholgebruik van automobilisten in Nederland, 
1997/1998, Stichting Wetenschappelijk Onderzoek Verkeersveiligheid (SWOV), Leidschendam.
I  Mattay, V. S., Callicott, J. H., Bertolino, A., et al. (2000), ‘Effects of dextroamphetamine on cognitive 
performance and cortical activation’, Neuroimage 12, pp. 268–75.
I  Matthews, A., Kirkby, K. C. and Martin, F. (2002), ‘The effects of single-dose lorazepam on memory 
and behavioural learning’, Journal of Psychopharmacology 16, pp. 345–54.
References
137
I  Maxwell, H. G., Dubois, S., Weaver, B. and Bedard, M. (2010), ‘The additive effects of alcohol and 
benzodiazepines on driving’, Canadian Journal of Public Health 101, pp. 353–7.
I  Meltzer, E. O. (2005), ‘Evaluation of the optimal oral antihistamine for patients with allergic rhinitis’, 
Mayo Clinic Proceedings 80, pp. 1170–6.
I  Meltzer, E. O., Casale, T. B., Gold, M. S., et al. (2003), ‘Efficacy and safety of clemastine-
pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of 
seasonal allergic rhinitis in a 1-day, placebo-controlled park study’, Annals of Allergy, Asthma and 
Immunology 90, pp. 79–86.
I  Menefee, L. A., Frank, E. D., Crerand, C., et al. (2004), ‘The effects of transdermal fentanyl on driving, 
cognitive performance, and balance in patients with chronic nonmalignant pain conditions’, Pain 
Medicine 5, pp. 42–9.
I  Menetrey, A., Augsburger, M. and Favrat, B. (2005), ‘Assessment of driving capability through the use 
of clinical and psychomotor tests in relation to blood cannabinoids levels following oral 
administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC’, 
Journal of Analytical Toxicology 29, pp. 327–38.
I  Meskali, M., Berthelon, C., Marie, S., Denise, P. and Bocca, M. L. (2009), ‘Residual effects of hypnotic 
drugs in aging drivers submitted to simulated accident scenarios: an exploratory study’, 
Psychopharmacology (Berlin) 207, pp. 461–7.
I  Mets, M. A., de Vries, J. M., de Senerpont Domis, L. M., et al. (2011), ‘Next-day effects of ramelteon 
(8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, 
psychomotor performance, and mood in healthy adult subjects’, Sleep 34, pp. 1327–34.
I  Meuleners, L. B., Duke, J., Lee, A. H., et al. (2011), ‘Psychoactive medications and crash involvement 
requiring hospitalization for older drivers: a population-based study’, Journal of the American 
Geriatric Society 59, pp. 1575–80.
I  Mills, K. C., Spruill, S. E., Kanne, R. W., Parkman, K. M. and Zhang, Y. (2001), ‘The influence of 
stimulants, sedatives, and fatigue on tunnel vision: risk factors for driving and piloting’, Human 
Factors 43, pp. 310–27.
I  Mintzer, M. Z. and Griffiths, R. R. (1999), ‘Triazolam and zolpidem: effects on human memory and 
attentional processes’, Psychopharmacology 144, pp. 8–19.
I  Mintzer, M. Z. and Griffiths, R. R. (2007), ‘A triazolam/amphetamine dose–effect interaction study: 
dissociation of effects on memory versus arousal’, Psychopharmacology (Berlin) 192, pp. 425–40.
I  Mintzer, M. Z. and Stitzer, M. L. (2002), ‘Cognitive impairment in methadone maintenance patients’, 
Drug and Alcohol Dependence 67, pp. 41–51.
I  Mintzer, M. Z., Correia, C. J. and Strain, E. C. (2004), ‘A dose–effect study of repeated administration 
of buprenorphine/naloxone on performance in opioid-dependent volunteers’, Drug and Alcohol 
Dependence 74, pp. 205–9.
I  Mintzer, M. Z., Copersino, M. L. and Stitzer, M. L. (2005), ‘Opioid abuse and cognitive performance’, 
Drug and Alcohol Dependence 78, pp. 225–30.
I  Mochizuki, H., Tashiro, M., Tagawa, M., et al. (2002), ‘The effects of a sedative antihistamine, 
d-chlorpheniramine, on visuomotor spatial discrimination and regional brain activity as measured by 
positron emission tomography (PET)’, Human Psychopharmacology — Clinical and Experimental 17, 
pp. 413–18.
I  Moeller, F. G., Barratt, E. S., Fischer, C. J., et al. (2004), ‘P300 event-related potential amplitude and 
impulsivity in cocaine-dependent subjects’, Neuropsychobiology 50, pp. 167–73.
I  Mohler, S. R., Nicholson, A., Harvey, P., Miura, Y. and Meeves, S. G. (2002), ‘The use of antihistamines 
in safety-critical jobs: a meeting report’, Current Medical Research and Opinion 18, pp. 332–7.
I  Monroe, E., Finn, A., Patel, P., et al. (2003), ‘Efficacy and safety of desloratadine 5 mg once daily in the 
treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial’, 
Journal of the American Academy of Dermatology 48, pp. 535–41.
Drug use, impaired driving and traffic accidents
138
I  Monterosso, J. R., Aron, A. R., Cordova, X., Xu, J. S. and London, E. D. (2005), ‘Deficits in response 
inhibition associated with chronic methamphetamine abuse’, Drug and Alcohol Dependence 79, 
pp. 273–7.
I  Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L. and Curran, H. V. (2004a), ‘Acute effects of 
ketamine on memory systems and psychotic symptoms in healthy volunteers’, 
Neuropsychopharmacology 29, pp. 208–18.
I  Morgan, C. J. A., Mofeez, A., Brandner, B., Bromley, L. and Curran, H. V. (2004b), ‘Ketamine impairs 
response inhibition and is positively reinforcing in healthy volunteers: a dose–response study’, 
Psychopharmacology 172, pp. 298–308.
I  Morgan, C. J. A., Riccelli, M., Maitland, C. H. and Curran, H. V. (2004c), ‘Long-term effects of ketamine: 
evidence for a persisting impairment of source memory in recreational users’, Drug and Alcohol 
Dependence 75, pp. 301–8.
I  Morgan, C. J. A., Monaghan, L. and Curran, H. V. (2004d), ‘Beyond the K-hole: a 3-year longitudinal 
investigation of the cognitive and subjective effects of ketamine in recreational users who have 
substantially reduced their use of the drug’, Addiction 99, pp. 1450–61.
I  Morgan, C. J. A., Perry, E. B., Cho, H. S., Krystal, J. H. and D’Souza, D. C. (2006a), ‘Greater vulnerability 
to the amnestic effects of ketamine in males’, Psychopharmacology 187, pp. 405–14.
I  Morgan, C. J. A., Rossell, S. L., Pepper, F., et al. (2006b), ‘Semantic priming after ketamine acutely in 
healthy volunteers and following chronic self-administration in substance users’, Biological 
Psychiatry 59, pp. 265–72.
I  Morin, C. M., Bastien, C. H., Brink, D. and Brown, T. R. (2003), ‘Adverse effects of temazepam in older 
adults with chronic insomnia’, Human Psychopharmacology — Clinical and Experimental 18, 
pp. 75–82.
I  Morland, J., Steentoft, A., Simonsen, K. W., et al. (2011), ‘Drugs related to motor vehicle crashes in 
northern European countries: a study of fatally injured drivers’, Accident Analysis and Prevention 43, 
pp. 1920–6.
I  Moskowitz, H. and Wilkinson, C. J. (2004), ‘Antihistamines and driving-related behavior: a review of 
the evidence for impairment’, DOT HS 809 714, US Department of Transportation, National Highway 
Traffic Safety Administration (NHTSA), Washington, DC.
I  Mura, P., Kintz, P., Ludes, B., et al. (2003), ‘Comparison of the prevalence of alcohol, cannabis and 
other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative 
study’, Forensic Science International 133, pp. 79–85.
I  Mura, P., Kintz, P., Dumestre, W., Raul, S. and Hauet, T. (2005), ‘THC can be detected in brain while 
absent in blood’, Journal of Analytical Toxicology 29, pp. 842–3.
I  Mura, P., Chatelain, C., Dumestre, V., et al. (2006), ‘Use of drugs of abuse in less than 30-year-old 
drivers killed in a road crash in France: a spectacular increase for cannabis, cocaine and 
amphetamines’, Forensic Science International 160, pp. 168–72.
I  Musshoff, F. and Madea, B. (2012), ‘Driving under the influence of amphetamine-like drugs’, Journal 
of Forensic Sciences 57, pp. 413–19.
I  Nebes, R. D., Pollock, B. G., Houck, P. R., et al. (2003), ‘Persistence of cognitive impairment in geriatric 
patients following antidepressant treatment: a randomized, double-blind clinical trial with 
nortriptyline and paroxetine’, Journal of Psychiatric Research 37, pp. 99–108.
I  Neutel, C. I. (1995), ‘Risk of traffic accident injury after a prescription for a benzodiazepine’, Annals of 
Epidemiology 5, pp. 239–44.
I  Neutel, I. (1998), ‘Benzodiazepine-related traffic accidents in young and elderly drivers’, Human 
Psychopharmacology — Clinical and Experimental (13 Suppl. 2), pp. S115–S123.
I  Newton, T. F., Kalechstein, A. D., Hardy, D. J., et al. (2004), ‘Association between quantitative EEG and 
neurocognition in methamphetamine-dependent volunteers’, Clinical Neurophysiology 115, 
pp. 194–8.
I  Nicholson, A. N., Stone, B. M., Turner, C. and Mills, S. L. (2002), ‘Central effects of cinnarizine: 
restricted use in aircrew’, Aviation Space and Environmental Medicine 73, pp. 570–4.
References
139
I  Nicholson, A. N., Handford, A. D. F., Turner, C. and Stone, B. M. (2003), ‘Studies on performance and 
sleepiness with the H-1-antihistamine, desloratadine’, Aviation Space and Environmental Medicine 
74, pp. 809–15.
I  Nicholson, A. N., Turner, C., Stone, B. M. and Robson, P. J. (2004), ‘Effect of Delta9-
tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young 
adults’, Journal of Clinical Psychopharmacology 24, pp. 305–13.
I  Nilsen, H. K., Landro, N. I., Kaasa, S., et al. (2011), ‘Driving functions in a video simulator in chronic 
non-malignant pain patients using and not using codeine’, European Journal of Pain 15, pp. 409–15.
I  Ning, L., Bo, L., Fraser, F. A. W., Ma, Y. Y. and Hu, X. T. (2005), ‘Gender effect on the right–left 
discrimination task in a sample of heroin-dependent patients’, Psychopharmacology 181,  
pp. 735–40.
I  Nordness, M. and Zacharisen, M. C. (2003), ‘High dose cetirizine: a case report’, Cutis 71, p. 396.
I  O’Hanlon, J. F., Robbe, H. W. J., Vermeeren, A., Van Leeuwen, C. and Danjou, P. E. (1998), 
‘Venlafaxine’s effects on healthy volunteers’ driving, psychomotor, and vigilance performance during 
15-day fixed and incremental dosing regimens’, Journal of Clinical Psychopharmacology 18, 
pp. 212–21.
I  O’Neill, W. M., Hanks, G. W., Simson, P., et al. (2000), ‘The cognitive and psychomotor effects of 
morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of 
dextropropoxyphene, morphine, lorazepam and placebo’, Pain 85, pp. 209–15.
I  Ojaniemi, K. K., Lintonen, T. P., Impinen, A. O., Lillsunde, P. M. and Ostamo, A. I. (2009), ‘Trends in 
driving under the influence of drugs: a register-based study of DUID suspects during 1977–2007’, 
Accident Analysis and Prevention 41, pp. 191–6.
I  Ornstein, T. J., Iddon, J. L., Baldacchino, A. M., et al. (2000), ‘Profiles of cognitive dysfunction in 
chronic amphetamine and heroin abusers’, Neuropsychopharmacology 23, pp. 113–26.
I  Orriols, L., Delorme, B., Gadegbeku, B., et al. (2010), ‘Prescription medicines and the risk of road 
traffic crashes: a French registry-based study’, PLoS Med 7, p. e1000366.
I  Orriols, L., Philip, P., Moore, N., et al. (2011), ‘Benzodiazepine-like hypnotics and the associated risk of 
road traffic accidents’, Clinical Pharmacology and Therapeutics 89, pp. 595–601.
I  Orriols, L., Queinec, R., Philip, P., et al. (2012), ‘Risk of injurious road traffic crash after prescription of 
antidepressants’, Journal of Clinical Psychiatry 73, pp. 1088–94.
I  Palmentier, J. P., Warren, R. and Gorczynski, L. Y. (2009), ‘Alcohol and drugs in suspected impaired 
drivers in Ontario from 2001 to 2005’, Journal of Forensic and Legal Medicine 16, pp. 444–8.
I  Papadodima, S. A., Athanaselis, S. A., Stefanidou, M. E., et al. (2008), ‘Driving under the influence in 
Greece: a 7-year survey (1998–2004)’, Forensic Science International 174, pp. 157–60.
I  Partinen, M., Hirvonen, K., Hublin, C., Halavaara, M. and Hiltunen, H. (2003), ‘Effects of after-midnight 
intake of zolpidem and temazepam on driving ability in women with non-organic insomnia’, Sleep 
Medicine 4, pp. 553–61.
I  Passalacqua, G. and Canonica, G. W. (2005), ‘A review of the evidence from comparative studies of 
levocetirizine and desloratadine for the symptoms of allergic rhinitis’, Clinical Therapeutics 27, 
pp. 979–92.
I  Passie, T., Karst, M., Wiese, B., Emrich, H. M. and Schneider, U. (2005), ‘Effects of different 
subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of 
consciousness in man’, Neuropsychobiology 51, pp. 226–33.
I  Patat, A., Paty, I. and Hindmarch, I. (2001), ‘Pharmacodynamic profile of zaleplon, a new non-
benzodiazepine hypnotic agent’, Human Psychopharmacology — Clinical and Experimental 16, 
pp. 369–92.
I  Pau, C. W. H., Lee, T. M. C. and Chan, S. F. F. (2002), ‘The impact of heroin on frontal executive 
functions’, Archives of Clinical Neuropsychology 17, pp. 663–70.
I  Paul, M. A., Gray, G., Kenny, G. and Pigeau, R. A. (2003), ‘Impact of melatonin, zaleplon, zopiclone, and 
temazepam on psychomotor performance’, Aviation Space and Environmental Medicine 74, 
pp. 1263–70.
Drug use, impaired driving and traffic accidents
140
I  Peretti, S., Judge, R. and Hindmarch, I. (2000), ‘Safety and tolerability considerations: tricyclic 
antidepressants vs. selective serotonin reuptake inhibitors’, Acta Psychiatrica Scandinavica 101, 
pp. 17–25.
I  Philipova, D., Tzenova, B., Iwanowitsch, A. and Bognar-Steinberg, I. (2004), ‘Influence of an 
antivertiginous combination a preparation of cinnarizine and dimenhydrinate on event-related 
potentials, reaction time and psychomotor performance — a randomized, double-blind, 3-way 
crossover study in healthy volunteers’, International Journal of Clinical Pharmacology and 
Therapeutics 42, pp. 218–31.
I  Pillay, S. S., Rogowska, J., Kanayama, G., et al. (2008), ‘Cannabis and motor function: fMRI changes 
following 28 days of discontinuation’, Experimental and Clinical Psychopharmacology 16, pp. 22–32.
I  Pirastu, R., Fais, R., Messina, M., et al. (2006), ‘Impaired decision-making in opiate-dependent 
subjects: effect of pharmacological therapies’, Drug and Alcohol Dependence 83, pp. 163–8.
I  Plaut, O. and Staub, C. (2000), ‘Driving under the influence of drugs in the canton of Geneva, 
Switzerland. Results and roadside survey project’, in: Laurell, H. and Schlyter, F. (eds.), Proceedings of 
the 15th International Conference on Alcohol, Drugs and Traffic Safety (Stockholm), International 
Council on Alcohol, Drugs and Traffic Safety (ICADTS), Oslo.
I  Poceta, J. S. (2011), ‘Zolpidem ingestion, automatisms, and sleep driving: a clinical and legal case 
series’, Journal of Clinical Sleep Medicine 7, pp. 632–8.
I  Podewils, L. J. and Lyketsos, C. G. (2002), ‘Tricyclic antidepressants and cognitive decline’, 
Psychosomatics 43, pp. 31–5.
I  Poirier, M. E., Galinowski, A., Amado, I., et al. (2004), ‘Double-blind comparative study of the action of 
repeated administration of Milnacipran versus placebo on cognitive functions in healthy volunteers’, 
Human Psychopharmacology — Clinical and Experimental 19, pp. 1–7.
I  Pope, H. G., Jr., Gruber, A. J., Hudson, J. I., Huestis, M. A. and Yurgelun-Todd, D. (2001), 
‘Neuropsychological performance in long-term cannabis users’, Archives of General Psychiatry 58, 
pp. 909–15.
I  Pressman, M. R. (2011), ‘Sleep driving: sleepwalking variant or misuse of z-drugs?’, Sleep Medicine 
Review 15, pp. 285–92.
I  Pulido, J., Barrio, G., Lardelli, P., et al. (2011a), ‘Cannabis use and traffic injuries’, Epidemiology 22, 
pp. 609–10.
I  Pulido, J., Barrio, G., Lardelli, P., et al. (2011b), ‘Association between cannabis and cocaine use, traffic 
injuries and use of protective devices’, European Journal of Public Health 21, pp. 753–5.
I  Quednow, B. B., Kuehn, K. U., Hoppe, C., et al. (2007), ‘Elevated impulsivity and impaired decision-
making cognition in heavy users of MDMA (‘ecstasy’)’, Psychopharmacology 189, pp. 517–30.
I  Rahman, Q. and Clarke, C. D. (2005), ‘Sex differences in neurocognitive functioning among abstinent 
recreational cocaine users’, Psychopharmacology 181, pp. 374–80.
I  Raja, S. N., Haythornthwaite, J. A., Pappagallo, M., et al. (2002), ‘Opioids versus antidepressants in 
postherpetic neuralgia: a randomized, placebo-controlled trial’, Neurology 59, pp. 1015–21.
I  Ramaekers, J. G. (2003a), ‘Pitfalls in estimating drug-related crash risk’, Trends in Pharmacological 
Sciences 24, pp. 114–15.
I  Ramaekers, J. G. (2003b), ‘Antidepressants and driver impairment: empirical evidence from a 
standard on-the-road test’, Journal of Clinical Psychiatry 64, pp. 20–9.
I  Ramaekers, J. G. and Vermeeren, A. (2000), ‘All antihistamines cross blood–brain barrier’, BMJ 321, 
p. 572.
I  Ramaekers, J. G., Kuypers, K. P. C., Wood, C. M., et al. (2004), ‘Immortal Deliverable D-R4.4: 
experimental studies on the effects of licit and illicit drugs on driving performance, psychomotor skills 
and cognitive function’, Austrian Road Safety Board, Vienna.
I  Ramaekers, J. G., Kauert, G., van Ruitenbeek, P., et al. (2006a), ‘High-potency marijuana impairs 
executive function and inhibitory motor control’, Neuropsychopharmacology 31, pp. 2296–303.
References
141
I  Ramaekers, J. G., Moeller, M. R., van Ruitenbeek, P., et al. (2006b), ‘Cognition and motor control as a 
function of Delta(9)-THC concentration in serum and oral fluid: limits of impairment’, Drug and 
Alcohol Dependence 85, pp. 114–22.
I  Ramaekers, J. G., Kuypers, K. P. and Samyn, N. (2006c), ‘Stimulant effects of 
3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving 
during intoxication and withdrawal’, Addiction 101, pp. 1614–21.
I  Ramaekers, J. G., Conen, S., de Kam, P. J., et al. (2011), ‘Residual effects of esmirtazapine on actual 
driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype’, 
Psychopharmacology (Berlin) 215, pp. 321–32.
I  Ramaekers, J. G., Kuypers, K. P., Bosker, W. M., et al. (2012), ‘Effects of stimulant drugs on actual and 
simulated driving: perspectives from four experimental studies conducted as part of the DRUID 
research consortium’, Psychopharmacology (Berlin) 222, pp. 413–18.
I  Rapeli, P., Kivisaari, R., Kahkonen, S., et al. (2005), ‘Do individuals with former amphetamine 
dependence have cognitive deficits?’, Nordic Journal of Psychiatry 59, pp. 293–7.
I  Rapoport, M. J., Lanctot, K. L., Streiner, D. L., et al. (2009), ‘Benzodiazepine use and driving: a 
meta-analysis’, Journal Clinical Psychiatry 70, pp. 663–73.
I  Ravera, S., van Rein, N., de Gier, J. J. and de Jong-van den Berg, L. T. (2011), ‘Road traffic accidents 
and psychotropic medication use in the Netherlands: a case–control study’, British Journal of Clinical 
Pharmacology 72, pp. 505–13.
I  Ravera, S., Ramaekers, J. G., de Jong-van den Berg, L. T. and de Gier, J. J. (2012), ‘Are selective 
serotonin reuptake inhibitors safe for drivers? What is the evidence?’, Clinical Therapeutics 34, 
pp. 1070–83.
I  Ricci, G., Majori, S., Mantovani, W., et al. (2008), ‘Prevalence of alcohol and drugs in urine of patients 
involved in road accidents’, Journal of Preventive Medicine and Hygiene 49, pp. 89–95.
I  Rich, J. B., Svoboda, E. and Brown, G. G. (2006), ‘Diazepam-induced prospective memory 
impairment and its relation to retrospective memory, attention, and arousal’, Human 
Psychopharmacology — Clinical and Experimental 21, pp. 101–8.
I  Richardson, G. S., Roehrs, T. A., Rosenthal, L., Koshorek, G. and Roth, T. (2002), ‘Tolerance to daytime 
sedative effects of H
1 
antihistamines’, Journal of Clinical Psychopharmacology 22, pp. 511–15.
I  Richer, I. and Bergeron, J. (2009), ‘Driving under the influence of cannabis: links with dangerous 
driving, psychological predictors, and accident involvement’, Accident Analysis and Prevention 41, 
pp. 299–307.
I  Richet, F., Marais, J., Serre, C. and Panconi, E. (2004), ‘Effects of milnacipran on driving vigilance’, 
International Journal of Psychiatry in Clinical Practice 8, pp. 109–15.
I  Ridout, F. and Hindmarch, I. (2001), ‘Effects of tianeptine and mianserin on car driving skills’, 
Psychopharmacology 154, pp. 356–61.
I  Ridout, F. and Hindmarch, I. (2003), ‘The effects of acute doses of fexofenadine, promethazine, and 
placebo on cognitive and psychomotor function in healthy Japanese volunteers’, Annals of Allergy, 
Asthma and Immunology 90, pp. 404–10.
I  Ridout, F., Shamsi, Z., Meadows, R., Johnson, S. and Hindmarch, I. (2003a), ‘A single-center, 
randomized, double-blind, placebo-controlled, crossover investigation of the effects of fexofenadine 
hydrochloride 180 mg alone and with alcohol, with hydroxyzine hydrochloride 50 mg as a positive 
internal control, on aspects of cognitive and psychomotor function related to driving a car’, Clinical 
Therapeutics 25, pp. 1518–38.
I  Ridout, F., Meadows, R., Johnsen, S. and Hindmarch, I. (2003b), ‘A placebo controlled investigation 
into the effects of paroxetine and mirtazapine on measures related to car driving performance’, 
Human Psychopharmacology 18, pp. 261–9.
I  Rizzo, M., Lamers, C. T. J., Sauer, C. G., et al. (2005), ‘Impaired perception of self-motion (heading) in 
abstinent ecstasy and marijuana users’, Psychopharmacology 179, pp. 559–66.
Drug use, impaired driving and traffic accidents
142
I  Robinson, J. E., Heaton, R. K. and O’Malley, S. S. (1999), ‘Neuropsychological functioning in cocaine 
abusers with and without alcohol dependence’, Journal of the International Neuropsychological 
Society 5, pp. 10–19.
I  Rogers, R. D., Everitt, B. J., Baldacchino, A., et al. (1999), ‘Dissociable deficits in the decision-making 
cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal 
cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms’, 
Neuropsychopharmacology 20, pp. 322–39.
I  Romano, E. and Voas, R. B. (2011), ‘Drug and alcohol involvement in four types of fatal crashes’, 
Journal of the Studies of Alcohol and Drugs 72, pp. 567–76.
I  Ronen, A., Chassidim, H. S., Gershon, P., et al. (2010), ‘The effect of alcohol, THC and their 
combination on perceived effects, willingness to drive and performance of driving and non-driving 
tasks’, Accident Analysis and Prevention 42, pp. 1855–65.
I  Rose, E. J., Simonotto, E., Spencer, E. P. and Ebmeier, K. P. (2006), ‘The effects of escitalopram on 
working memory and brain activity in healthy adults during performance of the n-back task’, 
Psychopharmacology 185, pp. 339–47.
I  Rowland, L. M., Astur, R. S., Jung, R. E., et al. (2005), ‘Selective cognitive impairments associated with 
NMDA receptor blockade in humans’, Neuropsychopharmacology 30, pp. 633–9.
I  Rush, C. R., Baker, R. W. and Wright, K. (1999), ‘Acute physiological and behavioral effects of oral 
cocaine in humans: a dose–response analysis’, Drug and Alcohol Dependence 55, pp. 1–12.
I  Sabatowski, R., Schwalen, S., Rettig, K., et al. (2003), ‘Driving ability under long-term treatment with 
transdermal fentanyl’, Journal of Pain and Symptom Management 25, pp. 38–47.
I  Saint-Martin, F., Dumur, J. P., Perez, I. and Izquierdo, I. (2004), ‘A randomized, double-blind, parallel-
group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H-1 
receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic 
rhinitis’, Journal of Investigational Allergology and Clinical Immunology 14, pp. 34–40.
I  Salmun, L. M., Gates, D., Scharf, M., et al. (2000), ‘Loratadine versus cetirizine: assessment of 
somnolence and motivation during the workday’, Clinical Therapeutics 22, pp. 573–82.
I  Salo, R., Nordahl, T.E., Possin, K., et al. (2002), ‘Preliminary evidence of reduced cognitive inhibition in 
methamphetamine-dependent individuals’, Psychiatry Research 111, pp. 65–74.
I  Salo, R., Nordahl, T. E., Moore, C., et al. (2005), ‘A dissociation in attentional control: evidence from 
methamphetamine dependence’, Biological Psychiatry 57, pp. 310–13.
I  Santamarina-Rubio, E., Perez, K., Ricart, I., et al. (2009), ‘Substance use among road traffic casualties 
admitted to emergency departments’, Injury Prevention 15, pp. 87–94.
I  Satish, U. and Streufert, S. (2003), ‘Treatment of hay fever with the antihistamine desloratadine: 
impact on performance of simple, intermediate, and complex task requirements’, Journal of Applied 
Biobehavioral Research 8, pp. 61–76.
I  Satish, U., Streufert, S., Dewan, M. and Voort, S. V. (2004), ‘Improvements in simulated real-world 
relevant performance for patients with seasonal allergic rhinitis: impact of desloratadine’, Allergy 59, 
pp. 415–20.
I  Schindler, S. D., Ortner, R., Peternell, A., et al. (2004), ‘Maintenance therapy with synthetic opioids 
and driving aptitude’, European Addiction Research 10, pp. 80–7.
I  Schmitt, J. A. J., Ramaekers, J. G., Kruizinga, M. J., et al. (2002), ‘Additional dopamine reuptake 
inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man’, Journal 
of Psychopharmacology 16, pp. 207–14.
I  Schmitt, J. A. J., Wingen, M., Riedel, W. J. and Ramaekers, J. G. (2004), ‘Immortal Deliverable R1.5: 
effects of depression and antidepressant therapy on driving performance’, Austrian Road Safety 
Board, Vienna.
I  Schneider, D., Kiessling, B., Wieczorek, M., et al. (2003), ‘Influence of 3 antivertiginous medications on 
the vigilance of healthy volunteers’, International Journal of Clinical Pharmacology and Therapeutics 
41, pp. 171–81.
References
143
I  Schneider, U., Bevilacqua, C., Jacobs, R., et al. (1999), ‘Effects of fentanyl and low doses of alcohol on 
neuropsychological performance in healthy subjects’, Neuropsychobiology 39, pp. 38–43.
I  Schulze, H., Schumacher, M., Urmeew, R. and Auerbach, K. (2012), ‘Final report: work performed, 
main results and recommendations, DRUID deliverables’, DRUID Deliverable 0.1.8, Bundesanstalt für 
Stassenwesen, Bergisch-Gladbach. 
I  Senna, M. C., Augsburger, M., Aebi, B., et al. (2010), ‘First nationwide study on driving under the 
influence of drugs in Switzerland’, Forensic Science International 198, pp. 11–16.
I  Serra-Grabulosa, J. M., Grau, C., Escera, C. and Sanchez-Turet, M. (2001), ‘The H-1-receptor 
antagonist dextro-chlorpheniramine impairs selective auditory attention in the absence of subjective 
awareness of this impairment’, Journal of Clinical Psychopharmacology 21, pp. 599–602.
I  Serra-Grabulosa, J.M., Sanchez-Turet, M. and Grau, C. (2002), ‘[The secondary effects of the 
antihistamine chlorpheniramine on the central nervous system]’, Revista de Neurologia 34,  
pp. 1178–82.
I  Sewell, R. A., Poling, J. and Sofuoglu, M. (2009), ‘The effect of cannabis compared with alcohol on 
driving’, American Journal of Addiction 18, pp. 185–93.
I  Sexton, B. F., Tunbridge, R., Brook-carter, N., Jackson, P. G. and Wright, K. (2000), ‘TRL 477: the 
influence of cannabis on driving’, Transport Research Laboratory, Wokingham, United Kingdom.
I  Sexton, B. F., Tunbridge, R. J., Board, A., et al. (2002), ‘TRL 543: the influence of cannabis and alcohol 
on driving’, Transport Research Laboratory, Wokingham, United Kingdom.
I  Shamsi, Z. and Hindmarch, I. (2000), ‘Sedation and antihistamines: a review of inter-drug differences 
using proportional impairment ratios’, Human Psychopharmacology — Clinical and Experimental 15, 
pp. S3–S30.
I  Shamsi, Z., Kimber, S. and Hindmarch, I. (2001), ‘An investigation into the effects of cetirizine on 
cognitive function and psychomotor performance in healthy volunteers’, European Journal of Clinical 
Pharmacology 56, pp. 865–71.
I  Shen, J., Moller, H. J., Wang, X., et al. (2009), ‘Mirtazapine, a sedating antidepressant, and improved 
driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 
patients’, Journal of Clinical Psychiatry 70, pp. 370–7.
I  Shmygalev, S., Damm, M., Weckbecker, K., et al. (2011), ‘The impact of long-term maintenance 
treatment with buprenorphine on complex psychomotor and cognitive function’, Drug and Alcohol 
Dependence 117, pp. 190–7.
I  Siepmann, M., Krause, S., Joraschky, P., Muck-Weymann, M. and Kirch, W. (2002), ‘The effects of St 
John’s wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison 
with amitriptyline and placebo in healthy men’, British Journal of Clinical Pharmacology 54,  
pp. 277–82.
I  Siepmann, M., Handel, J., Mueck-Weymann, M. and Kirch, W. (2004), ‘The effects of moclobemide on 
autonomic and cognitive functions in healthy volunteers’, Pharmacopsychiatry 37, pp. 81–7.
I  Silber, B. Y., Papafotiou, K., Croft, R. J., et al. (2005), ‘The effects of dexamphetamine on simulated 
driving performance’, Psychopharmacology 179, pp. 536–43.
I  Silber, B. Y., Croft, R. J., Papafotiou, K. and Stough, C. (2006), ‘The acute effects of d-amphetamine 
and methamphetamine on attention and psychomotor performance’, Psychopharmacology 187, 
pp. 154–69.
I  Silber, B. Y., Croft, R. J., Downey, L. A., et al. (2012a), ‘The effect of d-methamphetamine on simulated 
driving performance’, Human Psychopharmacology 27, pp. 139–44.
I  Silber, B. Y., Croft, R. J., Downey, L. A., et al. (2012b), ‘The effect of d,l-methamphetamine on 
simulated driving performance’, Psychopharmacology (Berlin) 219, pp. 1081–7.
I  Siliquini, R., Chiado Piat, S., Gianino, M. M. and Renga, G. (2007), ‘Drivers involved in road traffic 
accidents in Piedmont Region: psychoactive substances consumption’, Journal of Preventive 
Medicine and Hygiene 48, pp. 123–8.
I  Simon, S. L., Domier, C., Carnell, J., et al. (2000), ‘Cognitive impairment in individuals currently using 
methamphetamine’, American Journal on Addictions 9, pp. 222–31.
Drug use, impaired driving and traffic accidents
144
I  Simons, R., Martens, M., Ramaekers, J., et al. (2012), ‘Effects of dexamphetamine with and without 
alcohol on simulated driving’, Psychopharmacology (Berlin) 222, pp. 391–9.
I  Simpson, C. A. and Rush, C. R. (2002), ‘Acute performance-impairing and subject-rated effects of 
triazolam and temazepam, alone and in combination with ethanol, in humans’, Journal of 
Psychopharmacology 16, pp. 23–34.
I  Sinclair, D. R., Chung, F. and Smiley, A. (2003), ‘General anesthesia does not impair simulator driving 
skills in volunteers in the immediate recovery period — a pilot study’, Canadian Journal of 
Anaesthesia — Journal canadien d’anesthésie 50, pp. 238–45.
I  Sjogren, P., Thomsen, A. B. and Olsen, A. K. (2000a), ‘Impaired neuropsychological performance in 
chronic nonmalignant pain patients receiving long-term oral opioid therapy’, Journal of Pain and 
Symptom Management 19, pp. 100–8.
I  Sjogren, P., Olsen, A. K., Thomsen, A. B. and Dalberg, J. (2000b), ‘Neuropsychological performance in 
cancer patients: the role of oral opioids, pain and performance status’, Pain 86, pp. 237–45.
I  Smelson, D. A., Roy, A., Santana, S. and Engelhart, C. (1999), ‘Neuropsychological deficits in 
withdrawn cocaine-dependent males’, American Journal of Drug and Alcohol Abuse 25, pp. 377–81.
I  Smink, B. E., Ruiter, B., Lusthof, K. J., et al. (2005), ‘Drug use and the severity of a traffic accident’, 
Accident Analysis and Prevention 37, pp. 427–33.
I  Smink, B. E., Lusthof, K. J., de Gier, J. J., Uges, D. R. and Egberts, A. C. (2008a), ‘The relation between 
the blood benzodiazepine concentration and performance in suspected impaired drivers’, Journal of 
Forensic and Legal Medicine 15, pp. 483–8.
I  Smink, B. E., Movig, K. L., Lusthof, K. J., et al. (2008b), ‘The relation between the use of psychoactive 
substances and the severity of the injury in a group of crash-involved drivers admitted to a regional 
trauma center’, Traffic Injury Prevention 9, pp. 105–8.
I  Smink, B. E., Egberts, A. C., Lusthof, K. J., Uges, D. R. and de Gier, J. J. (2010), ‘The relationship 
between benzodiazepine use and traffic accidents: a systematic literature review’, CNS Drugs 24, 
pp. 639–53.
I  Smith, R. M., Tivarus, M., Campbell, H. L., Hillier, A. and Beversdorf, D. Q. (2006), ‘Apparent transient 
effects of recent “ecstasy” use on cognitive performance and extrapyramidal signs in human 
subjects’, Cognitive and Behavioral Neurology 19, pp. 157–64.
I  Snyder, P. J., Werth, J., Giordani, B., et al. (2005), ‘A method for determining the magnitude of change 
across different cognitive functions in clinical trials: the effects of acute administration of two 
different doses alprazolam’, Human Psychopharmacology — Clinical and Experimental 20,  
pp. 263–73.
I  Sobanski, E., Sabljic, D., Alm, B., et al. (2008), ‘Driving-related risks and impact of methylphenidate 
treatment on driving in adults with attention-deficit/hyperactivity disorder (ADHD)’, Journal of Neural 
Transmission 115, pp. 347–56.
I  Soderstrom, C.A., Dischinger, P.C., Kufera, J.A., Ho, S.M. and Shepard, A. (2005), ‘Crash culpability 
relative to age and sex for injured drivers using alcohol, marijuana or cocaine’, Annual Proceedings 
— Association for the Advancement of Automotive Medicine 49, pp. 315–30. 
I  Solowij, N., Stephens, R. S., Roffman, R. A., et al. (2002), ‘Cognitive functioning of long-term heavy 
cannabis users seeking treatment’, Journal of the American Medical Association 287, pp. 1123–31.
I  Soo-ampon, S., Wongwitdecha, N., Plasen, S., Hindmarch, I. and Boyle, J. (2004), ‘Effects of word 
frequency on recall memory following lorazepam, alcohol, and lorazepam alcohol interaction in 
healthy volunteers’, Psychopharmacology 176, pp. 420–5.
I  Soyka, M., Horak, M., Dittert, S. and Kagerer, S. (2001), ‘Less driving impairment on buprenorphine 
than methadone in drug-dependent patients?’, Journal of Neuropsychiatry and Clinical 
Neurosciences 13, pp. 527–8.
I  Soyka, M., Hock, B., Kagerer, S., et al. (2005), ‘Less impairment on one portion of a driving-relevant 
psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results 
of a randomized clinical trial’, Journal of Clinical Psychopharmacology 25, pp. 490–3.
References
145
I  Specka, M., Finkbeiner, T., Lodemann, E., et al. (2000), ‘Cognitive-motor performance of methadone-
maintained patients’, European Addiction Research 6, pp. 8–19.
I  Staner, L., Ertle, S., Boeijinga, P., et al. (2005), ‘Next-day residual effects of hypnotics in DSM-IV 
primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring’, 
Psychopharmacology 181, pp. 790–8.
I  Steentoft, A., Simonsen, K.W. and Linnet, K. (2010), ‘The frequency of drugs among Danish drivers 
before and after the introduction of fixed concentration limits’, Traffic Injury Prevention 11,  
pp. 329–33.
I  Stillwell, M. E. (2003), ‘Zaleplon and driving impairment’, Journal of Forensic Sciences 48, pp. 677–9.
I  Stoduto, G., Mann, R. E., Ialomiteanu, A., Wickens, C. M. and Brands, B. (2012), ‘Examining the link 
between collision involvement and cocaine use’, Drug and Alcohol Dependence 123, pp. 260–3.
I  Stoller, K. B., Bigelow, G. E., Walsh, S. L. and Strain, E. C. (2001), ‘Effects of buprenorphine/naloxone 
in opioid-dependent humans’, Psychopharmacology 154, pp. 230–42.
I  Stough, C., Downey, L. A., King, R., et al. (2012), ‘The acute effects of 
3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study’, 
Accident Analysis and Prevention 45, pp. 493–7.
I  Strain, E. C., Stoller, K., Walsh, S. L. and Bigelow, G. E. (2000), ‘Effects of buprenorphine versus 
buprenorphine/naloxone tablets in non-dependent opioid abusers’, Psychopharmacology 148, 
pp. 374–83.
I  Strand, M. C., Fjeld, B., Marianne, A. and Morland, J. (2011), ‘Psychomotor relevant performance: 1. 
After single dose administration of opioids, narcoanalgesics and hallucinogens to drug naïve 
subjects, 2. In patients treated chronically with morphine or methadone/buprenorphine’, DRUID 
Deliverable 1.1.2c, Bundesanstalt für Strassenwesen, Bergisch-Gladbach. 
I  Strik, J. J. M. H., Honig, A., Klinkenberg, E., Dijkstra, J. and Jolles, J. (2006), ‘Cognitive performance 
following fluoxetine treatment in depressed patients post myocardial infarction’, Acta 
Neuropsychiatrica 18, pp. 1–6.
I  Strumpf, M., Willweber-Strumpf, A., Herberg, K. W. and Zenz, M. (2005), ‘[Safety-relevant 
performance of patients on chronic opioid therapy]’, Der Schmerz 19, pp. 426–33.
I  Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2003), ‘Amphetamine effects on prepulse 
inhibition across-species: replication and parametric extension’, Neuropsychopharmacology 28, 
pp. 640–50.
I  Tagawa, M., Kano, M., Okamura, N., et al. (2002), ‘Differential cognitive effects of ebastine and 
(+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug 
concentration’, British Journal of Clinical Pharmacology 53, pp. 296–304.
I  Takahashi, H., Ishida-Yamamoto, A. and Iizuka, H. (2004), ‘Effects of bepotastine, cetirizine, 
fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and 
psychomotor performance’, Clinical and Experimental Dermatology 29, pp. 526–32.
I  Tashiro, M., Sakurada, Y., Iwabuchi, K., et al. (2004), ‘Central effects of fexofenadine and cetirizine: 
measurement of psychomotor performance, subjective sleepiness, and brain histamine H-1-receptor 
occupancy using C-11-doxepin positron emission tomography’, Journal of Clinical Pharmacology 44, 
pp. 890–900.
I  Tashiro, M., Horikawa, E., Mochizuki, H., et al. (2005), ‘Effects of fexofenadine and hydroxyzine on 
brake reaction time during car-driving with cellular phone use’, Human Psychopharmacology — 
Clinical and Experimental 20, pp. 501–9.
I  Tashiro, M., Sakurada, Y., Mochizuki, H., et al. (2008), ‘Effects of a sedative antihistamine, 
d-chlorpheniramine, on regional cerebral perfusion and performance during simulated car driving’, 
Human Psychopharmacology 23, pp. 139–50.
I  Tassain, V., Attal, N., Fletcher, D., et al. (2003), ‘Long term effects of oral sustained release morphine 
on neuropsychological performance in patients with chronic noncancer pain’, Pain 104, pp. 389–
400.
Drug use, impaired driving and traffic accidents
146
I  Theunissen, E. L., Vermeeren, A. and Ramaekers, J. G. (2006a), ‘Repeated-dose effects of 
mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance’, British 
Journal of Clinical Pharmacology 61, pp. 79–86.
I  Theunissen, E. L., van Kroonenburgh, M. J. P. G., van Deursen, J. A., Blom-Coenjaerts, C. and 
Ramaekers, J. G. (2006b), ‘Stimulating effects of the antihistamine fexofenadine: testing the 
dopamine transporter hypothesis’, Psychopharmacology 187, pp. 95–102.
I  Timoshanko, A., Stough, C., Vitetta, L. and Nathan, P. J. (2001), ‘A preliminary investigation on the 
acute pharmacodynamic effects of hypericum on cognitive and psychomotor performance’, 
Behavioural Pharmacology 12, pp. 635–40.
I  Tiplady, B., Hiroz, J., Holmes, L. and Drummond, G. (2003), ‘Errors in performance testing: a 
comparison of ethanol and temazepam’, Journal of Psychopharmacology 17, pp. 41–9.
I  Toomey, R., Lyons, M. J., Eisen, S. A., et al. (2003), ‘A twin study of the neuropsychological 
consequences of stimulant abuse’, Archives of General Psychiatry 60, pp. 303–10.
I  Toth, A. R., Varga, T., Molnar, A., Hideg, Z. and Somogyi, G. (2009), ‘The role of licit and illicit drugs in 
traffic (Hungary 2000–2007)’, Legal Medicine (Tokyo) (11 Suppl. 1), pp. S419–S422.
I  Trick, L., Stanley, N., Rigney, U. and Hindmarch, I. (2004), ‘A double-blind, randomized, 26-week study 
comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine 
and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression 
being treated in general practice’, Journal of Psychopharmacology 18, pp. 205–14.
I  Troy, S. M., Lucki, I., Unruh, M. A., et al. (2000), ‘Comparison of the effects of zaleplon, zolpidem and 
triazolam on memory, learning and psychomotor performance’, Journal of Clinical 
Psychopharmacology 20, pp. 328–37.
I  Turner, C., Handford, A. D. F. and Nicholson, A. N. (2006), ‘Sedation and memory: studies with a 
histamine H-1 receptor antagonist’, Journal of Psychopharmacology 20, pp. 506–17.
I  Valk, P. J. L., Van Roon, D. B., Simons, R. M. and Rikken, G. (2004), ‘Desloratadine shows no effect on 
performance during 6 h at 8 000 ft simulated cabin altitude’, Aviation Space and Environmental 
Medicine 75, pp. 433–8.
I  Van der Linden, T., Legrand, S. -A., Silverans, P. and Verstraete, A. G. (2012), ‘DUID: oral fluid and 
blood confirmation compared in Belgium’, Journal of Analytical Toxicology 36, pp. 418–21.
I  Van Laar, M., Volkerts, E. and Verbaten, M. (2001), ‘Subchronic effects of the GABA-agonist 
lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and 
daytime sleepiness in healthy volunteers’, Psychopharmacology 154, pp. 189–97.
I  Veldhuijzen, D. S., van Wijck, A. J. M., Wille, F., et al. (2006a), ‘Effect of chronic nonmalignant pain on 
highway driving performance’, Pain 122, pp. 28–35.
I  Veldhuijzen, D. S., van Wijck, A. J., Verster, J. C., et al. (2006b), ‘Acute and subchronic effects of 
amitriptyline 25 mg on actual driving in chronic neuropathic pain patients’, Journal of 
Psychopharmacology 20, pp. 782–8.
I  Veldstra, J. L., Brookhuis, K. A., de Waard, D., et al. (2012), ‘Effects of alcohol (BAC 0.5 parts per 
thousand) and ecstasy (MDMA 100 mg) on simulated driving performance and traffic safety’, 
Psychopharmacology 222, pp. 377–90.
I  Verdejo, A., Orozco-Gimenez, C., Sanchez-Jofre, M. M., de Arcos, F. A. and Perez-Garcia, M. (2004), 
‘[The impact exerted by the severity of recreational drug abuse on the different components of the 
executive function]’, Revista de Neurologia 38, pp. 1109–16.
I  Verdejo, A., Toribio, I., Orozco, C., Puente, K. L. and Perez-Garcifa, M. (2005), ‘Neuropsychological 
functioning in methadone maintenance patients versus abstinent heroin abusers’, Drug and Alcohol 
Dependence 78, pp. 283–8.
I  Verheyden, S. L., Henry, J. A. and Curran, H. V. (2003), ‘Acute, sub-acute and long-term subjective 
consequences of “ecstasy” (MDMA) consumption in 430 regular users’, Human 
Psychopharmacology — Clinical and Experimental 18, pp. 507–17.
I  Vermeeren, A. (2004), ‘Residual effects of short half-life non-benzodiazepine hypnotics’, CNS Drugs 
18, pp. 297–328.
References
147
I  Vermeeren, A. and Coenen, A. M. (2011), ‘Effects of the use of hypnotics on cognition’, Progress in 
Brain Research 190, pp. 89–103.
I  Vermeeren, A., Riedel, W. J., Van Boxtel, M. P. J., et al. (2002a), ‘Differential residual effects of zaleplon 
and zopiclone on actual driving: a comparison with a low dose of alcohol’, Sleep 25, pp. 224–31.
I  Vermeeren, A., Ramaekers, J. G. and O’Hanlon, J. F. (2002b), ‘Effects of emedastine and cetirizine, 
alone and with alcohol, on actual driving of males and females’, Journal of Psychopharmacology 16, 
pp. 57–64.
I  Verster, J. C. and Cox, D. J. (2008), ‘ADHD, methylphenidate and driving: does some legislation 
endanger public health?’, Journal of Psychopharmacology 22, pp. 227–9.
I  Verster, J. C. and Roth, T. (2012), ‘Gender differences in highway driving performance after 
administration of sleep medication: a review of the literature’, Traffic Injury Prevention 13, pp. 286–92.
I  Verster, J. C. and Roth, T. (2013), ‘Blood drug concentrations of benzodiazepines correlate poorly with 
actual driving impairment’, Sleep Medicine Review 17, pp. 153–9.
I  Verster, J. C. and Volkerts, E. R. (2004a), ‘Clinical pharmacology, clinical efficacy, and behavioral 
toxicity of alprazolam: a review of the literature’, CNS Drug Reviews 10, pp. 45–76.
I  Verster, J. C. and Volkerts, E. R. (2004b), ‘Antihistamines and driving ability: evidence from on-the-
road driving studies during normal traffic’, Annals of Allergy, Asthma and Immunology 92,  
pp. 294–304.
I  Verster, J. C., Volkerts, E. R., Schreuder, A. H. C. M., et al. (2002a), ‘Residual effects of middle-of-the-
night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor 
performance’, Journal of Clinical Psychopharmacology 22, pp. 576–83.
I  Verster, J. C., Volkerts, E. R. and Verbaten, M. N. (2002b), ‘Effects of alprazolam on driving ability, 
memory functioning and psychomotor performance: a randomized, placebo-controlled study’, 
Neuropsychopharmacology 27, pp. 260–9.
I  Verster, J. C., Volkerts, E. R., van Oosterwijck, A. W. A. A., et al. (2003a), ‘Acute and subchronic effects 
of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and 
mood’, Journal of Allergy and Clinical Immunology 111, pp. 623–7.
I  Verster, J. C., de Weert, A. M., Bijtjes, S. I. R., et al. (2003b), ‘Driving ability after acute and sub-chronic 
administration of levocetirizine and diphenhydramine: a randomized, double-blind, placebo-
controlled trial’, Psychopharmacology 169, pp. 84–90.
I  Verster, J. C., Veldhuijzen, D. S., Patat, A., Olivier, B. and Volkerts, E. R. (2006), ‘Hypnotics and driving 
safety: meta-analyses of randomized controlled trials applying the on-the-road driving test’, Current 
Drug Safety 1, pp. 63–71.
I  Verster, J. C., Volkerts, E. R., Olivier, B., Johnson, W. and Liddicoat, L. (2007), ‘Zolpidem and traffic 
safety — the importance of treatment compliance’, Current Drug Safety 2, pp. 220–6.
I  Verster, J. C., Spence, D. W., Shahid, A., Pandi-Perumal, S. R. and Roth, T. (2011), ‘Zopiclone as 
positive control in studies examining the residual effects of hypnotic drugs on driving ability’, Current 
Drug Safety 6, pp. 209–18.
I  Verstraete, A. G. (2004), ‘Detection times of drugs of abuse in blood, urine, and oral fluid’, Therapeutic 
Drug Monitoring 26, pp. 200–5.
I  Verstraete, A. G. (2012), ‘More reliable on-site detection of cannabis in oral fluid’, Clinical Chemistry 
58, pp. 1389–91.
I  Vignola, A., Lamoureux, C., Bastien, C. H. and Morin, C. M. (2000), ‘Effects of chronic insomnia and 
use of benzodiazepines on daytime performance in older adults’, Journals of Gerontology Series B 
— Psychological Sciences and Social Sciences 55, pp. 54–62.
I  Vindenes, V., Jordbru, D., Knapskog, A. B., et al. (2012), ‘Impairment based legislative limits for driving 
under the influence of non-alcohol drugs in Norway’, Forensic Science International 219, pp. 1–11.
I  Volkerts, E. R., Van Laar, M. W., Verbaten, M. N., Mulder, G. and Maes, R. A. A. (1997), ‘Effects of 
phentermine and pentobarbital on choice processes during multiple probability learning (MPL) and 
decision processes manipulated by pay-off conditions’, Human Psychopharmacology — Clinical and 
Experimental 12, pp. 379–92.
Drug use, impaired driving and traffic accidents
148
I  Volkow, N. D., Chang, L., Wang, G. J., et al. (2001), ‘Association of dopamine transporter reduction 
with psychomotor impairment in methamphetamine abusers’, American Journal of Psychiatry 158, 
pp. 377–82.
I  Vuurman, E., Theunissen, E., van Oers, A., van Leeuwen, C. and Jolles, J. (2007), ‘Lack of effects 
between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers’, Human 
Psychopharmacology 22, pp. 289–97.
I  Vuurman, E. F. P. M., Rikken, G. H., Muntjewerff, N. D., de Halleux, F. and Ramaekers, J. G. (2004), 
‘Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor 
performance measurements’, European Journal of Clinical Pharmacology 60, pp. 307–13.
I  Wadsworth, E. J. K., Moss, S. C., Simpson, S. A. and Smith, A. P. (2005), ‘SSRIs and cognitive 
performance in a working sample’, Human Psychopharmacology — Clinical and Experimental 20, 
pp. 561–72.
I  Wadsworth, E. J. K., Moss, S. C., Simpson, S. A. and Smith, A. P. (2006), ‘A community based 
investigation of the association between cannabis use, injuries and accidents’, Journal of 
Psychopharmacology 20, pp. 5–13.
I  Walker, D. J., Zacny, J. P., Galva, K. E. and Lichtor, J. L. (2001), ‘Subjective, psychomotor, and 
physiological effects of cumulative doses of mixed-action opioids in healthy volunteers’, 
Psychopharmacology 155, pp. 362–71.
I  Walsh, J. M., Verstraete, A. G. Huestis, M. A. and Morland, J. (2008), ‘Guidelines for research on 
drugged driving’, Addiction 103, 1258–1268.
I  Wareing, M., Murphy, P. N. and Fisk, J. E. (2004), ‘Visuospatial memory impairments in users of 
MDMA (‘ecstasy’)’, Psychopharmacology 173, pp. 391–7.
I  Weiler, J. M., Bloomfield, J. R., Woodworth, G. G., et al. (2000), ‘Effects of fexofenadine, 
diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the 
Iowa Driving Simulator’, Annals of Internal Medicine 132, pp. 354–63.
I  Weinstein, A., Brickner, O., Lerman, H., et al. (2008a), ‘A study investigating the acute dose–response 
effects of 13 mg and 17 mg Delta 9- tetrahydrocannabinol on cognitive-motor skills, subjective and 
autonomic measures in regular users of marijuana’, Journal of Psychopharmacology 22, pp. 441–51.
I  Weinstein, A., Brickner, O., Lerman, H., et al. (2008b), ‘Brain imaging study of the acute effects of 
Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of 
marijuana’, Psychopharmacology (Berlin) 196, pp. 119–31.
I  Wesensten, N. J., Killgore, W. D. S. and Balkin, T. J. (2005), ‘Performance and alertness effects of 
caffeine, dextro amphetamine, and modafinil during sleep deprivation’, Journal of Sleep Research 14, 
pp. 255–66.
I  Wilken, J. A., Berkowitz, R. and Kane, R. (2002), ‘Decrements in vigilance and cognitive functioning 
associated with ragweed-induced allergic rhinitis’, Annals of Allergy, Asthma and Immunology 89, 
pp. 372–80.
I  Wilken, J. A., Kane, R. L., Ellis, A. K., et al. (2003), ‘A comparison of the effect of diphenhydramine and 
desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic 
rhinitis’, Annals of Allergy, Asthma and Immunology 91, pp. 375–85.
I  Wilson, S. J., Bailey, J. E., Alford, C. and Nutt, D. J. (2000), ‘Sleep and daytime sleepiness the next day 
following single night-time dose of fluvoxamine, dothiepin and placebo in normal volunteers’, Journal 
of Psychopharmacology 14, pp. 378–86.
I  Wingen, M., Ramaekers, J. G. and Schmitt, J. A. J. (2006a), ‘Driving impairment in depressed patients 
receiving long-term antidepressant treatment’, Psychopharmacology 188, pp. 84–91.
I  Wingen, M., Langer, S. and Ramaekers, J. G. (2006b), ‘Verbal memory performance during 
subchronic challenge with a selective serotonergic and a mixed action antidepressant’, Human 
Psychopharmacology — Clinical and Experimental 21, pp. 473–9.
I  Wong, O. F., Tsui, K. L., Lam, T. S., et al. (2010), ‘Prevalence of drugged drivers among non-fatal driver 
casualties presenting to a trauma centre in Hong Kong’, Hong Kong Medical Journal 16, pp. 246–51.
References
149
I  Yang, Y. H., Lai, J. N., Lee, C. H., Wang, J. D. and Chen, P. C. (2011), ‘Increased risk of hospitalization 
related to motor vehicle accidents among people taking zolpidem: a case-crossover study’, Journal of 
Epidemiology 21, pp. 37–43.
I  Zhuo, X. Y., Cang, Y., Yan, H., Bu, J. and Shen, B. H. (2010), ‘The prevalence of drugs in motor vehicle 
accidents and traffic violations in Shanghai and neighboring cities’, Accident Analysis and Prevention 
42, pp. 2179–84.

European Monitoring Centre for Drugs and Drug Addiction 
Drug use, impaired driving and traffic accidents 
Luxembourg: Publications Office of the European Union 
2014 — 149 pp. — 21 × 29.7 cm
ISBN 978-92-9168-687-2 
doi:10.2810/26821

HOW TO OBTAIN EU PUBLICATIONS
Free publications
via EU Bookshop (http://bookshop.europa.eu)
at the European Union’s representations or 
delegations. You can obtain their contact details
on the Internet (http://ec.europa.eu) or by sending 
a fax to +352 2929-42758
Priced publications
via EU Bookshop (http://bookshop.europa.eu)
Priced subscriptions  
(e.g. annual series of the Official Journal of the 
European Union and reports of cases before the 
Court of Justice of the European Union)
via one of the sales agents of the Publications Office 
of the European Union (http://publications.europa.
eu/others/agents/index_en.htm)
IS
S
N
 2
3
1
4
-9
2
6
4
Second edition
T
D
-X
D
-1
4
-0
1
6
-E
N
-N
D
R
U
G
 U
S
E
, IM
P
A
IR
E
D
 D
R
IV
IN
G
 A
N
D
 T
R
A
F
F
IC
 A
C
C
ID
E
N
T
S
 
 S
econ
d
 ed
ition
About the EMCDDA
The European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level. 
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
About this series
EMCDDA Insights are topic-based reports that bring 
together current research and study findings on a 
particular issue in the drugs field. This report provides 
a comprehensive European picture on illicit drugs and 
medicines in connection with driving.
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